
<html lang="en"     class="pb-page"  data-request-id="857ac81c-821c-4c80-ab73-9a8f1b00e148"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b01386;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2020.63.issue-4;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3" /></meta><meta name="dc.Creator" content="Rizhen  Huang" /></meta><meta name="dc.Creator" content="Xiaoteng  Jing" /></meta><meta name="dc.Creator" content="Xiaochao  Huang" /></meta><meta name="dc.Creator" content="Yingming  Pan" /></meta><meta name="dc.Creator" content="Yilin  Fang" /></meta><meta name="dc.Creator" content="Guibin  Liang" /></meta><meta name="dc.Creator" content="Zhixin  Liao" /></meta><meta name="dc.Creator" content="Hengshan  Wang" /></meta><meta name="dc.Creator" content="Zhenfeng  Chen" /></meta><meta name="dc.Creator" content="Ye  Zhang" /></meta><meta name="dc.Description" content="Indoleamine-2,3-dioxygenase 1 (IDO1) and signal transducer and activator of transcription 3 (STAT3) are important targets in the tumor microenvironment for cancer therapy. In the present study, a s..." /></meta><meta name="Description" content="Indoleamine-2,3-dioxygenase 1 (IDO1) and signal transducer and activator of transcription 3 (STAT3) are important targets in the tumor microenvironment for cancer therapy. In the present study, a s..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 30, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01386" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01386" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01386" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01386" /></link>
        
    
    

<title>Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01386" /></meta><meta property="og:title" content="Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0003.jpeg" /></meta><meta property="og:description" content="Indoleamine-2,3-dioxygenase 1 (IDO1) and signal transducer and activator of transcription 3 (STAT3) are important targets in the tumor microenvironment for cancer therapy. In the present study, a set of naphthoquinone aromatic amide-oxime derivatives were designed, which stimulated the immune response via IDO1 inhibition and simultaneously displayed powerful antitumor activity against three selected cancer cell lines through suppressing STAT3 signaling. The representative compound 8u bound effectively to IDO1, with greater inhibitory activity relative to the commercial IDO1 inhibitor 4-amino-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L) in addition to the efficient suppression of nuclear translocation of STAT3. Consistently, in vivo assays demonstrated a higher antiproliferative activity of compound 8u in both wild-type B16-F10 isograft tumors and an athymic HepG2 xenograft model relative to 1-methyl-l-tryptophan (1-MT) and doxorubicin (DOX). This bifunctional compound with dual immunotherapeutic and anticancer efficacy may represent a new generation of highly efficacious drug candidates for cancer therapy." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01386"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01386">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/jctcce/largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/mamobx/largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01386&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01386&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01386&amp;href=/doi/10.1021/acs.jmedchem.9b01386" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1544-1563</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01787" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01409" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Rizhen Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rizhen Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div><div class="loa-info-affiliations-info">School of Pharmacy, Guilin Medical University, Guilin 541004, China</div><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rizhen++Huang">Rizhen Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoteng Jing</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoteng Jing</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoteng++Jing">Xiaoteng Jing</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaochao Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaochao Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaochao++Huang">Xiaochao Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingming Pan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingming Pan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingming++Pan">Yingming Pan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yilin Fang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yilin Fang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yilin++Fang">Yilin Fang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guibin Liang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guibin Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guibin++Liang">Guibin Liang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhixin Liao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhixin Liao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhixin++Liao">Zhixin Liao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hengshan Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hengshan Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#44332c212a23372c252a047572776a272b29"><span class="__cf_email__" data-cfemail="43342b262d24302b222d037275706d202c2e">[email protected]</span></a> (H.W.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hengshan++Wang">Hengshan Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6474-8323" title="Orcid link">http://orcid.org/0000-0001-6474-8323</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenfeng Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenfeng Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#caa9a2afa4b0ac8aadb2a4bfe4afaebfe4a9a4"><span class="__cf_email__" data-cfemail="81e2e9e4effbe7c1e6f9eff4afe4e5f4afe2ef">[email protected]</span></a> (Z.C.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenfeng++Chen">Zhenfeng Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6548-6131" title="Orcid link">http://orcid.org/0000-0002-6548-6131</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ye Zhang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ye Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Guilin Medical University, Guilin 541004, China</div><div class="loa-info-affiliations-info">State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University, Guilin 541004, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#7f05171e1118061a474e3f4e4d49511c1012"><span class="__cf_email__" data-cfemail="23594b424d445a461b12631211150d404c4e">[email protected]</span></a> (Y.Z.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ye++Zhang">Ye Zhang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6903-5602" title="Orcid link">http://orcid.org/0000-0002-6903-5602</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01386&amp;href=/doi/10.1021%2Facs.jmedchem.9b01386" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1544–1563</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 30, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 August 2019</li><li><span class="item_label"><b>Published</b> online</span>30 January 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 27 February 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01386" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01386</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1544%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRizhen%2BHuang%252C%2BXiaoteng%2BJing%252C%2BXiaochao%2BHuang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D4%26contentID%3Dacs.jmedchem.9b01386%26title%3DBifunctional%2BNaphthoquinone%2BAromatic%2BAmide-Oxime%2BDerivatives%2BExert%2BCombined%2BImmunotherapeutic%2Band%2BAntitumor%2BEffects%2Bthrough%2BSimultaneous%2BTargeting%2Bof%2BIndoleamine-2%252C3-dioxygenase%2Band%2BSignal%2BTransducer%2Band%2BActivator%2Bof%2BTranscription%2B3%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1563%26publicationDate%3DFebruary%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01386"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1276</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01386" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rizhen&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Xiaoteng&quot;,&quot;last_name&quot;:&quot;Jing&quot;},{&quot;first_name&quot;:&quot;Xiaochao&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Yingming&quot;,&quot;last_name&quot;:&quot;Pan&quot;},{&quot;first_name&quot;:&quot;Yilin&quot;,&quot;last_name&quot;:&quot;Fang&quot;},{&quot;first_name&quot;:&quot;Guibin&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Zhixin&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Hengshan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Zhenfeng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Ye&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;1544-1563&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01386&quot;},&quot;abstract&quot;:&quot;Indoleamine-2,3-dioxygenase 1 (IDO1) and signal transducer and activator of transcription 3 (STAT3) are important targets in the tumor microenvironment for cancer therapy. In the present study, a set of naphthoquinone aromatic amide-oxime derivatives were designed, which stimulated the immune response via IDO1 inhibition and simultaneously displayed powerful antitumor activity against three selected cancer cell lines through suppressing STAT3 signaling. The representative compound 8u bound effectively to IDO1, with greater inhibitory activity relative to the commercial IDO1 inhibitor 4-amino-N-(3-chloro-4-fluorophenyl)-N′-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L) in addition to the efficient suppression of nuclear translocation of STAT3. Consistently, in vivo assays demonstrated a higher antiproliferative activity of compound 8u in both wild-type B16-F10 isograft tumors and an athymic HepG2 xenograft model relative to 1-methyl-l-tryptophan (1-MT) and doxorubicin (DOX). This bifunctional compound with&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01386&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01386" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01386&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01386" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01386&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01386" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01386&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01386&amp;href=/doi/10.1021/acs.jmedchem.9b01386" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01386" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01386" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01386%26sid%3Dliteratum%253Aachs%26pmid%3D31999451%26genre%3Darticle%26aulast%3DHuang%26date%3D2020%26atitle%3DBifunctional%2BNaphthoquinone%2BAromatic%2BAmide-Oxime%2BDerivatives%2BExert%2BCombined%2BImmunotherapeutic%2Band%2BAntitumor%2BEffects%2Bthrough%2BSimultaneous%2BTargeting%2Bof%2BIndoleamine-2%252C3-dioxygenase%2Band%2BSignal%2BTransducer%2Band%2BActivator%2Bof%2BTranscription%2B3%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D4%26spage%3D1544%26epage%3D1563%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/jmcmar.2020.63.issue-4/20200227/jmcmar.2020.63.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0003.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Indoleamine-2,3-dioxygenase 1 (IDO1) and signal transducer and activator of transcription 3 (STAT3) are important targets in the tumor microenvironment for cancer therapy. In the present study, a set of naphthoquinone aromatic amide-oxime derivatives were designed, which stimulated the immune response via IDO1 inhibition and simultaneously displayed powerful antitumor activity against three selected cancer cell lines through suppressing STAT3 signaling. The representative compound <b>8u</b> bound effectively to IDO1, with greater inhibitory activity relative to the commercial IDO1 inhibitor 4-amino-<i>N</i>-(3-chloro-4-fluorophenyl)-<i>N</i>′-hydroxy-1,2,5-oxadiazole-3-carboximidamide (<b>IDO5L</b>) in addition to the efficient suppression of nuclear translocation of STAT3. Consistently, in vivo assays demonstrated a higher antiproliferative activity of compound <b>8u</b> in both wild-type B16-F10 isograft tumors and an athymic HepG2 xenograft model relative to 1-methyl-<span class="smallcaps smallerCapital">l</span>-tryptophan (<b>1-MT</b>) and doxorubicin (<b>DOX</b>). This bifunctional compound with dual immunotherapeutic and anticancer efficacy may represent a new generation of highly efficacious drug candidates for cancer therapy.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56510" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56510" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer immunotherapy approaches have been a significant focus of interest based on the hypothesis that progression of spontaneous malignancies can be suppressed by the immune system. Immune checkpoint therapy has been documented as a breakthrough in cancer immunotherapy, with remarkable therapeutic effects of anti-PDL1 (programmed death ligand 1), anti-PD1 (programmed cell death protein 1), and anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4) agents reported in multiple clinical trials as an alternative to conventional chemotherapy following the FDA approval of ipilumumab, pembrolizumab, and nivolumab.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> While immune checkpoint inhibitors have shown clinical success as cancer immunotherapy options, only a fraction of patients with advanced cancers respond effectively to these agents, highlighting the continued requirement for improved therapeutic strategies.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Recent accumulating evidence suggests that strategies combining immunotherapy and chemotherapy have enormous potential to enhance clinical benefits due to simultaneous targeting of different tumor cell survival pathways, which could aid in overcoming drug resistance in advanced-stage cancers.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> Indeed, a multipronged immune-chemotherapeutic approach would not only facilitate tumor shrinkage but, more importantly, reactivate the dormant immune response against malignancies to eliminate residual cancer cells. Several immune-chemotherapeutic approaches based on platinum (Pt) drugs incorporating IDO inhibitors have achieved therapeutic synergy to date.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> However, the clinical application of Pt-based drugs is inevitably limited by severe toxicity, acute side effects, and inherent or acquired drug resistance. Accordingly, the design and synthesis of novel immune-chemotherapeutic monomers have attracted considerable research attention in the field of medicinal chemistry.</div><div class="NLM_p">Indoleamine-2,3-dioxygenase 1 (IDO1) is a heme-containing oxidoreductase that catalyzes tryptophan catabolism to kynurenine through the kynurenine pathway.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> IDO-mediated rapid consumption of tryptophan results in the suppression of effector T-cell responses and enhancement of immunosuppression-modulated signals by T regulatory cells.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> IDO1-induced immune tolerance is widely considered as one of the most critical mechanisms evolved by tumors to escape immune surveillance.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Furthermore, constitutive overexpression of IDO1 in a variety of human tumors and host antigen-presenting cells has been correlated with different tumor progression parameters and poor prognosis.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> Preclinical studies on mouse tumor models have shown that systemic blockade of IDO1 activity with small-molecule inhibitors successfully impairs outgrowth of tumors, delays metastasis development, prolongs survival, and exerts synergistic therapeutic effects with anticancer drugs to facilitate regression of tumors that are otherwise recalcitrant to treatments. The collective findings in the literature validate the utility of IDO1 as a key target for cancer immunotherapy.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Several potent small-molecule IDO1 inhibitors that effectively stimulate antitumor immunity have been identified (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A), but only two of these molecules, 4-amino-<i>N</i>-(3-chloro-4-fluorophenyl)-<i>N</i>′-hydroxy-1,2,5-oxadiazole-3-carboximidamide (<b>IDO5L</b>) and <b>NLG919</b>, have entered clinical trials to date.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23">(19−23)</a> A key limitation of checkpoint inhibitors is that these molecules narrowly focus on modulating the immune synapse but do not address the critical molecular determinants primarily responsible for immune dysfunction in the tumor microenvironment.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a> Signal transducer and activator of transcription 3 (STAT3), a point of convergence for numerous oncogenic signaling pathways and a transcriptional regulator of diverse tumor-promoting factors, is constitutively activated in both tumor and immune cells within the tumor microenvironment and therefore presents an attractive therapeutic target.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> STAT3 regulates multiple genes crucial for tumor cell survival, proliferation, migration, and angiogenesis,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and its targeting in tumors with constitutive STAT3 activation has been shown to directly trigger tumor cell death and growth inhibition in vivo.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Additionally, constitutively activated STAT3 inhibits the expression of mediators necessary for immune activation and promotes the production of immunosuppressive factors that further stimulate STAT3 activity in diverse immune cell subsets, altering gene expression programs and thereby suppressing antitumor immune responses. Recent studies have shown that inhibition of STAT3 signaling in the hematopoietic system via ablation of STAT3 or treatment with specific blockers elicits multicomponent antitumor immunity.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Intriguingly, antitumor effects are more marked when tumor cells are sensitive to direct killing induced by STAT3 blockade,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> highlighting the enhanced therapeutic value of approaches targeting both the tumor and its microenvironment. Notably, STAT3 has been shown to maintain the transcriptional expression of IDO and PD-L1 in human cancers.<a onclick="showRef(event, 'ref26 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref26 ref32 ref33">(26,32,33)</a> In the current investigation, we aimed to develop a type of novel small inhibitor molecule targeting both IDO1 and STAT3.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of IDO1 and STAT3 inhibitors. (A) Structures of representative IDO1 inhibitors. (B) Naphthoquinone-based IDO1 and tryptophan 2,3-dioxygenase (TDO) inhibitors. (C) Naphthoquinone-based STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Naphthoquinone structural motifs, such as 1,4-naphthoquinone and its derivatives, exhibit multiple pharmacological activities and have been characterized as enzyme inhibitors.<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34−36)</a> A recent study documented that IDO1 is an essential target for naphthoquinone menadione displaying antitumor activity (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Some substituted naphthotriazolediones were additionally identified as tryptophan 2,3-dioxygenase (TDO) inhibitors using structure-based virtual screening.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> On the other hand, 1,4-naphthoquinone-based compounds are reported to bind directly to STAT3 and effectively reduce cancer growth in vivo (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C).<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> It is, thus, reasonable to expect that structural modification of the 1,4-naphthoquinone backbone could facilitate both immunomodulatory and antitumor efficacies through simultaneous targeting of IDO1 and STAT3. On the basis of the amide moiety of <b>Amg-1</b>, which is located at the expanded hydrophobic pocket,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> the aromatic amide was designed and drawn into the naphthoquinone skeleton for binding to the active pocket of IDO1, thus increasing the IDO1 inhibitory activity and antitumor activity. In addition, as inspired by the structure of IDO5L, the oxime moiety was also introduced into the naphthoquinone skeleton for binding to the iron of heme and expected to act as a donor or acceptor of hydrogen bonds when combined with STAT3. To our knowledge, the combination of the aromatic amide portion, oxime group, and naphthoquinone moiety has not been reported as a dual inhibitor of IDO1 and STAT3 in the literature. Therefore, a series of novel 1,4-naphthoquinone aromatic amide-oxime derivatives co-targeting IDO1 and STAT3 were designed and synthesized, with a view to developing effective anticancer agents that exert synergistic effects through inhibition of STAT3 signaling and simultaneous activation of the antitumor immune response via IDO1 blockage. Our experimental data clearly indicated that the most potent bifunctional inhibitor <b>8u</b> showed excellent in vivo antitumor efficacy in both wild-type B16-F10 isograft tumors and athymic nude mice, thereby presenting a more proficient immunochemotherapeutic agent against cancers that fail to respond to current immune checkpoint inhibitors or conventional chemotherapeutic agents.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07837" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07837" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The general procedures for the synthesis of 2-amino-1,4-naphthoquinone aromatic amide-oxime derivatives are described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. First, the reaction of commercially available phthalic anhydride (<b>1)</b> with <span class="smallcaps smallerCapital">l</span>-phenylalanine (<b>2</b>) in the presence of acetic acid generating compound <b>3</b> was performed as described in the literature.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> For the synthesis of compound <b>4</b>, compound <b>3</b> was treated with oxalyl chloride to produce phthalic imide acid chloride, which was substituted with aromatic primary amines to produce phthalic acid amide. Compound <b>4</b> reacted with hydrazine hydrate in the presence of ethanol at room temperature, thus generating aromatic amide derivatives (<b>5</b>). 2-Amino-1,4-naphthoquinone aromatic amide derivatives (<b>7</b>) were prepared, starting from 1,4-naphthoquinone (<b>6</b>), which was treated with aromatic amide derivatives (<b>5</b>) and triethylamine solution in water at room temperature for 18 h, followed by hydroxylamine hydrochloride in ethyl alcohol at 80 °C for 12 h, to obtain the corresponding 2-amino-1,4-naphthoquinone aromatic amide-oxime derivatives (<b>8</b>). These derivatives were converted to 2-amino-1,4-naphthoquinone oxime esters (<b>10</b>) through a neutral nucleophilic substitution reaction with 4-<i>tert</i>-butylbenzenesulfonyl chloride in dichloromethane in an ice bath. The structures of target compounds <b>7</b>, <b>8</b>, and <b>10</b> were confirmed via <sup>1</sup>H NMR, <sup>13</sup>C NMR, and high-resolution mass spectrometry (HRMS) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Pathway to Target Compounds <b>7</b>(<b>7a</b>–<b>7z</b>), <b>8</b>(<b>8a</b>–<b>8z</b>), and <b>10</b>(<b>10a</b>–<b>10c</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) phthalic anhydride, CH<sub>3</sub>COOH, 70 °C, 12 h; (b) oxalyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, aromatic primary amines, Et<sub>3</sub>N, room temperature (rt), 12 h; (c) hydrazine hydrate, CH<sub>3</sub>OH, rt, 8 h; (d) DMF, H<sub>2</sub>O, Et<sub>3</sub>N, rt, 18 h; (e) hydroxylamine, CH<sub>3</sub>CH<sub>2</sub>OH, 80 °C, 12 h; (f) CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 0 °C, 3 h.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Inhibition of IDO1 Activity</h3><div class="NLM_p">A diverse library of 2-amino-1,4-naphthoquinone aromatic amide-oxime derivatives was synthesized and assayed in vitro against activated human IDO1 using a standard enzymatic assay according to previous reports.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The potent <b>IDO5L</b>, one of the earliest IDO inhibitors characterized in the literature, was used as a positive control.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> IC<sub>50</sub> values obtained based on in vitro inhibition activities of 2-amino-1,4-naphthoquinone aromatic amide-oxime derivatives are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and IDO1 Inhibitory Activities of 2-Amino-1,4-Naphthoquinone Derivatives <b>7a</b>–<b>7z</b>, <b>8a</b>–<b>8z</b>, and <b>10a</b>–<b>10c</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0009.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compds.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">rhIDO1 IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">3.54 ± 0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.09 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.069 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.63 ± 0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.078 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8g</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">2.09 ± 0.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8h</b></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.68 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8i</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.082 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8j</b></td><td class="colsep0 rowsep0" align="left">2-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">2.53 ± 0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8k</b></td><td class="colsep0 rowsep0" align="left">3-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.95 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8l</b></td><td class="colsep0 rowsep0" align="left">4-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8m</b></td><td class="colsep0 rowsep0" align="left">2-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">8.19 ± 0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8n</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.53 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8o</b></td><td class="colsep0 rowsep0" align="left">4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.45 ± 0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8p</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8q</b></td><td class="colsep0 rowsep0" align="left">3-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">1.51 ± 0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8r</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">3.21 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8s</b></td><td class="colsep0 rowsep0" align="left">3,5-(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">8.27 ± 0.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8t</b></td><td class="colsep0 rowsep0" align="left">3-Br-4-F</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.074 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8u</b></td><td class="colsep0 rowsep0" align="left">3,5-(OCH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.046 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8v</b></td><td class="colsep0 rowsep0" align="left">3-F-4-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.097 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8w</b></td><td class="colsep0 rowsep0" align="left">3,5-(F)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.25 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8x</b></td><td class="colsep0 rowsep0" align="left">3-F-4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">2.22 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8y</b></td><td class="colsep0 rowsep0" align="left">3-Cl-4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">6.11 ± 0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8z</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>3</sub>-4-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">6.78 ± 0.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7d</b></td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7e</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7f</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7g</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7h</b></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7i</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7j</b></td><td class="colsep0 rowsep0" align="left">2-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7k</b></td><td class="colsep0 rowsep0" align="left">3-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7l</b></td><td class="colsep0 rowsep0" align="left">4-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7m</b></td><td class="colsep0 rowsep0" align="left">2-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7n</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7o</b></td><td class="colsep0 rowsep0" align="left">4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7p</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7q</b></td><td class="colsep0 rowsep0" align="left">3-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7r</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7s</b></td><td class="colsep0 rowsep0" align="left">3,5-(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7t</b></td><td class="colsep0 rowsep0" align="left">3-Br-4-F</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7u</b></td><td class="colsep0 rowsep0" align="left">3,5-(OCH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">4.84 ± 0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7v</b></td><td class="colsep0 rowsep0" align="left">3-F-4-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7w</b></td><td class="colsep0 rowsep0" align="left">3,5-(F)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7x</b></td><td class="colsep0 rowsep0" align="left">3-F-4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7y</b></td><td class="colsep0 rowsep0" align="left">3-Cl-4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7z</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>3</sub>-4-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOSO<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="left">9.60 ± 0.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">3-Br</td><td class="colsep0 rowsep0" align="left">NOSO<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOSO<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>IDO5L</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.073 ± 0.02</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data are mean ± SD values from three independent experiments.</p></div></div></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the newly synthesized 1,4-naphthoquinone aromatic amide-oxime derivative <b>8</b> was demonstrated to be a potent IDO1 inhibitor with the IC<sub>50</sub> value mostly in the nanomolar range. The oxime derivative <b>8</b> (except for <b>8m</b>, <b>8s</b>, and <b>8y</b>) was significantly more potent than the original lead compound <b>6</b> and its derivatives <b>7</b> and <b>10</b>. Notably, compound <b>8u</b> exhibited the best IDO1 inhibition activity relative to that of the commercial IDO1 inhibitor <b>IDO5L</b> and was, thus, chosen as the representative compound for further investigation as described below.</div><div class="NLM_p">Structure–activity relationship (SAR) studies were further conducted with the aim of identifying the structural requirements for IDO1 inhibition. The importance of a single substitution at the R<sup>1</sup> position of the phenyl ring was initially investigated. A strong preference for para-substitution was demonstrated by the eightfold improvement in the IDO1 inhibition activity of <i>p</i>-fluoro <b>8f</b> compared to that of <i>o</i>-fluoro <b>8d</b>. Similarly, introduction of a fluorine group at the meta-position of the phenyl ring (<b>8e</b>) improved the IDO1 inhibitory activity relative to that of <b>8d</b>, but the activity was slightly weaker than that of <b>8f</b>. Replacement of the fluorine group with a trifluoromethyl group (<b>8b, 8c</b>) resulted in a twofold greater inhibition of IDO1 than those of <b>8e</b> and <b>8f</b>. After replacement of the fluorine in compound <b>8f</b> with a chlorine (<b>8i</b>), bromine (<b>8l</b>), or methoxy (<b>8o</b>) group at the para-position on the phenyl ring, the presence of an electron-donating group on the phenyl ring resulted in a progressive loss of activity. Complete loss of activity was also achieved by introducing a methyl moiety at the ortho-position of the phenyl ring, thus generating compound <b>8p</b> (IC<sub>50</sub> > 10 μM). Regarding the effects of the electronic properties of the chemical group at R<sup>1</sup>, the IDO1 inhibitory activity improved in the order methyl < bromine < chlorine < fluorine < trifluoromethyl, thus highlighting an important role of the electron-withdrawing group in the inhibition of IDO1. Variations at R<sup>1</sup> caused substantial differences in inhibitory potency, presumably because of different affinities to the binding pocket.</div><div class="NLM_p">In addition, we investigated the influence of a second group on the phenyl ring. The compound with a second methyl group at position 2 (<b>8z</b>, IC<sub>50</sub> > 50 μM), compared to the 4-Br derivative (<b>8l</b>, IC<sub>50</sub> = 0.16 μM), did not show improved activity. In contrast, the addition of an <i>m</i>-fluoro substituent to <b>8l</b> was tolerated and generated <b>8v</b>, which showed strikingly improved potency. Compounds <b>8w</b>–<b>8y</b> had further substitutions at the 3-position of the phenyl ring. Unfortunately, these compounds displayed poor or retained inhibitory activity against IDO1. The presence of a bromine atom at the 3-position generated <b>8t</b> (IC<sub>50</sub> = 0.074 μM), which had a relatively greater inhibitory activity comparable to that of <b>8f</b>, but 12-fold more potent than that of <b>8k</b>. These results clearly suggested that the electronic and steric properties at the 3-position affect the IDO1 inhibitory activity. Intriguingly, the 3,5-dimethoxy substitution pattern produced the most potent compound, <b>8u</b> (IC<sub>50</sub> = 0.046 μM), which was ∼11-fold more active than the 3-methoxy derivative <b>8n</b> (IC<sub>50</sub> = 0.53 μM). The same compound was 179- and 5-fold more active than the 3,5-dimethyl (<b>8s</b>, IC<sub>50</sub> = 8.27 μM) and 3,5-difluoro (<b>8w</b>, IC<sub>50</sub> = 0.25 μM) derivatives, respectively.</div><div class="NLM_p">SAR studies revealed the importance of the unique oxime functional group in binding to IDO1. All modifications of the oxime pharmacophore generated significantly less potent derivatives (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Further modification of the carbonyl group of <b>7c</b> with an oxime group, thus generating <b>8c</b>, resulted in a 98-fold increase in the IDO1 inhibitory activity. Esterification of the oxime group in 4-<i>tert</i>-butylbenzenesulfonyl oxime esters (compound <b>10</b>) revealed the requirement of a free hydroxyl group for binding IDO1. Compounds <b>10b</b> and <b>10c</b> showed no activity. Only the trifluoromethyl substitution derivative, <b>10a</b>, showed measurable activity (albeit 106-fold lower), compared to that of its oxime analogue, <b>8b</b>, in the IDO1 assay. This significant loss of activity may be explained by additional esterification of the oxime moiety resulting in a steric clash with the heme group in IDO1, thus preventing the formation of the coordinate covalent bond with heme iron.</div><div class="NLM_p last">On the basis of the established SAR, the known binding affinities of compounds containing the oxime moiety to iron heme<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and data obtained with IDO1, we surmised that these IDO1 inhibitors may form a dative bond with heme iron in the ferrous state through the oxygen of the oxime moiety.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Molecular Docking</h3><div class="NLM_p">As revealed by SAR studies, <b>8u</b> exhibited the most potent inhibitory activity against IDO1. To understand the mechanisms underlying the improved potency of <b>8u</b> at the molecular level, molecular docking studies of <b>8u</b> in the active site of IDO1 were performed using SYBYL-X 2.0 software. The docking scores are summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Table S1</a>. The docking model showed that <b>8u</b> was strongly bound to the Trp-binding site with its naphthoquinone oxime core almost perpendicular to the heme plane (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The oxygen of the oxime moiety coordinated with heme iron in the catalytically active site, and the quinone part of <b>8u</b> located deep into the hydrophobic pocket (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), where it was appropriately positioned to facilitate π–π interactions with the quinone aromatic core of several aromatic groups (TYR126, PHE163, and PHE164). Additional lipophilic residues were in close contact with the quinone group (VAL130, CYS129, and LEU234). Remarkably, the hydroxyl hydrogen of the oxime moiety formed additional hydrogen bonds with the porphyrin ring of heme, which contributed to its inhibitory activity against IDO1. Furthermore, the phenyl ring of the phenylalanine moiety extended tightly into another hydrophobic pocket (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Figure S1A</a>) and interacted with LEU230, ARG231, PHE226, PHE227, and ILE354 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Figure S1B</a>). Notably, π–π interactions between the phenyl ring and side chain of PHE226 were observed, which may be essential for potent IDO1 inhibitory activity, consistent with earlier findings on the role of PHE226.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The NH of <b>8u</b> was situated in the vicinity of 7-propanoic acid group of the heme ring, where it formed a strong hydrogen bond. Specifically, the methoxy group in the R<sup>1</sup> position as an acceptor established one hydrogen bond with GLY236, which could also contribute to the improved potency of <b>8u</b>, and adopted a different rotamer, compared to previous studies.<a onclick="showRef(event, 'ref41 ref45'); return false;" href="javascript:void(0);" class="ref ref41 ref45">(41,45)</a> The tight packing of the molecule within the IDO1 active site (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Figure S1C</a>) clearly explained the lack of activity of the analogues bearing a methyl substituent at the R<sup>1</sup> position as well as the considerable challenges in modifying oxime features.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Proposed binding mode of compound <b>8u</b> in the active site of IDO1 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5">4PK5</a>). Heme is reported as a cyan stick, IDO1 structure is shown as a cartoon. (B) Key hydrogen bond interactions of compound <b>8u</b> in the active site of IDO1. Compound <b>8u</b>, IDO1 residues, and HEM are shown as gray stick, yellow stick, and cyan stick, respectively. The red dashed lines indicate the H-bond interaction between <b>8u</b> and IDO1. (C) Biophysical binding data supports the interaction of compound <b>8u</b> with human IDO1 protein. Dose–response curve determined by surface plasmon resonance (SPR) for the binding of IDO1 with <b>8u</b> is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> UV–Visible Spectroscopy</h3><div class="NLM_p last">UV–visible spectroscopy was performed to further confirm binding of compound <b>8u</b> with heme-containing IDO1 protein. The unique UV absorption properties of porphyrins are useful in heme protein studies.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Heme is a porphyrin ring with an iron at its center, which absorbs light at the UV–vis spectrum maximally at a wavelength of ∼400 nm depending on the oxidation and coordination states of its iron, characterized by the Soret band. Absorbance spectra of the heme group are highly sensitive to changes in the polarity of the heme environment upon ligand/substrate binding, usually resulting in pronounced changes in the spectral properties of heme.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Therefore, changes in UV–visible spectra induced by IDO1–ligand interactions could be exploited to evaluate binding to IDO1. To obtain a more direct indication of the binding site of compound <b>8u</b>, UV–visible spectra of ferric IDO1 were measured in the presence and absence of the compound (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Figure S2</a>). In the absence of <b>8u</b>, the absorption spectrum of ferric IDO1 exhibited a Soret peak at 403 nm, as described in the literature.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> The Soret peak shifted to 413 nm in the presence of <b>8u</b>, indicative of binding to IDO1 and coordination with the iron of the heme group.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Surface Plasmon Resonance Assays</h3><div class="NLM_p last">To provide definitive evidence of direct binding to IDO1, a surface plasmon resonance (SPR)-based binding assay was performed using a Biacore T200 instrument. This analytic technique facilitates measurement of the kinetic and thermodynamic parameters of ligand–protein complex formation and is widely utilized to investigate enzyme/inhibitor interactions.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Kinetic association and dissociation measurements were obtained, and the binding affinity of compound <b>8u</b> for IDO1 was determined with the aid of Biacore evaluation software. Compound <b>8u</b> efficiently interacted with the immobilized protein (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C), as demonstrated by the concentration-dependent responses for association and dissociation, respectively, and the clearly discernible exponential curves, indicative of binding to and dissociation from the IDO1 protein, with an equilibrium dissociation constant (<i>K</i><sub>D</sub>, representing binding affinity) of 0.08 μM. Notably, the kinetic dissociation constant (<i>K</i><sub>d</sub>) between compound <b>8u</b> and IDO1 was 0.0045 1/s, suggesting that the <b>8u</b>-IDO1 complexes formed were extremely stable. Our data provided definitive evidence of direct binding of derivatives of 2-amino-1,4-naphthoquinone aromatic amide-oxime derivatives to IDO1.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vivo Tumor Growth Inhibition</h3><div class="NLM_p">Compounds that directly interfere with IDO-mediated tryptophan catalysis exert antitumor effects. To establish whether IDO1 inhibition could similarly reverse immune tolerance in vivo, we treated C57BL/6 mice bearing B16-F10 with <b>8u</b> or 1-methyl-l-tryptophan (1-MT) for 21 days. IDO is not expressed in B16-F10 tumor cells, but rather detected in antigen-presenting cells within tumor-draining lymph nodes of the host animal.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> B16-F10 cells form highly aggressive, poorly immunogenic tumors that are resistant to a variety of immunotherapeutic strategies. Nevertheless, growth of tumor isografts formed by these cells can be suppressed significantly by direct inhibitors of IDO1.<a onclick="showRef(event, 'ref17 ref37'); return false;" href="javascript:void(0);" class="ref ref17 ref37">(17,37)</a> After 21 days, <b>8u</b> exhibited significantly stronger tumor inhibition than the other two groups (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">S3A</a>). Comparison of final mean tumor volumes between <b>8u</b>-treated and control animals at the 3-week endpoint revealed marked suppression of tumor growth following <b>8u</b> treatment of B16-F10 tumor-challenged mice (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) equating to a T/C ratio of 29.47% (150 mg/kg). Specifically, <b>8u</b> inhibited 70.53% of the tumor volume, while 1-MT reduced the tumor volume by 57.21% (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). The mice treated with <b>8u</b> showed marked reduction in total tumor weight, whereas the effect on tumor degeneration was smaller in the 1-MT-treated mice (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Figure S3B</a>). The body weights of the mice in each group increased gradually, confirming the safety of <b>8u</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Figure S3C</a>). Although <b>8u</b> was incapable of eliciting tumor regression, the compound effectively inhibited tumor growth, supporting its potential as a single agent for tumor therapy.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vivo anticancer activity of compound <b>8u</b>. (A) Effects of the indicated treatments of <b>8u</b> on B16-F10 melanoma tumor xenografts in C57BL/6 mice. The images of the tumors after administering with compound <b>8u</b> are also shown. (B) Tumor volumes were detected every 2 days for 21 days of duration. (C) Inhibition of tumor growth for compound <b>8u</b> and doxorubicin (DOX) in nude mice bearing HepG2 xenograft model. (D) Tumor volumes were detected every 3 days. Data represent three individual experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Evaluation of Antiproliferative Activity</h3><div class="NLM_p">Menadione, an anticancer agent with a naphthoquinone core, exhibits low micromolar potency against IDO.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Based on the finding that compound <b>8u</b> was an inhibitor of IDO1, we evaluated whether <b>8u</b> and other naphthoquinone derivatives exerted antitumor effects in Hct-116, SKOV3, A549, and HepG2 cancer cells via the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data are presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, showing potent cytotoxicity of several compounds in all of the cell lines examined. Notably, compounds <b>8</b> exhibited significantly greater antitumor activity relative to a number of other IDO inhibitors examined, which displayed weak activity when administered as single agents. There is growing consensus that the clinical efficacy of some chemotherapeutic agents additionally depends on their off-target immunomodulatory effects.<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> Indeed, the newly synthesized naphthoquinone derivatives <b>8</b> were potent antitumor agents with IC<sub>50</sub> values mostly in the nanomolar range. Among these, <b>8u</b> was the most potent depending on the cell line, with IC<sub>50</sub> values of 0.037 ± 0.01, 0.028 ± 0.01, 0.033 ± 0.01 μM, and 0.012 ± 0.01 against Hct-116, SKOV3, A549, and HepG2, respectively. However, the antitumor activity of compounds <b>7</b> that induced moderate IDO1 inhibition was relatively weak. Based on the collective kinetic and cell proliferation results, a window between IDO inhibitory activity and general cytotoxicity of compound <b>7</b> was hypothesized.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cytotoxic Activity of 2-Amino-1,4-Naphthoquinone Derivatives against Cancer Cell Lines<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0005.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="rowsep1 colsep0" colspan="6" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compds.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">Hct-116</th><th class="colsep0 rowsep0" align="center">SKOV3</th><th class="colsep0 rowsep0" align="center">A549</th><th class="colsep0 rowsep0" align="center">HepG2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">1.54 ± 0.43</td><td class="colsep0 rowsep0" align="left">1.25 ± 0.14</td><td class="colsep0 rowsep0" align="left">1.47 ± 0.39</td><td class="colsep0 rowsep0" align="left">1.15 ± 0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.10 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.09</td><td class="colsep0 rowsep0" align="left">0.07 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8c</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.083 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.055 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.074 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.068 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8d</b></td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.19 ± 0.10</td><td class="colsep0 rowsep0" align="left">0.14 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.09 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8e</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.89 ± 0.28</td><td class="colsep0 rowsep0" align="left">0.43 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.81 ± 0.21</td><td class="colsep0 rowsep0" align="left">0.73 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8f</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.098 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.10 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.05 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8g</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">1.09 ± 0.39</td><td class="colsep0 rowsep0" align="left">1.22 ± 0.31</td><td class="colsep0 rowsep0" align="left">1.18 ± 0.65</td><td class="colsep0 rowsep0" align="left">1.03 ± 0.49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8h</b></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.56 ± 0.26</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.09</td><td class="colsep0 rowsep0" align="left">0.53 ± 0.17</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8i</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.071 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.067 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.069 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.042 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8j</b></td><td class="colsep0 rowsep0" align="left">2-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">3.19 ± 0.47</td><td class="colsep0 rowsep0" align="left">2.96 ± 0.36</td><td class="colsep0 rowsep0" align="left">3.05 ± 0.46</td><td class="colsep0 rowsep0" align="left">1.80 ± 0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8k</b></td><td class="colsep0 rowsep0" align="left">3-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">1.22 ± 0.33</td><td class="colsep0 rowsep0" align="left">1.08 ± 0.28</td><td class="colsep0 rowsep0" align="left">1.21 ± 0.23</td><td class="colsep0 rowsep0" align="left">0.10 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8l</b></td><td class="colsep0 rowsep0" align="left">4-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.31 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.09</td><td class="colsep0 rowsep0" align="left">0.28 ± 0.15</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8m</b></td><td class="colsep0 rowsep0" align="left">2-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">1.41 ± 0.44</td><td class="colsep0 rowsep0" align="left">1.08 ± 0.33</td><td class="colsep0 rowsep0" align="left">1.23 ± 0.26</td><td class="colsep0 rowsep0" align="left">1.07 ± 0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8n</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.66 ± 0.19</td><td class="colsep0 rowsep0" align="left">0.44 ± 0.15</td><td class="colsep0 rowsep0" align="left">0.63 ± 0.11</td><td class="colsep0 rowsep0" align="left">0.06 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8o</b></td><td class="colsep0 rowsep0" align="left">4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.58 ± 0.28</td><td class="colsep0 rowsep0" align="left">0.41 ± 0.22</td><td class="colsep0 rowsep0" align="left">0.49 ± 0.21</td><td class="colsep0 rowsep0" align="left">0.04 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8p</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">9.72 ± 0.70</td><td class="colsep0 rowsep0" align="left">8.81 ± 0.78</td><td class="colsep0 rowsep0" align="left">9.08 ± 0.37</td><td class="colsep0 rowsep0" align="left">8.05 ± 0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8q</b></td><td class="colsep0 rowsep0" align="left">3-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">1.62 ± 0.12</td><td class="colsep0 rowsep0" align="left">1.15 ± 0.47</td><td class="colsep0 rowsep0" align="left">1.46 ± 0.36</td><td class="colsep0 rowsep0" align="left">1.23 ± 0.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8r</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">3.86 ± 0.53</td><td class="colsep0 rowsep0" align="left">2.75 ± 0.37</td><td class="colsep0 rowsep0" align="left">3.54 ± 0.28</td><td class="colsep0 rowsep0" align="left">1.29 ± 0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8s</b></td><td class="colsep0 rowsep0" align="left">3,5-(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">3.39 ± 0.23</td><td class="colsep0 rowsep0" align="left">2.84 ± 0.49</td><td class="colsep0 rowsep0" align="left">3.17 ± 0.34</td><td class="colsep0 rowsep0" align="left">2.57 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8t</b></td><td class="colsep0 rowsep0" align="left">4-F-3-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.097 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.073 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.088 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.056 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8u</b></td><td class="colsep0 rowsep0" align="left">3,5-(OCH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.037 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.028 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.033 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.012 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8v</b></td><td class="colsep0 rowsep0" align="left">3-F-4-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.092 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.07 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8w</b></td><td class="colsep0 rowsep0" align="left">3,5-(F)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">0.78 ± 0.13</td><td class="colsep0 rowsep0" align="left">0.64 ± 0.17</td><td class="colsep0 rowsep0" align="left">0.69 ± 0.29</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8x</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>3</sub>-3-F</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">2.55 ± 0.41</td><td class="colsep0 rowsep0" align="left">2.06 ± 0.28</td><td class="colsep0 rowsep0" align="left">2.34 ± 0.32</td><td class="colsep0 rowsep0" align="left">1.81 ± 0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8y</b></td><td class="colsep0 rowsep0" align="left">3-Cl-4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">6.53 ± 0.76</td><td class="colsep0 rowsep0" align="left">4.68 ± 0.42</td><td class="colsep0 rowsep0" align="left">6.50 ± 0.62</td><td class="colsep0 rowsep0" align="left">2.47 ± 0.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8z</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>3</sub>-4-Br</td><td class="colsep0 rowsep0" align="left">NOH</td><td class="colsep0 rowsep0" align="left">9.89 ± 0.55</td><td class="colsep0 rowsep0" align="left">7.27 ± 0.65</td><td class="colsep0 rowsep0" align="left">9.48 ± 0.41</td><td class="colsep0 rowsep0" align="left">4.78 ± 0.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7b</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">17.23 ± 0.38</td><td class="colsep0 rowsep0" align="left">16.52 ± 0.59</td><td class="colsep0 rowsep0" align="left">18.03 ± 0.51</td><td class="colsep0 rowsep0" align="left">13.26 ± 0.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7d</b></td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7e</b></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7f</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7g</b></td><td class="colsep0 rowsep0" align="left">2-Cl</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7h</b></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7i</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7j</b></td><td class="colsep0 rowsep0" align="left">2-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7k</b></td><td class="colsep0 rowsep0" align="left">3-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7l</b></td><td class="colsep0 rowsep0" align="left">4-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7m</b></td><td class="colsep0 rowsep0" align="left">2-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7n</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7o</b></td><td class="colsep0 rowsep0" align="left">4-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7p</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7q</b></td><td class="colsep0 rowsep0" align="left">3-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7r</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7s</b></td><td class="colsep0 rowsep0" align="left">3,5-(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7t</b></td><td class="colsep0 rowsep0" align="left">4-F-3-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7u</b></td><td class="colsep0 rowsep0" align="left">3,5-(OCH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">15.38 ± 0.76</td><td class="colsep0 rowsep0" align="left">13.69 ± 0.83</td><td class="colsep0 rowsep0" align="left">16.43 ± 0.92</td><td class="colsep0 rowsep0" align="left">11.44 ± 0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7v</b></td><td class="colsep0 rowsep0" align="left">3-F-4-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7w</b></td><td class="colsep0 rowsep0" align="left">3,5-(F)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7x</b></td><td class="colsep0 rowsep0" align="left">4-CH<sub>3</sub>-3-F</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7y</b></td><td class="colsep0 rowsep0" align="left">3-Cl-4-CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7z</b></td><td class="colsep0 rowsep0" align="left">2-CH<sub>3</sub>-4-Br</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOSO<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">3-Br</td><td class="colsep0 rowsep0" align="left">NOSO<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">3-OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NOSO<sub>2</sub>Ph</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">17.08 ± 0.58</td><td class="colsep0 rowsep0" align="left">16.27 ± 0.62</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>DOX</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.27 ± 0.08</td><td class="colsep0 rowsep0" align="left">0.16 ± 0.17</td><td class="colsep0 rowsep0" align="left">0.074 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.069 ± 0.02</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data are mean ± SD values from three independent experiments.</p></div></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Antitumor Potency of <b>8u</b> in Nude Mice in Vivo</h3><div class="NLM_p">To validate whether IDO1 might present an alternative target for compound <b>8u</b>, a xenograft model was prepared by injecting nude mice with human liver cancer HepG2 cells, followed by administration of two doses of <b>8u</b> once every 2 days. As depicted in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">S4A</a>, intravenous administration of <b>8u</b> at 10 or 20 mg/kg every 3 days for 21 consecutive days led to significant suppression of tumor growth (53.4 and 59.0%), compared to the vehicle group (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Figure S4B</a>). The antitumor effect of <b>8u</b> was additionally evident from the delayed increase in xenograft volume, compared to doxorubicin (DOX) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D). Notably, <b>8u</b> was well tolerated and induced no significant loss of body weight (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Figure S4C</a>), indicating that its antitumor activity does not require T cell involvement. However, we demonstrated in the previous IDO1 assay that <b>8u</b> is a potential IDO1 inhibitor that requires intact T-cell function to suppress tumor outgrowth in wild-type C57BL/6 mice.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> These findings suggested that <b>8u</b>-induced tumor elimination may involve alternative targets. The unique dual action of <b>8u</b> was evidently distinct from that of other known IDO1 inhibitors.</div><div class="NLM_p last">To our knowledge, some IDO1 inhibitors also have potential in vitro antitumor activity. For example, menadione is a known anticancer agent that exhibits low micromolar potency against IDO.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Moreover, Coluccia et al. reported that IDO1 inhibitors <b>5</b> and <b>21</b> induce dose-dependent growth inhibition in the IDO1 expressing cancer cell lines HTC116 and HT29.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> β-lapachone is a naturally occurring 1,2-naphthoquinone-based compound that has advanced into clinical trials, owing to its tumor-selective cytotoxic properties. However, recent studies have shown that IDO1 inhibitory activity is a previously unrecognized attribute of the clinical candidate β-lapachone.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The finding that β-lapachone shows IDO1 inhibitory activity adds a new dimension distinct from its cytotoxic properties in its potential utility as an anticancer agent, and a synergistic benefit may be achieved through its combined cytotoxic and immunologic effects. Another study has suggested that pyranonaphthoquinone-based compounds possess dual IDO1 and topoisomerase II inhibitory activity, thus inhibiting cell growth of human H460 cells.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> Compounds that integrate tumoricidal activity along with IDO1 inhibitory activity may produce substantially more robust single-agent antitumor responses than IDO1 inhibitors that do not exert a cytotoxic effect. Naphthoquinone-based compounds are reported to act as direct small-molecule inhibitors of signal transducer and activator of transcription 3 (STAT3).<a onclick="showRef(event, 'ref39 ref56'); return false;" href="javascript:void(0);" class="ref ref39 ref56">(39,56)</a> Recent studies have identified STAT3 as a modulator of tumor-induced immune suppression at many levels in the tumor microenvironment.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Furthermore, PD-L1 expression in cancer cells is mediated through the STAT3 pathway.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a> Since STAT3 mediates processes of carcinogenesis, such as tumor cell proliferation and survival, angiogenesis, and invasion, the STAT3 pathway may present a direct link between traditional oncogenesis and immune suppression. Many studies have reported constitutive expression of IDO1 and STAT3 in the four tested cancer cell lines, except for IDO1 in HepG2 cells.<a onclick="showRef(event, 'ref12 ref14 ref20 ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref12 ref14 ref20 ref60 ref61 ref62">(12,14,20,60−62)</a> The novel compound <b>8u</b> appears to regulate both IDO1 and STAT3 to disrupt the tumor microenvironment, inducing a potent synergistic antitumor effect. If so, this bifunctional inhibitor exerting both immunomodulatory and conventional chemotherapy effects via IDO1 inhibition may hold promise for cancers that respond poorly to conventional chemotherapeutics. The potent immune-chemotherapeutic effects of <b>8u</b> prompted us to hypothesize that STAT3 may also be a potential target of <b>8u</b>.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Compound <b>8u</b> Targets STAT3</h3><div class="NLM_p">To confirm our theory, STAT3 expression was detected via western blotting. Aberrant activation of STAT3 is known to contribute to malignant transformation and tumorigenesis, and its activity is ultimately dependent on the phosphorylation of Y705.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Treatment of SKOV3 cells with different concentrations of <b>8u</b> resulted in a significant decrease in phosphorylated STAT3 (p-STAT3) levels (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Specifically, the p-STAT3 (Y705) level was reduced in a dose-dependent manner while levels of p-STAT3 (S727) were not influenced by <b>8u</b> and total STAT3 expression remained unchanged (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). We further investigated the levels of other STAT proteins, including STAT1 and STAT5. Pretreatment with compound <b>8u</b> had no effect on the levels of other pSTAT proteins, as evident from western blot analyses (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). Subsequently, inhibition of STAT3 activation by <b>8u</b> was evaluated using a dual luciferase assay. We observed a reduction in luciferase expression in SKOV3 cells treated with <b>8u</b> but no changes in STAT1 and STAT5 transcriptional activity (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Figure S5</a>).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>8u</b> targeted STAT3. (A) Western blot analysis of p-STAT3(Y705), p-STAT3(S727), and total STAT3 after treatment of SKOV3 cells with <b>8u</b> at the indicated concentrations and for the indicated times. (B) Western blots of STAT1 and STAT5 from whole-cell lysates from cells were treated with <b>8u</b>. β-actin antibody was used as reference control. (C) Effects of compound <b>8u</b> (0.5 μM) on the nuclear translocation of the p-STAT3 protein induced by cytokine IL-6. After serum-free overnight treatment, SKOV3 cells were pretreated with <b>8u</b> for 8 h, followed by IL-6 (50 ng/mL) for 30 min, and then processed for STAT3 nuclear translocation detection by immunofluorescence staining. (D) SPR analysis of compound <b>8u</b> with STAT3 protein. The equilibrium dissociation constant (KD) value is 0.53 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Mechanistically, STAT3 nuclear translocation was examined via immunofluorescence staining. To this end, SKOV3 cells were treated for 6 h with 0.5 μM <b>8u</b>, followed by stimulation of STAT3 translocation by adding IL-6 for 30 min. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C, in SKOV3 cells treated with IL-6, intense nuclear fluorescence was observed, indicative of nuclear translocation of p-STAT3. Nuclear translocation of STAT3 in <b>8u</b>-treated cells was clearly inhibited relative to that in IL-6–stimulated cells. Based on these results, we suggest that inhibition of STAT3 phosphorylation by <b>8u</b> may have impaired its transcriptional activity by blocking nuclear translocation.</div><div class="NLM_p">The SPR binding assay was performed to further examine direct binding between <b>8u</b> and STAT3. In the BIAcore sensorgram, resonance curves exhibited strong binding patterns between the two molecules in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). The kinetic parameter, dissociation constant (<i>K</i><sub>D</sub>), determined using BIAcore evaluation software, was 0.53 μM, indicative of a high binding affinity.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Our collective data supported the hypothesis that <b>8u</b> specifically binds STAT3 protein with high affinity, thus indicating that STAT3 was also the potential target of <b>8u</b>.</div><div class="NLM_p">To further support the favorable in vitro and in vivo data of <b>8u</b> and to confirm that the 2-amino-1,4-naphthoquinone derivatives are bifunctional inhibitors, we detected the <i>K</i><sub>D</sub> values of selected compounds toward STAT3 (<b>8b</b>–<b>8f</b>, <b>8h</b>, <b>8q</b>, <b>8s</b>, and <b>7u</b>) using SPR assays (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">Table S2</a>). The 3-trifluoromethyl and 4-trifluoromethyl derivatives <b>8b</b> and <b>8c</b> both effectively bound STAT3 with an IC<sub>50</sub> value of 0.99 and 0.64 μM, respectively, and were only 1- to 2-fold less active than <b>8u</b>. Compound <b>7u</b>, in contrast, was 100-fold less active than <b>8u</b>, thus indicating that <b>8u</b> was the best compound, exhibiting the highest binding affinity toward STAT3 among these derivatives.</div><div class="NLM_p">We next evaluated the comparative antitumor efficacy of <b>8u</b> and the combination of 1-MT and stattic (STAT3 inhibitor) using the B16-F10 tumor-bearing C57BL/6 mice model (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B). The efficacy data showed that stattic at a dose of 50 mg/kg had a reduced tumor volume and burden during the treatment period with tumor growth inhibition of 59.3% (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). Treatment of tumor-bearing mice with the combination of 1-MT and stattic was slightly more effective at inhibiting tumor progression compared to <b>8u</b> alone. Normal increase of body weight was observed for all mice (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>E), indicating that <b>8u</b> efficiently suppressed tumor growth in mice without obvious side effects.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparative antitumor potency of <b>8u</b> and the combination of 1-MT and stattic in vivo in a B16-F10 tumor-challenged C57BL/6 mice model. (A) Representative images in B16-F10 bearing mice. (B) Representative photos of the tumors at the end of treatment. (C) Average weight of the tumors excised at the end of treatment. (D) Changes in tumor volume in different treatment groups measured every 2 days. (E) Changes in body weight in different treatment groups measured every 2 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52238" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52238" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have presented a novel example of organic compounds as multimodal anticancer agents that perform dual targeting of IDO1 and STAT3, inducing greater resistance to immune tolerance of the tumor microenvironment. SAR analyses facilitated the identification of the main pharmacophore groups of this new class of bifunctional inhibitors, among which derivative <b>8u</b> was determined as the most active compound. Our SPR analysis provided evidence for the strong binding affinity of <b>8u</b> toward IDO1 and STAT3. The quinone oxime core was critical for IDO1 inhibition, and the oxime oxygen acted as the iron-binding group. Remarkably, compound <b>8u</b> reduced tumor growth to a significant extent in both immunocompetent and nude mice, signifying dual anticancer and immunomodulatory activity. As elevated STAT3 is a common denominator of immune dysfunction in multiple cancer types, our novel bifunctional small-molecule immune modulator compound <b>8u</b> provides an effective cutting-edge immunochemotherapeutic agent for cancers that fail to respond to currently available immune checkpoint inhibitors by simultaneously disabling immune checkpoints and counteracting STAT3-mediated signaling pathways.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Information</h3><div class="NLM_p last">Compound <b>3</b> was synthesized according to the literature.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> All reagents were purchased from commercial sources and were used without further purification unless otherwise noted. Melting points were recorded on a WRS-IA apparatus without correction. Nuclear magnetic resonance (NMR) spectra were recorded in DMSO-<i>d</i><sub>6</sub> on Bruker Advance (500 or 400 MHz) with tetramethylsilane (TMS) as an internal standard. HRMS was measured in FTMS EI or electrospray ionization (ESI) mode, and the mass analyzer of the HRMS was time-of-flight (TOF). Flash column chromatography was performed on silica gel (200–300 mesh). All of the compounds submitted for biological studies were at least of 95% purity by reverse-phase high-performance liquid chromatography (RP-HPLC) on ODS column (250 mm × 4.6 mm, 5 μm) with an eluent of methanol/water (80:20, V/V).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Procedure for the Preparation of Compounds <b>7</b> and <b>8</b></h3><div class="NLM_p">Compound <b>3</b> (1 mmol) was added to dry CH<sub>2</sub>Cl<sub>2</sub> (15 mL) and stirred at 0 °C. Subsequently, oxalyl chloride (1.5 mmol) was dripped into the mixture and stirred at room temperature for 6 h. After the reaction, the solvent and excess oxalyl chloride were evaporated under reduced pressure. Aromatic primary amines (1 mmol) and triethylamine (0.5 mmol) were added to the mixture and stirred at room temperature for 0.5 h. After the reaction, the solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica gel eluted with petroleum ether/ethyl acetate (V/V = 6:1), thus yielding compound <b>4</b>. Compound <b>4</b> (1 mmol) and hydrazine hydrate (3 mmol) were added to ethanol (15 mL), and the mixture was stirred at room temperature for 8 h. After the reaction was completed, the solvent was evaporated under reduced pressure, and the crude product was purified with chromatography on silica gel and eluted with petroleum ether/ethyl acetate (V/V = 3:1) to obtain compound <b>5</b>. Compound <b>5</b> (2 mmol) and 1,4-naphthoquinone (3 mmol) were added to the mixture containing triethylamine (1 mmol) and stirred at room temperature for 18 h. After the reaction, the solvent was evaporated under reduced pressure and the crude product was purified by chromatography on silica gel and eluted with petroleum ether/ethyl acetate (V/V = 4:1), thus yielding compounds <b>7a</b>–<b>7z</b>. The structures were confirmed by <sup>1</sup>H NMR, <sup>13</sup>C NMR, and HR-MS.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>,3-diphenylpropanamide (<b>7a</b>)</h4><div class="NLM_p last">Yield: 70.2%, yellow solid, mp 101.7–103.2 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −40 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (s, 1H, NH), 8.00–7.95 (m, 1H, NH), 7.90 (dd, <i>J</i> = 7.6, 0.7 Hz, 1H, ArH), 7.79 (td, <i>J</i> = 7.5, 1.2 Hz, 1H, ArH), 7.71 (td, <i>J</i> = 7.5, 1.2 Hz, 1H, ArH), 7.55 (d, <i>J</i> = 7.7 Hz, 2H, ArH), 7.36–7.29 (m, 4H, ArH), 7.26 (t, <i>J</i> = 7.4 Hz, 2H, ArH), 7.19 (d, <i>J</i> = 7.6 Hz, 2H, ArH), 7.08 (t, <i>J</i> = 7.4 Hz, 1H, ArH), 5.70 (s, 1H, C═CH), 4.45 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.27 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.82, 181.00, 168.55, 147.50, 138.24, 136.92, 134.91, 132.68, 132.46, 130.19, 130.19, 129.24, 128.80, 128.80, 128.28,128.28, 126.68, 125.98, 125.37, 123.91, 119.74, 119.74,100.99, 57.55, 37.19. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 397.1547; found: 397. 1531. Purity: 97.66%.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(3-(trifluoromethyl)phenyl)propanamide (<b>7b</b>)</h4><div class="NLM_p last">Yield: 46.5%, yellow solid, mp 163.1–164.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −29 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.47 (s, 1H, NH), 8.02–7.96 (m, 2H, NH, ArH), 7.89 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, ArH), 7.83–7.76 (m, 2H, ArH), 7.71 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.57 (t, <i>J</i> = 8.0 Hz, 1H, ArH), 7.44 (d, <i>J</i> = 7.8 Hz, 1H, ArH), 7.34–7.29 (m, 2H, ArH), 7.26 (dd, <i>J</i> = 8.1, 6.7 Hz, 3H, ArH), 7.19 (ddd, <i>J</i> = 7.1, 3.8, 1.3 Hz, 1H, ArH), 5.69 (s, 1H, C═CH), 4.47 (dd, <i>J</i> = 14.8, 7.1 Hz, 1H, CH), 3.30 (d, <i>J</i> = 6.9 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.88, 180.99, 169.21, 147.63, 139.03, 136.91, 134.94, 132.67, 132.53, 130.21, 130.14, 129.24, 129.24, 128.32, 128.32, 126.73, 126.01, 125.39, 123.29, 120.28, 120.25, 115.81, 115.77, 101.07, 57.66, 37.01. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>19</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup>: 465.1421; found: 465.1401. Purity: 99.38%.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(4-(trifluoromethyl)phenyl)propanamide (<b>7c</b>)</h4><div class="NLM_p last">Yield: 45.8%, yellow solid, mp 212.7–213.7 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −32 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H, NH), 7.98 (d, <i>J</i> = 6.9 Hz, 1H, NH), 7.92–7.86 (m, 1H, ArH), 7.80 (ddd, <i>J</i> = 8.6, 6.7, 2.8 Hz, 3H, ArH), 7.74–7.67 (m, 3H, ArH), 7.35–7.24 (m, 5H, ArH), 7.18 (t, <i>J</i> = 7.1 Hz, 1H, ArH), 5.70 (s, 1H, C═CH), 4.49 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.30 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.84, 180.98, 169.27, 147.57, 141.82, 136.83, 134.92, 132.65, 132.50, 130.19, 129.23, 129.23, 128.30, 128.30, 126.72, 126.16, 126.12, 126.00, 125.37, 123.75, 122.93, 119.61, 119.61, 101.06, 57.65, 37.01. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>19</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup>: 487.1240; found: 487.1223. Purity: 96.05%.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(2-fluorophenyl)-3-phenylpropanamide (<b>7d</b>)</h4><div class="NLM_p last">Yield: 70.2%, yellow solid, mp 182.5–183.9 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −36 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.06 (s, 1H, NH), 7.97 (d, <i>J</i> = 7.4 Hz, 1H, NH), 7.90 (d, <i>J</i> = 6.9 Hz, 1H, ArH), 7.83–7.76 (m, 2H, ArH), 7.72 (td, <i>J</i> = 7.5, 1.1 Hz, 1H, ArH), 7.34 (d, <i>J</i> = 7.2 Hz, 2H, ArH), 7.27 (dd, <i>J</i> = 13.5, 6.0 Hz, 4H, ArH), 7.22–7.15 (m, 3H, ArH), 5.73 (s, 1H, C═CH), 4.63 (dd, <i>J</i> = 14.0, 8.0 Hz, 1H, CH), 3.28 (t, <i>J</i> = 6.2 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.86, 181.03, 169.21, 155.17, 152.73, 147.59, 136.93, 134.96, 132.67, 132.52, 130.21, 129.30, 129.30, 128.38, 128.28, 126.69, 126.01, 125.39, 124.53, 124.47, 115.75, 115.56, 101.09, 57.17, 37.18. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 415.1452; found: 415.1437. Purity: 98.24%.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(3-fluorophenyl)-3-phenylpropanamide (<b>7e</b>)</h4><div class="NLM_p last">Yield: 61.4%, yellow solid, mp 126.9–128.7 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −38 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.42 (s, 1H, NH), 7.97 (d, <i>J</i> = 7.5 Hz, 1H, NH), 7.91–7.85 (m, 1H, ArH), 7.85–7.77 (m, 1H, ArH), 7.72 (td, <i>J</i> = 7.5, 1.2 Hz, 1H, ArH), 7.54 (dd, <i>J</i> = 11.5, 1.9 Hz, 1H, ArH), 7.38–7.24 (m, 7H, ArH), 7.18 (t, <i>J</i> = 7.1 Hz, 1H, ArH), 6.92 (td, <i>J</i> = 8.4, 2.3 Hz, 1H, ArH), 5.67 (s, 1H, C═CH), 4.44 (dd, <i>J</i> = 14.7, 7.0 Hz, 1H, CH), 3.27 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.99, 181.08, 169.10, 163.37, 160.97, 147.70, 140.09, 139.99, 136.97, 135.08, 132.72, 132.66, 130.70, 130.28, 129.34, 128.42, 126.83, 126.13, 125.49, 115.51, 110.63, 106.67, 101.08, 57.69, 37.10. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 415.1452; found: 415.1437. Purity: 96.84%.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(4-fluorophenyl)-3-phenylpropanamide (<b>7f</b>)</h4><div class="NLM_p last">Yield: 76.6%, yellow solid, mp 192.4–194.2 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −33 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.22 (s, 1H, NH), 7.97 (dd, <i>J</i> = 7.6, 1.1 Hz, 1H, NH), 7.89 (dd, <i>J</i> = 7.6, 1.1 Hz, 1H, ArH), 7.80 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.74–7.69 (m, 1H, ArH), 7.59–7.53 (m, 2H, ArH), 7.33–7.22 (m, 5H, ArH), 7.21–7.13 (m, 3H, ArH), 5.69 (s, 1H, C═CH), 4.43 (dd, <i>J</i> = 14.8, 7.0 Hz, 1H, CH), 3.27 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.83, 181.00, 168.50, 159.57, 157.18, 147.56, 136.96, 134.93, 132.68, 132.49, 130.20, 129.25, 129.25, 128.30, 128.30, 126.69, 126.00, 125.38, 121.64, 121.56, 115.53, 115.31, 100.98, 57.53, 37.13. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 415.1452; found: 415.1436. Purity: 98.52%.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(2-Chlorophenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7g</b>)</h4><div class="NLM_p last">Yield: 71.8%, yellow solid, mp 187.9–189.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −42 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.88 (s, 1H, NH), 8.00–7.95 (m, 1H, NH), 7.91 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, ArH), 7.80 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.72 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.59 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H, ArH), 7.49 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H, ArH), 7.36 (t, <i>J</i> = 5.6 Hz, 2H, ArH), 7.33–7.26 (m, 4H, ArH), 7.25–7.18 (m, 2H, ArH), 5.81 (s, 1H, C═CH), 4.64 (dd, <i>J</i> = 14.1, 7.9 Hz, 1H, CH), 3.34–3.26 (m, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.86, 181.03, 169.19, 147.57, 136.94, 134.92, 134.11, 132.66, 132.50, 130.20, 129.55, 129.32, 129.32, 128.32, 128.32, 127.50, 127.11, 126.96, 126.71, 126.53, 125.98, 125.38, 101.41, 57.25, 37.14. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 431.1157; found: 431.1142. Purity: 96.43%.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-(3-Chlorophenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7h</b>)</h4><div class="NLM_p last">Yield: 63.3%, yellow solid, mp 193.0–194.2 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −39 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (s, 1H, NH), 7.97 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, NH), 7.89 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, ArH), 7.80 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.75 (t, <i>J</i> = 2.0 Hz, 1H, ArH), 7.72 (td, <i>J</i> = 7.5, 1.4 Hz, 1H, ArH), 7.44 (ddd, <i>J</i> = 8.2, 1.9, 1.0 Hz, 1H, ArH), 7.38–7.31 (m, 2H, ArH), 7.31–7.24 (m, 4H, ArH), 7.21–7.12 (m, 2H, ArH), 5.69 (s, 1H, C═CH), 4.44 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.28 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.85, 180.97, 168.99, 147.58, 139.68, 136.88, 134.92, 133.11, 132.65, 132.50, 130.54, 130.20, 129.23, 129.23, 128.30, 128.30, 126.71, 126.00, 125.38, 123.62, 119.17, 118.07, 101.04, 57.63, 37.02. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 431.1157; found: 431.1143. Purity: 97.75%.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(4-Chlorophenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7i</b>)</h4><div class="NLM_p last">Yield: 71.3%, yellow solid, mp 196.1–197.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −38 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.29 (s, 1H, NH), 7.96 (d, <i>J</i> = 7.5 Hz, 1H, NH), 7.89 (d, <i>J</i> = 6.9 Hz, 1H, ArH), 7.79 (dd, <i>J</i> = 10.8, 4.1 Hz, 1H, ArH), 7.71 (t, <i>J</i> = 7.5 Hz, 1H, ArH), 7.59 (d, <i>J</i> = 8.9 Hz, 2H, ArH), 7.37 (d, <i>J</i> = 8.8 Hz, 2H, ArH), 7.31 (d, <i>J</i> = 7.0 Hz, 2H, ArH), 7.25 (dd, <i>J</i> = 12.7, 5.0 Hz, 3H, ArH), 7.18 (t, <i>J</i> = 7.1 Hz, 1H, ArH), 5.69 (s, 1H, C═CH), 4.44 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.27 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.84, 180.98, 168.76, 147.55, 137.20, 136.91, 134.91, 132.66, 132.48, 130.19, 129.24, 129.24, 128.74, 128.74, 128.30, 128.30, 127.54, 126.71, 125.99, 125.38, 121.28, 121.28, 101.01, 57.59, 37.09. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>19</sub>ClN<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup>: 453.0976; found: 453.0958. Purity: 98.24%.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(2-Bromophenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7j</b>)</h4><div class="NLM_p last">Yield: 75.3%, yellow solid, mp 182.4–183.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −55 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.85 (s, 1H, NH), 7.98 (dd, <i>J</i> = 7.6, 1.1 Hz, 1H, NH), 7.91 (dd, <i>J</i> = 7.6, 1.1 Hz, 1H, ArH), 7.82 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.76–7.71 (m, 1H, ArH), 7.66 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H, ArH), 7.51 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H, ArH), 7.40–7.35 (m, 3H, ArH), 7.32–7.25 (m, 3H, ArH), 7.23–7.19 (m, 1H, ArH), 7.20–7.14 (m, 1H, ArH), 5.81 (s, 1H, C═CH), 4.60 (dd, <i>J</i> = 14.3, 7.7 Hz, 1H, CH), 3.31 (s, 1H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.85, 181.02, 169.08, 147.58, 136.99, 135.45, 134.94, 132.73, 132.66, 132.52, 130.20, 129.30, 129.30, 128.33, 128.33, 128.11, 127.58, 127.23, 126.70, 125.99, 125.38, 118.15, 101.47, 57.28, 37.05. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>BrN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 475.0652; found: 475.0632. Purity: 98.13%.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(3-Bromophenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7k</b>)</h4><div class="NLM_p last">Yield: 66.9%, yellow solid, mp 186.3–187.7 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −57 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H, NH), 7.98 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, NH), 7.90 (dd, <i>J</i> = 8.8, 1.3 Hz, 2H, ArH), 7.81 (td, <i>J</i> = 7.5, 1.4 Hz, 1H, ArH), 7.72 (td, <i>J</i> = 7.5, 1.4 Hz, 1H, ArH), 7.49 (dt, <i>J</i> = 7.1, 2.2 Hz, 1H, ArH), 7.32–7.30 (m, 2H, ArH), 7.29–7.24 (m, 4H, ArH), 7.19 (ddd, <i>J</i> = 7.1, 3.9, 1.4 Hz, 1H, ArH), 5.68 (s, 1H, C═CH), 4.44 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.28 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.84, 180.97, 168.95, 147.58, 139.81, 136.88, 134.93, 132.65, 132.51, 130.84, 130.19, 129.22, 129.22, 128.30, 128.30, 126.70, 126.51, 126.00, 125.38, 122.02, 121.53, 118.45, 101.03, 57.62, 37.00. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>BrN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 475.0652; found: 475.0632. Purity: 98.78%.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-(4-Bromophenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7l</b>)</h4><div class="NLM_p last">Yield: 68.5%, yellow solid, mp 210.8–212.1 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −46 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.27 (s, 1H, NH), 7.98 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, NH), 7.89 (dt, <i>J</i> = 8.7, 4.4 Hz, 1H, ArH), 7.81 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.73 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.52 (d, <i>J</i> = 2.1 Hz, 3H, ArH), 7.30 (dd, <i>J</i> = 10.4, 3.6 Hz, 2H, ArH), 7.27–7.16 (m, 3H, ArH), 5.68 (s, 1H, C═CH), 4.44 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.27 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.82, 180.99, 168.75, 147.57, 137.60, 136.89, 134.94, 132.66, 132.51, 131.65, 131.65, 130.20, 129.23, 129.23, 128.29, 128.29, 126.69, 126.01, 125.38, 121.64, 121.64, 115.56, 100.98, 57.59, 37.05. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>BrN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 475.0652; found: 475.0628. Purity: 98.87%.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(2-methoxyphenyl)-3-phenylpropanamide (<b>7m</b>)</h4><div class="NLM_p last">Yield: 72.9%, yellow solid, mp 131.8–133.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −52 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.54 (s, 1H, NH), 7.96 (d, <i>J</i> = 7.0 Hz, 1H, NH), 7.93–7.82 (m, 2H, ArH), 7.79 (td, <i>J</i> = 7.5, 1.0 Hz, 1H, ArH), 7.70 (td, <i>J</i> = 7.5, 1.1 Hz, 1H, ArH), 7.34 (d, <i>J</i> = 7.3 Hz, 2H, ArH), 7.30–7.17 (m, 4H, ArH), 7.09 (dd, <i>J</i> = 11.3, 4.2 Hz, 1H, ArH), 7.03 (d, <i>J</i> = 7.2 Hz, 1H, ArH), 6.96–6.88 (m, 1H ArH,), 5.79 (s, 1H, C═CH), 4.73 (dd, <i>J</i> = 14.0, 8.0 Hz, 1H, CH), 3.87–3.67 (m, 3H, CH<sub>3</sub>), 3.25 (t, <i>J</i> = 6.1 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.84, 181.07, 168.87, 150.05, 147.47, 137.02, 134.91, 132.68, 132.44, 130.16, 129.31, 129.31, 128.22, 128.22, 126.60, 126.45, 125.96, 125.36, 125.13, 122.37, 120.27, 111.36, 101.26, 57.16, 55.77, 37.31. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 427.1652; found: 427.1638. Purity: 95.15%.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(3-methoxyphenyl)-3-phenylpropanamide (<b>7n</b>)</h4><div class="NLM_p last">Yield: 68.9%, yellow solid, mp 115.3∼116.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −50 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (s, 1H, NH), 7.96 (dd, <i>J</i> = 7.7, 1.1 Hz, 1H, NH), 7.89 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, ArH), 7.78 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.70 (td, <i>J</i> = 7.5, 1.4 Hz, 1H, ArH), 7.34–7.30 (m, 2H, ArH), 7.29–7.17 (m, 6H ArH,), 7.14–7.10 (m, 1H, ArH), 6.66 (ddd, <i>J</i> = 8.2, 2.5, 0.7 Hz, 1H, ArH), 5.69 (s, 1H, C═CH), 4.44 (dd, <i>J</i> = 14.8, 7.1 Hz, 1H, CH), 3.38 (s, 3H, CH<sub>3</sub>), 3.27 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.81, 180.98, 168.61, 159.52, 147.50, 139.44, 136.95, 134.89, 132.66, 132.44, 130.17, 129.63, 129.24, 128.28, 126.67, 125.97, 125.36, 111.90, 109.36, 105.43, 100.98, 57.61, 55.00, 37.16. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 427.1652; found: 427.1637. Purity: 98.71%.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(4-methoxyphenyl)-3-phenylpropanamide (<b>7o</b>)</h4><div class="NLM_p last">Yield: 78.9%, yellow solid, mp 149.8–151.7 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −45 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.06 (s, 1H, NH), 7.94 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, NH), 7.88 (dd, <i>J</i> = 7.6, 0.9 Hz, 1H, ArH), 7.76 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.68 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.47–7.42 (m, 2H, ArH), 7.30 (dd, <i>J</i> = 12.3, 5.4 Hz, 2H, ArH), 7.26 (t, <i>J</i> = 7.4 Hz, 2H, ArH), 7.21–7.15 (m, 2H, ArH), 6.92–6.86 (m, 2H, ArH), 5.70 (s, 1H, C═CH), 4.42 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.70 (d, <i>J</i> = 3.7 Hz, 3H, CH<sub>3</sub>), 3.26 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.88, 181.03, 168.11, 155.77, 147.51, 137.00, 134.92, 132.73, 132.47, 131.33, 130.21, 129.31, 129.31, 128.33, 128.33, 126.73, 126.01, 125.41, 121.44, 121.44, 113.98, 113.98, 101.00, 57.50, 55.21, 37.31. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 427.1652; found: 427.1637. Purity: 98.91%.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(<i>o</i>-tolyl)propanamide (<b>7p</b>)</h4><div class="NLM_p last">Yield: 70.5%, yellow solid, mp 119.5–120.7 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −61 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.54 (s, 1H, NH), 7.98 (d, <i>J</i> = 7.1 Hz, 1H, NH), 7.90 (d, <i>J</i> = 7.0 Hz, 1H, ArH), 7.86–7.78 (m, 2H, ArH), 7.72 (td, <i>J</i> = 7.6, 1.1 Hz, 1H, ArH), 7.34 (d, <i>J</i> = 7.3 Hz, 2H, ArH), 7.26 (dd, <i>J</i> = 15.8, 8.0 Hz, 3H, ArH), 7.18 (t, <i>J</i> = 7.2 Hz, 1H, ArH), 7.14–7.07 (m, 1H, ArH), 7.04 (d, <i>J</i> = 7.3 Hz, 1H, ArH), 6.91 (t, <i>J</i> = 7.6 Hz, 1H, ArH), 5.76 (d, <i>J</i> = 9.3 Hz, 1H, C═CH), 4.72 (dd, <i>J</i> = 13.9, 8.1 Hz, 1H, CH), 3.81 (d, <i>J</i> = 4.0 Hz, 3H, CH<sub>3</sub>), 3.32–3.18 (m, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.85, 181.09, 168.88, 150.05, 147.51, 137.05, 134.97, 132.68, 132.50, 130.18, 129.32, 129.32, 128.23, 128.23, 126.61, 126.42, 126.00, 125.37, 125.15, 122.39, 120.28, 111.37, 101.22, 57.15, 55.78, 37.27. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup>: 433.1523; found: 433.150. Purity: 99.77%.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(<i>m</i>-tolyl)propanamide (<b>7q</b>)</h4><div class="NLM_p last">Yield: 60.2%, yellow solid, mp 147.5–149.0 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −59 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.12 (s, 1H, NH), 7.98–7.92 (m, 1H, NH), 7.88 (d, <i>J</i> = 7.0 Hz, 1H, ArH), 7.76 (td, <i>J</i> = 7.5, 1.1 Hz, 1H, ArH), 7.67 (td, <i>J</i> = 7.5, 1.1 Hz, 1H, ArH), 7.43–7.36 (m, 2H, ArH), 7.33 (d, <i>J</i> = 7.2 Hz, 2H, ArH), 7.30–7.16 (m, 5H, ArH), 6.89 (d, <i>J</i> = 7.5 Hz, 1H, ArH), 5.70 (s, 1H, C═CH), 4.45 (dd, <i>J</i> = 14.4, 7.3 Hz, 1H, CH), 3.28 (d, <i>J</i> = 6.0 Hz, 2H, CH<sub>2</sub>), 2.26 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.82, 180.99, 168.53, 147.52, 138.22, 138.06, 137.00, 134.87, 132.68, 132.42, 130.17, 129.27, 129.27, 128.66, 128.30, 128.30, 126.69, 125.96, 125.37, 124.59, 120.22, 116.88, 101.01, 57.65, 37.21, 21.12. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub> [M + H] <sup>+</sup>: 411.1703; found: 411.1688. Purity: 98.92%.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(<i>p</i>-tolyl)propanamide (<b>7r</b>)</h4><div class="NLM_p last">Yield: 70.5%, yellow solid, mp 97.2–99.1 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −54 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.10 (s, 1H, NH), 7.94 (dd, <i>J</i> = 7.6, 0.9 Hz, 1H, NH), 7.88 (dd, <i>J</i> = 7.6, 0.8 Hz, 1H, ArH), 7.76 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.67 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.45 (d, <i>J</i> = 8.4 Hz, 2H, ArH), 7.32 (d, <i>J</i> = 7.1 Hz, 2H, ArH), 7.26 (t, <i>J</i> = 7.5 Hz, 2H, ArH), 7.18 (dt, <i>J</i> = 9.6, 6.5 Hz, 2H, ArH), 7.11 (d, <i>J</i> = 8.3 Hz, 2H, ArH), 5.70 (s, 1H,C═CH), 4.44 (dd, <i>J</i> = 14.7, 7.1 Hz, 1H, CH), 3.27 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>), 2.23 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.79, 180.96, 168.31, 147.46, 136.97, 135.73, 134.84, 132.90, 132.67, 132.39, 130.16, 129.25, 129.25, 129.16, 129.16, 128.27, 128.27, 126.66, 125.94, 125.34, 119.75, 119.75, 100.97, 57.54, 37.25, 20.44. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup>: 433.1523; found: 433.1505. Purity: 99.46%.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(3,5-Dimethylphenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7s</b>)</h4><div class="NLM_p last">Yield: 63.7%, yellow solid, mp 122.0–123.8 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −48 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.03 (s, 1H, NH), 7.96 (dd, <i>J</i> = 7.6, 0.9 Hz, 1H, NH), 7.89 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, ArH), 7.79 (td, <i>J</i> = 7.5, 1.2 Hz, 1H, ArH), 7.70 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.34–7.30 (m, 2H, ArH), 7.27 (t, <i>J</i> = 7.5 Hz, 2H, ArH), 7.20 (q, <i>J</i> = 7.7 Hz, 4H, ArH), 6.71 (s, 1H, ArH), 5.68 (s, 1H, C═CH), 4.42 (dd, <i>J</i> = 14.2, 7.6 Hz, 1H, CH), 3.30–3.17 (m, 2H, CH<sub>2</sub>), 2.22 (s, 6H, 2CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.80, 180.99, 168.43, 147.53, 138.14, 137.81, 137.81, 137.01, 134.90, 132.67, 132.45, 130.18, 130.18, 129.24, 129.24, 128.29, 128.29, 126.66, 125.97, 125.37, 125.37, 117.40, 100.97, 57.66, 37.17, 21.02, 21.02. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>27</sub>H<sub>25</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 425.1860; found: 425.1843. Purity: 98.52%.</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(4-Bromo-3-fluorophenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7t</b>)</h4><div class="NLM_p last">Yield: 69.9%, yellow solid, mp 242.5–244.2 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −39 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.45 (s, 1H, NH), 7.96 (dd, J = 7.6, 1.0 Hz, 1H, NH), 7.89 (dd, J = 7.6, 1.0 Hz, 1H, ArH), 7.79 (td, J = 7.5, 1.3 Hz, 1H, ArH), 7.71 (ddd, J = 9.4, 5.8, 1.7 Hz, 2H, ArH), 7.64 (t, J = 8.4 Hz, 1H, ArH), 7.29 (ddd, J = 18.4, 11.7, 4.6 Hz, 6H, ArH), 7.21–7.15 (m, 1H, ArH), 5.68 (s, 1H, C═CH), 4.45 (q, J = 7.0 Hz, 1H, CH), 3.28 (d, J = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.83, 180.94, 169.15, 159.21, 156.79, 147.57, 139.45, 136.84, 134.90, 133.43, 132.62, 132.48, 130.17, 129.21, 129.21, 128.29, 128.29, 126.71, 125.98, 125.36, 116.99, 116.96, 107.79, 101.05, 57.63, 36.95. HR-MS (m/z) (ESI): calcd for C<sub>25</sub>H<sub>17</sub>BrFN<sub>2</sub>O<sub>3</sub> [M-H]<sup>−</sup>: 491.0412; found: 491.0414. Purity: 97.99%.</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-(3,5-Dimethoxyphenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7u</b>)</h4><div class="NLM_p last">Yield: 73.0%, yellow solid, mp 197.0–198.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −43 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.04 (s, 1H, NH), 7.97 (dd, <i>J</i> = 7.6, 0.9 Hz, 1H, NH), 7.90 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, ArH), 7.81 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.72 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.29 (dt, <i>J</i> = 14.9, 4.6 Hz, 4H, ArH), 7.23–7.16 (m, 3H, ArH), 7.08 (dd, <i>J</i> = 8.7, 2.3 Hz, 1H, ArH), 6.90 (d, <i>J</i> = 8.8 Hz, 1H, ArH), 5.68 (s, 1H, C═CH), 4.41 (dd, <i>J</i> = 14.7, 7.0 Hz, 1H, CH), 3.72 (d, <i>J</i> = 4.7 Hz, 6H, 2CH<sub>3</sub>), 3.26 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.89, 169.77, 160.55, 160.55, 145.26, 140.46, 140.12, 137.17, 133.88, 132.95, 129.23, 129.23, 129.01, 128.45, 128.35, 128.35, 126.68, 125.86, 122.35, 97.89, 97.89, 95.82, 91.41, 57.89, 55.16, 55.16, 37.62. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>27</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 457.1758; found: 457.1740. Purity: 96.71%.</div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(4-Bromo-3-fluorophenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7v</b>)</h4><div class="NLM_p last">Yield: 55.3%, yellow solid, mp 228.9–230.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −36 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.47 (s, 1H, NH), 7.96 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, NH), 7.89 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, ArH), 7.79 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.71 (ddd, <i>J</i> = 8.6, 4.9, 1.9 Hz, 2H, ArH), 7.63 (t, <i>J</i> = 8.4 Hz, 1H, ArH), 7.34–7.22 (m, 6H, ArH), 7.21–7.14 (m, 1H, ArH), 5.68 (s, 1H, C═CH), 4.45 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.28 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.84, 180.95, 169.15, 159.21, 156.80, 147.55, 139.35, 136.81, 134.90, 133.42, 132.63, 132.48, 130.17, 129.22, 129.22, 128.30, 128.30, 126.72, 125.98, 125.37, 116.97, 107.54, 101.07, 57.62, 36.98. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>19</sub>BrFN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 493.0558; found: 493.0592. Purity: 96.68%.</div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(3,5-Difluorophenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7w</b>)</h4><div class="NLM_p last">Yield: 65.8%, yellow solid, mp 171.2–173.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −35 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.50 (s, 1H, NH), 7.98–7.94 (m, 1H, NH), 7.89 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, ArH), 7.78 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.70 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.33–7.24 (m, 7H, ArH), 7.22–7.16 (m, 1H, ArH), 6.96–6.89 (m, 1H, ArH), 5.68 (s, 1H, C═CH), 4.45 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.28 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.88, 180.95, 169.34, 163.56, 161.14, 147.57, 140.74, 136.80, 134.91, 132.63, 132.50, 130.18, 129.23, 129.23, 128.32, 128.32, 126.74, 125.99, 125.38, 102.69, 102.40, 101.12, 99.05, 57.67, 36.94. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>19</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 433.1358; found: 433.1345. Purity: 98.99%.</div></div><div id="sec4_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-((1,4-Dioxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(2-fluoro-4-methylphenyl)-3-phenylpropanamide (<b>7x</b>)</h4><div class="NLM_p last">Yield: 70.5%, yellow solid, mp 158.2–160.7 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −41 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.95 (s, 1H, NH), 7.96 (dd, <i>J</i> = 7.7, 1.0 Hz, 1H, NH), 7.90 (dd, <i>J</i> = 7.7, 1.0 Hz, 1H, ArH), 7.79 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.70 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.60 (t, <i>J</i> = 8.3 Hz, 1H, ArH), 7.39–7.32 (m, 2H, ArH), 7.27 (t, <i>J</i> = 7.5 Hz, 2H, ArH), 7.19 (ddd, <i>J</i> = 7.2, 6.6, 3.4 Hz, 2H, ArH), 7.08 (dd, <i>J</i> = 11.8, 1.1 Hz, 1H, ArH), 6.96 (d, <i>J</i> = 8.1 Hz, 1H, ArH), 5.73 (s, 1H, C═CH), 4.60 (dt, <i>J</i> = 14.0, 7.1 Hz, 1H, CH), 3.34–3.20 (m, 2H, CH<sub>2</sub>), 2.27 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.83, 181.00, 169.03, 155.13, 152.70, 147.51, 136.92, 134.89, 132.67, 132.45, 130.18, 129.29, 129.29, 128.25, 128.25, 126.66, 125.96, 125.36, 124.80, 124.49, 122.55, 122.43, 101.07, 57.11, 37.22, 20.35. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup>: 451.1428; found: 451.1410. Purity: 98.63%.</div></div><div id="sec4_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(3-Chloro-4-methylphenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7y</b>)</h4><div class="NLM_p last">Yield: 71.2%, yellow solid, mp 99.8–101.4 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −70 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.22 (s, 1H, NH), 7.97 (dd, J = 7.6, 0.9 Hz, 1H, NH), 7.89 (dd, J = 7.6, 1.0 Hz, 1H, ArH), 7.80 (td, J = 7.5, 1.3 Hz, 1H, ArH), 7.72 (ddd, J = 8.9, 5.6, 1.3 Hz, 2H, ArH), 7.29 (tdd, J = 16.3, 8.6, 3.7 Hz, 7H, ArH), 7.18 (ddd, J = 7.0, 3.8, 1.4 Hz, 1H, ArH), 5.68 (s, 1H, C═CH), 4.43 (q, J = 7.0 Hz, 1H, CH), 3.27 (d, J = 6.8 Hz, 2H, CH<sub>2</sub>), 2.26 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.80, 180.95, 168.70, 147.56, 137.34, 136.91, 134.90, 132.99, 132.64, 132.47, 131.24, 130.58, 130.18, 129.22, 129.22, 128.28, 128.28, 126.67, 125.97, 125.36, 119.66, 118.30, 100.98, 57.57, 37.03, 18.94. HR-MS (m/z) (ESI): calcd for C<sub>26</sub>H<sub>22</sub>ClN<sub>2</sub>O<sub>3</sub> [M + H] <sup>+</sup>: 445.1313; found: 475.1306. Purity: 98.19%.</div></div><div id="sec4_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-(4-Bromo-2-methylphenyl)-2-((1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>7z</b>)</h4><div class="NLM_p last">Yield: 69.8%, yellow solid, mp 78.5–80.3 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −85 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.66 (s, 1H, NH), 8.18 (d, <i>J</i> = 8.0 Hz, 1H, NH), 8.05 (d, <i>J</i> = 7.3 Hz, 1H, ArH), 7.73–7.64 (m, 1H, ArH), 7.62–7.53 (m, 1H, ArH), 7.41 (d, <i>J</i> = 2.0 Hz, 1H, ArH), 7.32 (dt, <i>J</i> = 14.9, 4.9 Hz, 5H, ArH), 7.27–7.19 (m, 2H, ArH), 6.69 (s, 1H, C═CH), 6.30 (d, <i>J</i> = 7.9 Hz, 1H, ArH), 4.49 (q, <i>J</i> = 7.2 Hz, 1H, CH), 3.28–3.19 (m, 2H, CH<sub>2</sub>), 2.08 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.91, 169.88, 145.28, 140.51, 137.17, 135.14, 134.91, 133.92, 132.94, 132.80, 129.34, 129.34, 129.01, 128.82, 128.48, 128.40, 128.40, 127.06, 126.73, 125.86, 122.38, 117.80, 91.77, 57.44, 37.72, 17.46. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>21</sub>BrN<sub>2</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup>: 511.0628; found: 511.0607. Purity: 97.39%.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> General Procedure for the Preparation of Compounds <b>8</b></h3><div class="NLM_p">To a solution of 1,4-naphthoquinone-2-aminoacylation-substituted anilines (1 mmol) in absolute ethanol (25 mL) was added hydroxylamine hydrochloride (1 mmol). The resulting mixture was refluxed at 80 °C for 12 h. Water (15 mL) was added, and the reaction mixture was extracted with dichloromethane (3 × 20 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The residue was purified by flash chromatography (light petroleum/ethyl acetate, V/V = 4:1) to give compounds <b>8</b> as a yellow-green solid.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>Z</i>)-2-((4-(Hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>,3-diphenylpropanamide (<b>8a</b>)</h4><div class="NLM_p last">Yield: 50.6%, yellow-green solid, mp 230.0–231.2 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −36 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.27 (s, 1H, OH), 8.12 (d, <i>J</i> = 7.9 Hz, 1H, NH), 8.05–7.97 (m, 1H, ArH), 7.70–7.60 (m, 1H, ArH), 7.61–7.52 (m, 1H, ArH), 7.50 (d, <i>J</i> = 7.7 Hz, 2H, ArH), 7.34–7.22 (m, 7H, ArH), 7.18 (td, <i>J</i> = 5.7, 2.5 Hz, 1H, ArH), 7.06 (t, <i>J</i> = 7.4 Hz, 1H, ArH), 6.58 (s, 1H, C═CH), 6.25 (d, <i>J</i> = 8.0 Hz, 1H, NH), 4.35 (dd, <i>J</i> = 13.6, 7.8 Hz, 1H, CH), 3.23–3.12 (m, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 180.44, 170.28, 145.80, 140.88, 138.63, 137.39, 134.21, 133.59, 129.67, 129.67, 129.63, 129.38, 129.38, 128.89, 128.79, 128.79, 127.28, 126.36, 124.56, 122.83, 120.28, 120.28, 91.85, 58.27, 38.02. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 434.1475; found: 434.1469. Purity: 98.13%.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>Z</i>)-2-((4-(Hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(3-(trifluoromethyl)phenyl)propanamide (<b>8b</b>)</h4><div class="NLM_p last">Yield: 38.9%, yellow-green solid, mp 122.2–123.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −26 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (s, 1H, OH), 10.54 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.8 Hz, 1H, NH), 8.10–7.98 (m, 2H, ArH), 7.78 (d, <i>J</i> = 8.3 Hz, 1H, ArH), 7.71–7.64 (m, 1H, ArH), 7.60–7.53 (m, 2H, ArH), 7.43 (d, <i>J</i> = 8.2 Hz, 1H, ArH), 7.35–7.25 (m, 4H, ArH), 7.20 (t, <i>J</i> = 7.0 Hz, 1H, ArH), 6.60 (s, 1H, C═CH), 6.36 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.40 (dd, <i>J</i> = 14.4, 7.1 Hz, 1H, CH), 3.24 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.85, 170.32, 145.23, 140.48, 139.19, 137.08, 133.86, 132.95, 130.16, 129.23, 129.23, 129.01, 128.45, 128.37, 128.37, 126.72, 125.85, 125.42, 123.18, 122.34, 120.18, 115.69, 115.65, 91.42, 57.95, 37.50. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>20</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 502.1349; found: 502.1341. Purity: 95.55%.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>Z</i>)-2-((4-(Hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(4-(trifluoromethyl)phenyl)propanamide (<b>8c</b>)</h4><div class="NLM_p last">Yield: 48.2%, yellow-green solid, mp 197.1–198.7 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −28 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.33 (s, 1H, OH), 10.57 (s, 1H, NH), 8.16 (dd, <i>J</i> = 8.0, 0.6 Hz, 1H, ArH), 8.06 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.78 (d, <i>J</i> = 8.6 Hz, 2H, ArH), 7.67 (dd, <i>J</i> = 11.2, 5.2 Hz, 3H, ArH), 7.60–7.54 (m, 1H, ArH), 7.35–7.24 (m, 4H ArH,), 7.20 (ddd, <i>J</i> = 6.7, 3.9, 1.7 Hz, 1H, ArH), 6.60 (s, 1H, C═CH), 6.36 (d, <i>J</i> = 8.2 Hz, 1H, NH), 4.43 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.24 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.84, 170.34, 145.21, 141.99, 140.42, 136.99, 133.85, 132.93, 129.21, 129.21, 128.99, 128.42, 128.33, 128.33, 126.69, 126.18, 126.14, 125.83, 123.94, 123.62, 122.32, 119.49, 119.49, 91.42, 57.88, 37.46. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>21</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 480.1530; found: 480.1521. Purity: 98.05%.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>Z</i>)-<i>N</i>-(2-Fluorophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8d</b>)</h4><div class="NLM_p last">Yield: 55.3%, yellow-green solid, mp 226.5–228.2 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −33 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.38 (s, 1H, OH), 10.09 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.8 Hz, 1H, ArH), 8.04 (d, <i>J</i> = 7.1 Hz, 1H, ArH), 7.77 (td, <i>J</i> = 7.8, 2.9 Hz, 1H, ArH), 7.70–7.65 (m, 1H, ArH), 7.60–7.53 (m, 1H, ArH), 7.28 (dt, <i>J</i> = 9.5, 4.4 Hz, 5H, ArH), 7.18 (ddd, <i>J</i> = 9.7, 8.9, 3.2 Hz, 3H, ArH), 6.64 (s, 1H, C═CH), 6.33 (d, <i>J</i> = 8.3 Hz, 1H, NH), 4.57 (dd, <i>J</i> = 14.6, 7.1 Hz, 1H, CH), 3.21 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 180.05, 170.36, 155.27, 152.83, 145.41, 140.57, 137.21, 133.99, 133.11, 129.41, 129.41, 129.16, 128.54, 128.45, 128.45, 126.82, 125.97, 125.50, 124.59, 122.48, 115.87, 115.68, 91.65, 57.42, 37.71. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 452.1381; found: 452.1380. Purity: 99.66%.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>Z</i>)-<i>N</i>-(3-Fluorophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8e</b>)</h4><div class="NLM_p last">Yield: 49.9%, yellow-green solid, mp 201.8–203.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −30 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.37 (s, 1H, OH), 10.45 (s, 1H, NH), 8.19–8.14 (m, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 0.8 Hz, 1H, ArH), 7.71–7.63 (m, 1H ArH,), 7.60–7.52 (m, 2H, ArH), 7.36 (dd, <i>J</i> = 11.4, 4.7 Hz, 1H, ArH), 7.33–7.25 (m, 6H, ArH), 7.23–7.16 (m, 1H, ArH), 6.90 (td, <i>J</i> = 8.2, 1.8 Hz, 1H, ArH), 6.60 (s, 1H, C═CH), 6.35 (d, <i>J</i> = 8.2 Hz, 1H, NH), 4.40 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.22 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.89, 170.13, 163.36, 160.96, 145.27, 140.48, 140.23, 140.12, 137.11, 133.89, 132.98, 130.61, 129.26, 129.03, 128.47, 128.39, 126.74, 125.89, 122.37, 115.38, 110.42, 106.55, 91.44, 57.90, 37.55. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>3</sub> Na [M + Na] <sup>+</sup>: 452.1381; found: 452.1377. Purity: 96.24%.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (<i>Z</i>)-<i>N</i>-(4-Fluorophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8f</b>)</h4><div class="NLM_p last">Yield: 56.6%, yellow-green solid, mp 181.7–182.9 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −29 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.36 (s, 1H, OH), 10.35 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.8 Hz, 1H, ArH), 8.05 (d, <i>J</i> = 7.1 Hz, 1H, ArH), 7.74–7.64 (m, 1H, ArH), 7.61–7.51 (m, 4H, ArH), 7.34–7.25 (m, 5H, ArH), 7.17 (dt, <i>J</i> = 17.7, 7.9 Hz, 4H, ArH), 6.61 (s, 1H, C═CH), 6.32 (d, <i>J</i> = 5.4 Hz, 1H, NH), 4.39 (d, <i>J</i> = 4.7 Hz, 1H, CH), 3.22 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.93, 169.64, 159.56, 157.17, 145.30, 140.48, 137.19, 134.88, 134.85, 133.93, 132.96, 129.29, 129.02, 128.49, 128.38, 126.72, 125.89, 122.39, 121.58, 121.50, 115.56, 115.34, 91.43, 57.79, 37.66. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 452.1381; found: 452.1381. Purity: 98.42%.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>Z</i>)-<i>N</i>-(2-Chlorophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8g</b>)</h4><div class="NLM_p last">Yield: 55.9%, yellow-green solid, mp 133.7–134.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −37 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.36 (s, 1H, OH), 9.86 (s, 1H, NH), 8.17 (d, <i>J</i> = 8.0 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H, ArH), 7.71–7.65 (m, 1H, ArH), 7.62 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H, ArH), 7.59–7.54 (m, 1H, ArH), 7.48 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H, ArH), 7.32 (ddd, <i>J</i> = 9.9, 7.3, 5.4 Hz, 5H, ArH), 7.20 (ddd, <i>J</i> = 9.2, 3.5, 1.5 Hz, 2H, ArH), 6.68 (s, 1H, C═CH), 6.39 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.55 (dd, <i>J</i> = 14.5, 7.1 Hz, 1H, CH), 3.27 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.92, 170.18, 145.28, 140.51, 137.21, 134.30, 133.92, 132.97, 129.57, 129.33, 129.33, 129.03, 128.47, 128.39, 128.39, 127.54, 126.96, 126.83, 126.72, 126.29, 125.86, 122.38, 91.89, 57.52, 37.54. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>21</sub>ClN<sub>3</sub>O<sub>3</sub> Na [M + H]<sup>+</sup>: 446.1266; found: 446.1267. Purity: 95.24%.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>Z</i>)-<i>N</i>-(3-Chlorophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8h</b>)</h4><div class="NLM_p last">Yield: 48.6%, yellow-green solid, mp 160.2–161.9 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −35 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.36 (s, 1H, OH), 10.42 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.9 Hz, 1H, ArH), 8.05 (d, <i>J</i> = 7.6 Hz, 1H, ArH), 7.75 (s, 1H, ArH), 7.67 (dd, <i>J</i> = 11.2, 4.0 Hz, 1H, ArH), 7.57 (t, <i>J</i> = 7.3 Hz, 1H, ArH), 7.43 (d, <i>J</i> = 8.5 Hz, 1H, ArH), 7.37–7.25 (m, 5H, ArH), 7.19 (t, <i>J</i> = 6.6 Hz, 1H, ArH), 7.13 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H, ArH), 6.59 (s, 1H, C═CH), 6.33 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.39 (dd, <i>J</i> = 14.4, 7.0 Hz, 1H, CH), 3.22 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.87, 170.11, 145.24, 140.45, 139.87, 137.06, 133.87, 133.14, 132.96, 130.59, 129.24, 129.24, 129.02, 128.45, 128.37, 128.37, 126.72, 125.86, 123.53, 122.35, 119.10, 118.02, 91.44, 57.89, 37.50. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>21</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 446.1266; found: 446.1252. Purity: 95.42%.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>Z</i>)-<i>N</i>-(4-Chlorophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8i</b>)</h4><div class="NLM_p last">Yield: 53.2%, yellow-green solid, mp 194.5–196.0 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −33 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (s, 1H, OH), 10.36 (s, 1H, NH), 8.17 (d, <i>J</i> = 7.9 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H, ArH), 7.70–7.63 (m, 1H, ArH), 7.61–7.54 (m, 3H, ArH), 7.40–7.34 (m, 2H, ArH), 7.32–7.24 (m, 4H, ArH), 7.19 (dt, <i>J</i> = 9.2, 4.2 Hz, 1H, ArH), 6.61 (s, 1H, C═CH), 6.33 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.40 (dd, <i>J</i> = 14.5, 7.0 Hz, 1H, CH), 3.22 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.89, 169.85, 145.27, 140.45, 137.39, 137.09, 133.89, 132.92, 129.24, 129.24, 128.98, 128.75, 128.75, 128.46, 128.35, 128.35, 127.43, 126.69, 125.85, 122.35, 121.21, 121.21, 91.43, 57.83, 37.60. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>ClN<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 468.1085; found: 468.1084. Purity: 6.41%.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (<i>Z</i>)-<i>N</i>-(2-Bromophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8j</b>)</h4><div class="NLM_p last">Yield: 57.2%, yellow-green solid, mp 160.6–162.3 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −49 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.30 (s, 1H, OH), 9.75 (s, 1H, NH), 8.11 (dd, <i>J</i> = 8.0, 0.6 Hz, 1H, ArH), 7.99 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.65–7.56 (m, 2H, ArH), 7.50 (ddd, <i>J</i> = 9.6, 7.0, 1.4 Hz, 2H, ArH), 7.32–7.27 (m, 3H, ArH), 7.23 (t, <i>J</i> = 7.5 Hz, 2H, ArH), 7.18–7.12 (m, 1H, ArH), 7.08 (td, <i>J</i> = 7.8, 1.6 Hz, 1H, ArH), 6.61 (s, 1H, C═CH), 6.33 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.44 (dd, <i>J</i> = 13.8, 7.8 Hz, 1H, CH), 3.25–3.19 (m, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.91, 170.10, 145.28, 140.55, 137.27, 135.63, 133.92, 132.98, 132.76, 129.32, 129.32, 129.04, 128.47, 128.42, 128.42, 128.17, 127.45, 126.94, 126.73, 125.86, 122.39, 117.95, 91.96, 57.60, 37.48. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>21</sub>BrN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 490.0761; found: 490.0744. Purity: 98.33%.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>Z</i>)-<i>N</i>-(3-Bromophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8k</b>)</h4><div class="NLM_p last">Yield: 51.1%, yellow-green solid, mp 137.1–138.3 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −46 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (s, 1H, OH), 10.38 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.5 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.88 (d, <i>J</i> = 1.8 Hz, 1H, ArH), 7.68 (td, <i>J</i> = 7.8, 1.4 Hz, 1H, ArH), 7.62–7.53 (m, 1H, ArH), 7.47 (dt, <i>J</i> = 7.1, 2.1 Hz, 1H, ArH), 7.34–7.25 (m, 6H, ArH), 7.20 (ddt, <i>J</i> = 8.5, 5.5, 2.9 Hz, 1H, ArH), 6.58 (s, 1H, C═CH), 6.33 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.37 (dd, <i>J</i> = 14.5, 7.1 Hz, 1H, CH), 3.22 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.88, 170.10, 145.25, 140.47, 140.01, 137.06, 133.87, 132.99, 130.91, 129.24, 129.24, 129.05, 128.45, 128.39, 128.39, 126.74, 126.45, 125.88, 122.36, 121.96, 121.60, 118.41, 91.44, 57.91, 37.51. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>21</sub>BrN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 490.0761; found: 490.0760. Purity: 97.18%.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>Z</i>)-<i>N</i>-(4-Bromophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8l</b>)</h4><div class="NLM_p last">Yield: 54.1%, yellow-green solid, mp 180.9–182.4 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −42 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (s, 1H, OH), 10.35 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.9 Hz, 1H, ArH), 8.09–8.01 (m, 1H, ArH), 7.73–7.61 (m, 1H, ArH), 7.62–7.47 (m, 5H, ArH), 7.28 (t, <i>J</i> = 7.3 Hz, 4H, ArH), 7.19 (dt, <i>J</i> = 9.2, 4.2 Hz, 1H, ArH), 6.60 (s, 1H, C═CH), 6.33 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.39 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.22 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.91, 169.90, 145.29, 140.46, 137.82, 137.09, 133.90, 132.97, 131.69, 131.69, 129.26, 129.26, 129.03, 128.47, 128.38, 128.38, 126.73, 125.89, 122.37, 121.60, 121.60, 115.49, 91.43, 57.88, 37.59. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>20</sub>BrN<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 512.0580; found: 512.0580. Purity: 96.35%.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>Z</i>)-2-((4-(Hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(2-methoxyphenyl)-3-phenylpropanamide (<b>8m</b>)</h4><div class="NLM_p last">Yield: 54.8%, yellow solid, mp 183.3∼184.4 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −47 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (s, 1H, OH), 9.49 (s, 1H, NH), 8.17 (dd, <i>J</i> = 8.0, 0.6 Hz, 1H, ArH), 8.06 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.88 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H, ArH), 7.71–7.64 (m, 1H, ArH), 7.61–7.51 (m, 1H, ArH), 7.34–7.31 (m, 2H, ArH), 7.26 (t, <i>J</i> = 7.4 Hz, 2H, ArH), 7.21–7.16 (m, 1H, ArH), 7.11–7.05 (m, 1H, ArH), 7.02 (dd, <i>J</i> = 8.2, 1.3 Hz, 1H, ArH), 6.93–6.88 (m, 1H, ArH), 6.65 (s, 1H, C═CH), 6.41 (d, <i>J</i> = 8.3 Hz, 1H, NH), 4.63 (dd, <i>J</i> = 14.3, 7.4 Hz, 1H, CH), 3.76 (s, 3H, CH<sub>3</sub>), 3.21 (d, <i>J</i> = 6.9 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.92, 169.74, 149.85, 145.27, 140.48, 137.34, 133.91, 132.92, 129.30, 129.30, 128.98, 128.44, 128.25, 128.25, 126.65, 126.56, 125.82, 124.91, 122.35, 122.00, 120.33, 111.38, 91.65, 57.43, 55.80, 37.58. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 442.1761; found: 442.1748. Purity: 98.43%.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>Z</i>)-2-((4-(Hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(3-methoxyphenyl)-3-phenylpropanamide (<b>8n</b>)</h4><div class="NLM_p last">Yield: 50.6%, yellow-green solid, mp 115.4–117.2 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −45 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.34 (s, 1H, OH), 10.21 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.5 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.71–7.65 (m, 1H, ArH), 7.60–7.54 (m, 1H, ArH), 7.32–7.18 (m, 7H, ArH), 7.12–7.07 (m, 1H, ArH), 6.65 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H, ArH), 6.60 (s, 1H, C═CH), 6.30 (d, <i>J</i> = 8.2 Hz, 1H, NH), 4.38 (dd, <i>J</i> = 14.3, 7.3 Hz, 1H, CH), 3.72 (s, 3H, CH<sub>3</sub>), 3.20 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.90, 169.71, 159.56, 145.26, 140.45, 139.62, 137.17, 133.88, 132.96, 129.67, 129.24, 129.24, 129.02, 128.45, 128.35, 128.35, 126.68, 125.86, 122.35, 111.89, 109.29, 105.38, 91.40, 57.83, 55.05, 37.63. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 442.1761; found: 442.1760. Purity: 97.69%.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (<i>Z</i>)-2-((4-(Hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(4-methoxyphenyl)-3-phenylpropanamide (<b>8o</b>)</h4><div class="NLM_p last">Yield: 55.7%, yellow-green solid, mp 93.3–94.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −41 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.33 (s, 1H, OH), 10.06 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.6 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.73–7.64 (m, 1H, ArH), 7.62–7.53 (m, 1H, ArH), 7.51–7.38 (m, 2H, ArH), 7.33–7.26 (m, 4H, ArH), 7.20 (dd, <i>J</i> = 5.8, 2.8 Hz, 1H, ArH), 6.97–6.82 (m, 2H, ArH), 6.59 (s, 1H, C═CH), 6.28 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.35 (dd, <i>J</i> = 14.4, 7.0 Hz, 1H, CH), 3.19 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.91, 169.12, 155.64, 145.28, 140.44, 137.22, 133.90, 132.95, 131.50, 129.25, 129.25, 129.01, 128.46, 128.34, 128.34, 126.66, 125.86, 122.35, 121.30, 121.30, 113.96, 113.96, 91.35, 57.67, 55.23, 37.69. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 442.1761; found: 442.1761. Purity: 98.51%.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (<i>Z</i>)-2-((4-(Hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(<i>o</i>-tolyl)propanamide (<b>8p</b>)</h4><div class="NLM_p last">Yield: 50.1%, yellow-green solid, mp 230.4–231.7 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −56 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.37 (s, 1H, OH), 9.62 (s, 1H, NH), 8.18 (d, <i>J</i> = 7.9 Hz, 1H, ArH), 8.06 (d, <i>J</i> = 7.1 Hz, 1H, ArH), 7.72–7.66 (m, 1H, ArH), 7.60–7.54 (m, 1H, ArH), 7.38–7.22 (m, 6H, ArH), 7.20–7.06 (m, 3H, ArH), 6.71 (s, 1H, C═CH), 6.32 (d, <i>J</i> = 8.0 Hz, 1H, NH), 4.53–4.43 (m, 1H, CH), 3.28–3.21 (m, 2H, CH<sub>2</sub>), 2.09 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.93, 169.68, 145.28, 140.53, 137.28, 135.68, 133.92, 132.94, 132.19, 130.37, 129.34, 129.34, 129.01, 128.49, 128.39, 128.39, 126.70, 126.00, 125.85, 125.65, 125.28, 122.37, 91.72, 57.46, 37.76, 17.76. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 448.1632; found: 448.1628. Purity: 99.28%.</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (<i>Z</i>)-2-((4-(Hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(<i>m</i>-tolyl)propanamide (<b>8q</b>)</h4><div class="NLM_p last">Yield: 49.0%, yellow-green solid, mp 124.5–125.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −54 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (s, 1H, OH), 10.15 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.6 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H, ArH), 7.73–7.63 (m, 1H, ArH), 7.64–7.48 (m, 1H, ArH), 7.42–7.25 (m, 6H, ArH), 7.24–7.14 (m, 2H, ArH), 6.88 (d, <i>J</i> = 7.5 Hz, 1H, ArH), 6.60 (s, 1H,C═CH), 6.31 (d, <i>J</i> = 8.2 Hz, 1H, NH), 4.38 (dd, <i>J</i> = 14.5, 7.2 Hz, 1H, CH), 3.20 (d, <i>J</i> = 6.9 Hz, 2H, CH<sub>2</sub>), 2.26 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.94, 169.64, 145.31, 140.50, 138.42, 138.11, 137.23, 133.92, 133.00, 129.28, 129.28, 129.05, 128.73, 128.48, 128.39, 128.39, 126.71, 125.90, 124.53, 122.39, 120.19, 116.84, 91.41, 57.86, 37.67, 21.20. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 426.1812; found: 426.1810. Purity: 99.23%.</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>Z</i>)-2-((4-(Hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(<i>p</i>-tolyl)propanamide (<b>8r</b>)</h4><div class="NLM_p last">Yield: 50.5%, yellow-green solid, mp 138.9–140.4 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −50 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.36 (s, 1H, OH), 10.24 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.6 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 0.9 Hz, 1H, ArH), 7.70–7.64 (m, 1H, ArH), 7.59–7.53 (m, 1H, ArH), 7.44 (d, <i>J</i> = 8.4 Hz, 2H, ArH), 7.33–7.23 (m, 5H, ArH), 7.21–7.16 (m, 1H, ArH), 7.10 (d, <i>J</i> = 8.3 Hz, 2H, ArH), 6.60 (s, 1H, C═CH), 6.29 (d, <i>J</i> = 8.2 Hz, 1H, NH), 4.40 (dd, <i>J</i> = 14.1, 7.4 Hz, 1H, CH), 3.29–3.12 (d, 2H, CH<sub>2</sub>), 2.24 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.90, 169.39, 145.24, 140.41, 137.22, 135.98, 133.91, 132.92, 132.74, 129.26, 129.26, 129.17, 129.17, 128.97, 128.44, 128.31, 128.31, 126.63, 125.84, 122.35, 119.67, 119.67, 91.36, 57.68, 37.67, 20.50. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>23</sub>N<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 448.1632; found: 448.1619. Purity: 99.08%.</div></div><div id="sec4_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (<i>Z</i>)-<i>N</i>-(3,5-Dimethylphenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8s</b>)</h4><div class="NLM_p last">Yield: 52.5%, yellow-green solid, mp 131.4–133.2 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −44 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.34 (s, 1H, OH), 10.06 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.6 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.72–7.64 (m, 1H, ArH), 7.60–7.54 (m, 1H, ArH), 7.31–7.25 (m, 4H, ArH), 7.21–7.17 (m, 3H, ArH), 6.64 (d, <i>J</i> = 49.4 Hz, 2H, ArH, C═CH), 6.30 (d, <i>J</i> = 8.2 Hz, 1H, NH), 4.36 (dd, <i>J</i> = 14.2, 7.4 Hz, 1H, CH), 3.20–3.16 (m, 2H, CH<sub>2</sub>), 2.22 (s, 6H, 2CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.94, 169.58, 145.30, 140.50, 138.35, 137.89, 137.89, 137.24, 133.91, 133.00, 129.27, 129.27, 129.06, 128.47, 128.39, 128.39, 126.71, 125.89, 125.33, 122.39, 117.37, 117.37, 91.40, 57.90, 37.67, 21.11, 21.11. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>27</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 462.1788; found: 462.1788. Purity: 97.32%.</div></div><div id="sec4_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (<i>Z</i>)-<i>N</i>-(3-Bromo-4-fluorophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8t</b>)</h4><div class="NLM_p last">Yield: 55.5%, yellow-green solid, mp 170.2–171.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −34 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (s, 1H, OH), 10.53 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.8 Hz, 1H, ArH), 8.05 (d, <i>J</i> = 7.0 Hz, 1H, ArH), 7.72–7.55 (m, 4H, ArH), 7.28 (d, <i>J</i> = 6.8 Hz, 5H, ArH), 7.20 (dd, <i>J</i> = 5.9, 2.6 Hz, 1H, ArH), 6.58 (s, 1H, C═CH), 6.35 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.38 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.22 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.82, 170.25, 159.24, 156.83, 145.20, 140.42, 139.61, 136.98, 133.83, 133.46, 132.94, 129.21, 129.21, 129.00, 128.42, 128.35, 126.71, 125.84, 122.32, 116.92, 107.68, 101.47, 91.41, 57.90, 37.44. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>19</sub>BrFN<sub>3</sub>O<sub>3</sub> Na [M + Na]<sup>+</sup>: 530.0486; found: 530.0488. Purity: 99.87%.</div></div><div id="sec4_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (<i>Z</i>)-<i>N</i>-(3,5-Dimethoxyphenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl) amino)-3-phenylpropanamide (<b>8u</b>)</h4><div class="NLM_p last">Yield: 50.5%, yellow-green solid, mp 122.5∼123.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −39 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (s, 1H, OH), 10.19 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.9 Hz, 1H, ArH), 8.10–8.02 (m, 1H, ArH), 7.72–7.63 (m, 1H, ArH), 7.56 (dd, <i>J</i> = 11.1, 4.0 Hz, 1H, ArH), 7.38–7.25 (m, 4H, ArH), 7.20 (dt, <i>J</i> = 9.1, 4.2 Hz, 1H, ArH), 6.81 (d, <i>J</i> = 2.2 Hz, 2H, ArH), 6.59 (s, 1H, C═CH), 6.30 (d, <i>J</i> = 8.2 Hz, 1H, NH), 6.24 (t, <i>J</i> = 2.2 Hz, 1H, ArH), 4.37 (dd, <i>J</i> = 14.1, 7.5 Hz, 1H, CH), 3.71 (s, 6H,CH<sub>3</sub>, CH<sub>3</sub>), 3.26–3.14 (m, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.89, 169.77, 160.55, 160.55, 145.26, 140.46, 140.12, 137.17, 133.88, 132.95, 129.23, 129.23, 129.01, 128.45, 128.35, 128.35, 126.68, 125.86, 122.35, 97.89, 97.89, 95.82, 91.41, 57.89, 55.16, 55.16, 37.62. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>27</sub>H<sub>26</sub>N<sub>3</sub>O<sub>5</sub> [M + H]<sup>+</sup>: 472.1867; found: 472.1851. Purity: 99.45%.</div></div><div id="sec4_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (<i>Z</i>)-<i>N</i>-(4-Bromo-3-fluorophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8v</b>)</h4><div class="NLM_p last">Yield: 49.2%, yellow-green solid, mp 122.2∼124.2 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −33 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.47 (s, 1H, OH), 7.99 (dd, <i>J</i> = 7.6, 0.9 Hz, 1H, NH), 7.90 (dd, <i>J</i> = 7.6, 1.0 Hz, 1H, ArH), 7.82 (td, <i>J</i> = 7.5, 1.3 Hz, 1H, ArH), 7.76–7.62 (m, 3H, ArH), 7.36–7.15 (m, 7H, ArH), 5.67 (s, 1H, C═CH), 4.44 (q, <i>J</i> = 7.0 Hz, 1H, CH), 3.27 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 181.89, 181.00, 169.19, 147.63, 139.47, 139.37, 136.85, 135.01, 133.50, 132.66, 132.59, 130.22, 129.25, 128.34, 126.75, 126.06, 125.42, 117.05, 107.82, 107.55, 101.64, 101.44, 101.06, 57.64, 36.96. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>19</sub>BrFN<sub>3</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup>: 530.0486; found: 530.0471. Purity: 99.16%.</div></div><div id="sec4_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (<i>Z</i>)-<i>N</i>-(3,5-Difluorophenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8w</b>)</h4><div class="NLM_p last">Yield: 43.5%, yellow-green solid, mp 166.0–167.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −31 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.35 (s, 1H, OH), 10.57 (s, 1H, NH), 8.20–8.15 (m, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.68 (td, <i>J</i> = 7.8, 1.4 Hz, 1H, ArH), 7.61–7.53 (m, 1H, ArH), 7.37–7.26 (m, 6H, ArH), 7.21 (dd, <i>J</i> = 5.9, 2.8 Hz, 1H, ArH), 6.93 (tt, <i>J</i> = 9.3, 2.3 Hz, 1H, ArH), 6.57 (s, 1H, C═CH), 6.34 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.38 (dd, <i>J</i> = 14.5, 7.0 Hz, 1H, CH) 3.23 (d, <i>J</i> = 6.8 Hz, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.82, 170.43, 163.72, 161.30, 145.21, 140.87, 140.43, 136.93, 133.83, 132.95, 129.20, 129.20, 129.01, 128.42, 128.36, 128.36, 126.73, 125.84, 122.32, 102.59, 102.30, 98.96, 91.46, 57.95, 37.40. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>25</sub>H<sub>19</sub>F<sub>2</sub>N<sub>3</sub>O<sub>3</sub>Na [M + Na]<sup>+</sup>: 470.1287; found: 470.1270. Purity: 98.14%.</div></div><div id="sec4_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (<i>Z</i>)-<i>N</i>-(2-Fluoro-4-methylphenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8x</b>)</h4><div class="NLM_p last">Yield: 60.2%, yellow-green solid, mp 218.5–220.4 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −36 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.96 (s, 1H, NH), 8.16 (dd, <i>J</i> = 8.0, 0.6 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.72–7.65 (m, 1H, ArH), 7.58 (dt, <i>J</i> = 8.3, 4.7 Hz, 2H, ArH), 7.30 (dt, <i>J</i> = 14.9, 4.6 Hz, 4H, ArH), 7.23–7.17 (m, 1H, ArH), 7.08 (dd, <i>J</i> = 11.8, 1.1 Hz, 1H, ArH), 6.96 (d, <i>J</i> = 8.2 Hz, 1H, ArH), 6.63 (s, 1H, C═CH), 6.32 (d, <i>J</i> = 8.3 Hz, 1H, NH), 4.55 (q, <i>J</i> = 6.9 Hz, 1H, CH), 3.21 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>), 2.27 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.91, 170.03, 155.08, 152.64, 145.27, 140.44, 137.15, 136.01, 133.91, 132.94, 129.30, 128.99, 128.45, 128.30, 126.65, 125.84, 124.83, 124.80, 124.38, 122.63, 116.05, 115.86, 91.49, 57.24, 37.63, 20.41. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>23</sub>FN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 444.1718; found: 444.1704. Purity: 99.34%.</div></div><div id="sec4_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (<i>Z</i>)-<i>N</i>-(3-Chloro-4-methylphenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8y</b>)</h4><div class="NLM_p last">Yield: 51.2%, yellow-green solid, mp 172.6–174.5 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −67 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.28 (s, 1H, OH), 10.30 (s, 1H, NH), 8.16 (d, <i>J</i> = 7.5 Hz, 1H, ArH), 8.05 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H, ArH), 7.72 (d, <i>J</i> = 2.0 Hz, 1H, ArH), 7.70–7.65 (m, 1H, ArH), 7.60–7.54 (m, 1H, ArH), 7.33 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H, ArH), 7.30–7.26 (m, 4H, ArH), 7.20 (td, <i>J</i> = 5.7, 2.6 Hz, 1H, ArH), 6.65–6.64 (m, 1H, ArH), 6.58 (s, 1H,C═CH), 6.31 (d, <i>J</i> = 8.1 Hz, 1H, NH), 4.36 (dd, <i>J</i> = 14.5, 7.0 Hz, 1H, CH), 3.21 (d, <i>J</i> = 6.7 Hz, 2H, CH<sub>2</sub>), 2.26 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.85, 169.80, 145.22, 140.42, 137.52, 137.06, 133.86, 133.02, 132.94, 131.27, 130.49, 129.21, 129.21, 129.00, 128.43, 128.34, 128.34, 126.69, 125.84, 122.33, 119.59, 118.25, 91.40, 57.81, 37.52, 18.96. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>23</sub>ClN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 460.1422; found: 460.1405. Purity: 96.83%.</div></div><div id="sec4_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (<i>Z</i>)-<i>N</i>-(4-Bromo-2-methylphenyl)-2-((4-(hydroxyimino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>8z</b>)</h4><div class="NLM_p last">Yield: 52.8%, yellow-green solid, mp 234.5–236.0 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −83 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.66 (s, 1H, NH), 8.18 (d, <i>J</i> = 8.0 Hz, 1H, ArH), 8.05 (d, <i>J</i> = 7.3 Hz, 1H, ArH), 7.73–7.63 (m, 1H, ArH), 7.61–7.52 (m, 1H, ArH), 7.41 (d, <i>J</i> = 2.0 Hz, 1H, ArH), 7.35–7.28 (m, 4H, ArH), 7.27–7.20 (m, 2H, ArH), 6.69 (s, 1H, C═CH), 6.30 (d, <i>J</i> = 7.9 Hz, 1H, NH), 4.49 (q, <i>J</i> = 7.2 Hz, 1H, CH), 3.27–3.17 (m, 2H, CH<sub>2</sub>), 2.08 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.91, 169.88, 145.28, 140.51, 137.17, 135.14, 134.91, 133.92, 132.94, 132.80, 129.34, 129.34, 129.01, 128.82, 128.48, 128.40, 128.40, 127.06, 126.73, 125.86, 122.38, 117.80, 91.77, 57.44, 37.72, 17.46. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>26</sub>H<sub>23</sub>BrN<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 504.0917; found: 504.0903. Purity: 96.23%.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> General Procedure for the Preparation of Compounds <b>10</b></h3><div class="NLM_p">Under argon protection, a solution of compound <b>8b</b>, <b>8k</b>, or <b>8n</b> (2 mmol) in dichloromethane (10 mL) was treated with 4-<i>tert</i>-butylbenzenesulfonyl chloride (3 mmol), and the resulting mixture was stirred for 30 min under an ice bath. Then, triethylamine (4 mmol) was added and the mixture was stirred for 10 min. The reaction was quenched with ice water (20 mL), extracted with dichloromethane (3 × 10 mL), dried (Na<sub>2</sub>SO4), filtered, and concentrated. The residue was purified by flash chromatography (light petroleum/ethyl acetate, V/V = 8:1) to give compounds <b>10</b> as a yellow solid.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (<i>E</i>)-2-((4-((((4-(<i>tert</i>-Butyl)phenyl)sulfonyl)oxy)imino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenyl-<i>N</i>-(3-(trifluoromethyl)phenyl)propanamide (<b>10a</b>)</h4><div class="NLM_p last">Yield: 80.1%, yellow solid, mp 121.4–122.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −25 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (s, 1H, NH), 8.07 (s, 1H, NH), 7.98 (dd, <i>J</i> = 7.7, 1.3 Hz, 1H, ArH), 7.95–7.92 (m, 1H, ArH), 7.84 (dd, <i>J</i> = 15.3, 8.5 Hz, 3H, ArH), 7.66–7.53 (m, 5H, ArH), 7.46 (d, <i>J</i> = 7.8 Hz, 1H, ArH), 7.34 (d, <i>J</i> = 7.0 Hz, 2H, ArH), 7.25 (t, <i>J</i> = 7.5 Hz, 2H, ArH), 7.16 (t, <i>J</i> = 7.3 Hz, 2H, ArH), 6.12 (s, 1H, C═CH), 4.56 (dd, <i>J</i> = 13.8, 7.7 Hz, 1H, CH), 3.32–3.18 (m, 2H, CH<sub>2</sub>), 1.22 (d, <i>J</i> = 11.2 Hz, 9H, 3CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.14, 169.46, 157.86, 151.72, 143.46, 139.06, 136.92, 134.02, 131.98, 131.12, 130.19, 129.30, 129.30, 129.00, 128.33, 128.33, 128.28, 128.28, 126.73, 126.32, 126.32, 125.34, 124.34, 123.16, 122.69, 120.30, 115.72, 88.16, 57.85, 37.45, 34.97, 31.04, 30.52, 30.52, 30.52, 26.32. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>36</sub>H<sub>33</sub>N<sub>3</sub>O<sub>5</sub>S [M + H]<sup>+</sup>: 676.2088; found: 676.2062. Purity: 97.24%.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (<i>E</i>)-<i>N</i>-(3-Bromophenyl)-2-((4-((((4-(<i>tert</i>-butyl)phenyl)sulfonyl)oxy)imino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-3-phenylpropanamide (<b>10b</b>)</h4><div class="NLM_p last">Yield: 85.2%, yellow solid, mp 121.0–122.6 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −22 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.54 (s, 1H, NH), 8.01 (dd, <i>J</i> = 7.7, 1.3 Hz, 1H, NH), 7.96–7.92 (m, 2H, ArH), 7.88–7.80 (m, 2H, ArH), 7.69 (td, <i>J</i> = 7.6, 1.5 Hz, 1H, ArH), 7.63 (td, <i>J</i> = 7.6, 1.2 Hz, 1H, ArH), 7.60–7.56 (m, 2H, ArH), 7.49 (dt, <i>J</i> = 7.2, 2.0 Hz, 1H, ArH), 7.35–7.30 (m, 4H, ArH), 7.25 (t, <i>J</i> = 7.5 Hz, 2H, ArH), 7.15 (dd, <i>J</i> = 17.3, 7.7 Hz, 2H, ArH), 6.09 (s, 1H, C═CH), 4.51 (dd, <i>J</i> = 14.0, 7.5 Hz, 1H, CH), 3.32–3.15 (m, 2H, CH<sub>2</sub>), 1.23 (s, 9H, 3CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.21, 169.27, 157.98, 151.80, 143.49, 139.86, 136.90, 134.18, 131.98, 131.28, 131.17, 130.98, 129.34, 129.34, 129.07, 128.40, 128.40, 128.33, 126.80, 126.66, 126.44, 126.44, 125.36, 124.39, 123.23, 122.04, 121.70, 118.51, 88.20, 57.85, 37.47, 35.09, 30.65, 30.65, 30.65. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>35</sub>H<sub>32</sub>BrN<sub>3</sub>O<sub>5</sub>S [M + Na]<sup>+</sup>: 708.1138; found: 708.1109. Purity: 99.12%.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (<i>E</i>)-2-((4-((((4-(<i>tert</i>-Butyl)phenyl)sulfonyl)oxy)imino)-1-oxo-1,4-dihydronaphthalen-2-yl)amino)-<i>N</i>-(3-methoxyphenyl)-3-phenylpropanamide (<b>10c</b>)</h4><div class="NLM_p last">Yield: 85.5%, yellow solid, mp 107.4–108.9 °C. [α]<sub class="stack">D</sub><sup class="stack">20</sup> = −18 (<i>c</i> 0.1, AcOEt). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H, NH), 7.95 (dd, <i>J</i> = 7.6, 1.4 Hz, 1H, NH), 7.89 (dd, <i>J</i> = 13.0, 5.0 Hz, 3H, ArH), 7.61–7.52 (m, 2H, ArH), 7.36–7.30 (m, 4H, ArH), 7.26 (dt, <i>J</i> = 7.7, 6.1 Hz, 4H, ArH), 7.17 (d, <i>J</i> = 7.6 Hz, 2H, ArH), 7.09 (d, <i>J</i> = 8.1 Hz, 1H, ArH), 6.70 (dd, <i>J</i> = 8.2, 1.8 Hz, 1H, ArH), 6.11 (s, 1H, C═CH), 4.54 (dd, <i>J</i> = 14.0, 7.5 Hz, 1H, CH), 3.74 (s, 3H, CH<sub>3</sub>), 3.30–3.21 (m, 2H, CH<sub>2</sub>), 1.22 (d, <i>J</i> = 11.7 Hz, 9H, 3CH<sub>3</sub>). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 179.15, 168.88, 159.60, 157.85, 151.76, 143.39, 139.53, 137.00, 133.99, 132.00, 131.13, 131.09, 129.73, 129.32, 129.32, 128.96, 128.31, 128.31, 126.69, 126.62, 126.37, 126.37, 125.35, 124.38, 123.15, 111.88, 109.36, 105.39, 88.10, 57.76, 55.01, 34.99, 31.05, 30.56, 30.56, 30.56. HR-MS (<i>m</i>/<i>z</i>) (ESI): calcd for C<sub>36</sub>H<sub>36</sub>N<sub>3</sub>O<sub>6</sub>S [M + H]<sup>+</sup>: 638.2319; found: 638.2294. Purity: 98.14%.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Enzymatic Assays</h3><div class="NLM_p last">IDO1 inhibition assays were carried out according to the manufacturers’ procedures, as described previously.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The standard assay mixture (100 μL) contained 50 mM potassium phosphate buffer (pH = 6.5), 10 mM ascorbate, 10 μM methylene blue, 100 μg/mL catalase, 1 mM <span class="smallcaps smallerCapital">l</span>-tryptophan, and 10 μg/mL of rhIDO1. The plate was incubated at 37 °C in a dark environment, and reactions were terminated after 60 min by the addition of 50 μL of fluorogenic developer solution and further incubated at 45 °C in the dark for 3 h. The plate was then allowed to cool to room temperature for at least 1 h. After centrifugation at 1500 g for 5 min at 20 °C, the fluorescence intensity (Ex/Em = 402/488 nm) was measured with a Fluoroskan Ascent microplate reader (Infinite M1000 Pro, Tecan US, Morrisville, NC) in endpoint mode. All determinations were carried out in triplicate.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Cell Viability Assays</h3><div class="NLM_p last">The cell lines Hct-116, HepG2, A549, and SKOV3 were obtained from the Shanghai Cell Bank at the Chinese Academy of Sciences. Hct-116, HepG2, and SKOV3 cell lines were grown on 96-well microtiter plates at a density of 10 × 10<sup>5</sup> cells/well in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS. DMEM and FBS were obtained from Gibco-Thermo (BRL Co. Ltd.). The plates were incubated at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>/95% air overnight. The cells were then exposed to different concentrations of target compounds and DOX and incubated for another 48 h. The cells were stained with 10 μL of MTT in an incubator for approximately 4 h. The medium was discharged and replaced by 100 mL of dimethyl sulfoxide (DMSO). The O.D. value was read at 570/630 nm with a spectrophotometer.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Molecular Docking</h3><div class="NLM_p last">All docking studies were carried out in Sybyl-X 2.0 on a Windows workstation. The crystal structure of the IDO1 proteins was retrieved from the RCSB Protein Data Bank (IDO1: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5">4PK5</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The synthetic analogues <b>7</b>, <b>8</b>, and <b>10</b> were selected for the docking studies. The 3D structures of these selected compounds were first built with Sybyl-X 2.0 sketch, and this was followed by energy minimization with the MMFF94 force field and Gasteiger-Marsili charges. We used Powell’s method for optimizing the geometry with a distance-dependent dielectric constant and a termination energy gradient of 0.005 kcal/mol. All selected compounds were automatically docked into the binding pocket of IDO1 through an empirical scoring function and a patented search engine in the Surflex docking program. Before the docking process, the natural ligand was extracted, and the water molecules were removed from the crystal structure. Subsequently, the protein was prepared with the Biopolymer module implemented in Sybyl. The polar hydrogen atoms were added, and other parameters were established by default to estimate the binding affinity characterized by the Surflex-Dock scores in the software. The Surflex-Dock total scores, which were expressed in −log 10 (<i>K</i><sub>d</sub>) units to represent binding affinities, were applied to estimate the ligand–receptor interactions of newly designed molecules.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> SPR Experiments</h3><div class="NLM_p last">Surface plasmon resonance experiments were performed with a Biacore T200 instrument at 25 °C. Sensor chips, buffer stock solutions, and immobilization reagents were from GE Healthcare. Recombinant human IDO1 was Novoprotein. Other reagents were obtained from Sigma. For immobilization, PBS was used as the running buffer. The four flow cells were treated in the same manner to optimize throughput. In summary, by using a CM5 chip, spots 1 and 2 were activated with the coupling reagents EDC and NHS for 10 min. IDO1 at a concentration of 20 μg/mL in 10 mM sodium acetate, pH 5, was injected onto the surface for 10 and 5 min at spots 1 and 2, respectively, to generate surfaces with high and low densities. The immobilization levels ranged from 2302 to 1823 RU at spot 1 and from 948 to 1112 RU at spot 2. The unmodified spot 3 was used as a reference. For kinetics and affinity measurements, PBS (containing 0.05% DMSO) was used as the running buffer and sample dilution buffer. Dose–response relationships were determined with a twofold sample dilution from 0 to 500 μM and an injection time of 60 s. For data processing, binding curves were corrected for variations in DMSO concentration and normalized by molecular weight. The <i>K</i><sub>D</sub> values reported were derived from steady-state binding responses and therefore correspond to the equilibrium binding affinities of the compounds.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> UV–Visible Spectra</h3><div class="NLM_p last">UV–visible scans (200–700 nm) were performed and recorded on a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.) with 100 μM IDO1 mixed with 2 mM tested compounds.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Western Blotting</h3><div class="NLM_p last">Total cell lysates from cultured SKOV-3 cells after compound <b>8u</b> treatment, as described earlier, were obtained by lysing the cells in ice-cold RIPA buffer with protease and phosphatase inhibitors. Lysates were stored at −20 °C until use. The protein concentrations were quantified by the Bradford method (BIO-RAD) with a Multimode Varioscan instrument (Thermo Fisher Scientific). Equal amounts of protein per lane were applied to a 12% sodium dodecyl sulfate polyacrylamide gel for electrophoresis (SDS-PAGE) and transferred to a poly(vinylidene difluoride) (PVDF) membrane (Amersham Biosciences). After the membrane was blocked at room temperature for 2 h in the blocking solution, primary antibody was added and incubated at 4 °C overnight. Antibodies to STAT3 were purchased from Abcam. After three TBST washes, the membrane was incubated with corresponding horseradish peroxidase-labeled secondary antibody (1:2000) (Santa Cruz Biotechnology) at room temperature for 1 h. Membranes were washed with TBST three times for 15 min, and the protein blots were detected with chemiluminescent reagent (Thermo Fisher Scientific, Ltd.). The X-ray films were developed with a developer and fixed with a fixer solution.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Immunofluorescence Staining</h3><div class="NLM_p last">Studies were performed as previously described.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Briefly, SKOV3 cells were cultured in six-well plates (2 × 10<sup>5</sup> cells per well) for 24 h, pretreated with compound <b>8u</b> at 0.5 μM for 6 h, and then treated with IL-6 for another 30 min. The cells were then washed and fixed with anhydrous methanol for 15 min at room temperature, permeabilized with 0.1% Triton X-100 for 15 min, and blocked with 1% bovine serum albumin (BSA) for 10 min at room temperature. Next, the cells were incubated with primary p-STAT3 antibody in PBS overnight at 4 °C followed by FITC-conjugated antibody secondary antibodies. After being washed with PBS three times, the cells were incubated in 10 μM 4′,6-diamidino-2-phenylindole (DAPI) for 15 min in the dark. The fluorescence of the p-STAT3 protein and nuclei was red and blue, respectively, and live cell imaging was simultaneously accomplished with a fluorescence microscope (Olympus BX-51, Tokyo, Japan).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Luciferase Assays</h3><div class="NLM_p last">Cells were seeded in 24-well plates and transiently transfected with STAT reporter plasmid (0.2 μg per well, Addgene) and <i>Renilla</i> luciferase control reporter plasmid pRL-CMV (0.1 μg per well, Promega), with Lipofectamine 2000 reagent (Invitrogen). Then, the cells were incubated in complete medium for 24 h with <b>8u</b>. After the treatment, the cells were harvested in 100 μL of passive lysis buffer (Promega) per well. A 25 μL aliquot of cell lysate was subjected to a luciferase assay with a dual-luciferase assay kit (Promega). STAT luciferase activity was measured with an EnVision Mutilabel Reader (PerkinElmer). Relative luciferase activity was calculated after the activity of STAT-dependent firefly luciferase had been normalized to that of <i>Renilla</i> luciferase.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> In Vivo Antitumor Efficacy in Nude Mice</h3><div class="NLM_p">The in vivo antitumor activity of compound <b>8u</b> was evaluated in the human hepatocellular carcinoma cell line HepG2 in BALB/c nude mice. Five-week-old male BALB/c nude mice were purchased from Shanghai Ling Chang Biotechnology Co. Ltd. (China), and tumors were induced through a subcutaneous injection of 1 × 10<sup>7</sup> cells in 100 μL of sterile PBS into the dorsal region. The animals were divided into four groups, starting on the second day. When the tumors reached a volume of 100–150 mm<sup>3</sup> in all mice on day 15, the first group was injected via the tail vein with an equivalent volume of 5% dextrose as the vehicle control. The second group was treated with doxorubicin at a dose of 5 mg/kg body weight once every 3 days for 3 weeks. The third and fourth groups were treated with complex <b>8u</b> at doses of 10 mg/kg or 30 mg/kg body weight once every 3 days for 3 weeks, respectively. All compounds were dissolved in vehicle. Tumor volumes and body weights were recorded every other day after drug treatment. All mice were sacrificed after 3 weeks of treatment, and the tumor volumes were measured with electronic digital calipers and examined by measurement of the length (<i>A</i>) and width (<i>B</i>) to calculate the volume (<i>V</i> = <i>AB</i><sup>2</sup>/2).</div><div class="NLM_p last">B16F10 melanoma was established in C57BL/6 mice through a subcutaneous injection of 1 × 10<sup>7</sup> cultured cells. The animals were divided into four groups starting on the first day. The four groups were subsequently administered 5% dextrose, <span class="smallcaps smallerCapital">d</span>-1-MT (200 mg/kg), <b>8u</b> (100 mg/kg), and <b>8u</b> (150 mg/kg), by tail vein injection once every 2 days for 3 weeks. Tumor volumes and body weights were recorded as described above.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Statistical Analysis</h3><div class="NLM_p last">All of the results were expressed as mean ± SD where applicable. GraphPad Prism 6 software (GraphPad Software) was used for statistical analysis. All of the results are expressed as mean ± S.D.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01386" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06618" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06618" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01386?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01386</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Binding modes of <b>8u</b> in complex with IDO1 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5">4PK5</a>); UV spectra of ferric IDO1 without and with compound <b>8u</b>; effects of the indicated treatments of <b>8u</b> on B16-F10 melanoma tumor xenografts in C57BL/6 mice; inhibition of tumor growth for compound <b>8u</b> and doxorubicin (DOX) in nude mice bearing HepG2 xenograft model; inhibitory effects of <b>8u</b> on STATs; table of docking scores (kcal/mol) for all studied compounds; table of STAT3 binding affinities of selected 2-amino-1,4-naphthoquinone derivatives; and <sup>1</sup>H NMR, <sup>13</sup>C NMR, HR-MS, and HPLC of target compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf">jm9b01386_si_001.pdf (8.18 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_002.csv">jm9b01386_si_002.csv (6.33 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01386" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86608" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86608" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hengshan Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal
University, Guilin 541004, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6474-8323" title="Orcid link">http://orcid.org/0000-0001-6474-8323</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#91e6f9f4fff6e2f9f0ffd1a0a7a2bff2fefc"><span class="__cf_email__" data-cfemail="4e39262b20293d262f200e7f787d602d2123">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenfeng Chen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal
University, Guilin 541004, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6548-6131" title="Orcid link">http://orcid.org/0000-0002-6548-6131</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#76151e13180c1036110e180358131203581518"><span class="__cf_email__" data-cfemail="c3a0aba6adb9a583a4bbadb6eda6a7b6eda0ad">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ye Zhang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Guilin Medical University, Guilin 541004, China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal
University, Guilin 541004, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6903-5602" title="Orcid link">http://orcid.org/0000-0002-6903-5602</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f78d9f9699908e92cfc6b7c6c5c1d994989a"><span class="__cf_email__" data-cfemail="750f1d141b120c104d44354447435b161a18">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rizhen Huang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal
University, Guilin 541004, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Guilin Medical University, Guilin 541004, China</span>; 
    <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research and School
of Chemistry and Chemical Engineering, Southeast
University, Nanjing 211189, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoteng Jing</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal
University, Guilin 541004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaochao Huang</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research and School
of Chemistry and Chemical Engineering, Southeast
University, Nanjing 211189, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingming Pan</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal
University, Guilin 541004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yilin Fang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal
University, Guilin 541004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guibin Liang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory for the Chemistry and Molecular Engineering of Medicinal
Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal
University, Guilin 541004, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhixin Liao</span> - <span class="hlFld-Affiliation affiliation">Jiangsu
Province Hi-Tech Key Laboratory for Biomedical Research and School
of Chemistry and Chemical Engineering, Southeast
University, Nanjing 211189, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>R.H. and X.J. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e9028-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33204" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33204" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors are grateful to the National Natural Science Foundation of China (21431001, 21501032, and 81760626), the Ministry of Education Innovation Team Fund (IRT_16R15 and 2016GXNSFGA380005), the Innovative Team & Outstanding Talent Program of Colleges and Universities in Guangxi (2017-38), Guangxi New Century Ten, Hundred and Thousand Talents Project ([2017]42), Natural Science Foundation of Guangxi Province (2016GXNSFAA380300 and AB17292075), and Guangxi Funds for Distinguished Experts.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">IDO1</td><td class="NLM_def"><p class="first last">indoleamine-2,3-dioxygenase 1</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">IDO5L</td><td class="NLM_def"><p class="first last">4-amino-<i>N</i>-(3-chloro-4-fluorophenyl)-<i>N</i>′-hydroxy-1, 2, 5-oxadiazole-3-carboximidamide</p></td></tr><tr><td class="NLM_term">1-MT</td><td class="NLM_def"><p class="first last">1-methyl-<span class="smallcaps smallerCapital">l</span>-tryptophan</p></td></tr><tr><td class="NLM_term">DOX</td><td class="NLM_def"><p class="first last">doxorubicin</p></td></tr><tr><td class="NLM_term">PDL1</td><td class="NLM_def"><p class="first last">programmed death ligand 1</p></td></tr><tr><td class="NLM_term">PD1</td><td class="NLM_def"><p class="first last">programmed cell death protein 1</p></td></tr><tr><td class="NLM_term">CTLA4</td><td class="NLM_def"><p class="first last">cytotoxic T-lymphocyte-associated protein 4</p></td></tr><tr><td class="NLM_term">Pt</td><td class="NLM_def"><p class="first last">platinum</p></td></tr><tr><td class="NLM_term">TDO</td><td class="NLM_def"><p class="first last">tryptophan 2,3-dioxygenase</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high-resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">SDS-PAGE</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate polyacrylamide gel electrophoresis</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">PVDF</td><td class="NLM_def"><p class="first last">poly(vinylidene difluoride)</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i91">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60713" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60713" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 64 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">The future of immune checkpoint therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1126/science.aaa8172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1126%2Fscience.aaa8172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=25838373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Wmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=56-61&author=P.+Sharmaauthor=J.+P.+Allison&title=The+future+of+immune+checkpoint+therapy&doi=10.1126%2Fscience.aaa8172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The future of immune checkpoint therapy</span></div><div class="casAuthors">Sharma, Padmanee; Allison, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6230</span>),
    <span class="NLM_cas:pages">56-61</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clin. advances and provided a new weapon against cancer.  This therapy has elicited durable clin. responses and, in a fraction of patients, long-term remissions where patients exhibit no clin. signs of cancer for many years.  The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment.  This will provide valuable information regarding the dynamic nature of the immune response and regulation of addnl. pathways that will need to be targeted through combination therapies to provide survival benefit for greater nos. of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYdwRFIm59-7Vg90H21EOLACvtfcHk0lgaiZJMvd85vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Wmurg%253D&md5=d63ae85b9c651ec64a3b5b002c609e35</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa8172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa8172%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520future%2520of%2520immune%2520checkpoint%2520therapy%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D56%26epage%3D61%26doi%3D10.1126%2Fscience.aaa8172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span> <span> </span><span class="NLM_article-title">Targeting the mechanisms of tumoral immune tolerance with small molecule inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1038/nrc1929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc1929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=16862192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFGlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=613-625&author=A.+J.+Mullerauthor=P.+A.+Scherle&title=Targeting+the+mechanisms+of+tumoral+immune+tolerance+with+small+molecule+inhibitors&doi=10.1038%2Fnrc1929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors</span></div><div class="casAuthors">Muller, Alexander J.; Scherle, Peggy A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">613-625</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer immunotherapy has been predominantly focused on biol. based intervention strategies.  However, recent advances in the understanding of tumor-host interactions at the mol. level have revealed targets that might be amenable to intervention with small-mol. inhibitors.  In particular, key effectors of tumoral immune escape have been identified that contribute to a dominant tolerogenic state that is suspected of limiting the successful implementation of treatment strategies that rely on boosting immune function.  Within the context of the pathophysiol. of cancer-assocd. immune tolerance, this Review delineates potential mol. targets for therapeutic intervention and the progress that has been made in developing small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo85LieVsa74bVg90H21EOLACvtfcHk0liNXx5j3tQrXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFGlu7s%253D&md5=0e803b9767d6f4b6b59febefae7e96e2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1929%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26atitle%3DTargeting%2520the%2520mechanisms%2520of%2520tumoral%2520immune%2520tolerance%2520with%2520small%2520molecule%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D613%26epage%3D625%26doi%3D10.1038%2Fnrc1929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kane, L. P.</span></span> <span> </span><span class="NLM_article-title">T cell Ig and mucin domain proteins and immunity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">2743</span>– <span class="NLM_lpage">2749</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0902937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.4049%2Fjimmunol.0902937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20200285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1yisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=2743-2749&author=L.+P.+Kane&title=T+cell+Ig+and+mucin+domain+proteins+and+immunity&doi=10.4049%2Fjimmunol.0902937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">T Cell Ig and Mucin Domain Proteins and Immunity</span></div><div class="casAuthors">Kane, Lawrence P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2743-2749</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Proteins of the transmembrane (or T cell) Ig and mucin domain (TIM) family are expressed by multiple cell types within the immune systems of rodents and humans.  Studies over the last several years have suggested that these proteins may be promising targets for therapeutic manipulation of immune responses.  This review discusses the progress that has been made in understanding TIM protein function in the immune system, as well as some of the unresolved issues that remain on the road to eventually targeting TIM proteins for enhancing or inhibiting immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLQsmSomlwWrVg90H21EOLACvtfcHk0liNXx5j3tQrXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1yisrg%253D&md5=3d390a9bf54fd42ffcc73f5b798af8ab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902937%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DL.%2BP.%26atitle%3DT%2520cell%2520Ig%2520and%2520mucin%2520domain%2520proteins%2520and%2520immunity%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D2743%26epage%3D2749%26doi%3D10.4049%2Fjimmunol.0902937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Couzin-Frankel, J.</span></span> <span> </span><span class="NLM_article-title">New highlight of cancer immunotherapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1126/science.342.6165.1432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1126%2Fscience.342.6165.1432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24357284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotF2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=1432-1433&author=J.+Couzin-Frankel&title=New+highlight+of+cancer+immunotherapy&doi=10.1126%2Fscience.342.6165.1432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy</span></div><div class="casAuthors">Couzin-Frankel, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">6165</span>),
    <span class="NLM_cas:pages">1432-1433</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxASV1j-6kL7Vg90H21EOLACvtfcHk0liNXx5j3tQrXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotF2qsg%253D%253D&md5=2e0995fd567c5b59f40c46981da0bef4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.342.6165.1432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.342.6165.1432%26sid%3Dliteratum%253Aachs%26aulast%3DCouzin-Frankel%26aufirst%3DJ.%26atitle%3DNew%2520highlight%2520of%2520cancer%2520immunotherapy%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D1432%26epage%3D1433%26doi%3D10.1126%2Fscience.342.6165.1432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linette, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwala, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaheen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernstoff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salama, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span> <span> </span><span class="NLM_article-title">Nivolumab and ipilimumab versus ipilimumab in untreated melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">2006</span>– <span class="NLM_lpage">2017</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1414428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1056%2FNEJMoa1414428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=25891304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BC2MjmtValsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=2006-2017&author=M.+A.+Postowauthor=J.+Chesneyauthor=A.+C.+Pavlickauthor=C.+Robertauthor=K.+Grossmannauthor=D.+McDermottauthor=G.+P.+Linetteauthor=N.+Meyerauthor=J.+K.+Giguereauthor=S.+S.+Agarwalaauthor=M.+Shaheenauthor=M.+S.+Ernstoffauthor=D.+Minorauthor=A.+K.+Salamaauthor=M.+Taylorauthor=P.+A.+Ottauthor=L.+M.+Rollinauthor=C.+Horakauthor=P.+Gagnierauthor=J.+D.+Wolchokauthor=F.+S.+Hodi&title=Nivolumab+and+ipilimumab+versus+ipilimumab+in+untreated+melanoma&doi=10.1056%2FNEJMoa1414428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab and ipilimumab versus ipilimumab in untreated melanoma</span></div><div class="casAuthors">Postow Michael A; Chesney Jason; Pavlick Anna C; Robert Caroline; Grossmann Kenneth; McDermott David; Linette Gerald P; Meyer Nicolas; Giguere Jeffrey K; Agarwala Sanjiv S; Shaheen Montaser; Ernstoff Marc S; Minor David; Salama April K; Taylor Matthew; Ott Patrick A; Rollin Linda M; Horak Christine; Gagnier Paul; Wolchok Jedd D; Hodi F Stephen</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2006-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma.  METHODS:  In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects.  The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors.  RESULTS:  Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group.  The median duration of response was not reached in either group.  The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001).  Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors.  Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy.  Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication.  CONCLUSIONS:  The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy.  Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsaUZ3ot54z9Hxxy173TfNfW6udTcc2ebbCgY9lr0nh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjmtValsw%253D%253D&md5=81184ce1ba06905bd9799478bacd74ad</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1414428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1414428%26sid%3Dliteratum%253Aachs%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DChesney%26aufirst%3DJ.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DGrossmann%26aufirst%3DK.%26aulast%3DMcDermott%26aufirst%3DD.%26aulast%3DLinette%26aufirst%3DG.%2BP.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DGiguere%26aufirst%3DJ.%2BK.%26aulast%3DAgarwala%26aufirst%3DS.%2BS.%26aulast%3DShaheen%26aufirst%3DM.%26aulast%3DErnstoff%26aufirst%3DM.%2BS.%26aulast%3DMinor%26aufirst%3DD.%26aulast%3DSalama%26aufirst%3DA.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DP.%2BA.%26aulast%3DRollin%26aufirst%3DL.%2BM.%26aulast%3DHorak%26aufirst%3DC.%26aulast%3DGagnier%26aufirst%3DP.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DNivolumab%2520and%2520ipilimumab%2520versus%2520ipilimumab%2520in%2520untreated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D2006%26epage%3D2017%26doi%3D10.1056%2FNEJMoa1414428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanneman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Combining immunotherapy and targeted therapies in cancer treatment</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1038/nrc3237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc3237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=22437869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVehtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=237-251&author=M.+Vannemanauthor=G.+Dranoff&title=Combining+immunotherapy+and+targeted+therapies+in+cancer+treatment&doi=10.1038%2Fnrc3237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Combining immunotherapy and targeted therapies in cancer treatment</span></div><div class="casAuthors">Vanneman, Matthew; Dranoff, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  During the past two decades, the paradigm for cancer treatment has evolved from relatively nonspecific cytotoxic agents to selective, mechanism-based therapeutics.  Cancer chemotherapies were initially identified through screens for compds. that killed rapidly dividing cells.  These drugs remain the backbone of current treatment, but they are limited by a narrow therapeutic index, significant toxicities and frequently acquired resistance.  More recently, an improved understanding of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy.  Targeted approaches aim to inhibit mol. pathways that are crucial for tumor growth and maintenance; whereas, immunotherapy endeavors to stimulate a host immune response that effectuates long-lived tumor destruction.  Targeted therapies and cytotoxic agents also modulate immune responses, which raises the possibility that these treatment strategies might be effectively combined with immunotherapy to improve clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXt9BTvySH7rVg90H21EOLACvtfcHk0litFk_E_UCwJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVehtrg%253D&md5=e1ed968896a11cea34456010a72fca57</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc3237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3237%26sid%3Dliteratum%253Aachs%26aulast%3DVanneman%26aufirst%3DM.%26aulast%3DDranoff%26aufirst%3DG.%26atitle%3DCombining%2520immunotherapy%2520and%2520targeted%2520therapies%2520in%2520cancer%2520treatment%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D237%26epage%3D251%26doi%3D10.1038%2Fnrc3237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span> <span> </span><span class="NLM_article-title">Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1016/j.it.2016.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.it.2016.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=27216414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVaktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=462-476&author=P.+E.+Hughesauthor=S.+Caenepeelauthor=L.+C.+Wu&title=Targeted+therapy+and+checkpoint+immunotherapy+combinations+for+the+treatment+of+cancer&doi=10.1016%2Fj.it.2016.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer</span></div><div class="casAuthors">Hughes, Paul E.; Caenepeel, Sean; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">462-476</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Many advances in the treatment of cancer have been driven by the development of targeted therapies that inhibit oncogenic signaling pathways and tumor-assocd. angiogenesis, as well as by the recent development of therapies that activate a patient's immune system to unleash antitumor immunity.  Some targeted therapies can have effects on host immune responses, in addn. to their effects on tumor biol.  These immune-modulating effects, such as increasing tumor antigenicity or promoting intratumoral T cell infiltration, provide a rationale for combining these targeted therapies with immunotherapies.  Here, we discuss the immune-modulating effects of targeted therapies against the MAPK and VEGF signaling pathways, and how they may synergize with immunomodulatory antibodies that target PD1/PDL1 and CTLA4.  We critically examine the rationale in support of these combinations in light of the current understanding of the underlying mechanisms of action of these therapies.  We also discuss the available preclin. and clin. data for these combination approaches and their implications regarding mechanisms of action.  Insights from these studies provide a framework for considering addnl. combinations of targeted therapies and immunotherapies for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre7tfWjsJ7d7Vg90H21EOLACvtfcHk0lhVgV-OBd8agg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVaktb8%253D&md5=e8fdc59f2b44786448691d39ef0027ba</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2016.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2016.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DTargeted%2520therapy%2520and%2520checkpoint%2520immunotherapy%2520combinations%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DTrends%2520Immunol.%26date%3D2016%26volume%3D37%26spage%3D462%26epage%3D476%26doi%3D10.1016%2Fj.it.2016.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, C. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W. H.</span></span> <span> </span><span class="NLM_article-title">Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1002/anie.201402879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1002%2Fanie.201402879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXot1Sgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=6752-6756&author=D.+Y.+Q.+Wongauthor=C.+H.+F.+Yeoauthor=W.+H.+Ang&title=Immuno-chemotherapeutic+platinum%28IV%29+prodrugs+of+cisplatin+as+multimodal+anticancer+agents&doi=10.1002%2Fanie.201402879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents</span></div><div class="casAuthors">Wong, Daniel Yuan Qiang; Yeo, Charmian Hui Fang; Ang, Wee Han</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">There is growing consensus that the clin. therapeutic efficacy of some chemotherapeutic agents depends on their off-target immune-modulating effects.  Pt anticancer drugs have previously been identified to be potent immunomodulators of both the innate and the adaptive immune system.  Nevertheless, there has been little development in the rational design of Pt-based chemotherapeutic agents to exploit their immune-activating capabilities.  The FPR1/2 formyl peptide receptors are highly expressed in immune cells, as well as in many metastatic cancers.  Herein, we report a rationally designed multimodal PtIV prodrug contg. a FPR1/2-targeting peptide that combines chemotherapy with immunotherapy to achieve therapeutic synergy and demonstrate the feasibility of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6CGrj7BBfLVg90H21EOLACvtfcHk0lhVgV-OBd8agg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXot1Sgs7w%253D&md5=33c922b754e9032e120a8f0722f770eb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fanie.201402879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201402879%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DD.%2BY.%2BQ.%26aulast%3DYeo%26aufirst%3DC.%2BH.%2BF.%26aulast%3DAng%26aufirst%3DW.%2BH.%26atitle%3DImmuno-chemotherapeutic%2520platinum%2528IV%2529%2520prodrugs%2520of%2520cisplatin%2520as%2520multimodal%2520anticancer%2520agents%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D6752%26epage%3D6756%26doi%3D10.1002%2Fanie.201402879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immune-chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.+R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28IV%29+pro-drug+preferentially+targets+indoleamine-2%2C3-dioxygenase%2C+providing+enhanced+ovarian+cancer+immune-chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0liFUQjHNkid9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528IV%2529%2520pro-drug%2520preferentially%2520targets%2520indoleamine-2%252C3-dioxygenase%252C%2520providing%2520enhanced%2520ovarian%2520cancer%2520immune-chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">A cisplatin-loaded immuno-chemotherapeutic nanohybrid bearing immune checkpoint inhibitors for enhanced cervical cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3426</span>– <span class="NLM_lpage">3430</span>, <span class="refDoi"> DOI: 10.1002/anie.201800422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1002%2Fanie.201800422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlalsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3426-3430&author=N.+Wangauthor=Z.+Wangauthor=Z.+Xuauthor=X.+Chenauthor=G.+Zhu&title=A+cisplatin-loaded+immuno-chemotherapeutic+nanohybrid+bearing+immune+checkpoint+inhibitors+for+enhanced+cervical+cancer+therapy&doi=10.1002%2Fanie.201800422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy</span></div><div class="casAuthors">Wang, Na; Wang, Zhigang; Xu, Zoufeng; Chen, Xianfeng; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3426-3430</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The efficacy of conventional chemotherapy is hindered by cancer cell escape from the immune system.  A multifunctional nanohybrid system is reported for effective immunochemotherapy against cervical cancer.  This nanohybrid contains both immune checkpoint inhibitor and cisplatin anticancer prodrug, showing improved cellular accumulation and increased binding of Pt to DNA and resulting in elevated apoptosis than using cisplatin alone when tested in cervical cancer cells.  The immune checkpoint inhibitor enables the inhibition of indoleamine-2,3-dioxygenase and reverses immunosuppressive T cells to recognize cancer cells, leading to T cell proliferation and activation, cancer cell cycle arrest, and ultimately increased cancer cell death.  The nanohybrid is also active in vivo against the growth of human cervical tumors.  Overall, a strategy is provided using a multifunctional nanohybrid system to boost the antitumor activity of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE2q4eLm-CS7Vg90H21EOLACvtfcHk0liFUQjHNkid9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlalsbo%253D&md5=05cd2f86034d70a7d4f8a944594e1778</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fanie.201800422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201800422%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DA%2520cisplatin-loaded%2520immuno-chemotherapeutic%2520nanohybrid%2520bearing%2520immune%2520checkpoint%2520inhibitors%2520for%2520enhanced%2520cervical%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D3426%26epage%3D3430%26doi%3D10.1002%2Fanie.201800422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röhrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9421</span>– <span class="NLM_lpage">9437</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9421-9437&author=U.+F.+R%C3%B6hrigauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=Challenges+in+the+discovery+of+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+inhibitors&doi=10.1021%2Facs.jmedchem.5b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9421-9437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies.  Many novel IDO1 inhibitor scaffolds have been described, and a few potent compds. have entered clin. trials.  However, a significant no. of the reported compds. contain problematic functional groups, suggesting that enzyme inhibition could be the result of undesirable side reactions instead of selective binding to IDO1.  Here, we describe issues in the employed exptl. protocols, review and classify reported IDO1 inhibitors, and suggest different approaches for confirming viable inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR3nr-l4vgNLVg90H21EOLACvtfcHk0ljRfk7c_cugYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D&md5=1b44178d33badc00215915c28d027b5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00326%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6hrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DChallenges%2520in%2520the%2520discovery%2520of%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9421%26epage%3D9437%26doi%3D10.1021%2Facs.jmedchem.5b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uyttenhove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Théta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eynde, B. J. V.</span></span> <span> </span><span class="NLM_article-title">Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1274</span>, <span class="refDoi"> DOI: 10.1038/nm934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnm934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=14502282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1Clu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=1269-1274&author=C.+Uyttenhoveauthor=L.+Pilotteauthor=I.+Th%C3%A9taauthor=V.+Stroobantauthor=D.+Colauauthor=N.+Parmentierauthor=T.+Boonauthor=B.+J.+V.+Eynde&title=Evidence+for+a+tumoral+immune+resistance+mechanism+based+on+tryptophan+degradation+by+indoleamine+2%2C3-dioxygenase&doi=10.1038%2Fnm934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</span></div><div class="casAuthors">Uyttenhove, Catherine; Pilotte, Luc; Theate, Ivan; Stroobant, Vincent; Colau, Didier; Parmentier, Nicolas; Boon, Thierry; Van den Eynde, Benoit J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1269-1274</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">T lymphocytes undergo proliferation arrest when exposed to tryptophan shortage, which can be provoked by indoleamine 2,3-dioxygenase (IDO), an enzyme that is expressed in placenta and catalyzes tryptophan degrdn.  Here we show that most human tumors constitutively express IDO.  We also obsd. that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice.  This effect is accompanied by a lack of accumulation of specific T cells at the tumor site and can be partly reverted by systemic treatment of mice with an inhibitor of IDO, in the absence of noticeable toxicity.  These results suggest that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2g0Nw1Orz7rVg90H21EOLACvtfcHk0ljRfk7c_cugYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1Clu7c%253D&md5=c2be3620862064fb40da547f976ccf95</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm934%26sid%3Dliteratum%253Aachs%26aulast%3DUyttenhove%26aufirst%3DC.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DTh%25C3%25A9ta%26aufirst%3DI.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DParmentier%26aufirst%3DN.%26aulast%3DBoon%26aufirst%3DT.%26aulast%3DEynde%26aufirst%3DB.%2BJ.%2BV.%26atitle%3DEvidence%2520for%2520a%2520tumoral%2520immune%2520resistance%2520mechanism%2520based%2520on%2520tryptophan%2520degradation%2520by%2520indoleamine%25202%252C3-dioxygenase%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D1269%26epage%3D1274%26doi%3D10.1038%2Fnm934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span> <span> </span><span class="NLM_article-title">Indolamine 2,3-dioxygenase and tumor-induced tolerance</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1172/JCI31178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1172%2FJCI31178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=17476344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Omtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=1147-1154&author=D.+H.+Munnauthor=A.+L.+Mellor&title=Indolamine+2%2C3-dioxygenase+and+tumor-induced+tolerance&doi=10.1172%2FJCI31178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase and tumor-induced tolerance</span></div><div class="casAuthors">Munn, David H.; Mellor, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1147-1154</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Tumors arise from normal cells of the body through genetic mutation.  Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; i.e., it is tolerant of these antigens.  This acquired state of tolerance must be overcome for cancer immunotherapy to succeed.  Indoleamine 2,3-dioxygenase (IDO) is one mol. mechanism that contributes to tumor-induced tolerance.  IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression.  It can also function as an antagonist to other activators of antitumor immunity.  Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmm42-SIElbVg90H21EOLACvtfcHk0li2SDi2BoY7bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Omtro%253D&md5=b8faf9b3398a23896cca34128636c787</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1172%2FJCI31178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31178%26sid%3Dliteratum%253Aachs%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26atitle%3DIndolamine%25202%252C3-dioxygenase%2520and%2520tumor-induced%2520tolerance%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D1147%26epage%3D1154%26doi%3D10.1172%2FJCI31178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Godin-Ethier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanafi, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccirillo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, R.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6985</span>– <span class="NLM_lpage">6991</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1158%2F1078-0432.CCR-11-1331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=22068654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6985-6991&author=J.+Godin-Ethierauthor=L.+A.+Hanafiauthor=C.+A.+Piccirilloauthor=R.+Lapointe&title=Indoleamine+2%2C3-dioxygenase+expression+in+human+cancers%3A+clinical+and+immunologic+perspectives&doi=10.1158%2F1078-0432.CCR-11-1331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives</span></div><div class="casAuthors">Godin-Ethier, Jessica; Hanafi, Laila-Aicha; Piccirillo, Ciriaco A.; Lapointe, Rejean</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6985-6991</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolizing enzyme with immune-regulating activities in many contexts, such as fetal protection, allograft protection, and cancer progression.  Clin. trials are currently evaluating IDO inhibition with 1-methyltryptophan in cancer immunotherapy.  However, the exact role of tryptophan catabolism by IDO in human cancers remains poorly understood.  Here, we review several studies that correlate IDO expression in human cancer samples and tumor-draining lymph nodes, with relevant clin. or immunol. parameters.  IDO expression in various histol. cancer types seems to decrease tumor infiltration of immune cells and to increase the proportion of regulatory T lymphocytes in the infiltrate.  The impact of IDO on different immune cell infiltration leads to the conclusion that IDO neg. regulates the recruitment of antitumor immune cells.  In addn., increased IDO expression correlates with diverse tumor progression parameters and shorter patient survival.  In summary, in the vast majority of the reported studies, IDO expression is correlated with a less favorable prognosis.  As we may see results from the first clin. trials with 1-methyltryptophan in years to come, this review brings together IDO studies from human studies and aims to help appreciate outcomes from current and future trials.  Consequently, IDO inhibition seems a promising approach for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFcLrhJoibc7Vg90H21EOLACvtfcHk0li2SDi2BoY7bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7rO&md5=4fe628fdb524657dba690497e7d0f067</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1331%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Ethier%26aufirst%3DJ.%26aulast%3DHanafi%26aufirst%3DL.%2BA.%26aulast%3DPiccirillo%26aufirst%3DC.%2BA.%26aulast%3DLapointe%26aufirst%3DR.%26atitle%3DIndoleamine%25202%252C3-dioxygenase%2520expression%2520in%2520human%2520cancers%253A%2520clinical%2520and%2520immunologic%2520perspectives%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6985%26epage%3D6991%26doi%3D10.1158%2F1078-0432.CCR-11-1331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8321</span>– <span class="NLM_lpage">8331</span>, <span class="refDoi"> DOI: 10.1021/jm401195n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401195n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8321-8331&author=S.+Yangauthor=X.+Liauthor=F.+Huauthor=Y.+Liauthor=Y.+Yangauthor=J.+Yanauthor=C.+Kuangauthor=Q.+Yang&title=Discovery+of+tryptanthrin+derivatives+as+potent+inhibitors+of+indoleamine+2%2C3-dioxygenase+with+therapeutic+activity+in+Lewis+lung+cancer+%28LLC%29+tumor-bearing+mice&doi=10.1021%2Fjm401195n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice</span></div><div class="casAuthors">Yang, Shuangshuang; Li, Xishuai; Hu, Fangfang; Li, Yinlong; Yang, Yunyun; Yan, Junkai; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8321-8331</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO-1) is emerging as an important new therapeutic target for the treatment of cancer, neurol. disorders, and other diseases that are characterized by pathol. tryptophan metab.  However, only a few structural classes are known to be IDO-1 inhibitors.  In this study, a natural compd. tryptanthrin was discovered to be a novel potent IDO-1 inhibitor by screening of indole-based structures.  Three series of 13 tryptanthrin derivs. were synthesized, and the structure-activity anal. was undertaken.  The optimization led to the identification of 5c, which exhibited the inhibitory activity at a nanomolar level.  In vitro 5c dramatically augmented the proliferation of T cells.  When administered to Lewis lung cancer (LLC) tumor-bearing mice, 5c significantly inhibited IDO-1 activity and suppressed tumor growth.  In addn., 5c reduced the nos. of Foxp3+ regulatory T cells (Tregs), which are known to prevent the development of efficient antitumor immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5ioPL3rWy1bVg90H21EOLACvtfcHk0lhGS9Y8hEtcDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrjL&md5=ac744f81ce97b0435f2bfd240e1393a1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm401195n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401195n%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520tryptanthrin%2520derivatives%2520as%2520potent%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520with%2520therapeutic%2520activity%2520in%2520Lewis%2520lung%2520cancer%2520%2528LLC%2529%2520tumor-bearing%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8321%26epage%3D8331%26doi%3D10.1021%2Fjm401195n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heikkila, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaara, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Smitten, K. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakkila, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leidenius, M. H. K.</span></span> <span> </span><span class="NLM_article-title">Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-9-231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1186%2F1471-2407-9-231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=19604349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BD1Mrktl2qsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=231-241&author=A.+S.+Mansfieldauthor=P.+S.+Heikkilaauthor=A.+T.+Vaaraauthor=K.+A.+J.+von+Smittenauthor=J.+M.+Vakkilaauthor=M.+H.+K.+Leidenius&title=Simultaneous+Foxp3+and+IDO+expression+is+associated+with+sentinel+lymph+node+metastases+in+breast+cancer&doi=10.1186%2F1471-2407-9-231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer</span></div><div class="casAuthors">Mansfield Aaron S; Heikkila Paivi S; Vaara Ari T; von Smitten Karl A J; Vakkila Jukka M; Leidenius Marjut H K</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There is evidence that the immune systems of patients with breast cancer are dysfunctional.  Regulatory T cells (Tregs), and IDO, an immunosuppressive enzyme, are associated with more advanced disease in some cancers and may promote immunologic tolerance to tumors.  Our aim was to assess whether expression of Foxp3, a marker of Tregs, and IDO were linked with nodal metastasis in breast cancer patients.  Inhibitors of IDO are available and could potentially demonstrate utility in breast cancer if IDO drives progression of disease.  METHODS:  Sentinel lymph nodes (SLN) of 47 breast cancer patients with varying degrees of nodal disease and 10 controls were evaluated for expression of Foxp3 and IDO using immunohistochemistry.  Positively stained cells were quantified and their distribution within the SLN noted.  RESULTS:  The proportion of Foxp3+ cells was higher in SLN of cancer patients than controls (19% v. 10%, p < 0.001).  Specifically, there were more Foxp3+ cells in SLN with metastasis than tumor-free SLN (20% v. 14%, p = 0.02).  The proportion IDO+ cell in SLN of cancer patients was not statistically different than controls (4.0% v. 1.6%, p = 0.08).  In order to demonstrate the combined immunosuppressive effect of Foxp3 and IDO, we categorized each SLN as positive or negative for Foxp3 and IDO.  The Foxp3+/IDO+ group almost exclusively consisted of cancer patients with node positive disease.  CONCLUSION:  In conclusion, our study shows that Foxp3+ cells are associated with more advanced disease in breast cancer, a finding that is proving to be true in many other cancers.  As IDO has been found to promote differentiation of Tregs, IDO may become a suitable target to abrogate the development of T-cell tolerance and to promote an effective immune response to breast cancer.  Our results about the combined expression of IDO and Foxp3 in metastastic SLN support this assumption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiWWVmEk4LDwpJitSxOdIlfW6udTcc2eZuVS1BCnMbOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mrktl2qsQ%253D%253D&md5=a9993b26a4dd34154b5272c37a05dac6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-9-231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-9-231%26sid%3Dliteratum%253Aachs%26aulast%3DMansfield%26aufirst%3DA.%2BS.%26aulast%3DHeikkila%26aufirst%3DP.%2BS.%26aulast%3DVaara%26aufirst%3DA.%2BT.%26aulast%3Dvon%2BSmitten%26aufirst%3DK.%2BA.%2BJ.%26aulast%3DVakkila%26aufirst%3DJ.%2BM.%26aulast%3DLeidenius%26aufirst%3DM.%2BH.%2BK.%26atitle%3DSimultaneous%2520Foxp3%2520and%2520IDO%2520expression%2520is%2520associated%2520with%2520sentinel%2520lymph%2520node%2520metastases%2520in%2520breast%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D231%26epage%3D241%26doi%3D10.1186%2F1471-2407-9-231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1845</span>– <span class="NLM_lpage">1853</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1158%2F0008-5472.CAN-09-3613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20160032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1845-1853&author=A.+J.+Mullerauthor=J.+B.+DuHadawayauthor=D.+Jallerauthor=P.+Curtisauthor=R.+Metzauthor=G.+C.+Prendergast&title=Immunotherapeutic+suppression+of+indoleamine+2%2C3-dioxygenase+and+tumor+growth+with+ethyl+pyruvate&doi=10.1158%2F0008-5472.CAN-09-3613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate</span></div><div class="casAuthors">Muller, Alexander J.; DuHadaway, James B.; Jaller, Daniel; Curtis, Peter; Metz, Richard; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1845-1853</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Efforts to improve cancer care in the developing world will benefit from the identification of simple, inexpensive, and broadly applicable medical modalities based on emergent innovations in treatment, such as targeting mechanisms of tumoral immune tolerance.  In this report, we offer preclin. evidence that the low-cost, anti-inflammatory agent Et pyruvate elicits a potent immune-based antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic enzyme for many human tumors.  Consistent with its reported ability to interfere with NF-κB function, Et pyruvate blocks IDO induction both in vitro and in vivo.  Antitumor activity was achieved in mice with a noncytotoxic dosing regimen of Et pyruvate shown previously to protect against lethality from sepsis.  Similar outcomes were obtained with the functional Et pyruvate analog 2-acetamidoacrylate.  Et pyruvate was ineffective at suppressing tumor outgrowth in both athymic and Ido1-deficient mice, providing in vivo corroboration of the importance of T-cell-dependent immunity and IDO targeting for Et pyruvate to achieve antitumor efficacy.  Although Et pyruvate has undergone early-phase clin. testing, this was done without consideration of its possible applicability to cancer.  Our findings that IDO is effectively blocked by Et pyruvate treatment deepen emerging links between IDO and inflammatory processes.  Further, these findings rationalize oncol. applications for this agent by providing a compelling basis to reposition Et pyruvate as a low-cost immunochemotherapy for clin. evaluation in cancer patients.  Cancer Res; 70(5); 1845-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkSC_ZW9ndLVg90H21EOLACvtfcHk0lj9b-apY4M1nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWju78%253D&md5=3d6e683754a5f97ef5215319ad454e2c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3613%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DJaller%26aufirst%3DD.%26aulast%3DCurtis%26aufirst%3DP.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DImmunotherapeutic%2520suppression%2520of%2520indoleamine%25202%252C3-dioxygenase%2520and%2520tumor%2520growth%2520with%2520ethyl%2520pyruvate%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1845%26epage%3D1853%26doi%3D10.1158%2F0008-5472.CAN-09-3613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donover, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutanto-Ward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1038/nm1196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnm1196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=15711557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BD2M7hs1Wiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=312-319&author=A.+J.+Mullerauthor=J.+B.+DuHadawayauthor=P.+S.+Donoverauthor=E.+Sutanto-Wardauthor=G.+C.+Prendergast&title=Inhibition+of+indoleamine+2%2C3-dioxygenase%2C+an+immunoregulatory+target+of+the+cancer+suppression+gene+Bin1%2C+potentiates+cancer+chemotherapy&doi=10.1038%2Fnm1196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</span></div><div class="casAuthors">Muller Alexander J; DuHadaway James B; Donover P Scott; Sutanto-Ward Erika; Prendergast George C</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">312-9</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Immune escape is a crucial feature of cancer progression about which little is known.  Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can facilitate immune escape.  Not known is how IDO becomes elevated or whether IDO inhibitors will be useful for cancer treatment.  Here we show that IDO is under genetic control of Bin1, which is attenuated in many human malignancies.  Mouse knockout studies indicate that Bin1 loss elevates the STAT1- and NF-kappaB-dependent expression of IDO, driving escape of oncogenically transformed cells from T cell-dependent antitumor immunity.  In MMTV-Neu mice, an established breast cancer model, we show that small-molecule inhibitors of IDO cooperate with cytotoxic agents to elicit regression of established tumors refractory to single-agent therapy.  Our findings suggest that Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors may improve responses to cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmoMRy8m8ZDAyMywPm6HgQfW6udTcc2eZp7882vN-gPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7hs1Wiuw%253D%253D&md5=2871eb26a11432381462091144b227f1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnm1196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1196%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DDonover%26aufirst%3DP.%2BS.%26aulast%3DSutanto-Ward%26aufirst%3DE.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibition%2520of%2520indoleamine%25202%252C3-dioxygenase%252C%2520an%2520immunoregulatory%2520target%2520of%2520the%2520cancer%2520suppression%2520gene%2520Bin1%252C%2520potentiates%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D312%26epage%3D319%26doi%3D10.1038%2Fnm1196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7364</span>– <span class="NLM_lpage">7367</span>, <span class="refDoi"> DOI: 10.1021/jm900518f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900518f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7364-7367&author=E.+W.+Yueauthor=B.+Doutyauthor=B.+Waylandauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=C.+Liuauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=B.+Metcalfauthor=P.+A.+Scherleauthor=A.+P.+Combs&title=Discovery+of+potent+competitive+inhibitors+of+indoleamine+2%2C3-dioxygenase+with+in+vivo+pharmacodynamic+activity+and+efficacy+in+a+mouse+melanoma+model&doi=10.1021%2Fjm900518f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span></div><div class="casAuthors">Yue, Eddy W.; Douty, Brent; Wayland, Brian; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Liu, Changnian; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Metcalf, Brian; Scherle, Peggy A.; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7364-7367</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).  Optimization led to the identification of (I), which is a potent (HeLa IC50 = 19 nM) competitive inhibitor of IDO.  Testing of I in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsq88hx0J77Vg90H21EOLACvtfcHk0lji4sRZzW5BQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D&md5=328d92bffb88a86da030c31eff707dc6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm900518f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900518f%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520potent%2520competitive%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520with%2520in%2520vivo%2520pharmacodynamic%2520activity%2520and%2520efficacy%2520in%2520a%2520mouse%2520melanoma%2520model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7364%26epage%3D7367%26doi%3D10.1021%2Fjm900518f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passacantilli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famiglini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsilinakos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoccoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisinni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regina, G. L.</span></span> <span> </span><span class="NLM_article-title">New inhibitors of indoleamine 2,3-dioxygenase 1: molecular modeling studies, synthesis, and biological evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9760</span>– <span class="NLM_lpage">9773</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9760-9773&author=A.+Colucciaauthor=S.+Passacantilliauthor=V.+Famigliniauthor=M.+Sabatinoauthor=A.+Patsilinakosauthor=R.+Ragnoauthor=C.+Mazzoccoliauthor=L.+Sisinniauthor=A.+Okunoauthor=O.+Takikawaauthor=R.+Silvestriauthor=G.+L.+Regina&title=New+inhibitors+of+indoleamine+2%2C3-dioxygenase+1%3A+molecular+modeling+studies%2C+synthesis%2C+and+biological+evaluation&doi=10.1021%2Facs.jmedchem.6b00718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation</span></div><div class="casAuthors">Coluccia, Antonio; Passacantilli, Sara; Famiglini, Valeria; Sabatino, Manuela; Patsilinakos, Alexandros; Ragno, Rino; Mazzoccoli, Carmela; Sisinni, Lorenza; Okuno, Alato; Takikawa, Osamu; Silvestri, Romano; La Regina, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9760-9773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy.  Herein, we report a virtual screening study which led to the identification of compd. I as a new IDO1 inhibitor.  In order to improve the biol. activity of the identified hit, arylthioindoles were synthesized and tested.  Among these, deriv. II exhibited an IC50 value of 7 μM, being the most active compd. of the series.  Furthermore, compds. I and II induced a dose-dependent growth inhibition in IDO1 expressing cancer cell lines HTC116 and HT29.  3-D QSAR studies were carried out in order to rationalize obtained results and suggest new chem. modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxfHwAbMNZXrVg90H21EOLACvtfcHk0lji4sRZzW5BQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtL7I&md5=9a1267db6fdeadfbbb693464ba4dddd6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00718%26sid%3Dliteratum%253Aachs%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DPassacantilli%26aufirst%3DS.%26aulast%3DFamiglini%26aufirst%3DV.%26aulast%3DSabatino%26aufirst%3DM.%26aulast%3DPatsilinakos%26aufirst%3DA.%26aulast%3DRagno%26aufirst%3DR.%26aulast%3DMazzoccoli%26aufirst%3DC.%26aulast%3DSisinni%26aufirst%3DL.%26aulast%3DOkuno%26aufirst%3DA.%26aulast%3DTakikawa%26aufirst%3DO.%26aulast%3DSilvestri%26aufirst%3DR.%26aulast%3DRegina%26aufirst%3DG.%2BL.%26atitle%3DNew%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%25201%253A%2520molecular%2520modeling%2520studies%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9760%26epage%3D9773%26doi%3D10.1021%2Facs.jmedchem.6b00718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Phenyl benzenesulfonylhydrazides exhibit selective indoleamine 2,3-dioxygenase inhibition with potent in vivo pharmacodynamic activity and antitumor efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ltLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=419-430&author=S.+Y.+Linauthor=T.+K.+Yehauthor=C.+C.+Kuoauthor=J.+S.+Songauthor=M.+F.+Chengauthor=F.+Y.+Liaoauthor=M.+W.+Chaoauthor=H.+L.+Huangauthor=Y.+L.+Chenauthor=C.+Y.+Yangauthor=M.+H.+Wuauthor=C.+L.+Hsiehauthor=W.+Hsiaoauthor=Y.+H.+Pengauthor=J.+S.+Wuauthor=L.+M.+Linauthor=M.+Sunauthor=Y.+S.+Chaoauthor=C.+Shihauthor=S.+Y.+Wuauthor=S.+L.+Panauthor=M.+S.+Hungauthor=S.+H.+Ueng&title=Phenyl+benzenesulfonylhydrazides+exhibit+selective+indoleamine+2%2C3-dioxygenase+inhibition+with+potent+in+vivo+pharmacodynamic+activity+and+antitumor+efficacy&doi=10.1021%2Facs.jmedchem.5b01640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy</span></div><div class="casAuthors">Lin, Shu-Yu; Yeh, Teng-Kuang; Kuo, Ching-Chuan; Song, Jen-Shin; Cheng, Ming-Fu; Liao, Fang-Yu; Chao, Min-Wu; Huang, Han-Li; Chen, Yi-Lin; Yang, Chun-Yu; Wu, Mine-Hsine; Hsieh, Chia-Ling; Hsiao, Wenchi; Peng, Yi-Hui; Wu, Jian-Sung; Lin, Li-Mei; Sun, Manwu; Chao, Yu-Sheng; Shih, Chuan; Wu, Su-Ying; Pan, Shiow-Lin; Hung, Ming-Shiu; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tryptophan metab. has been recognized as an important mechanism in immune tolerance.  Indoleamine 2,3-dioxygenase plays a key role in local tryptophan metab. via the kynurenine pathway and has emerged as a therapeutic target for cancer immunotherapy.  The prior study identified Ph benzenesulfonyl hydrazide as a potent in vitro (though not in vivo) inhibitor of indoleamine 2,3-dioxygenase.  Further lead optimization to improve in vitro potencies and pharmacokinetic profiles resulted in N'-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl hydrazide (I), which demonstrated 59% oral bioavailability and 73% of tumor growth delay without apparent body wt. loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg.  Accordingly, I is proposed as a potential drug lead worthy of advanced preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOxVvjSCi13LVg90H21EOLACvtfcHk0li308FM2ODbLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ltLjE&md5=63287615c2b038f657cab148d4747e03</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01640%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DHsiao%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DL.%2BM.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DPhenyl%2520benzenesulfonylhydrazides%2520exhibit%2520selective%2520indoleamine%25202%252C3-dioxygenase%2520inhibition%2520with%2520potent%2520in%2520vivo%2520pharmacodynamic%2520activity%2520and%2520antitumor%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D419%26epage%3D430%26doi%3D10.1021%2Facs.jmedchem.5b01640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottemanne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannellè, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauwenberghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordonnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroose, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrerié, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eynde, B. V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel and selective indoleamine 2,3-dioxygenase (IDO-1) inhibitor 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and its characterization as a potential clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9617</span>– <span class="NLM_lpage">9629</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00974</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00974" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9617-9629&author=S.+Crosignaniauthor=P.+Binghamauthor=P.+Bottemanneauthor=H.+Cannell%C3%A8author=S.+Cauwenberghsauthor=M.+Cordonnierauthor=D.+Dalvieauthor=F.+Derooseauthor=J.+L.+Fengauthor=B.+Gomesauthor=S.+Greasleyauthor=S.+E.+Kaiserauthor=M.+Krausauthor=M.+Negreri%C3%A9author=K.+Maegleyauthor=N.+Millerauthor=B.+W.+Murrayauthor=M.+Schneiderauthor=J.+Soloweijauthor=A.+E.+Stewartauthor=J.+Tumangauthor=V.+R.+Tortiauthor=B.+V.+D.+Eyndeauthor=M.+Wythes&title=Discovery+of+a+novel+and+selective+indoleamine+2%2C3-dioxygenase+%28IDO-1%29+inhibitor+3-%285-fluoro-1H-indol-3-yl%29pyrrolidine-2%2C5-dione+%28EOS200271%2FPF-06840003%29+and+its+characterization+as+a+potential+clinical+candidate&doi=10.1021%2Facs.jmedchem.7b00974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate</span></div><div class="casAuthors">Crosignani, Stefano; Bingham, Patrick; Bottemanne, Pauline; Cannelle, Helene; Cauwenberghs, Sandra; Cordonnier, Marie; Dalvie, Deepak; Deroose, Frederik; Feng, Jun Li; Gomes, Bruno; Greasley, Samantha; Kaiser, Stephen E.; Kraus, Manfred; Negrerie, Michel; Maegley, Karen; Miller, Nichol; Murray, Brion W.; Schneider, Manfred; Soloweij, James; Stewart, Albert E.; Tumang, Joseph; Torti, Vince R.; Van Den Eynde, Benoit; Wythes, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9617-9629</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment.  IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function.  As such, IDO-1 is a nexus for the induction of a key immunosuppressive mechanism and represents an important immunotherapeutic target in oncol.  Starting from HTS hit I, IDO-1 inhibitor II has been developed.  The structure-activity relationship around II is described and rationalized using the x-ray crystal structure of II bound to human IDO-1, which shows that II, differently from most of the IDO-1 inhibitors described so far, does not bind to the heme iron atom and has a novel binding mode.  Clin. candidate II shows good potency in an IDO-1 human whole blood assay and also shows a very favorable ADME profile leading to favorable predicted human pharmacokinetic properties, including a predicted half-life of 16-19 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogfHmZRAC-dLVg90H21EOLACvtfcHk0liYYq458w2QjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK&md5=dc2e45c243aa22c100ccc39db9b5918a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00974%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBottemanne%26aufirst%3DP.%26aulast%3DCannell%25C3%25A8%26aufirst%3DH.%26aulast%3DCauwenberghs%26aufirst%3DS.%26aulast%3DCordonnier%26aufirst%3DM.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDeroose%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DGreasley%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DS.%2BE.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DNegreri%25C3%25A9%26aufirst%3DM.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSoloweij%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTumang%26aufirst%3DJ.%26aulast%3DTorti%26aufirst%3DV.%2BR.%26aulast%3DEynde%26aufirst%3DB.%2BV.%2BD.%26aulast%3DWythes%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520and%2520selective%2520indoleamine%25202%252C3-dioxygenase%2520%2528IDO-1%2529%2520inhibitor%25203-%25285-fluoro-1H-indol-3-yl%2529pyrrolidine-2%252C5-dione%2520%2528EOS200271%252FPF-06840003%2529%2520and%2520its%2520characterization%2520as%2520a%2520potential%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9617%26epage%3D9629%26doi%3D10.1021%2Facs.jmedchem.7b00974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Important hydrogen bond networks in indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor design revealed by crystal structures of imidazoleisoindole derivatives with IDO1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKjtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=282-293&author=Y.+H.+Pengauthor=S.+H.+Uengauthor=C.+T.+Tsengauthor=M.+S.+Hungauthor=J.+S.+Songauthor=J.+S.+Wuauthor=F.+Y.+Liaoauthor=Y.+S.+Fanauthor=M.+H.+Wuauthor=W.+C.+Hsiaoauthor=C.+C.+Hsuehauthor=S.+Y.+Linauthor=C.+Y.+Chengauthor=C.+H.+Tuauthor=L.+C.+Leeauthor=M.+F.+Chengauthor=K.+S.+Shiaauthor=C.+Shihauthor=S.+Y.+Wu&title=Important+hydrogen+bond+networks+in+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+inhibitor+design+revealed+by+crystal+structures+of+imidazoleisoindole+derivatives+with+IDO1&doi=10.1021%2Facs.jmedchem.5b01390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1</span></div><div class="casAuthors">Peng, Yi-Hui; Ueng, Shau-Hua; Tseng, Chen-Tso; Hung, Ming-Shiu; Song, Jen-Shin; Wu, Jian-Sung; Liao, Fang-Yu; Fan, Yu-Shiou; Wu, Mine-Hsine; Hsiao, Wen-Chi; Hsueh, Ching-Cheng; Lin, Shu-Yu; Cheng, Chia-Yi; Tu, Chih-Hsiang; Lee, Lung-Chun; Cheng, Ming-Fu; Shia, Kak-Shan; Shih, Chuan; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune escape of tumors, is a therapeutic target for the cancer immunotherapy.  A no. of IDO1 inhibitors have been identified, but only limited structural biol. studies of IDO1 inhibitors are available to provide insights on the binding mechanism of IDO1.  In this study, we present the structure of IDO1 in complex with 24, a NLG919 analog with potent activity.  The complex structure revealed the imidazole nitrogen atom of 24 to coordinate with the heme iron, and the imidazoleisoindole core situated in pocket A with the 1-cyclohexylethanol moiety extended to pocket B to interact with the surrounding residues.  Most interestingly, 24 formed an extensive hydrogen bond network with IDO1, which is a distinct feature of IDO1/24 complex structure and is not obsd. in the other IDO1 complex structures.  Further structure-activity relationship, UV spectra, and structural biol. studies of several analogs of 24 demonstrated that extensive hydrophobic interactions and the unique hydrogen bonding network contribute to the great potency of imidazoleisoindole derivs.  These results are expected to facilitate the structure-based drug design of new IDO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodJqtuECqcsrVg90H21EOLACvtfcHk0lhaFoHn9Z8Xcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKjtLnJ&md5=2258be36595a3fa8e6c9064b2f15e1de</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01390%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26aulast%3DTseng%26aufirst%3DC.%2BT.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DFan%26aufirst%3DY.%2BS.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsiao%26aufirst%3DW.%2BC.%26aulast%3DHsueh%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DCheng%26aufirst%3DC.%2BY.%26aulast%3DTu%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DShia%26aufirst%3DK.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26atitle%3DImportant%2520hydrogen%2520bond%2520networks%2520in%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitor%2520design%2520revealed%2520by%2520crystal%2520structures%2520of%2520imidazoleisoindole%2520derivatives%2520with%2520IDO1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D282%26epage%3D293%26doi%3D10.1021%2Facs.jmedchem.5b01390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhavoronkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artemov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysocki, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmagadda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidransky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrello, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedi, A.</span></span> <span> </span><span class="NLM_article-title">Bifunctional immune checkpoint-targeted antibodyligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy</span>. <i>Nat. commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">741</span> <span class="refDoi"> DOI: 10.1038/s41467-017-02696-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fs41467-017-02696-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=29467463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BC1MrktVWnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=R.+Raviauthor=K.+A.+Noonanauthor=V.+Phamauthor=R.+Bediauthor=A.+Zhavoronkovauthor=I.+V.+Ozerovauthor=E.+Makarevauthor=A.+V.+Artemovauthor=P.+T.+Wysockiauthor=R.+Mehraauthor=S.+Nimmagaddaauthor=L.+Marchionniauthor=D.+Sidranskyauthor=I.+M.+Borrelloauthor=E.+Izumchenkoauthor=A.+Bedi&title=Bifunctional+immune+checkpoint-targeted+antibodyligand+traps+that+simultaneously+disable+TGF%CE%B2+enhance+the+efficacy+of+cancer+immunotherapy&doi=10.1038%2Fs41467-017-02696-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy</span></div><div class="casAuthors">Ravi Rajani; Pham Vui; Wysocki Piotr T; Sidransky David; Izumchenko Evgeny; Bedi Atul; Noonan Kimberly A; Borrello Ivan M; Bedi Rishi; Zhavoronkov Alex; Ozerov Ivan V; Makarev Eugene; V Artemov Artem; Mehra Ranee; Nimmagadda Sridhar; Marchionni Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">741</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1).  Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in the tumor microenvironment by inducing regulatory T cells (Tregs) and inhibiting CD8(+) and TH1 cells.  To address this therapeutic challenge, we invent bifunctional antibody-ligand traps (Y-traps) comprising an antibody targeting CTLA-4 or PD-L1 fused to a TGFβ receptor II ectodomain sequence that simultaneously disables autocrine/paracrine TGFβ in the target cell microenvironment (a-CTLA4-TGFβRIIecd and a-PDL1-TGFβRIIecd). a-CTLA4-TGFβRIIecd is more effective in reducing tumor-infiltrating Tregs and inhibiting tumor progression compared with CTLA-4 antibody (Ipilimumab).  Likewise, a-PDL1-TGFβRIIecd exhibits superior antitumor efficacy compared with PD-L1 antibodies (Atezolizumab or Avelumab).  Our data demonstrate that Y-traps counteract TGFβ-mediated differentiation of Tregs and immune tolerance, thereby providing a potentially more effective immunotherapeutic strategy against cancers that are resistant to current immune checkpoint inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLqYwFBe0wFSCEBeYuoi7AfW6udTcc2eZYJpnibmkRv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrktVWnsw%253D%253D&md5=df34e44475f80baee5692fb615fa09a2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02696-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02696-6%26sid%3Dliteratum%253Aachs%26aulast%3DRavi%26aufirst%3DR.%26aulast%3DNoonan%26aufirst%3DK.%2BA.%26aulast%3DPham%26aufirst%3DV.%26aulast%3DBedi%26aufirst%3DR.%26aulast%3DZhavoronkov%26aufirst%3DA.%26aulast%3DOzerov%26aufirst%3DI.%2BV.%26aulast%3DMakarev%26aufirst%3DE.%26aulast%3DArtemov%26aufirst%3DA.%2BV.%26aulast%3DWysocki%26aufirst%3DP.%2BT.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DNimmagadda%26aufirst%3DS.%26aulast%3DMarchionni%26aufirst%3DL.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DBorrello%26aufirst%3DI.%2BM.%26aulast%3DIzumchenko%26aufirst%3DE.%26aulast%3DBedi%26aufirst%3DA.%26atitle%3DBifunctional%2520immune%2520checkpoint-targeted%2520antibodyligand%2520traps%2520that%2520simultaneously%2520disable%2520TGF%25CE%25B2%2520enhance%2520the%2520efficacy%2520of%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520commun.%26date%3D2018%26volume%3D9%26doi%3D10.1038%2Fs41467-017-02696-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span> <span> </span><span class="NLM_article-title">Immunosuppressive networks in the tumour environment and their therapeutic relevance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1038/nrc1586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc1586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=15776005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=263-274&author=W.+Zou&title=Immunosuppressive+networks+in+the+tumour+environment+and+their+therapeutic+relevance&doi=10.1038%2Fnrc1586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Immunosuppressive networks in the tumor environment and their therapeutic relevance</span></div><div class="casAuthors">Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  It is well known that many tumors are potentially immunogenic, as corroborated by the presence of tumor-specific immune responses in vivo.  Nonetheless, spontaneous clearance of established tumors by endogenous immune mechanisms is rare.  Therefore, the focus of most cancer immunotherapies is to supplement essential immunogenic elements to boost tumor-specific immunity.  Why then has tumor immunotherapy resulted in a generally poor clin. efficiency.  The reason might lie in the increasingly documented fact that tumors develop diverse strategies that escape tumor-specific immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYn6QskoTkQrVg90H21EOLACvtfcHk0lgUS5w8jf9zSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7g%253D&md5=46d0056c242606494cfb09740ffa3fc2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc1586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1586%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DW.%26atitle%3DImmunosuppressive%2520networks%2520in%2520the%2520tumour%2520environment%2520and%2520their%2520therapeutic%2520relevance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D263%26epage%3D274%26doi%3D10.1038%2Fnrc1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span> <span> </span><span class="NLM_article-title">Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nri1995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnri1995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=17186030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCht7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=41-51&author=H.+Yuauthor=M.+Kortylewskiauthor=D.+Pardoll&title=Crosstalk+between+cancer+and+immune+cells%3A+role+of+STAT3+in+the+tumour+microenvironment&doi=10.1038%2Fnri1995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment</span></div><div class="casAuthors">Yu, Hua; Kortylewski, Marcin; Pardoll, Drew</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-51</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immune cells in the tumor microenvironment not only fail to mount an effective anti-tumor immune response, but also interact intimately with the transformed cells to promote oncogenesis actively.  Signal transducer and activator of transcription 3 (STAT3), which is a point of convergence for numerous oncogenic signaling pathways, is constitutively activated both in tumor cells and in immune cells in the tumor microenvironment.  Constitutively activated STAT3 inhibits the expression of mediators necessary for immune activation against tumor cells.  Furthermore, STAT3 activity promotes the prodn. of immunosuppressive factors that activate STAT3 in diverse immune-cell subsets, altering gene expression programs and, thereby, restraining anti-tumor immune responses.  As such, STAT3 propagates several levels of crosstalk between tumor cells and their immunol. microenvironment, leading to tumor-induced immunosuppression.  Consequently, STAT3 has emerged as a promising target for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYT6B6OheWubVg90H21EOLACvtfcHk0ljVw1pd6QUpiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCht7fE&md5=1b6bd983fb7a7baba5d3a4087cbd65ce</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnri1995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1995%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DKortylewski%26aufirst%3DM.%26aulast%3DPardoll%26aufirst%3DD.%26atitle%3DCrosstalk%2520between%2520cancer%2520and%2520immune%2520cells%253A%2520role%2520of%2520STAT3%2520in%2520the%2520tumour%2520microenvironment%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D41%26epage%3D51%26doi%3D10.1038%2Fnri1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1038/nrc3818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc3818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=25342631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=736-746&author=H.+Yuauthor=H.+Leeauthor=A.+Herrmannauthor=R.+Buettnerauthor=R.+Jove&title=Revisiting+STAT3+signalling+in+cancer%3A+new+and+unexpected+biological+functions&doi=10.1038%2Fnrc3818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span></div><div class="casAuthors">Yu, Hua; Lee, Heehyoung; Herrmann, Andreas; Buettner, Ralf; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">736-746</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins, particularly STAT3, are among the most promising new targets for cancer therapy.  In addn. to interleukin-6 (IL-6) and its family members, multiple pathways, including G-protein-coupled receptors (GPCRs), Toll-like receptors (TLRs) and microRNAs were recently identified to regulate JAK-STAT signalling in cancer.  Well known for its role in tumor cell proliferation, survival, invasion and immunosuppression, JAK-STAT3 signalling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche.  In addn. to its established role as a transcription factor in cancer, STAT3 regulates mitochondrion functions, as well as gene expression through epigenetic mechanisms.  Newly identified regulators and functions of JAK-STAT3 in tumors are important targets for potential therapeutic strategies in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3PGL62I5KvrVg90H21EOLACvtfcHk0ljVw1pd6QUpiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF&md5=355a07303813d7ecadb4b085c33c5e0a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrc3818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3818%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DRevisiting%2520STAT3%2520signalling%2520in%2520cancer%253A%2520new%2520and%2520unexpected%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D736%26epage%3D746%26doi%3D10.1038%2Fnrc3818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6645</span>– <span class="NLM_lpage">6668</span>, <span class="refDoi"> DOI: 10.1021/jm300207s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300207s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6645-6668&author=B.+Debnathauthor=S.+Xuauthor=N.+Neamati&title=Small+molecule+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28Stat3%29+protein&doi=10.1021%2Fjm300207s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span></div><div class="casAuthors">Debnath, Bikash; Xu, Shili; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6645-6668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (Stat3) is a transcription factor belonging to the STAT protein family, members of which regulate a wide variety of biol. processes, including cell growth, proliferation, survival, differentiation, development, movement and inflammation in response to extracellular signaling mols. such as cytokines and growth factors.  Receptor assocd. tyrosine kinases phosphorylate Stat3 protein at Tyr705 and enable it to dimerize and subsequently enter the nucleus where it activates the transcription of its target genes.  Accumulating evidence has established Stat3's role in oncogenesis, cardiovascular diseases, rheumatoid arthritis, fibrotic, and Alzheimer's diseases.  Thus, Stat3 inhibition is a promising therapeutic approach not only for cancer, but also for other diseases.  Although Stat3 has been considered as an important therapeutic target, progress in discovery and development of effective and specific Stat3 inhibitors remains slow.  In this article we summarize Stat3 inhibitors published between 2006 and 2011.  New strategies along with novel technologies are required to achieve breakthrough in the development of Stat3 inhibitors that can be translated into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWQl9gV1-ZLVg90H21EOLACvtfcHk0li_jaAcfdS-8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D&md5=f5f3ac9f8fc2326c75edd2a9c136275b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300207s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300207s%26sid%3Dliteratum%253Aachs%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528Stat3%2529%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6645%26epage%3D6668%26doi%3D10.1021%2Fjm300207s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibi, M.</span></span> <span> </span><span class="NLM_article-title">Roles of STAT3 in mediating the cell growth, dierentiation and survival signals relayed through the IL-6 family of cytokine receptors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2548</span>– <span class="NLM_lpage">2556</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fsj.onc.1203551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10851053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVGhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2548-2556&author=T.+Hiranoauthor=K.+Ishiharaauthor=M.+Hibi&title=Roles+of+STAT3+in+mediating+the+cell+growth%2C+dierentiation+and+survival+signals+relayed+through+the+IL-6+family+of+cytokine+receptors&doi=10.1038%2Fsj.onc.1203551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors</span></div><div class="casAuthors">Hirano, Toshio; Ishihara, Katsuhiko; Hibi, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2548-2556</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 161 refs.  Members of the IL-6 cytokine family are involved in a variety of biol. responses, including the immune response, inflammation, hematopoiesis, and oncogenesis by regulating cell growth, survival, and differentiation.  These cytokines use gp130 as a common receptor subunit.  The binding of ligand to gp130 activates the JAK/STAT signal transduction pathway, where STAT3 plays a central role in transmitting the signals from the membrane to the nucleus.  STAT3 is essential for gp130-mediated cell survival and G1 to S cell-cycle-transition signals.  Both c-myc and pim have been identified as target genes of STAT3 and together can compensate for STAT3 in cell survival and cell-cycle transition.  STAT3 is also required for gp130-mediated maintenance of the pluripotential state of proliferating embryonic stem cells and for the gp130-induced macrophage differentiation of M1 cells.  Furthermore, STAT3 regulates cell movement, such as leukocyte, epidermal cell, and keratinocyte migration.  STAT3 also appears to regulate B cell differentiation into antibody-forming plasma cells.  Since the IL-6/gp130/STAT3 signaling pathway is involved in both B cell growth and differentiation into plasma cells it is likely to play a central role in the generation of plasma cell neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3d_L_4rbebVg90H21EOLACvtfcHk0li_jaAcfdS-8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVGhsbY%253D&md5=01613b7de53ff21fe213230ff9528809</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203551%26sid%3Dliteratum%253Aachs%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DIshihara%26aufirst%3DK.%26aulast%3DHibi%26aufirst%3DM.%26atitle%3DRoles%2520of%2520STAT3%2520in%2520mediating%2520the%2520cell%2520growth%252C%2520dierentiation%2520and%2520survival%2520signals%2520relayed%2520through%2520the%2520IL-6%2520family%2520of%2520cytokine%2520receptors%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D2548%26epage%3D2556%26doi%3D10.1038%2Fsj.onc.1203551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span> <span> </span><span class="NLM_article-title">Antagonizing STAT3 dimerization with a rhodium(III) complex</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">9178</span>– <span class="NLM_lpage">9182</span>, <span class="refDoi"> DOI: 10.1002/anie.201404686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1002%2Fanie.201404686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVKlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=9178-9182&author=D.+L.+Maauthor=L.+J.+Liuauthor=K.+H.+Leungauthor=Y.+T.+Chenauthor=H.+J.+Zhongauthor=D.+S.+H.+Chanauthor=H.+M.+D.+Wangauthor=C.+H.+Leung&title=Antagonizing+STAT3+dimerization+with+a+rhodium%28III%29+complex&doi=10.1002%2Fanie.201404686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonizing STAT3 Dimerization with a Rhodium(III) Complex</span></div><div class="casAuthors">Ma, Dik-Lung; Liu, Li-Juan; Leung, Ka-Ho; Chen, Yen-Ting; Zhong, Hai-Jing; Chan, Daniel Shiu-Hin; Wang, Hui-Min David; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">9178-9182</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Kinetically inert metal complexes have arisen as promising alternatives to existing platinum and ruthenium chemotherapeutics.  Reported herein, to the knowledge, is the first example of a substitutionally inert, Group 9 organometallic compd. as a direct inhibitor of signal transducer and activator of transcription 3 (STAT3) dimerization.  From a series of cyclometalated rhodium(III) and iridium(III) complexes, a rhodium(III) complex emerged as a potent inhibitor of STAT3 that targeted the SH2 domain and inhibited STAT3 phosphorylation and dimerization.  Significantly, the complex exhibited potent antitumor activities in an in vivo mouse xenograft model of melanoma.  This study demonstrates that rhodium complexes may be developed as effective STAT3 inhibitors with potent antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomCWV-3XvfFbVg90H21EOLACvtfcHk0ljWj1urcjeW2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVKlurs%253D&md5=6972af909d01a82ae3acabb013601bd9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.201404686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201404686%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DD.%2BL.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DLeung%26aufirst%3DK.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DZhong%26aufirst%3DH.%2BJ.%26aulast%3DChan%26aufirst%3DD.%2BS.%2BH.%26aulast%3DWang%26aufirst%3DH.%2BM.%2BD.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26atitle%3DAntagonizing%2520STAT3%2520dimerization%2520with%2520a%2520rhodium%2528III%2529%2520complex%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D9178%26epage%3D9182%26doi%3D10.1002%2Fanie.201404686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kujawski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilon-Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Inhibiting stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1314</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1038/nm1325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnm1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=16288283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yisr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1314-1321&author=M.+Kortylewskiauthor=M.+Kujawskiauthor=T.+Wangauthor=S.+Weiauthor=S.+Zhangauthor=S.+Pilon-Thomasauthor=G.+Niuauthor=H.+Kayauthor=J.+Mul%C3%A9author=W.+G.+Kerrauthor=R.+Joveauthor=D.+Pardollauthor=H.+Yu&title=Inhibiting+stat3+signaling+in+the+hematopoietic+system+elicits+multicomponent+antitumor+immunity&doi=10.1038%2Fnm1325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity</span></div><div class="casAuthors">Kortylewski, Marcin; Kujawski, Maciej; Wang, Tianhong; Wei, Sheng; Zhang, Shumin; Pilon-Thomas, Shari; Niu, Guilian; Kay, Heidi; Mule, James; Kerr, William G.; Jove, Richard; Pardoll, Drew; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1314-1321</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The immune system can act as an extrinsic suppressor of tumors.  Thus, tumor progression depends in part on mechanisms that down-modulate intrinsic immune surveillance.  Identifying these inhibitory pathways may provide promising targets to enhance antitumor immunity.  Here, the authors show that Stat3 is constitutively activated in diverse tumor-infiltrating immune cells, and ablating Stat3 in hematopoietic cells triggers an intrinsic immune-surveillance system that inhibits tumor growth and metastasis.  The authors obsd. a markedly enhanced function of dendritic cells, T cells, natural killer (NK) cells, and neutrophils in tumor-bearing mice with Stat3-/- hematopoietic cells, and showed that tumor regression requires immune cells.  Targeting Stat3 with a small-mol. drug induces T cell- and NK cell-dependent growth inhibition of established tumors otherwise resistant to direct killing by the inhibitor.  Thus, Stat3 signaling restrains natural tumor immune surveillance and inhibiting hematopoietic Stat3 in tumor-bearing hosts elicits multicomponent therapeutic antitumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolny_AzPS9lLVg90H21EOLACvtfcHk0lj_MF1W-dP9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yisr3I&md5=69d67d733f183d81742dde37f367053d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnm1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1325%26sid%3Dliteratum%253Aachs%26aulast%3DKortylewski%26aufirst%3DM.%26aulast%3DKujawski%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DPilon-Thomas%26aufirst%3DS.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DKay%26aufirst%3DH.%26aulast%3DMul%25C3%25A9%26aufirst%3DJ.%26aulast%3DKerr%26aufirst%3DW.%2BG.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DInhibiting%2520stat3%2520signaling%2520in%2520the%2520hematopoietic%2520system%2520elicits%2520multicomponent%2520antitumor%2520immunity%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D1314%26epage%3D1321%26doi%3D10.1038%2Fnm1325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Litzenburger, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauschenbach, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höfer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platten, M.</span></span> <span> </span><span class="NLM_article-title">Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.18632%2Foncotarget.1637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24657910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BC2crmtlelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1038-1051&author=U.+M.+Litzenburgerauthor=C.+A.+Opitzauthor=F.+Sahmauthor=K.+J.+Rauschenbachauthor=S.+Trumpauthor=M.+Winterauthor=M.+Ottauthor=K.+Ochsauthor=C.+Lutzauthor=X.+Liuauthor=N.+Anastasovauthor=I.+Lehmannauthor=T.+H%C3%B6ferauthor=A.+Deimlingauthor=W.+Wickauthor=M.+Platten&title=Constitutive+IDO+expression+in+human+cancer+is+sustained+by+an+autocrine+signaling+loop+involving+IL-6%2C+STAT3+and+the+AHR&doi=10.18632%2Foncotarget.1637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR</span></div><div class="casAuthors">Litzenburger Ulrike M; Opitz Christiane A; Sahm Felix; Rauschenbach Katharina J; Trump Saskia; Winter Marcus; Ott Martina; Ochs Katharina; Lutz Christian; Liu Xiangdong; Anastasov Natasa; Lehmann Irina; Hofer Thomas; von Deimling Andreas; Wick Wolfgang; Platten Michael</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1038-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Indoleamine-2,3-dioxygenase (IDO) inhibitors have entered clinical trials based on their ability to restore anti-tumor immunity in preclinical studies.  However, the mechanisms leading to constitutive expression of IDO in human tumors are largely unknown.  Here we analyzed the pathways mediating constitutive IDO expression in human cancer.  IDO-positive tumor cells and tissues showed basal phosphorylation and acetylation of STAT3 as evidenced by western blotting and immunoprecipitation.  Inhibition of IL-6 or STAT3 using siRNA and/or pharmacological inhibitors reduced IDO mRNA and protein expression as well as kynurenine formation.  In turn, IDO enzymatic activity activated the AHR as shown by the induction of AHR target genes.  IDO-mediated AHR activation induced IL-6 expression, while inhibition or knockdown of the AHR reduced IL-6 expression.  IDO activity thus sustains its own expression via an autocrine AHR-IL-6-STAT3 signaling loop.  Inhibition of the AHR-IL-6-STAT3 signaling loop restored T-cell proliferation in mixed leukocyte reactions performed in the presence of IDO-expressing human cancer cells.  Identification of the IDO-AHR-IL-6-STAT3 signaling loop maintaining IDO expression in human cancers reveals novel therapeutic targets for the inhibition of this core pathway promoting immunosuppression of human cancers.  The relevance of the IDO-AHR-IL-6-STAT3 transcriptional circuit is underscored by the finding that high expression of its members IDO, STAT3 and the AHR target gene CYP1B1 is associated with reduced relapse-free survival in lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQ4F7N8tAxhwqdek-gHSrIfW6udTcc2eaMoLJZot6R0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmtlelug%253D%253D&md5=fe0bcfa48ed6b492ff6dff5dff5c869c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1637%26sid%3Dliteratum%253Aachs%26aulast%3DLitzenburger%26aufirst%3DU.%2BM.%26aulast%3DOpitz%26aufirst%3DC.%2BA.%26aulast%3DSahm%26aufirst%3DF.%26aulast%3DRauschenbach%26aufirst%3DK.%2BJ.%26aulast%3DTrump%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DAnastasov%26aufirst%3DN.%26aulast%3DLehmann%26aufirst%3DI.%26aulast%3DH%25C3%25B6fer%26aufirst%3DT.%26aulast%3DDeimling%26aufirst%3DA.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DPlatten%26aufirst%3DM.%26atitle%3DConstitutive%2520IDO%2520expression%2520in%2520human%2520cancer%2520is%2520sustained%2520by%2520an%2520autocrine%2520signaling%2520loop%2520involving%2520IL-6%252C%2520STAT3%2520and%2520the%2520AHR%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D1038%26epage%3D1051%26doi%3D10.18632%2Foncotarget.1637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagishita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nokihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiya, T.</span></span> <span> </span><span class="NLM_article-title">The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-smallcell lung cancer</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/mt.2015.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fmt.2015.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=25597412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=717-727&author=Y.+Fujitaauthor=S.+Yagishitaauthor=K.+Hagiwaraauthor=Y.+Yoshiokaauthor=N.+Kosakaauthor=F.+Takeshitaauthor=T.+Fujiwaraauthor=K.+Tsutaauthor=H.+Nokiharaauthor=T.+Tamuraauthor=H.+Asamuraauthor=M.+Kawaishiauthor=K.+Kuwanoauthor=T.+Ochiya&title=The+clinical+relevance+of+the+miR-197%2FCKS1B%2FSTAT3-mediated+PD-L1+network+in+chemoresistant+non-smallcell+lung+cancer&doi=10.1038%2Fmt.2015.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer</span></div><div class="casAuthors">Fujita, Yu; Yagishita, Shigehiro; Hagiwara, Keitaro; Yoshioka, Yusuke; Kosaka, Nobuyoshi; Takeshita, Fumitaka; Fujiwara, Tomohiro; Tsuta, Koji; Nokihara, Hiroshi; Tamura, Tomohide; Asamura, Hisao; Kawaishi, Makoto; Kuwano, Kazuyoshi; Ochiya, Takahiro</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-727</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Programmed cell death ligand-1 (PD-L1) has recently gained considerable attention for its role in tumor immune escape.  Here, we identify a miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer (NSCLC), independent of immunoinhibitory signals.  MiR-197 is downregulated in platinum-resistant NSCLC specimens, resulting in the promotion of chemoresistance, tumorigenicity, and pulmonary metastasis in vitro and in vivo.  Mechanistic investigations reveal that a miR-197-mediated CKS1B/STAT3 axis exerts tumor progression regulated by various oncogenic genes (Bcl-2, c-Myc, and cyclin D1), and PD-L1 is a putative biomarker of this axis.  Furthermore, we demonstrate that a miR-197 mimic sensitizes PD-L1high drug-resistant cells to chemotherapy.  These results indicate that the biol. interaction between PD-L1 and chemoresistance occurs through the microRNA regulatory cascade.  More importantly, expression levels of miR-197 are inversely correlated with PD-L1 expression (n = 177; P = 0.026) and are assocd. with worse overall survival (P = 0.015).  Our discoveries suggest that the miR-197/CKS1B/STAT3-mediated network can drive tumor PD-L1 expression as a biomarker of this cascade, and miR-197 replacement therapy may be a potential treatment strategy for chemoresistant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3_HY07pVy6LVg90H21EOLACvtfcHk0ljvmCv-djGX1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOqs7o%253D&md5=0f14ec8da56cb12e0361771d8ff50203</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fmt.2015.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2015.10%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DYagishita%26aufirst%3DS.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DYoshioka%26aufirst%3DY.%26aulast%3DKosaka%26aufirst%3DN.%26aulast%3DTakeshita%26aufirst%3DF.%26aulast%3DFujiwara%26aufirst%3DT.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DAsamura%26aufirst%3DH.%26aulast%3DKawaishi%26aufirst%3DM.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DOchiya%26aufirst%3DT.%26atitle%3DThe%2520clinical%2520relevance%2520of%2520the%2520miR-197%252FCKS1B%252FSTAT3-mediated%2520PD-L1%2520network%2520in%2520chemoresistant%2520non-smallcell%2520lung%2520cancer%26jtitle%3DMol.%2520Ther.%26date%3D2015%26volume%3D23%26spage%3D717%26epage%3D727%26doi%3D10.1038%2Fmt.2015.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">2-phenoxy-1,4-naphthoquinones: from a multitarget antitrypanosomal to a potential antitumor profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6422</span>– <span class="NLM_lpage">6434</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00748</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00748" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6422-6434&author=F.+Pratiauthor=C.+Bergaminiauthor=M.+T.+Molinaauthor=F.+Falchiauthor=A.+Cavalliauthor=M.+Kaiserauthor=R.+Brunauthor=R.+Fatoauthor=M.+L.+Bolognesi&title=2-phenoxy-1%2C4-naphthoquinones%3A+from+a+multitarget+antitrypanosomal+to+a+potential+antitumor+profile&doi=10.1021%2Facs.jmedchem.5b00748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile</span></div><div class="casAuthors">Prati, Federica; Bergamini, Christian; Molina, Maria Teresa; Falchi, Federico; Cavalli, Andrea; Kaiser, Marcel; Brun, Reto; Fato, Romana; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6422-6434</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivs. was initially developed to optimize the antitrypanosomatid profile of the multitarget hit compd. B6 (1).  The whole series was evaluated against the three most important human trypanosomatid pathogens (Trypanosoma brucei rhodesiense, Trypanosoma cruzi, and Leishmania donovani), and two compds. (14 and 21) showed good activity, despite a concomitant mammalian cytotoxicity.  Furthermore, a subset also inhibited the glycolytic TbGAPDH enzyme in vitro.  In light of these results and aware of the antitumor properties of quinones, the anticancer potential of some selected derivs. was investigated.  Intriguingly, the tested compds. displayed antitumor activity, while being less toxic against noncancerous cells.  The obsd. cytotoxic potency was ascribed to a multitarget mechanism of action accounting for hGAPDH inhibition and mitochondrial toxicity.  Overall, the development of further derivs., able to finely modulate multiple pathways of cancer or parasite cell metab., might lead to more effective treatments against these devastating diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt4mNbBYvHMLVg90H21EOLACvtfcHk0ljvmCv-djGX1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs7jP&md5=cc969a5d9e4ad7d18e3b7ebd7340e863</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00748%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DBergamini%26aufirst%3DC.%26aulast%3DMolina%26aufirst%3DM.%2BT.%26aulast%3DFalchi%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DFato%26aufirst%3DR.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3D2-phenoxy-1%252C4-naphthoquinones%253A%2520from%2520a%2520multitarget%2520antitrypanosomal%2520to%2520a%2520potential%2520antitumor%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6422%26epage%3D6434%26doi%3D10.1021%2Facs.jmedchem.5b00748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Alonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orellana, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estévez-Braun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelo, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Sacau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machín, F.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">6761</span>– <span class="NLM_lpage">6772</span>, <span class="refDoi"> DOI: 10.1021/jm800499x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800499x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKlurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6761-6772&author=S.+Jim%C3%A9nez-Alonsoauthor=H.+C.+Orellanaauthor=A.+Est%C3%A9vez-Braunauthor=A.+G.+Raveloauthor=E.+P%C3%A9rez-Sacauauthor=F.+Mach%C3%ADn&title=Design+and+synthesis+of+a+novel+series+of+pyranonaphthoquinones+as+topoisomerase+II+catalytic+inhibitors&doi=10.1021%2Fjm800499x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of a Novel Series of Pyranonaphthoquinones as Topoisomerase II Catalytic Inhibitors</span></div><div class="casAuthors">Jimenez-Alonso, Sandra; Chavez Orellana, Haydee; Estevez-Braun, Ana; Ravelo, Angel G.; Perez-Sacau, Elisa; Machin, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6761-6772</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of previous pharmacophore modeling studies of naphthoquinones derivs., a new set of pyranonaphthoquinones, e. g. I, was designed and prepd.  These compds. were obtained through a direct and highly efficient approach based on an intramol. domino Knoevenagel hetero Diels-Alder reaction from lawsone (2-hydroxynaphthoquinone) and a variety of aldehydes contg. an alkene.  The synthesized pyranonaphthoquinones were evaluated against the α isoform of human topoisomerase II (hTopoIIα).  Among the 11 derivs. studied, we found that six of them act as catalytic inhibitors of the enzyme in vitro.  These six derivs. strongly preclude the enzyme from decatenating or relaxing suitable substrates.  Finally, we correlate their active/inactive status with docking studies of these novel compds. into the ATPase domain of hTopoIIα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSqywp9jc7gbVg90H21EOLACvtfcHk0ljO6v6wHFGIDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKlurjK&md5=1fdb6ddd077087415b8ba3c8f8cc605f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm800499x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800499x%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-Alonso%26aufirst%3DS.%26aulast%3DOrellana%26aufirst%3DH.%2BC.%26aulast%3DEst%25C3%25A9vez-Braun%26aufirst%3DA.%26aulast%3DRavelo%26aufirst%3DA.%2BG.%26aulast%3DP%25C3%25A9rez-Sacau%26aufirst%3DE.%26aulast%3DMach%25C3%25ADn%26aufirst%3DF.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520novel%2520series%2520of%2520pyranonaphthoquinones%2520as%2520topoisomerase%2520II%2520catalytic%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6761%26epage%3D6772%26doi%3D10.1021%2Fjm800499x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WGuida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.1021/jm201118h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201118h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVGlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1978-1998&author=Y.+Geauthor=A.+Kaziauthor=F.+Marsilioauthor=Y.+Luoauthor=S.+Jainauthor=W.+Brooksauthor=K.+G.+Danielauthor=C.+WGuidaauthor=S.+M.+Sebtiauthor=H.+R.+Lawrence&title=Discovery+and+synthesis+of+hydronaphthoquinones+as+novel+proteasome+inhibitors&doi=10.1021%2Fjm201118h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Synthesis of Hydronaphthoquinones as Novel Proteasome Inhibitors</span></div><div class="casAuthors">Ge, Yiyu; Kazi, Aslamuzzaman; Marsilio, Frank; Luo, Yunting; Jain, Sanjula; Brooks, Wesley; Daniel, Kenyon G.; Guida, Wayne C.; Sebti, Said M.; Lawrence, Harshani R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1978-1998</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Screening efforts led to the identification of PI-8182 (I, 2-[[1-hydroxy-4-[(2-thienylsulfonyl)amino]-2-naphthalenyl]thio]acetic acid), an inhibitor of the chymotrypsin-like (CT-L) activity of the proteasome.  Compd. I contains a hydronaphthoquinone pharmacophore with a thioglycolic acid side chain at position 2 and thiophene sulfonamide at position 4.  An efficient synthetic route to the hydronaphthoquinone sulfonamide scaffold was developed, and compd. I was synthesized inhouse to confirm the structure and activity (IC50 = 3.0 ± 1.6 μM [n = 25]).  Novel hydronaphthoquinone derivs. of I were designed, synthesized, and evaluated as proteasome inhibitors.  The structure-activity relationship (SAR) guided synthesis of more than 170 derivs. revealed that the thioglycolic acid side chain is required and the carboxylic acid group of this side chain is crit. to the CT-L inhibitory activity of compd. I.  Furthermore, replacement of the carboxylic acid with carboxylic acid isosteres such as tetrazole or triazole greatly improves potency.  Compds. with a thio-tetrazole or thio-triazole side chain in position 2, where the thiophene was replaced by hydrophobic aryl moieties, were the most active compds. with up to 20-fold greater CT-L inhibition (IC50 = 150 nM) than compd. I.  The synthetic iterations described here not only led to improving potency in vitro but also resulted in the identification of compds. that are more active such as N-[4-hydroxy-3-(1H-tetrazol-5-ylthio)-1-naphthalenyl]-4'-(trifluoromethyl)biphenyl-4-sulfonamide (IC50 = 0.44 to 1.01 μM) than I (IC50 = 3.54 to 7.22 μM) at inhibiting the proteasome CT-L activity in intact breast cancer cells.  Treatment with this more active compd. also resulted in the accumulation of ubiquitinated cellular proteins and inhibition of tumor cell proliferation of breast cancer cells.  The hit I and its analog inhibited proteasome CT-L activity irreversibly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofTgJ17P5sRrVg90H21EOLACvtfcHk0ljO6v6wHFGIDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVGlsA%253D%253D&md5=d663a8a5444fba3c6a005666dbbab280</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm201118h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201118h%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DY.%26aulast%3DKazi%26aufirst%3DA.%26aulast%3DMarsilio%26aufirst%3DF.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DBrooks%26aufirst%3DW.%26aulast%3DDaniel%26aufirst%3DK.%2BG.%26aulast%3DWGuida%26aufirst%3DC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520hydronaphthoquinones%2520as%2520novel%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1978%26epage%3D1998%26doi%3D10.1021%2Fjm201118h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaLonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1021/jm7014155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7014155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislKqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1706-1718&author=S.+Kumarauthor=W.+P.+Malachowskiauthor=J.+B.+DuHadawayauthor=J.+M.+LaLondeauthor=P.+J.+Carrollauthor=D.+Jallerauthor=R.+Metzauthor=G.+C.+Prendergastauthor=A.+J.+Muller&title=Indoleamine+2%2C3-dioxygenase+is+the+anticancer+target+for+a+novel+series+of+potent+naphthoquinone-based+inhibitors&doi=10.1021%2Fjm7014155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors</span></div><div class="casAuthors">Kumar, Sanjeev; Malachowski, William P.; DuHadaway, James B.; LaLonde, Judith M.; Carroll, Patrick J.; Jaller, Daniel; Metz, Richard; Prendergast, George C.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1706-1718</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathol. immune suppression.  While small mol. inhibitors of IDO exist, there remains a dearth of high-potency compds. offering in vivo efficacy and clin. translational potential.  In this study, the authors address this gap by defining a new class of naphthoquinone-based IDO inhibitors exemplified by the natural product menadione, which is shown in mouse tumor models to have similar antitumor activity to previously characterized IDO inhibitors.  Genetic validation that IDO is the crit. in vivo target is demonstrated using IDO-null mice.  Elaboration of menadione to a pyranonaphthoquinone has yielded low nanomolar potency inhibitors, including new compds. which are the most potent reported to date (Ki = 61-70 nM).  Synthetic accessibility of this class will facilitate preclin. chem.-genetic studies as well as further optimization of pharmacol. parameters for clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1ZM1JKuRtPbVg90H21EOLACvtfcHk0lh3OkvzCNC4Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislKqtL4%253D&md5=9d3c1bc16796927ab88fc5d6b6ef065a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm7014155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7014155%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DLaLonde%26aufirst%3DJ.%2BM.%26aulast%3DCarroll%26aufirst%3DP.%2BJ.%26aulast%3DJaller%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DIndoleamine%25202%252C3-dioxygenase%2520is%2520the%2520anticancer%2520target%2520for%2520a%2520novel%2520series%2520of%2520potent%2520naphthoquinone-based%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1706%26epage%3D1718%26doi%3D10.1021%2Fjm7014155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Identification of substituted naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7807</span>– <span class="NLM_lpage">7819</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7807-7819&author=J.+S.+Wuauthor=S.+Y.+Linauthor=F.+Y.+Liaoauthor=W.+C.+Hsiaoauthor=L.+C.+Leeauthor=Y.+H.+Pengauthor=C.+L.+Hsiehauthor=M.+H.+Wuauthor=J.+S.+Songauthor=A.+Yuehauthor=C.+H.+Chenauthor=S.+H.+Yehauthor=C.+Y.+Liuauthor=S.+Y.+Linauthor=T.+K.+Yehauthor=J.+T.+A.+Hsuauthor=C.+Shihauthor=S.+H.+Uengauthor=M.+S.+Hungauthor=S.+Y.+Wu&title=Identification+of+substituted+naphthotriazolediones+as+novel+tryptophan+2%2C3-dioxygenase+%28TDO%29+inhibitors+through+structure-based+virtual+screening&doi=10.1021%2Facs.jmedchem.5b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening</span></div><div class="casAuthors">Wu, Jian-Sung; Lin, Shu-Yu; Liao, Fang-Yu; Hsiao, Wen-Chi; Lee, Lung-Chun; Peng, Yi-Hui; Hsieh, Chia-Ling; Wu, Mine-Hsine; Song, Jen-Shin; Yueh, Andrew; Chen, Chun-Hwa; Yeh, Shiu-Hwa; Liu, Chia-Yeh; Lin, Shu-Yi; Yeh, Teng-Kuang; Hsu, John T.-A.; Shih, Chuan; Ueng, Shau-Hua; Hung, Ming-Shiu; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7807-7819</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based virtual screening strategy, comprising homol. modeling, ligand-support binding site optimization, virtual screening, and structure clustering anal., was developed and used to identify novel tryptophan 2,3-dioxygenase (TDO) inhibitors.  Compd. 1 (IC50 = 711 nM), selected by virtual screening, showed inhibitory activity toward TDO and was subjected to structural modifications and mol. docking studies.  This resulted in the identification of a potent TDO selective inhibitor (11e, IC50 = 30 nM), making it a potential compd. for further investigation as a cancer therapeutic and other TDO-related targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_08WPyOJIMbVg90H21EOLACvtfcHk0lh3OkvzCNC4Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7vI&md5=3aea83affb3164c94f8cbfead21dbcce</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00921%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DHsiao%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DYueh%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DYeh%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%2BA.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26atitle%3DIdentification%2520of%2520substituted%2520naphthotriazolediones%2520as%2520novel%2520tryptophan%25202%252C3-dioxygenase%2520%2528TDO%2529%2520inhibitors%2520through%2520structure-based%2520virtual%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7807%26epage%3D7819%26doi%3D10.1021%2Facs.jmedchem.5b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2718</span>– <span class="NLM_lpage">2731</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2718-2731&author=W.+Yuauthor=C.+Liauthor=W.+Zhangauthor=Y.+Xiaauthor=S.+Liauthor=J.+Linauthor=K.+Yuauthor=M.+Liuauthor=L.+Yangauthor=J.+Luoauthor=Y.+Chenauthor=H.+Sunauthor=L.+Kong&title=Discovery+of+an+orally+selective+inhibitor+of+signal+transducer+and+activator+of+transcription+3+using+advanced+multiple+ligand+simultaneous+docking&doi=10.1021%2Facs.jmedchem.6b01489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking</span></div><div class="casAuthors">Yu, Wenying; Li, Chenglong; Zhang, Wenda; Xia, Yuanzheng; Li, Shanshan; Lin, Jia-yuh; Yu, Keqin; Liu, Mu; Yang, Lei; Luo, Jianguang; Chen, Yijun; Sun, Hongbin; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2718-2731</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting signal transducer and activator of transcription 3 (STAT3) is a potential anticancer strategy.  However, STAT3 inhibitors with good selectivity and bioavailability are rare.  The aim of this study was to discover selective direct STAT3 inhibitors with good drug-likeness.  By advanced multiple ligand simultaneous docking (AMLSD) method, compd. 9 (5,8-dioxo-6-((2-(piperazin-1-yl)phenyl)amino)-5,8-dihydronaphthalene-1-sulfonamide) was designed as an orally-bioavailable STAT3 inhibitor, which presented superior druggability and selectivity to other representative STAT3 inhibitors.  Compd. 9 directly and selectively inhibited the pY705 site of STAT3 with an affinity (Ki) of 440nM.  The IC50 of 9 for breast cancer cell MDA-MB-231 was 184-fold lower than its IC50 for normal breast epithelial cell MCF-10A.  Compd. 9 in vivo induced significant antitumor responses better than Gefitinib and its therapeutic index should be over 100, indicating good safety of 9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiT8F_tCrky7Vg90H21EOLACvtfcHk0ljmoNSnV5_l5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D&md5=d9554e49fd17a559e8c7171f36c53607</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01489%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520selective%2520inhibitor%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520using%2520advanced%2520multiple%2520ligand%2520simultaneous%2520docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2718%26epage%3D2731%26doi%3D10.1021%2Facs.jmedchem.6b01489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandur, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, B. B.</span></span> <span> </span><span class="NLM_article-title">5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-09-0257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1158%2F1541-7786.MCR-09-0257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20068065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=107-118&author=S.+K.+Sandurauthor=M.+K.+Pandeyauthor=B.+Sungauthor=B.+B.+Aggarwal&title=5-hydroxy-2-methyl-1%2C4-naphthoquinone%2C+a+vitamin+K3+analogue%2C+suppresses+STAT3+activation+pathway+through+induction+of+protein+tyrosine+phosphatase%2C+SHP-1%3A+potential+role+in+chemosensitization&doi=10.1158%2F1541-7786.MCR-09-0257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">5-Hydroxy-2-Methyl-1,4-Naphthoquinone, a Vitamin K3 Analogue, Suppresses STAT3 Activation Pathway through Induction of Protein Tyrosine Phosphatase, SHP-1: Potential Role in Chemosensitization</span></div><div class="casAuthors">Sandur, Santosh K.; Pandey, Manoj K.; Sung, Bokyung; Aggarwal, Bharat B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-118</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The activation of signal transducers and activators of transcription 3 (STAT3) has been linked with carcinogenesis through survival, proliferation, and angiogenesis of tumor cells.  Agents that can suppress STAT3 activation have potential not only for prevention but also for treatment of cancer.  In the present report, we investigated whether 5-hydroxy-2-methyl-1,4-naphthoquinone (plumbagin), an analog of vitamin K, and isolated from chitrak (Plumbago zeylanica), an Ayurvedic medicinal plant, can modulate the STAT3 pathway.  We found that plumbagin inhibited both constitutive and interleukin 6-inducible STAT3 phosphorylation in multiple myeloma (MM) cells and this correlated with the inhibition of c-Src, Janus-activated kinase (JAK)1, and JAK2 activation.  Vanadate, however, reversed the plumbagin-induced downregulation of STAT3 activation, suggesting the involvement of a protein tyrosine phosphatase.  Indeed, we found that plumbagin induced the expression of the protein tyrosine phosphatase, SHP-1, and silencing of the SHP-1 abolished the effect of plumbagin.  This agent also downregulated the expression of STAT3-regulated cyclin D1, Bcl-xL, and vascular endothelial growth factor; activated caspase-3; induced poly (ADP ribose) polymerase cleavage; and increased the sub-G1 population of MM cells.  Consistent with these results, overexpression of constitutive active STAT3 significantly reduced the plumbagin-induced apoptosis.  When compared with AG490, a rationally designed STAT3/JAK2 inhibitor, plumbagin was found more potent in suppressing the proliferation of cells.  Plumbagin also significantly potentiated the apoptotic effects of thalidomide and bortezomib in MM cells.  Overall, these results suggest that the plumbagin inhibits STAT3 activation pathway through the induction of SHP-1 and this may mediate the sensitization of STAT3 overexpressing cancers to chemotherapeutic agents.Mol Cancer Res; 8(1); 107-118.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEfWjYszUxp7Vg90H21EOLACvtfcHk0lhs-iao1X0uaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVChtQ%253D%253D&md5=70d7ff84abe86dceee49dd6e75dcabf0</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-09-0257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-09-0257%26sid%3Dliteratum%253Aachs%26aulast%3DSandur%26aufirst%3DS.%2BK.%26aulast%3DPandey%26aufirst%3DM.%2BK.%26aulast%3DSung%26aufirst%3DB.%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26atitle%3D5-hydroxy-2-methyl-1%252C4-naphthoquinone%252C%2520a%2520vitamin%2520K3%2520analogue%252C%2520suppresses%2520STAT3%2520activation%2520pathway%2520through%2520induction%2520of%2520protein%2520tyrosine%2520phosphatase%252C%2520SHP-1%253A%2520potential%2520role%2520in%2520chemosensitization%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2010%26volume%3D8%26spage%3D107%26epage%3D118%26doi%3D10.1158%2F1541-7786.MCR-09-0257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tojo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamioka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal structures and structure–activity relationships of imidazothiazole derivatives as IDO1 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1021/ml500247w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500247w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1119-1123&author=S.+Tojoauthor=T.+Kohnoauthor=T.+Tanakaauthor=S.+Kamiokaauthor=Y.+Otaauthor=T.+Ishiiauthor=K.+Kamimotoauthor=S.+Asanoauthor=Y.+Isobe&title=Crystal+structures+and+structure%E2%80%93activity+relationships+of+imidazothiazole+derivatives+as+IDO1+inhibitors&doi=10.1021%2Fml500247w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors</span></div><div class="casAuthors">Tojo, Shingo; Kohno, Tetsuya; Tanaka, Tomoyuki; Kamioka, Seiji; Ota, Yosuke; Ishii, Takayuki; Kamimoto, Keiko; Asano, Shigehiro; Isobe, Yoshiaki</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as a promising target for the treatment of several diseases, including neurol. disorders and cancer.  We report here the crystal structures of two IDO1/IDO1 inhibitor complexes, one of which shows that Amg-1 is directly bound to the heme iron of IDO1 with a clear induced fit.  We also describe the identification and preliminary optimization of imidazothiazole derivs. as novel IDO1 inhibitors.  Using our crystal structure information and structure-activity relationships (SAR) at the pocket-B of IDO1, we found a series of urea derivs. as potent IDO1 inhibitors and revealed that generation of an induced fit and the resulting interaction with Phe226 and Arg231 are essential for potent IDO1 inhibitory activity.  The results of this study are very valuable for understanding the mechanism of IDO1 activation, which is very important for structure-based drug design (SBDD) to discover potent IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO6dAvsq0nObVg90H21EOLACvtfcHk0lhs-iao1X0uaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLnI&md5=7eaf3faae0c29a60de5f23a48a079af7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fml500247w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500247w%26sid%3Dliteratum%253Aachs%26aulast%3DTojo%26aufirst%3DS.%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKamioka%26aufirst%3DS.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DKamimoto%26aufirst%3DK.%26aulast%3DAsano%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DY.%26atitle%3DCrystal%2520structures%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520imidazothiazole%2520derivatives%2520as%2520IDO1%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1119%26epage%3D1123%26doi%3D10.1021%2Fml500247w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hazimi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Faham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghazzali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Farhan, K.</span></span> <span> </span><span class="NLM_article-title">Microwave irradiation: a facile, scalable and convenient method for synthesis of N-phthaloylamino acids</span>. <i>Arab. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1016/j.arabjc.2010.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.arabjc.2010.06.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=285-289&author=H.+M.+Al-Hazimiauthor=A.+El-Fahamauthor=M.+Ghazzaliauthor=K.+Al-Farhan&title=Microwave+irradiation%3A+a+facile%2C+scalable+and+convenient+method+for+synthesis+of+N-phthaloylamino+acids&doi=10.1016%2Fj.arabjc.2010.06.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.arabjc.2010.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.arabjc.2010.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Hazimi%26aufirst%3DH.%2BM.%26aulast%3DEl-Faham%26aufirst%3DA.%26aulast%3DGhazzali%26aufirst%3DM.%26aulast%3DAl-Farhan%26aufirst%3DK.%26atitle%3DMicrowave%2520irradiation%253A%2520a%2520facile%252C%2520scalable%2520and%2520convenient%2520method%2520for%2520synthesis%2520of%2520N-phthaloylamino%2520acids%26jtitle%3DArab.%2520J.%2520Chem.%26date%3D2012%26volume%3D5%26spage%3D285%26epage%3D289%26doi%3D10.1016%2Fj.arabjc.2010.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3403</span>– <span class="NLM_lpage">3406</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.bmcl.2014.05.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24939758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3403-3406&author=M.+F.+Chengauthor=M.+S.+Hungauthor=J.+S.+Songauthor=S.+Y.+Linauthor=F.+Y.+Liaoauthor=M.+H.+Wuauthor=W.+Hsiaoauthor=C.+L.+Hsiehauthor=J.+S.+Wuauthor=Y.+S.+Chaoauthor=C.+Shihauthor=S.+Y.+Wuauthor=S.+H.+Ueng&title=Discovery+and+structure-activity+relationships+of+phenyl+benzenesulfonylhydrazides+as+novel+indoleamine+2%2C3-dioxygenase+inhibitors&doi=10.1016%2Fj.bmcl.2014.05.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Cheng, Ming-Fu; Hung, Ming-Shiu; Song, Jen-Shin; Lin, Shu-Yu; Liao, Fang-Yu; Wu, Mine-Hsine; Hsiao, Wenchi; Hsieh, Chia-Ling; Wu, Jian-Sung; Chao, Yu-Sheng; Shih, Chuan; Wu, Su-Ying; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3403-3406</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of Ph benzenesulfonylhydrazides has been identified as potent inhibitors of indoleamine 2,3-dioxygenase (IDO), and their structure-activity relationship was explored.  Coupling reactions between various benzenesulfonyl chlorides and phenylhydrazides were utilized to synthesize the sulfonylhydrazides bearing various substituents.  Compd. 3i exhibited 61 nM of IC50 in enzymic assay and 172 nM of EC50 in the HeLa cell.  The computational study of 3i suggested that the major interactions between 3i and IDO protein are the coordination of sulfone and heme iron, the hydrogen bonding and hydrophobic interactions between 3i and IDO.  This novel class of IDO inhibitor provides a new direction to discover effective anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCMHnPLf2u5LVg90H21EOLACvtfcHk0li6Ar0zdwzfVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrM&md5=560f7daccbb56934079c186991fd1b52</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.084%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsiao%26aufirst%3DW.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DDiscovery%2520and%2520structure-activity%2520relationships%2520of%2520phenyl%2520benzenesulfonylhydrazides%2520as%2520novel%2520indoleamine%25202%252C3-dioxygenase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3403%26epage%3D3406%26doi%3D10.1016%2Fj.bmcl.2014.05.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, W.</span></span> <span> </span><span class="NLM_article-title">Why is the oxidation state of iron crucial for the activity of heme dependent aldoxime dehydratase? A QM/MM study</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">9396</span>– <span class="NLM_lpage">9408</span>, <span class="refDoi"> DOI: 10.1021/jp305510c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp305510c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCmtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2012&pages=9396-9408&author=R.+Z.+Liaoauthor=W.+Thiel&title=Why+is+the+oxidation+state+of+iron+crucial+for+the+activity+of+heme+dependent+aldoxime+dehydratase%3F+A+QM%2FMM+study&doi=10.1021%2Fjp305510c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Why Is the Oxidation State of Iron Crucial for the Activity of Heme-Dependent Aldoxime Dehydratase? A QM/MM Study</span></div><div class="casAuthors">Liao, Rong-Zhen; Thiel, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">9396-9408</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-5207</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldoxime dehydratase is a heme-contg. enzyme that utilizes the ferrous rather than the ferric ion to catalyze the synthesis of nitriles by dehydration of the substrate.  We report a theor. study of this enzyme aimed at elucidating its catalytic mechanism and understanding this oxidn. state preference (Fe2+ vs. Fe3+).  The uncatalyzed dehydration reaction was modeled by including three and four water mols. to assist in the proton transfer, but the computed barriers were very high at both the DFT (B3LYP) and coupled cluster CCSD(T) levels.  The enzymic dehydration of Z-acetaldoxime was explored through QM/MM calcn. using two different QM regions and covering all three possible spin states.  The reaction starts by substrate coordination to Fe2+ via its nitrogen atom to form a six-coordinated singlet reactant complex.  The ferrous heme catalyzes the N-O bond cleavage by transferring one electron to the antibond in the singlet state, while His320 functions as a general acid to deliver a proton to the leaving hydroxide, thus facilitating its departure.  The key intermediate is identified as an FeIII(CH3CH=N·) species (triplet or open-shell singlet), with the closed-shell singlet FeII(CH3CH=N+) being about 6 kcal/mol higher.  Subsequently, the same His320 residue abstrs. the α-proton, coupled with electron transfer back to the iron center.  Both steps are calcd. to have feasible barriers (14-15 kcal/mol), in agreement with exptl. kinetic studies.  For the same mode of substrate coordination, the ferric heme does not catalyze the N-O bond cleavage, because the reaction is endothermic by about 40 kcal/mol, mainly due to the energetic penalty for oxidizing the ferric heme.  The alternative binding option, in which the anionic aldoxime coordinates to the ferric ion via its oxyanion, also results in a high barrier (around 30 kcal/mol), mainly because of the large endothermicity assocd. with the generation of a suitable base (neutral His320) for proton abstraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnw_Dxn1xpvbVg90H21EOLACvtfcHk0li6Ar0zdwzfVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCmtrzK&md5=e9157236a8fedbd4ab62ab94a51ee8ee</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjp305510c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp305510c%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DR.%2BZ.%26aulast%3DThiel%26aufirst%3DW.%26atitle%3DWhy%2520is%2520the%2520oxidation%2520state%2520of%2520iron%2520crucial%2520for%2520the%2520activity%2520of%2520heme%2520dependent%2520aldoxime%2520dehydratase%253F%2520A%2520QM%252FMM%2520study%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2012%26volume%3D116%26spage%3D9396%26epage%3D9408%26doi%3D10.1021%2Fjp305510c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takvorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immunooncology</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=486-491&author=E.+W.+Yueauthor=R.+Sparksauthor=P.+Polamauthor=D.+Modiauthor=B.+Doutyauthor=B.+Waylandauthor=B.+Glassauthor=A.+Takvorianauthor=J.+Glennauthor=W.+Zhuauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=T.+Emmauthor=P.+A.+Scherleauthor=B.+Metcalfauthor=A.+P.+Combs&title=INCB24360+%28Epacadostat%29%2C+a+highly+potent+and+selective+indoleamine-2%2C3-dioxygenase+1+%28IDO1%29+inhibitor+for+immunooncology&doi=10.1021%2Facsmedchemlett.6b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology</span></div><div class="casAuthors">Yue, Eddy W.; Sparks, Richard; Polam, Padmaja; Modi, Dilip; Douty, Brent; Wayland, Brian; Glass, Brian; Takvorian, Amy; Glenn, Joseph; Zhu, Wenyu; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Emm, Tom; Scherle, Peggy A.; Metcalf, Brian; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A data-centric medicinal chem. approach led to the invention of a potent and selective IDO1 inhibitor 4f, INCB24360 (epacadostat).  The mol. structure of INCB24360 contains several previously unknown or underutilized functional groups in drug substances, including a hydroxyamidine, furazan, bromide and sulfamide.  These moieties taken together in a single structure afford a compd. which falls outside of "drug-like" space.  Nevertheless, the in vitro ADME data is consistent with the good cell permeability and oral bioavailability obsd. in all species (rat, dog, monkey) tested.  The extensive intramol. hydrogen bonding obsd. in the small mol. crystal structure of 4f is believed to significantly contribute to the obsd. permeability and PK.  Epacadostat in combination with anti-PD1 mAb pembrolizumab is currently being studied in a phase 3 clin. trial in patients with unresectable or metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpm79ArpY1yLVg90H21EOLACvtfcHk0ljp_tiP_eu35w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D&md5=92bebde519334e9e2a776250bb0258ac</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00391%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DSparks%26aufirst%3DR.%26aulast%3DPolam%26aufirst%3DP.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DGlass%26aufirst%3DB.%26aulast%3DTakvorian%26aufirst%3DA.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DINCB24360%2520%2528Epacadostat%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520indoleamine-2%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitor%2520for%2520immunooncology%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D486%26epage%3D491%26doi%3D10.1021%2Facsmedchemlett.6b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röhrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosdidier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5270</span>– <span class="NLM_lpage">5290</span>, <span class="refDoi"> DOI: 10.1021/jm300260v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300260v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1yiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5270-5290&author=U.+F.+R%C3%B6hrigauthor=S.+R.+Majjigapuauthor=A.+Grosdidierauthor=S.+Bronauthor=V.+Stroobantauthor=L.+Pilotteauthor=D.+Colauauthor=P.+Vogelauthor=B.+J.+Van+den%0AEyndeauthor=V.+Zoeteauthor=O.+Michielin&title=Rational+design+of+4-aryl-1%2C2%2C3-triazoles+for+indoleamine+2%2C3-dioxygenase+1+inhibition&doi=10.1021%2Fjm300260v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Grosdidier, Aurelien; Bron, Sylvian; Stroobant, Vincent; Pilotte, Luc; Colau, Didier; Vogel, Pierre; Van den Eynde, Benoit J.; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5270-5290</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an important therapeutic target for the treatment of diseases such as cancer that involve pathol. immune escape.  Starting from the scaffold of our previously discovered IDO1 inhibitor 4-phenyl-1,2,3-triazole, we used computational structure-based methods to design more potent ligands.  This approach yielded highly efficient low mol. wt. inhibitors, the most active being of nanomolar potency both in an enzymic and in a cellular assay, while showing no cellular toxicity and a high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO).  A quant. structure-activity relationship based on the electrostatic ligand-protein interactions in the docked binding modes and on the quantum chem. derived charges of the triazole ring demonstrated a good explanatory power for the obsd. activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CFYZnWiLSLVg90H21EOLACvtfcHk0lgsDhenOc_TqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1yiu7c%253D&md5=6ba6c0b628165673cd49c7a950ed885e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm300260v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300260v%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6hrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DGrosdidier%26aufirst%3DA.%26aulast%3DBron%26aufirst%3DS.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DRational%2520design%2520of%25204-aryl-1%252C2%252C3-triazoles%2520for%2520indoleamine%25202%252C3-dioxygenase%25201%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5270%26epage%3D5290%26doi%3D10.1021%2Fjm300260v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schenkman, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sligar, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinti, D. L.</span></span> <span> </span><span class="NLM_article-title">Substrate interaction with cytochrome P-450</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/0163-7258(81)90075-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2F0163-7258%2881%2990075-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=7019934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADyaL3MXhtFKjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1981&pages=43-71&author=J.+B.+Schenkmanauthor=S.+G.+Sligarauthor=D.+L.+Cinti&title=Substrate+interaction+with+cytochrome+P-450&doi=10.1016%2F0163-7258%2881%2990075-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate interaction with cytochrome P-450</span></div><div class="casAuthors">Schenkman, John B.; Sligar, Stephen G.; Cinti, Dominick L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-71</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    </div><div class="casAbstract">A review with 127 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMfbDvPjv3o7Vg90H21EOLACvtfcHk0lgsDhenOc_TqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhtFKjtLk%253D&md5=b9d1f290388d5a8754c16ece14cdc049</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0163-7258%2881%2990075-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0163-7258%252881%252990075-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchenkman%26aufirst%3DJ.%2BB.%26aulast%3DSligar%26aufirst%3DS.%2BG.%26aulast%3DCinti%26aufirst%3DD.%2BL.%26atitle%3DSubstrate%2520interaction%2520with%2520cytochrome%2520P-450%26jtitle%3DPharmacol.%2520Ther.%26date%3D1981%26volume%3D12%26spage%3D43%26epage%3D71%26doi%3D10.1016%2F0163-7258%2881%2990075-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyauchi, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winfield, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finniear, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotinou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djordjevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsirka, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachary, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selwood, D. L.</span></span> <span> </span><span class="NLM_article-title">Small molecule neuropilin-1 antagonists combine antiangiogenic and antitumor activity with immune modulation through reduction of transforming trowth factor beta (TGFβ) production in regulatory T-cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4135</span>– <span class="NLM_lpage">4154</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00210</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00210" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFSgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4135-4154&author=J.+Powellauthor=F.+Motaauthor=D.+Steadmanauthor=C.+Soudyauthor=J.+T.+Miyauchiauthor=S.+Crosbyauthor=A.+Jarvisauthor=T.+Reisingerauthor=N.+Winfieldauthor=G.+Evansauthor=A.+Finniearauthor=T.+Yellandauthor=Y.+T.+Chouauthor=A.+W.+E.+Chanauthor=A.+O.+Learyauthor=L.+Chengauthor=D.+Liuauthor=C.+Fotinouauthor=C.+Milagreauthor=J.+F.+Martinauthor=H.+Jiaauthor=P.+Frankelauthor=S.+Djordjevicauthor=S.+E.+Tsirkaauthor=I.+C.+Zacharyauthor=D.+L.+Selwood&title=Small+molecule+neuropilin-1+antagonists+combine+antiangiogenic+and+antitumor+activity+with+immune+modulation+through+reduction+of+transforming+trowth+factor+beta+%28TGF%CE%B2%29+production+in+regulatory+T-cells&doi=10.1021%2Facs.jmedchem.8b00210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells</span></div><div class="casAuthors">Powell, Jonathan; Mota, Filipa; Steadman, David; Soudy, Christelle; Miyauchi, Jeremy T.; Crosby, Stuart; Jarvis, Ashley; Reisinger, Tifelle; Winfield, Natalie; Evans, Graham; Finniear, Aled; Yelland, Tamas; Chou, Yi-Tai; Chan, A. W. Edith; O'Leary, Andrew; Cheng, Lili; Liu, Dan; Fotinou, Constantina; Milagre, Carla; Martin, John F.; Jia, Haiyan; Frankel, Paul; Djordjevic, Snezana; Tsirka, Stella E.; Zachary, Ian C.; Selwood, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4135-4154</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the design, synthesis and comprehensive biol. evaluation of a range of some potent small-mol. neuropilin-1 (NRP1) antagonists.  NRP1 is implicated in the immune response to tumors, particularly in Treg cell fragility, required for PD1 checkpoint blockade.  The design of these compds. was based on a previously identified compd. EG00229 which was used a starting point for optimization.  Through targeting of specific amino-acid residues addnl. H-bonding interactions were introduced, which led to increases in binding affinity and potency.  The design of these mols. was informed and supported by X-ray crystal structures.  Pharmacokinetic data was obtained for some of the most potent compds., and compd. 1 (EG01377) was identified as having properties suitable for further investigation.  Compd. 1 was then tested in several in vitro assays, and was shown to have anti-angiogenic, anti-migratory and anti-tumor effects.  Remarkably, 1 was shown to be selective for NRP1 over the closely related protein NRP2.  In purified Nrp1+, FoxP3+, CD25+ populations of Tregs from mice 1 was able to block a glioma conditioned medium induced increase in TGFβ prodn.  This study therefore represents a comprehensive characterization of a small-mol. NRP1 antagonist, and provides the basis for future in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNGxPChEZvNbVg90H21EOLACvtfcHk0liuw6i1TVlpoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFSgu7c%253D&md5=3917a78cce28364a8db538e6fae98582</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00210%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DMota%26aufirst%3DF.%26aulast%3DSteadman%26aufirst%3DD.%26aulast%3DSoudy%26aufirst%3DC.%26aulast%3DMiyauchi%26aufirst%3DJ.%2BT.%26aulast%3DCrosby%26aufirst%3DS.%26aulast%3DJarvis%26aufirst%3DA.%26aulast%3DReisinger%26aufirst%3DT.%26aulast%3DWinfield%26aufirst%3DN.%26aulast%3DEvans%26aufirst%3DG.%26aulast%3DFinniear%26aufirst%3DA.%26aulast%3DYelland%26aufirst%3DT.%26aulast%3DChou%26aufirst%3DY.%2BT.%26aulast%3DChan%26aufirst%3DA.%2BW.%2BE.%26aulast%3DLeary%26aufirst%3DA.%2BO.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DFotinou%26aufirst%3DC.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DJ.%2BF.%26aulast%3DJia%26aufirst%3DH.%26aulast%3DFrankel%26aufirst%3DP.%26aulast%3DDjordjevic%26aufirst%3DS.%26aulast%3DTsirka%26aufirst%3DS.%2BE.%26aulast%3DZachary%26aufirst%3DI.%2BC.%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26atitle%3DSmall%2520molecule%2520neuropilin-1%2520antagonists%2520combine%2520antiangiogenic%2520and%2520antitumor%2520activity%2520with%2520immune%2520modulation%2520through%2520reduction%2520of%2520transforming%2520trowth%2520factor%2520beta%2520%2528TGF%25CE%25B2%2529%2520production%2520in%2520regulatory%2520T-cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4135%26epage%3D4154%26doi%3D10.1021%2Facs.jmedchem.8b00210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Expression of indoleamine 2,3- dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1172/JCI21583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1172%2FJCI21583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=15254595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFWmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2004&pages=280-290&author=D.+H.+Munnauthor=M.+D.+Sharmaauthor=D.+Hou&title=Expression+of+indoleamine+2%2C3-+dioxygenase+by+plasmacytoid+dendritic+cells+in+tumor-draining+lymph+nodes&doi=10.1172%2FJCI21583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes</span></div><div class="casAuthors">Munn, David H.; Sharma, Madhav D.; Hou, Deyan; Baban, Babak; Lee, Jeffrey R.; Antonia, Scott J.; Messina, Jane L.; Chandler, Phillip; Koni, Pandelakis A.; Mellor, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-290</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">One mechanism contributing to immunol. unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs.  We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).  Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs.  Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs.  Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice.  Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19.  We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGNDuxa-Ss3bVg90H21EOLACvtfcHk0liuw6i1TVlpoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFWmsbg%253D&md5=da173363d15fb2bda14b1be20d2e41cd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1172%2FJCI21583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI21583%26sid%3Dliteratum%253Aachs%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DSharma%26aufirst%3DM.%2BD.%26aulast%3DHou%26aufirst%3DD.%26atitle%3DExpression%2520of%2520indoleamine%25202%252C3-%2520dioxygenase%2520by%2520plasmacytoid%2520dendritic%2520cells%2520in%2520tumor-draining%2520lymph%2520nodes%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D114%26spage%3D280%26epage%3D290%26doi%3D10.1172%2FJCI21583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza, S. M.</span></span> <span> </span><span class="NLM_article-title">The anticancer effects of vitamin K</span>. <i>Altern. Med. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=12946240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BD3svgslGgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=303-318&author=D.+W.+Lamsonauthor=S.+M.+Plaza&title=The+anticancer+effects+of+vitamin+K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The anticancer effects of vitamin K</span></div><div class="casAuthors">Lamson Davis W; Plaza Steven M</div><div class="citationInfo"><span class="NLM_cas:title">Alternative medicine review : a journal of clinical therapeutic</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-18</span>
        ISSN:<span class="NLM_cas:issn">1089-5159</span>.
    </div><div class="casAbstract">Vitamin K, an essential nutrient often associated with the clotting cascade, has been the focus of considerable research demonstrating an anticancer potential.  Much of this research has focused on vitamin K3, although vitamins K2 and K1 have also been shown to have anticancer effects.  Early studies of vitamin K3 employed an oxidative model to explain the anticancer effects seen in both in vitro and in vivo studies; however, this model does not adequately address the action of vitamins K1 and K2.  Recent research has demonstrated the anticancer action of vitamin K may act at the level of tyrosine kinases and phosphatases, modulating various transcription factors such as Myc and Fos.  Tyrosine kinases associated with cyclins have also been shown to be affected by vitamin K, which can lead to cell cycle arrest and cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnvsAxza7Swkg6wdEZmT2rfW6udTcc2eZo9tAvTjEMwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgslGgtA%253D%253D&md5=7211b5edc1c7eaf4ecf2112517ad7827</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLamson%26aufirst%3DD.%2BW.%26aulast%3DPlaza%26aufirst%3DS.%2BM.%26atitle%3DThe%2520anticancer%2520effects%2520of%2520vitamin%2520K%26jtitle%3DAltern.%2520Med.%2520Rev.%26date%3D2003%26volume%3D8%26spage%3D303%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitvogel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">The secret ally: immunostimulation by anticancer drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nrd3626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrd3626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=22301798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=215-233&author=L.+Galluzziauthor=L.+Senovillaauthor=L.+Zitvogelauthor=G.+Kroemer&title=The+secret+ally%3A+immunostimulation+by+anticancer+drugs&doi=10.1038%2Fnrd3626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The secret ally: immunostimulation by anticancer drugs</span></div><div class="casAuthors">Galluzzi, Lorenzo; Senovilla, Laura; Zitvogel, Laurence; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-233</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  It has recently become clear that the tumor microenvironment, and in particular the immune system, has a crucial role in modulating tumor progression and response to therapy.  Indicators of an ongoing immune response, such as the compn. of the intratumoral immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome.  Moreover, several anticancer agents - including classical chemotherapeutics and targeted compds. - stimulate tumor-specific immune responses either by inducing the immunogenic death of tumor cells or by engaging immune effector mechanisms.  Here, we discuss the mol. and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouW7RYumw6QrVg90H21EOLACvtfcHk0liJF1MvN7koUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gitb4%253D&md5=abed8d097aa5bb5588e6d553eead9a16</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnrd3626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3626%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DZitvogel%26aufirst%3DL.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DThe%2520secret%2520ally%253A%2520immunostimulation%2520by%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D215%26epage%3D233%26doi%3D10.1038%2Fnrd3626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bracci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistigu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belardelli, F.</span></span> <span> </span><span class="NLM_article-title">Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1038/cdd.2013.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fcdd.2013.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=23787994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCqtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=15-25&author=L.+Bracciauthor=G.+Schiavoniauthor=A.+Sistiguauthor=F.+Belardelli&title=Immune-based+mechanisms+of+cytotoxic+chemotherapy%3A+implications+for+the+design+of+novel+and+rationale-based+combined+treatments+against+cancer&doi=10.1038%2Fcdd.2013.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer</span></div><div class="casAuthors">Bracci, L.; Schiavoni, G.; Sistigu, A.; Belardelli, F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-25</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Conventional anticancer chemotherapy has been historically thought to act through direct killing of tumor cells.  This concept stems from the fact that cytotoxic drugs interfere with DNA synthesis and replication.  Accumulating evidence, however, indicates that the antitumor activities of chemotherapy also rely on several off-target effects, esp. directed to the host immune system, that cooperate for successful tumor eradication.  Chemotherapeutic agents stimulate both the innate and adaptive arms of the immune system through several modalities: (i) by promoting specific rearrangements on dying tumor cells, which render them visible to the immune system; (ii) by influencing the homeostasis of the hematopoietic compartment through transient lymphodepletion followed by rebound replenishment of immune cell pools; (iii) by subverting tumor-induced immunosuppressive mechanisms and (iv) by exerting direct or indirect stimulatory effects on immune effectors.  Among the indirect ways of immune cell stimulation, some cytotoxic drugs have been shown to induce an immunogenic type of cell death in tumor cells, resulting in the emission of specific signals that trigger phagocytosis of cell debris and promote the maturation of dendritic cells, ultimately resulting in the induction of potent antitumor responses.  Here, we provide an extensive overview of the multiple immune-based mechanisms exploited by the most commonly employed cytotoxic drugs, with the final aim of identifying prerequisites for optimal combination with immunotherapy strategies for the development of more effective treatments against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB7GLQr9KSpbVg90H21EOLACvtfcHk0lgzrFLwX5zMhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCqtbnE&md5=93bba735c9d507198e7892d830805f8d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.67%26sid%3Dliteratum%253Aachs%26aulast%3DBracci%26aufirst%3DL.%26aulast%3DSchiavoni%26aufirst%3DG.%26aulast%3DSistigu%26aufirst%3DA.%26aulast%3DBelardelli%26aufirst%3DF.%26atitle%3DImmune-based%2520mechanisms%2520of%2520cytotoxic%2520chemotherapy%253A%2520implications%2520for%2520the%2520design%2520of%2520novel%2520and%2520rationale-based%2520combined%2520treatments%2520against%2520cancer%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2014%26volume%3D21%26spage%3D15%26epage%3D25%26doi%3D10.1038%2Fcdd.2013.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flick, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaLonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">The tumor-selective cytotoxic agent β-lapachone is a potent inhibitor of IDO1</span>. <i>Int. J. Tryptophan Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.4137/IJTR.S12094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.4137%2FIJTR.S12094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24023520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2gs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=35-45&author=H.+E.+Flickauthor=J.+M.+LaLondeauthor=W.+P.+Malachowskiauthor=A.+J.+Muller&title=The+tumor-selective+cytotoxic+agent+%CE%B2-lapachone+is+a+potent+inhibitor+of+IDO1&doi=10.4137%2FIJTR.S12094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The tumor-selective cytotoxic agent β-lapachone is a potent inhibitor of IDO1</span></div><div class="casAuthors">Flick, Hollie E.; LaLonde, Judith M.; Malachowski, William P.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Tryptophan Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-45</span>CODEN:
                <span class="NLM_cas:coden">IJTRBS</span>;
        ISSN:<span class="NLM_cas:issn">1178-6469</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">β-Lapachone is a naturally occurring 1,2-naphthoquinone-based compd. that has been advanced into clin. trials based on its tumor-selective cytotoxic properties.  Previously, we focused on the related 1,4-naphthoquinone pharmacophore as a basic core structure for developing a series of potent indoleamine 2,3-dioxygenase 1 (IDO1) enzyme inhibitors.  In this study, we identified IDO1 inhibitory activity as a previously unrecognized attribute of the clin. candidate β-lapachone.  Enzyme kinetics-based anal. of β-lapachone indicated an uncompetitive mode of inhibition, while computational modeling predicted binding within the IDO1 active site consistent with other naphthoquinone derivs.  Inhibition of IDO1 has previously been shown to breach the pathogenic tolerization that constrains the immune system from being able to mount an effective anti-tumor response.  Thus, the finding that β-lapachone has IDO1 inhibitory activity adds a new dimension to its potential utility as an anti-cancer agent distinct from its cytotoxic properties, and suggests that a synergistic benefit can be achieved from its combined cytotoxic and immunol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVmjPfcd508LVg90H21EOLACvtfcHk0lgzrFLwX5zMhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2gs73M&md5=d432e109c20ca5a92c26d6dda24ef4b7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.4137%2FIJTR.S12094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FIJTR.S12094%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DH.%2BE.%26aulast%3DLaLonde%26aufirst%3DJ.%2BM.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520tumor-selective%2520cytotoxic%2520agent%2520%25CE%25B2-lapachone%2520is%2520a%2520potent%2520inhibitor%2520of%2520IDO1%26jtitle%3DInt.%2520J.%2520Tryptophan%2520Res.%26date%3D2013%26volume%3D6%26spage%3D35%26epage%3D45%26doi%3D10.4137%2FIJTR.S12094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridewell, D. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosim-Satyaputra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ching, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamie, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span> <span> </span><span class="NLM_article-title">Natural product-inspired pyranonaphthoquinone inhibitors of indoleamine 2,3-dioxygenase-1 (IDO-1)</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1071/CH12393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1071%2FCH12393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=40-49&author=D.+J.+A.+Bridewellauthor=J.+Sperryauthor=J.+R.+Smithauthor=P.+Kosim-Satyaputraauthor=L.+M.+Chingauthor=J.+F.+Jamieauthor=M.+A.+Brimble&title=Natural+product-inspired+pyranonaphthoquinone+inhibitors+of+indoleamine+2%2C3-dioxygenase-1+%28IDO-1%29&doi=10.1071%2FCH12393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Natural Product-Inspired Pyranonaphthoquinone Inhibitors of Indoleamine 2,3-Dioxygenase-1 (IDO-1)*</span></div><div class="casAuthors">Bridewell, David J. A.; Sperry, Jonathan; Smith, Jason R.; Kosim-Satyaputra, Priambudi; Ching, Lai-Ming; Jamie, Joanne F.; Brimble, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Australian Journal of Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-49</span>CODEN:
                <span class="NLM_cas:coden">AJCHAS</span>;
        ISSN:<span class="NLM_cas:issn">0004-9425</span>.
    
            (<span class="NLM_cas:orgname">CSIRO Publishing</span>)
        </div><div class="casAbstract">A series of pyranonaphthoquinone derivs. possessing structural features present in both natural products annulin B and exiguamine A have been shown to exhibit low micromolar inhibition of indoleamine 2,3-dioxygenase-1 (IDO-1).  These inhibitors retain activity against the enzyme in a cellular context with an approx. one-log loss of dose potency against IDO-1 in cells.  One particular analog, triazole 8 shows good inhibition of IDO-1 along with little loss of cell viability at low drug concns.  These results have extended the naphthoquinone series of novel IDO-1 inhibitors based on lead compds. from nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG_O1UCqyQf7Vg90H21EOLACvtfcHk0ljKLJ_Q_Y6cEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVylsLY%253D&md5=236dfa68088e25fdabca5e2ab6e1f288</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1071%2FCH12393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1071%252FCH12393%26sid%3Dliteratum%253Aachs%26aulast%3DBridewell%26aufirst%3DD.%2BJ.%2BA.%26aulast%3DSperry%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DJ.%2BR.%26aulast%3DKosim-Satyaputra%26aufirst%3DP.%26aulast%3DChing%26aufirst%3DL.%2BM.%26aulast%3DJamie%26aufirst%3DJ.%2BF.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26atitle%3DNatural%2520product-inspired%2520pyranonaphthoquinone%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase-1%2520%2528IDO-1%2529%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D40%26epage%3D49%26doi%3D10.1071%2FCH12393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzo-Castrillejo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machínb, F.</span></span> <span> </span><span class="NLM_article-title">Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7131</span>– <span class="NLM_lpage">7137</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.08.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.bmc.2009.08.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=19783445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ais7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7131-7137&author=J.+Sperryauthor=I.+Lorenzo-Castrillejoauthor=M.+A.+Brimbleauthor=F.+Mach%C3%ADnb&title=Pyranonaphthoquinone+derivatives+of+eleutherin%2C+ventiloquinone+L%2C+thysanone+and+nanaomycin+A+possessing+a+diverse+topoisomerase+II+inhibition+and+cytotoxicity+spectrum&doi=10.1016%2Fj.bmc.2009.08.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum</span></div><div class="casAuthors">Sperry, Jonathan; Lorenzo-Castrillejo, Isabel; Brimble, Margaret A.; Machin, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7131-7137</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of pyranonaphthoquinone derivs. related to the known topoisomerase II inhibitor eleutherin have been shown to act as specific topoisomerase II catalytic inhibitors, with several analogs displaying greater potency than the natural product itself.  Amongst the compds. tested were the natural products ventiloquinone L and thysanone with a diverse range of topoisomerase II inhibition properties being obsd.  Interestingly, the natural products are generally weaker inhibitors than their synthetic counterparts, emphasizing that subtle changes in the basic mol. structure of a natural product led to significant changes in the inhibition profile.  It has also been demonstrated for the first time that analogs related to nanaomycin A and cardinalin-type dimeric pyranonaphthoquinones exhibit potent topoisomerase II inhibitory properties.  With respect to structural features, it appears that the nature of the substituents at C1 on the pyran ring and oxygenated substituents on the aryl ring are crit. for anti-topoII activity.  Importantly, the topoisomerase II inhibition strength does not correlate well with the measured cytotoxicity against yeast, indicating that other mol. features in the pyranonaphthoquinone family must be considered for the design and use of this structural class as highly specific topoisomerase II inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbSbL4p1TXtLVg90H21EOLACvtfcHk0ljKLJ_Q_Y6cEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ais7vL&md5=a72aa9abe49e8716eac942ca1e8a0f63</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.064%26sid%3Dliteratum%253Aachs%26aulast%3DSperry%26aufirst%3DJ.%26aulast%3DLorenzo-Castrillejo%26aufirst%3DI.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26aulast%3DMach%25C3%25ADnb%26aufirst%3DF.%26atitle%3DPyranonaphthoquinone%2520derivatives%2520of%2520eleutherin%252C%2520ventiloquinone%2520L%252C%2520thysanone%2520and%2520nanaomycin%2520A%2520possessing%2520a%2520diverse%2520topoisomerase%2520II%2520inhibition%2520and%2520cytotoxicity%2520spectrum%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D7131%26epage%3D7137%26doi%3D10.1016%2Fj.bmc.2009.08.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel STAT3 small molecule inhibitors via in silico site directed fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4402</span>– <span class="NLM_lpage">4412</span>, <span class="refDoi"> DOI: 10.1021/jm400080c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400080c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4402-4412&author=W.+Yuauthor=H.+Xiaoauthor=J.+Linauthor=C.+Li&title=Discovery+of+novel+STAT3+small+molecule+inhibitors+via+in+silico+site+directed+fragment-based+drug+design&doi=10.1021%2Fjm400080c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel STAT3 Small Molecule Inhibitors via in Silico Site-Directed Fragment-Based Drug Design</span></div><div class="casAuthors">Yu, Wenying; Xiao, Hui; Lin, Jiayuh; Li, Chenglong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4402-4412</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription 3 (STAT3) has been validated as an attractive therapeutic target for cancer therapy.  To stop both STAT3 activation and dimerization, a viable strategy is to design inhibitors blocking its SH2 domain phosphotyrosine binding site that is responsible for both actions.  A new fragment-based drug design (FBDD) strategy, in silico site-directed FBDD, was applied in this study.  A designed novel compd., 5,8-dioxo-6-(pyridin-3-ylamino)-5,8-dihydronaphthalene-1-sulfonamide (LY5), was confirmed to bind to STAT3 SH2 by fluorescence polarization assay.  In addn., four out of the five chosen compds. have IC50 values lower than 5 μM for the U2OS cancer cells. 8 (LY5) has an IC50 range in 0.5-1.4 μM in various cancer cell lines. 8 also suppresses tumor growth in an in vivo mouse model.  This study has demonstrated the utility of this approach and could be used to other drug targets in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq76v3IMxJHwLVg90H21EOLACvtfcHk0ljKLJ_Q_Y6cEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVOktbk%253D&md5=7231b2e9682f9e9046debcaa461a1d59</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm400080c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400080c%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520STAT3%2520small%2520molecule%2520inhibitors%2520via%2520in%2520silico%2520site%2520directed%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4402%26epage%3D4412%26doi%3D10.1021%2Fjm400080c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STATs in cancer inflammation and immunity: a leading role for STAT3</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1038/nrc2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=19851315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=798-809&author=H.+Yuauthor=D.+Pardollauthor=R.+Jove&title=STATs+in+cancer+inflammation+and+immunity%3A+a+leading+role+for+STAT3&doi=10.1038%2Fnrc2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">STATs in cancer inflammation and immunity: a leading role for STAT3</span></div><div class="casAuthors">Yu, Hua; Pardoll, Drew; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">798-809</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in detg. whether immune responses in the tumor microenvironment promote or inhibit cancer.  Persistently activated STAT3 and, to some extent, STAT5 increase tumor cell proliferation, survival and invasion while suppressing anti-tumor immunity.  The persistent activation of STAT3 also mediates tumor-promoting inflammation.  STAT3 has this dual role in tumor inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-κB (NF-κB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-κB-mediated T helper 1 anti-tumor immune responses.  Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvEMN5YrxbbVg90H21EOLACvtfcHk0lgXAPAfx3pQgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP&md5=e431d0bd9eabd8f1ef703211be3d5cc9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnrc2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2734%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTATs%2520in%2520cancer%2520inflammation%2520and%2520immunity%253A%2520a%2520leading%2520role%2520for%2520STAT3%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D798%26epage%3D809%26doi%3D10.1038%2Fnrc2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, D. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiderski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span> <span> </span><span class="NLM_article-title">Leukemia cell–targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-07-517987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1182%2Fblood-2013-07-517987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24169824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=15-25&author=D.+M.+S.+Hossainauthor=C.+D.+Santosauthor=Q.+Zhangauthor=A.+Kozlowskaauthor=H.+Liuauthor=C.+Gaoauthor=D.+Moreiraauthor=P.+Swiderskiauthor=A.+Jozwiakauthor=J.+Klineauthor=S.+Formanauthor=R.+Bhatiaauthor=Y.+H.+Kuoauthor=M.+Kortylewski&title=Leukemia+cell%E2%80%93targeted+STAT3+silencing+and+TLR9+triggering+generate+systemic+antitumor+immunity&doi=10.1182%2Fblood-2013-07-517987"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity</span></div><div class="casAuthors">Hossain, Dewan Md. Sakib; Dos Santos, Cedric; Zhang, Qifang; Kozlowska, Anna; Liu, Hongjun; Gao, Chan; Moreira, Dayson; Swiderski, Piotr; Jozwiak, Agnieszka; Kline, Justin; Forman, Stephen; Bhatia, Ravi; Kuo, Ya-Huei; Kortylewski, Marcin</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-25</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is an oncogene and immune checkpoint commonly activated in cancer cells and in tumor-assocd. immune cells.  We previously developed an immunostimulatory strategy based on targeted Stat3 silencing in Toll-like receptor 9 (TLR9)-pos. hematopoietic cells using CpG-small interfering RNA (siRNA) conjugates.  Here, we assessed the therapeutic effect of systemic STAT3 blocking/TLR9 triggering in disseminated acute myeloid leukemia (AML).  We used mouse Cbfb-MYH11/Mpl-induced leukemia model, which mimics human inv(16) AML.  Our results demonstrate that i.v. delivered CpG-Stat3 siRNA, but not control oligonucleotides, can eradicate established AML and impair leukemia-initiating potential.  These antitumor effects require host's effector T cells but not TLR9-pos. antigen-presenting cells.  Instead, CpG-Stat3 siRNA has direct immunogenic effect on AML cells in vivo upregulating major histocompatibility complex class-II, costimulatory and proinflammatory mediators, such as interleukin-12, while downregulating coinhibitory PD-L1 mol.  Systemic injections of CpG-Stat3 siRNA generate potent tumor antigen-specific immune responses, increase the ratio of tumor-infiltrating CD8+ T cells to regulatory T cells in various organs, and result in CD8+ T-cell-dependent regression of leukemia.  Our findings underscore the potential of using targeted STAT3 inhibition/TLR9 triggering to break tumor tolerance and induce immunity against AML and potentially other TLR9-pos. blood cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoa3zReNBlrLVg90H21EOLACvtfcHk0lgXAPAfx3pQgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVClsQ%253D%253D&md5=15bd14a956844af565dd4b3c72bd7da8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-517987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-517987%26sid%3Dliteratum%253Aachs%26aulast%3DHossain%26aufirst%3DD.%2BM.%2BS.%26aulast%3DSantos%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DKozlowska%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DMoreira%26aufirst%3DD.%26aulast%3DSwiderski%26aufirst%3DP.%26aulast%3DJozwiak%26aufirst%3DA.%26aulast%3DKline%26aufirst%3DJ.%26aulast%3DForman%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DKuo%26aufirst%3DY.%2BH.%26aulast%3DKortylewski%26aufirst%3DM.%26atitle%3DLeukemia%2520cell%25E2%2580%2593targeted%2520STAT3%2520silencing%2520and%2520TLR9%2520triggering%2520generate%2520systemic%2520antitumor%2520immunity%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D15%26epage%3D25%26doi%3D10.1182%2Fblood-2013-07-517987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toor, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkord, E.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1080/14728222.2018.1471137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1080%2F14728222.2018.1471137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=29702007" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=547-557&author=V.+S.+Nairauthor=S.+M.+Toorauthor=B.+R.+Aliauthor=E.+Elkord&title=Dual+inhibition+of+STAT1+and+STAT3+activation+downregulates+expression+of+PD-L1+in+human+breast+cancer+cells&doi=10.1080%2F14728222.2018.1471137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1080%2F14728222.2018.1471137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2018.1471137%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DV.%2BS.%26aulast%3DToor%26aufirst%3DS.%2BM.%26aulast%3DAli%26aufirst%3DB.%2BR.%26aulast%3DElkord%26aufirst%3DE.%26atitle%3DDual%2520inhibition%2520of%2520STAT1%2520and%2520STAT3%2520activation%2520downregulates%2520expression%2520of%2520PD-L1%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2018%26volume%3D22%26spage%3D547%26epage%3D557%26doi%3D10.1080%2F14728222.2018.1471137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temkin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntzen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieghart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck-Radosavljevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffert, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.12.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.ccr.2009.12.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20227042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVWqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=286-297&author=G.+Heauthor=G.+Y.+Yuauthor=V.+Temkinauthor=H.+Ogataauthor=C.+Kuntzenauthor=T.+Sakuraiauthor=W.+Sieghartauthor=M.+Peck-Radosavljevicauthor=H.+L.+Leffertauthor=M.+Karin&title=Hepatocyte+IKK%CE%B2%2FNF-%CE%BAB+inhibits+tumor+promotion+and+progression+by+preventing+oxidative+stress-driven+STAT3+activation&doi=10.1016%2Fj.ccr.2009.12.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation</span></div><div class="casAuthors">He, Guobin; Yu, Guann-Yi; Temkin, Vladislav; Ogata, Hisanobu; Kuntzen, Christian; Sakurai, Toshiharu; Sieghart, Wolfgang; Peck-Radosavljevic, Markus; Leffert, Hyam L.; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-297</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The NF-κB activating kinase IKKβ suppresses early chem. induced liver tumorigenesis by inhibiting hepatocyte death and compensatory proliferation.  To study IKKβ's role in late tumor promotion and progression, we developed a transplant system that allows initiated mouse hepatocytes to form hepatocellular carcinomas (HCC) in host liver after a long latency.  Deletion of IKKβ long after initiation accelerated HCC development and enhanced proliferation of tumor initiating cells.  These effects of IKKβ/NF-κB were cell autonomous and correlated with increased accumulation of reactive oxygen species that led to JNK and STAT3 activation.  Hepatocyte-specific STAT3 ablation prevented HCC development.  The neg. crosstalk between NF-κB and STAT3, which is also evident in human HCC, is a crit. regulator of liver cancer development and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVvGfhbfqwL7Vg90H21EOLACvtfcHk0lhTyS6j4H-xmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVWqtb8%253D&md5=fd21b8a893dd147e8eada63aebccb810</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.12.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.12.048%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DG.%2BY.%26aulast%3DTemkin%26aufirst%3DV.%26aulast%3DOgata%26aufirst%3DH.%26aulast%3DKuntzen%26aufirst%3DC.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DSieghart%26aufirst%3DW.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DLeffert%26aufirst%3DH.%2BL.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DHepatocyte%2520IKK%25CE%25B2%252FNF-%25CE%25BAB%2520inhibits%2520tumor%2520promotion%2520and%2520progression%2520by%2520preventing%2520oxidative%2520stress-driven%2520STAT3%2520activation%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26spage%3D286%26epage%3D297%26doi%3D10.1016%2Fj.ccr.2009.12.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">STAT3 is necessary for proliferation and survival in colon cancer–initiating cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">7226</span>– <span class="NLM_lpage">7237</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1158%2F0008-5472.CAN-10-4660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=21900397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=7226-7237&author=L.+Linauthor=A.+Liuauthor=Z.+Pengauthor=H.-J.+Linauthor=P.-K.+Liauthor=C.+Liauthor=J.+Lin&title=STAT3+is+necessary+for+proliferation+and+survival+in+colon+cancer%E2%80%93initiating+cells&doi=10.1158%2F0008-5472.CAN-10-4660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells</span></div><div class="casAuthors">Lin, Li; Liu, Aiguo; Peng, Zhengang; Lin, Huey-Jen; Li, Pui-Kai; Li, Chenglong; Lin, Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7226-7237</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">STAT3 is constitutively activated in colon cancer but its contributions in cancer-initiating cells have not been explored.  In this study, we characterized STAT3 in aldehyde dehydrogenase (ALDH)-pos. (ALDH+) and CD133-pos. (CD133+) subpopulations of human colon tumor cells that exhibited more potent tumor-initiating ability than ALDH-/CD133- cells in tumor xenograft assays in mice.  We found that ALDH+/CD133+ cells expressed higher levels of the active phosphorylated form of STAT3 than either ALDH-/CD133- or unfractionated colon cancer cells.  STAT3 inhibition by RNA interference-mediated knockdown or small-mol. inhibitors LLL12 or Stattic blocked downstream target gene expression, cell viability, and tumorsphere-forming capacity in cancer-initiating cells.  Similarly, treatment of mouse tumor xenografts with STAT3 short hairpin RNA (shRNA), interleukin 6 shRNA, or LLL12 inhibited tumor growth.  Our results establish that STAT3 is constitutively activated in colon cancer-initiating cells and that these cells are sensitive to STAT3 inhibition.  These findings establish a powerful rationale to develop STAT3 inhibitory strategies for treating advanced colorectal cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRqdoOohnuUrVg90H21EOLACvtfcHk0lhTyS6j4H-xmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmsb%252FE&md5=3819d2dbe037ec37fd5426cc333d212e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4660%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DH.-J.%26aulast%3DLi%26aufirst%3DP.-K.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DSTAT3%2520is%2520necessary%2520for%2520proliferation%2520and%2520survival%2520in%2520colon%2520cancer%25E2%2580%2593initiating%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D7226%26epage%3D7237%26doi%3D10.1158%2F0008-5472.CAN-10-4660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercado-Uribe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bast, R. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">2730</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1002/cncr.22293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1002%2Fcncr.22293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=17063503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCmu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=2730-2740&author=D.+G.+Rosenauthor=I.+Mercado-Uribeauthor=G.+Yangauthor=R.+C.+Bastauthor=H.+M.+Aminauthor=R.+Laiauthor=J.+Liu&title=The+role+of+constitutively+active+signal+transducer+and+activator+of+transcription+3+in+ovarian+tumorigenesis+and+prognosis&doi=10.1002%2Fcncr.22293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The role of constitutively active signal tranducer and activator of transcription 3 in ovarian tumorigenesis and prognosis</span></div><div class="casAuthors">Rosen, Daniel G.; Mercado-Uribe, Imelda; Yang, Gong; Bast, Robert C., Jr.; Amin, Hesham M.; Lai, Raymond; Liu, Jinsong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2730-2740</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND. Signal transducer and activator of transcription 3 (Stat3), which is a latent transcription factor that participates in the transcriptional activation of apoptosis and cell cycle progression, has been implicated as an oncogene in several neoplastic diseases.  However, the specific role of Stat3 in ovarian carcinogenesis remains poorly understood.  The objectives of the current study were to examine the effect of Stat3 activation on the phenotypic transformation of an immortalized, non-tumorigenic ovarian epithelial cell line and to evaluate the expression of tyrosine-activated Stat3 (pStat3) in tissue microarrays from 303 ovarian carcinomas to det. its prognostic relevance and to correlate its expression with several upstream oncogenes of Stat3 and with the oncogenes involved in apoptosis and proliferation.  METHODS. Overexpression of pStat3 was weakly tumorigenic and produced measurable tumors in mice in 1 of 3 clones.  Using tissue microarrays from a large group of patients with primary ovarian carcinoma, the expression of pStat3 was correlated with the expression of growth factor receptors (HER-2/neu and epidermal growth factor receptor [EGFR]), interleukin 6, and the proliferation and apoptosis markers Ki-67, Bcl-2, and Bcl-xL and with clinicopathol. variables and patient survival.  RESULTS. High pStat3 expression in the tumor tissue microarray was assocd. with high levels of HER-2/neu, EGFR, and Ki-67.  No correlation was obsd. between overall pStat3 levels and any other clinicopathol. variables tested.  High nuclear expression of pStat3 (>10% of pos.-stained cells) was linked with poor overall survival.  CONCLUSIONS. The activation and translocation of pStat3 to the nucleus are frequent events in ovarian carcinoma that are assocd. with a poor prognosis.  Further studies are needed to elucidate the mechanism of activation of Stat3, its effects on downstream targets, and its role in the neoplastic transformation of epithelial ovarian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXSLNY-ed0jrVg90H21EOLACvtfcHk0lhKjsdK-UdxRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCmu7bM&md5=c67244c62ab24f7829ba687ef9d39839</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22293%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DD.%2BG.%26aulast%3DMercado-Uribe%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DBast%26aufirst%3DR.%2BC.%26aulast%3DAmin%26aufirst%3DH.%2BM.%26aulast%3DLai%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520constitutively%2520active%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520in%2520ovarian%2520tumorigenesis%2520and%2520prognosis%26jtitle%3DCancer%26date%3D2006%26volume%3D107%26spage%3D2730%26epage%3D2740%26doi%3D10.1002%2Fcncr.22293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">A novel small-molecule disrupts stat3 SH2 domain–phosphotyrosine interactions and stat3-dependent tumor processes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1398</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2010.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.bcp.2010.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20067773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVCnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2010&pages=1398-1409&author=X.+Zhangauthor=P.+Yueauthor=S.+Fletcherauthor=W.+Zhaoauthor=P.+T.+Gunningauthor=J.+Turkson&title=A+novel+small-molecule+disrupts+stat3+SH2+domain%E2%80%93phosphotyrosine+interactions+and+stat3-dependent+tumor+processes&doi=10.1016%2Fj.bcp.2010.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes</span></div><div class="casAuthors">Zhang, Xiaolei; Yue, Peibin; Fletcher, Steven; Zhao, Wei; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1398-1409</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mol. modeling of the phosphotyrosine (pTyr)-SH2 domain interaction in the Stat3:Stat3 dimerization, combined with in silico structural anal. of the Stat3 dimerization disruptor, S3I-201, has furnished a diverse set of analogs.  We present evidence from in vitro biochem. and biophys. studies that the structural analog, S3I-201.1066 (I) directly interacts with Stat3 or the SH2 domain, with an affinity (KD) of 2.74 μM, and disrupts the binding of Stat3 to the cognate pTyr-peptide, GpYLPQTV-NH2, with an IC50 of 23 μM.  Moreover, I selectively blocks the assocn. of Stat3 with the epidermal growth factor receptor (EGFR), and inhibits Stat3 tyrosine phosphorylation and nuclear translocation in EGF-stimulated mouse fibroblasts.  In cancer cells that harbor aberrant Stat3 activity, I inhibits constitutive Stat3 DNA-binding and transcriptional activities.  By contrast, I has no effect on Src activation or the EGFR-mediated activation of the Erk1/2MAPK pathway.  I selectively suppresses the viability, survival, and malignant transformation of the human breast and pancreatic cancer lines and the v-Src-transformed mouse fibroblasts harboring persistently active Stat3.  Treatment with I of malignant cells harboring aberrantly active Stat3 down-regulated the expression of c-Myc, Bcl-xL, Survivin, the matrix metalloproteinase 9, and VEGF.  The in vivo administration of I-induced significant antitumor response in mouse models of human breast cancer, which correlates with the inhibition of constitutively active Stat3 and the suppression of known Stat3-regulated genes.  Our studies identify a novel small-mol. that binds with a high affinity to Stat3, blocks Stat3 activation and function, and thereby induces antitumor response in human breast tumor xenografts harboring persistently active Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxJzIoqCaQHbVg90H21EOLACvtfcHk0lhKjsdK-UdxRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVCnsL8%253D&md5=4a196103d1d0f6d057715ff4cd2d7498</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DA%2520novel%2520small-molecule%2520disrupts%2520stat3%2520SH2%2520domain%25E2%2580%2593phosphotyrosine%2520interactions%2520and%2520stat3-dependent%2520tumor%2520processes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D79%26spage%3D1398%26epage%3D1409%26doi%3D10.1016%2Fj.bcp.2010.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaganathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">A cell-permeable STAT3 SH2 domain mimetic inhibits STAT3 activation and induces antitumor cell effects in vitro</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">35855</span>– <span class="NLM_lpage">35865</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.154088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1074%2Fjbc.M110.154088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20807764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlyntLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=35855-35865&author=W.+Zhaoauthor=S.+Jaganathanauthor=J.+Turkson&title=A+cell-permeable+STAT3+SH2+domain+mimetic+inhibits+STAT3+activation+and+induces+antitumor+cell+effects+in+vitro&doi=10.1074%2Fjbc.M110.154088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A Cell-permeable Stat3 SH2 Domain Mimetic Inhibits Stat3 Activation and Induces Antitumor Cell Effects in Vitro</span></div><div class="casAuthors">Zhao, Wei; Jaganathan, Soumya; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">35855-35865</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Given the role of constitutively active Signal Transducer and Activator of Transcription (Stat) 3 in human tumors, Stat3 inhibitors would be useful as novel therapeutics and as tools for probing Stat3-mediated tumor processes.  We herein report that a 28-mer peptide, SPI, derived from the Stat3 SH2 domain, replicates Stat3 biochem. properties.  Studies show SPI and Stat3 (or Stat3 SH2 domain) bind with similar affinities to known Stat3-binding phosphotyrosine (pY) peptide motifs, including those of the epidermal growth factor receptor (EGFR) and the high-affinity, IL-6R/gp130-derived pY-peptide, GpYLPQTV-NH2.  Consequently, SPI functions as a potent and selective inhibitor of Stat3 SH2 domain:pTyr interactions and disrupts the binding of Stat3 to the IL-6R/gp130 peptide, GpYLPQTV-NH2.  Fluorescence imaging and immunofluorescence staining/laser-scanning confocal microscopy show SPI is cell membrane-permeable, assocs. with the cytoplasmic tail of EGFR in NIH3T3/hEGFR, and is present in the cytoplasm, but strongly localized at the plasma membrane and in the nucleus in malignant cells harboring persistently active Stat3.  Moreover, SPI specifically blocks constitutive Stat3 phosphorylation, DNA binding activity, and transcriptional function in malignant cells, with little or no effect on the induction of Stat1, Stat5, and Erk1/2MAPK pathways, or on general pTyr profile at the concns. that inhibit Stat3 activity.  Significantly, treatment with SPI of human breast, pancreatic, prostate, and non-small cell lung cancer cells harboring constitutively active Stat3 induced extensive morphol. changes, assocd. with viability loss and apoptosis.  Our study identifies SPI as a novel mol. probe for interrogating Stat3 signaling and that functions as a selective inhibitor of Stat3 activation with antitumor cell effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5xNMqd5Ho5rVg90H21EOLACvtfcHk0lg5uPFK8hkXcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlyntLfL&md5=a1ac33150ab27d501fdb519800a3b406</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.154088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.154088%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DJaganathan%26aufirst%3DS.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DA%2520cell-permeable%2520STAT3%2520SH2%2520domain%2520mimetic%2520inhibits%2520STAT3%2520activation%2520and%2520induces%2520antitumor%2520cell%2520effects%2520in%2520vitro%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D35855%26epage%3D35865%26doi%3D10.1074%2Fjbc.M110.154088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jinyun Dong, Xiang-Dong Cheng, Wei-Dong Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Jiang-Jiang Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 8884-8915. <a href="https://doi.org/10.1021/acs.jmedchem.1c00629" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00629</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00629%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BUpdate%252Bon%252BDevelopment%252Bof%252BSmall-Molecule%252BSTAT3%252BInhibitors%252Bfor%252BCancer%252BTherapy%25253A%252BFrom%252BPhosphorylation%252BInhibition%252Bto%252BProtein%252BDegradation%26aulast%3DDong%26aufirst%3DJinyun%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D06042021%26date%3D25062021%26volume%3D64%26issue%3D13%26spage%3D8884%26epage%3D8915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xi Feng, Dongdong Liao, Dongyu Liu, An Ping, Zhiyu Li, <span class="NLM_string-name hlFld-ContribAuthor">Jinlei Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15115-15139. <a href="https://doi.org/10.1021/acs.jmedchem.0c00925" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00925</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00925%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BIndoleamine%252B2%25252C3-Dioxygenase%252B1%252BInhibitors%252Bfor%252BCancer%252BTherapy%252Band%252BBeyond%25253A%252BA%252BRecent%252BPerspective%26aulast%3DFeng%26aufirst%3DXi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31052020%26date%3D20112020%26volume%3D63%26issue%3D24%26spage%3D15115%26epage%3D15139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Zhang</span>, <span class="hlFld-ContribAuthor ">Guiying  Zhang</span>, <span class="hlFld-ContribAuthor ">Shujing  Xu</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances of quinones as a privileged structure in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113632. <a href="https://doi.org/10.1016/j.ejmech.2021.113632" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113632</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113632%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bof%252Bquinones%252Bas%252Ba%252Bprivileged%252Bstructure%252Bin%252Bdrug%252Bdiscovery%26aulast%3DZhang%26aufirst%3DLi%26date%3D2021%26volume%3D223%26spage%3D113632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuyao  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhong</span>, <span class="hlFld-ContribAuthor ">Bingbing  Li</span>, <span class="hlFld-ContribAuthor ">Shumin  Ouyang</span>, <span class="hlFld-ContribAuthor ">Lin  Deng</span>, <span class="hlFld-ContribAuthor ">Jianshan  Mo</span>, <span class="hlFld-ContribAuthor ">Shuo  Shi</span>, <span class="hlFld-ContribAuthor ">Nan  Lv</span>, <span class="hlFld-ContribAuthor ">Ruibo  Wu</span>, <span class="hlFld-ContribAuthor ">Peiqing  Liu</span>, <span class="hlFld-ContribAuthor ">Wenhao  Hu</span>, <span class="hlFld-ContribAuthor ">Xiaolei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanxiang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113525. <a href="https://doi.org/10.1016/j.ejmech.2021.113525" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113525%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdiscovery%252Bof%252Bpotent%252Band%252Bselective%252Bsmall-molecule%252Binhibitors%252Btargeting%252Bsignal%252Btransducer%252Band%252Bactivator%252Bof%252Btranscription%252B3%252B%252528STAT3%252529%26aulast%3DHuang%26aufirst%3DQiuyao%26date%3D2021%26volume%3D221%26spage%3D113525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  Bao</span>, <span class="hlFld-ContribAuthor ">Xiongda  Xie</span>, <span class="hlFld-ContribAuthor ">Wenhao  Hu</span>, <span class="hlFld-ContribAuthor ">Xinfang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Gold‐Catalyzed Carbocyclization/C=N Bond Formation Cascade of Alkyne‐Tethered Diazo Compounds with Benzo[
              c
              ]isoxazoles for the Assembly of 4‐Iminonaphthalenones and Indenes. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>63 </em><a href="https://doi.org/10.1002/adsc.202100602" title="DOI URL">https://doi.org/10.1002/adsc.202100602</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202100602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202100602%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DGold%2525E2%252580%252590Catalyzed%252BCarbocyclization%25252FC%25253DN%252BBond%252BFormation%252BCascade%252Bof%252BAlkyne%2525E2%252580%252590Tethered%252BDiazo%252BCompounds%252Bwith%252BBenzo%25255B%252Bc%252B%25255Disoxazoles%252Bfor%252Bthe%252BAssembly%252Bof%252B4%2525E2%252580%252590Iminonaphthalenones%252Band%252BIndenes%26aulast%3DBao%26aufirst%3DMing%26date%3D2021%26date%3D2021%26volume%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Dolšak</span>, <span class="hlFld-ContribAuthor ">Stanislav  Gobec</span>, <span class="hlFld-ContribAuthor ">Matej  Sova</span>. </span><span class="cited-content_cbyCitation_article-title">Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>221 </em>, 107746. <a href="https://doi.org/10.1016/j.pharmthera.2020.107746" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2020.107746</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2020.107746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2020.107746%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DIndoleamine%252Band%252Btryptophan%252B2%25252C3-dioxygenases%252Bas%252Bimportant%252Bfuture%252Btherapeutic%252Btargets%26aulast%3DDol%25C5%25A1ak%26aufirst%3DAna%26date%3D2021%26volume%3D221%26spage%3D107746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulun  Chen</span>, <span class="hlFld-ContribAuthor ">Jing  Tan</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">The ups, downs and new trends of IDO1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104815. <a href="https://doi.org/10.1016/j.bioorg.2021.104815" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104815</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104815%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DThe%252Bups%25252C%252Bdowns%252Band%252Bnew%252Btrends%252Bof%252BIDO1%252Binhibitors%26aulast%3DChen%26aufirst%3DShulun%26date%3D2021%26volume%3D110%26spage%3D104815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Susi  Zhu</span>, <span class="hlFld-ContribAuthor ">Yeye  Guo</span>, <span class="hlFld-ContribAuthor ">Xu  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Mingzhu  Yin</span>, <span class="hlFld-ContribAuthor ">Xiang  Chen</span>, <span class="hlFld-ContribAuthor ">Cong  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2021,</strong> <em>503 </em>, 240-248. <a href="https://doi.org/10.1016/j.canlet.2020.11.018" title="DOI URL">https://doi.org/10.1016/j.canlet.2020.11.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2020.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2020.11.018%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DPyruvate%252Bkinase%252BM2%252B%252528PKM2%252529%252Bin%252Bcancer%252Band%252Bcancer%252Btherapeutics%26aulast%3DZhu%26aufirst%3DSusi%26date%3D2021%26volume%3D503%26spage%3D240%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rahul  Singh</span>, <span class="hlFld-ContribAuthor ">Deepak B.  Salunke</span>. </span><span class="cited-content_cbyCitation_article-title">Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113071. <a href="https://doi.org/10.1016/j.ejmech.2020.113071" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113071%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiverse%252Bchemical%252Bspace%252Bof%252Bindoleamine-2%25252C3-dioxygenase%252B1%252B%252528Ido1%252529%252Binhibitors%26aulast%3DSingh%26aufirst%3DRahul%26date%3D2021%26volume%3D211%26spage%3D113071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gui-Bin  Liang</span>, <span class="hlFld-ContribAuthor ">Jian-Hua  Wei</span>, <span class="hlFld-ContribAuthor ">Hong  Jiang</span>, <span class="hlFld-ContribAuthor ">Ri-Zhen  Huang</span>, <span class="hlFld-ContribAuthor ">Jing-Ting  Qin</span>, <span class="hlFld-ContribAuthor ">Hui-Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Heng-Shan  Wang</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112951. <a href="https://doi.org/10.1016/j.ejmech.2020.112951" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112951</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112951%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bevaluation%252Bof%252Bnew%252B1%25252C8-naphthalimide%252Bderivatives%252Btargeting%252Bnuclear%252BDNA%26aulast%3DLiang%26aufirst%3DGui-Bin%26date%3D2021%26volume%3D210%26spage%3D112951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulei  Pan</span>, <span class="hlFld-ContribAuthor ">Yangli  Zhou</span>, <span class="hlFld-ContribAuthor ">Qiusheng  Wang</span>, <span class="hlFld-ContribAuthor ">Yanlin  Wang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Luyi  Huang</span>, <span class="hlFld-ContribAuthor ">Jinshan  Nan</span>, <span class="hlFld-ContribAuthor ">Linli  Li</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112703. <a href="https://doi.org/10.1016/j.ejmech.2020.112703" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112703</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112703%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bstructure-activity%252Brelationship%252Bstudies%252Bof%252B1-aryl-1H-naphtho%25255B2%25252C3-d%25255D%25255B1%25252C2%25252C3%25255Dtriazole-4%25252C9-dione%252Bderivatives%252Bas%252Bpotent%252Bdual%252Binhibitors%252Bof%252Bindoleamine%252B2%25252C3-dioxygenase%252B1%252B%252528IDO1%252529%252Band%252Btrytophan%252B2%25252C3-dioxygenase%252B%252528TDO%252529%26aulast%3DPan%26aufirst%3DShulei%26date%3D2020%26volume%3D207%26spage%3D112703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sailan  Zou</span>, <span class="hlFld-ContribAuthor ">Qiyu  Tong</span>, <span class="hlFld-ContribAuthor ">Bowen  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Tian</span>, <span class="hlFld-ContribAuthor ">Xianghui  Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting STAT3 in Cancer Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2020,</strong> <em>19 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-020-01258-7" title="DOI URL">https://doi.org/10.1186/s12943-020-01258-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-020-01258-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-020-01258-7%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DTargeting%252BSTAT3%252Bin%252BCancer%252BImmunotherapy%26aulast%3DZou%26aufirst%3DSailan%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaobo  Zhou</span>, <span class="hlFld-ContribAuthor ">Riping  Xiao</span>, <span class="hlFld-ContribAuthor ">Ming  Chen</span>, <span class="hlFld-ContribAuthor ">Li‐Ping  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Uscharin Oxime Analogues and Their Biological Evaluation as HIF‐1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (42)
                                     , 12869-12872. <a href="https://doi.org/10.1002/slct.202003586" title="DOI URL">https://doi.org/10.1002/slct.202003586</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202003586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202003586%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DSynthesis%252Bof%252BUscharin%252BOxime%252BAnalogues%252Band%252BTheir%252BBiological%252BEvaluation%252Bas%252BHIF%2525E2%252580%2525901%252BInhibitors%26aulast%3DZhou%26aufirst%3DXiaobo%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D42%26spage%3D12869%26epage%3D12872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0003.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of IDO1 and STAT3 inhibitors. (A) Structures of representative IDO1 inhibitors. (B) Naphthoquinone-based IDO1 and tryptophan 2,3-dioxygenase (TDO) inhibitors. (C) Naphthoquinone-based STAT3 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Pathway to Target Compounds <b>7</b>(<b>7a</b>–<b>7z</b>), <b>8</b>(<b>8a</b>–<b>8z</b>), and <b>10</b>(<b>10a</b>–<b>10c</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) phthalic anhydride, CH<sub>3</sub>COOH, 70 °C, 12 h; (b) oxalyl chloride, CH<sub>2</sub>Cl<sub>2</sub>, aromatic primary amines, Et<sub>3</sub>N, room temperature (rt), 12 h; (c) hydrazine hydrate, CH<sub>3</sub>OH, rt, 8 h; (d) DMF, H<sub>2</sub>O, Et<sub>3</sub>N, rt, 18 h; (e) hydroxylamine, CH<sub>3</sub>CH<sub>2</sub>OH, 80 °C, 12 h; (f) CH<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, 0 °C, 3 h.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Proposed binding mode of compound <b>8u</b> in the active site of IDO1 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5">4PK5</a>). Heme is reported as a cyan stick, IDO1 structure is shown as a cartoon. (B) Key hydrogen bond interactions of compound <b>8u</b> in the active site of IDO1. Compound <b>8u</b>, IDO1 residues, and HEM are shown as gray stick, yellow stick, and cyan stick, respectively. The red dashed lines indicate the H-bond interaction between <b>8u</b> and IDO1. (C) Biophysical binding data supports the interaction of compound <b>8u</b> with human IDO1 protein. Dose–response curve determined by surface plasmon resonance (SPR) for the binding of IDO1 with <b>8u</b> is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vivo anticancer activity of compound <b>8u</b>. (A) Effects of the indicated treatments of <b>8u</b> on B16-F10 melanoma tumor xenografts in C57BL/6 mice. The images of the tumors after administering with compound <b>8u</b> are also shown. (B) Tumor volumes were detected every 2 days for 21 days of duration. (C) Inhibition of tumor growth for compound <b>8u</b> and doxorubicin (DOX) in nude mice bearing HepG2 xenograft model. (D) Tumor volumes were detected every 3 days. Data represent three individual experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Compound <b>8u</b> targeted STAT3. (A) Western blot analysis of p-STAT3(Y705), p-STAT3(S727), and total STAT3 after treatment of SKOV3 cells with <b>8u</b> at the indicated concentrations and for the indicated times. (B) Western blots of STAT1 and STAT5 from whole-cell lysates from cells were treated with <b>8u</b>. β-actin antibody was used as reference control. (C) Effects of compound <b>8u</b> (0.5 μM) on the nuclear translocation of the p-STAT3 protein induced by cytokine IL-6. After serum-free overnight treatment, SKOV3 cells were pretreated with <b>8u</b> for 8 h, followed by IL-6 (50 ng/mL) for 30 min, and then processed for STAT3 nuclear translocation detection by immunofluorescence staining. (D) SPR analysis of compound <b>8u</b> with STAT3 protein. The equilibrium dissociation constant (KD) value is 0.53 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/medium/jm9b01386_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Comparative antitumor potency of <b>8u</b> and the combination of 1-MT and stattic in vivo in a B16-F10 tumor-challenged C57BL/6 mice model. (A) Representative images in B16-F10 bearing mice. (B) Representative photos of the tumors at the end of treatment. (C) Average weight of the tumors excised at the end of treatment. (D) Changes in tumor volume in different treatment groups measured every 2 days. (E) Changes in body weight in different treatment groups measured every 2 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-4/acs.jmedchem.9b01386/20200221/images/large/jm9b01386_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01386&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i91">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01323" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01323" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 64 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">The future of immune checkpoint therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1126/science.aaa8172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1126%2Fscience.aaa8172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=25838373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Wmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=56-61&author=P.+Sharmaauthor=J.+P.+Allison&title=The+future+of+immune+checkpoint+therapy&doi=10.1126%2Fscience.aaa8172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The future of immune checkpoint therapy</span></div><div class="casAuthors">Sharma, Padmanee; Allison, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6230</span>),
    <span class="NLM_cas:pages">56-61</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clin. advances and provided a new weapon against cancer.  This therapy has elicited durable clin. responses and, in a fraction of patients, long-term remissions where patients exhibit no clin. signs of cancer for many years.  The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment.  This will provide valuable information regarding the dynamic nature of the immune response and regulation of addnl. pathways that will need to be targeted through combination therapies to provide survival benefit for greater nos. of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYdwRFIm59-7Vg90H21EOLACvtfcHk0lglBvt6fu6Phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Wmurg%253D&md5=d63ae85b9c651ec64a3b5b002c609e35</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa8172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa8172%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520future%2520of%2520immune%2520checkpoint%2520therapy%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D56%26epage%3D61%26doi%3D10.1126%2Fscience.aaa8172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span> <span> </span><span class="NLM_article-title">Targeting the mechanisms of tumoral immune tolerance with small molecule inhibitors</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1038/nrc1929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc1929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=16862192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFGlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=613-625&author=A.+J.+Mullerauthor=P.+A.+Scherle&title=Targeting+the+mechanisms+of+tumoral+immune+tolerance+with+small+molecule+inhibitors&doi=10.1038%2Fnrc1929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors</span></div><div class="casAuthors">Muller, Alexander J.; Scherle, Peggy A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">613-625</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer immunotherapy has been predominantly focused on biol. based intervention strategies.  However, recent advances in the understanding of tumor-host interactions at the mol. level have revealed targets that might be amenable to intervention with small-mol. inhibitors.  In particular, key effectors of tumoral immune escape have been identified that contribute to a dominant tolerogenic state that is suspected of limiting the successful implementation of treatment strategies that rely on boosting immune function.  Within the context of the pathophysiol. of cancer-assocd. immune tolerance, this Review delineates potential mol. targets for therapeutic intervention and the progress that has been made in developing small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo85LieVsa74bVg90H21EOLACvtfcHk0lglBvt6fu6Phg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFGlu7s%253D&md5=0e803b9767d6f4b6b59febefae7e96e2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1929%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26atitle%3DTargeting%2520the%2520mechanisms%2520of%2520tumoral%2520immune%2520tolerance%2520with%2520small%2520molecule%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D613%26epage%3D625%26doi%3D10.1038%2Fnrc1929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kane, L. P.</span></span> <span> </span><span class="NLM_article-title">T cell Ig and mucin domain proteins and immunity</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">2743</span>– <span class="NLM_lpage">2749</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0902937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.4049%2Fjimmunol.0902937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20200285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXis1yisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=2743-2749&author=L.+P.+Kane&title=T+cell+Ig+and+mucin+domain+proteins+and+immunity&doi=10.4049%2Fjimmunol.0902937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">T Cell Ig and Mucin Domain Proteins and Immunity</span></div><div class="casAuthors">Kane, Lawrence P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2743-2749</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">A review.  Proteins of the transmembrane (or T cell) Ig and mucin domain (TIM) family are expressed by multiple cell types within the immune systems of rodents and humans.  Studies over the last several years have suggested that these proteins may be promising targets for therapeutic manipulation of immune responses.  This review discusses the progress that has been made in understanding TIM protein function in the immune system, as well as some of the unresolved issues that remain on the road to eventually targeting TIM proteins for enhancing or inhibiting immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLQsmSomlwWrVg90H21EOLACvtfcHk0linUh7QeiTcWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXis1yisrg%253D&md5=3d390a9bf54fd42ffcc73f5b798af8ab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902937%26sid%3Dliteratum%253Aachs%26aulast%3DKane%26aufirst%3DL.%2BP.%26atitle%3DT%2520cell%2520Ig%2520and%2520mucin%2520domain%2520proteins%2520and%2520immunity%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D2743%26epage%3D2749%26doi%3D10.4049%2Fjimmunol.0902937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Couzin-Frankel, J.</span></span> <span> </span><span class="NLM_article-title">New highlight of cancer immunotherapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1126/science.342.6165.1432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1126%2Fscience.342.6165.1432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24357284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotF2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=1432-1433&author=J.+Couzin-Frankel&title=New+highlight+of+cancer+immunotherapy&doi=10.1126%2Fscience.342.6165.1432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy</span></div><div class="casAuthors">Couzin-Frankel, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">6165</span>),
    <span class="NLM_cas:pages">1432-1433</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxASV1j-6kL7Vg90H21EOLACvtfcHk0linUh7QeiTcWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotF2qsg%253D%253D&md5=2e0995fd567c5b59f40c46981da0bef4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.342.6165.1432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.342.6165.1432%26sid%3Dliteratum%253Aachs%26aulast%3DCouzin-Frankel%26aufirst%3DJ.%26atitle%3DNew%2520highlight%2520of%2520cancer%2520immunotherapy%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D1432%26epage%3D1433%26doi%3D10.1126%2Fscience.342.6165.1432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chesney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linette, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguere, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwala, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaheen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernstoff, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salama, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span> <span> </span><span class="NLM_article-title">Nivolumab and ipilimumab versus ipilimumab in untreated melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">2006</span>– <span class="NLM_lpage">2017</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1414428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1056%2FNEJMoa1414428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=25891304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BC2MjmtValsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=2006-2017&author=M.+A.+Postowauthor=J.+Chesneyauthor=A.+C.+Pavlickauthor=C.+Robertauthor=K.+Grossmannauthor=D.+McDermottauthor=G.+P.+Linetteauthor=N.+Meyerauthor=J.+K.+Giguereauthor=S.+S.+Agarwalaauthor=M.+Shaheenauthor=M.+S.+Ernstoffauthor=D.+Minorauthor=A.+K.+Salamaauthor=M.+Taylorauthor=P.+A.+Ottauthor=L.+M.+Rollinauthor=C.+Horakauthor=P.+Gagnierauthor=J.+D.+Wolchokauthor=F.+S.+Hodi&title=Nivolumab+and+ipilimumab+versus+ipilimumab+in+untreated+melanoma&doi=10.1056%2FNEJMoa1414428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab and ipilimumab versus ipilimumab in untreated melanoma</span></div><div class="casAuthors">Postow Michael A; Chesney Jason; Pavlick Anna C; Robert Caroline; Grossmann Kenneth; McDermott David; Linette Gerald P; Meyer Nicolas; Giguere Jeffrey K; Agarwala Sanjiv S; Shaheen Montaser; Ernstoff Marc S; Minor David; Salama April K; Taylor Matthew; Ott Patrick A; Rollin Linda M; Horak Christine; Gagnier Paul; Wolchok Jedd D; Hodi F Stephen</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2006-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma.  METHODS:  In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects.  The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors.  RESULTS:  Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group.  The median duration of response was not reached in either group.  The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001).  Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors.  Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy.  Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication.  CONCLUSIONS:  The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy.  Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsaUZ3ot54z9Hxxy173TfNfW6udTcc2eYy7PcZnso_3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjmtValsw%253D%253D&md5=81184ce1ba06905bd9799478bacd74ad</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1414428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1414428%26sid%3Dliteratum%253Aachs%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DChesney%26aufirst%3DJ.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DGrossmann%26aufirst%3DK.%26aulast%3DMcDermott%26aufirst%3DD.%26aulast%3DLinette%26aufirst%3DG.%2BP.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DGiguere%26aufirst%3DJ.%2BK.%26aulast%3DAgarwala%26aufirst%3DS.%2BS.%26aulast%3DShaheen%26aufirst%3DM.%26aulast%3DErnstoff%26aufirst%3DM.%2BS.%26aulast%3DMinor%26aufirst%3DD.%26aulast%3DSalama%26aufirst%3DA.%2BK.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DP.%2BA.%26aulast%3DRollin%26aufirst%3DL.%2BM.%26aulast%3DHorak%26aufirst%3DC.%26aulast%3DGagnier%26aufirst%3DP.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DNivolumab%2520and%2520ipilimumab%2520versus%2520ipilimumab%2520in%2520untreated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D2006%26epage%3D2017%26doi%3D10.1056%2FNEJMoa1414428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanneman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Combining immunotherapy and targeted therapies in cancer treatment</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1038/nrc3237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc3237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=22437869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVehtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=237-251&author=M.+Vannemanauthor=G.+Dranoff&title=Combining+immunotherapy+and+targeted+therapies+in+cancer+treatment&doi=10.1038%2Fnrc3237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Combining immunotherapy and targeted therapies in cancer treatment</span></div><div class="casAuthors">Vanneman, Matthew; Dranoff, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  During the past two decades, the paradigm for cancer treatment has evolved from relatively nonspecific cytotoxic agents to selective, mechanism-based therapeutics.  Cancer chemotherapies were initially identified through screens for compds. that killed rapidly dividing cells.  These drugs remain the backbone of current treatment, but they are limited by a narrow therapeutic index, significant toxicities and frequently acquired resistance.  More recently, an improved understanding of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy.  Targeted approaches aim to inhibit mol. pathways that are crucial for tumor growth and maintenance; whereas, immunotherapy endeavors to stimulate a host immune response that effectuates long-lived tumor destruction.  Targeted therapies and cytotoxic agents also modulate immune responses, which raises the possibility that these treatment strategies might be effectively combined with immunotherapy to improve clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXt9BTvySH7rVg90H21EOLACvtfcHk0limHMVlXz8Lhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVehtrg%253D&md5=e1ed968896a11cea34456010a72fca57</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrc3237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3237%26sid%3Dliteratum%253Aachs%26aulast%3DVanneman%26aufirst%3DM.%26aulast%3DDranoff%26aufirst%3DG.%26atitle%3DCombining%2520immunotherapy%2520and%2520targeted%2520therapies%2520in%2520cancer%2520treatment%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D237%26epage%3D251%26doi%3D10.1038%2Fnrc3237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caenepeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L. C.</span></span> <span> </span><span class="NLM_article-title">Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">462</span>– <span class="NLM_lpage">476</span>, <span class="refDoi"> DOI: 10.1016/j.it.2016.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.it.2016.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=27216414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvVaktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=462-476&author=P.+E.+Hughesauthor=S.+Caenepeelauthor=L.+C.+Wu&title=Targeted+therapy+and+checkpoint+immunotherapy+combinations+for+the+treatment+of+cancer&doi=10.1016%2Fj.it.2016.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer</span></div><div class="casAuthors">Hughes, Paul E.; Caenepeel, Sean; Wu, Lawren C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">462-476</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Many advances in the treatment of cancer have been driven by the development of targeted therapies that inhibit oncogenic signaling pathways and tumor-assocd. angiogenesis, as well as by the recent development of therapies that activate a patient's immune system to unleash antitumor immunity.  Some targeted therapies can have effects on host immune responses, in addn. to their effects on tumor biol.  These immune-modulating effects, such as increasing tumor antigenicity or promoting intratumoral T cell infiltration, provide a rationale for combining these targeted therapies with immunotherapies.  Here, we discuss the immune-modulating effects of targeted therapies against the MAPK and VEGF signaling pathways, and how they may synergize with immunomodulatory antibodies that target PD1/PDL1 and CTLA4.  We critically examine the rationale in support of these combinations in light of the current understanding of the underlying mechanisms of action of these therapies.  We also discuss the available preclin. and clin. data for these combination approaches and their implications regarding mechanisms of action.  Insights from these studies provide a framework for considering addnl. combinations of targeted therapies and immunotherapies for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre7tfWjsJ7d7Vg90H21EOLACvtfcHk0likw7__FXTmlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvVaktb8%253D&md5=e8fdc59f2b44786448691d39ef0027ba</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2016.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2016.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DP.%2BE.%26aulast%3DCaenepeel%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%2BC.%26atitle%3DTargeted%2520therapy%2520and%2520checkpoint%2520immunotherapy%2520combinations%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DTrends%2520Immunol.%26date%3D2016%26volume%3D37%26spage%3D462%26epage%3D476%26doi%3D10.1016%2Fj.it.2016.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, C. H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W. H.</span></span> <span> </span><span class="NLM_article-title">Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span>, <span class="refDoi"> DOI: 10.1002/anie.201402879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1002%2Fanie.201402879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXot1Sgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=6752-6756&author=D.+Y.+Q.+Wongauthor=C.+H.+F.+Yeoauthor=W.+H.+Ang&title=Immuno-chemotherapeutic+platinum%28IV%29+prodrugs+of+cisplatin+as+multimodal+anticancer+agents&doi=10.1002%2Fanie.201402879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Immuno-Chemotherapeutic Platinum(IV) Prodrugs of Cisplatin as Multimodal Anticancer Agents</span></div><div class="casAuthors">Wong, Daniel Yuan Qiang; Yeo, Charmian Hui Fang; Ang, Wee Han</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">There is growing consensus that the clin. therapeutic efficacy of some chemotherapeutic agents depends on their off-target immune-modulating effects.  Pt anticancer drugs have previously been identified to be potent immunomodulators of both the innate and the adaptive immune system.  Nevertheless, there has been little development in the rational design of Pt-based chemotherapeutic agents to exploit their immune-activating capabilities.  The FPR1/2 formyl peptide receptors are highly expressed in immune cells, as well as in many metastatic cancers.  Herein, we report a rationally designed multimodal PtIV prodrug contg. a FPR1/2-targeting peptide that combines chemotherapy with immunotherapy to achieve therapeutic synergy and demonstrate the feasibility of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqe6CGrj7BBfLVg90H21EOLACvtfcHk0likw7__FXTmlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXot1Sgs7w%253D&md5=33c922b754e9032e120a8f0722f770eb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fanie.201402879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201402879%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DD.%2BY.%2BQ.%26aulast%3DYeo%26aufirst%3DC.%2BH.%2BF.%26aulast%3DAng%26aufirst%3DW.%2BH.%26atitle%3DImmuno-chemotherapeutic%2520platinum%2528IV%2529%2520prodrugs%2520of%2520cisplatin%2520as%2520multimodal%2520anticancer%2520agents%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D6752%26epage%3D6756%26doi%3D10.1002%2Fanie.201402879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Awuah, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemann, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">A Pt(IV) pro-drug preferentially targets indoleamine-2,3-dioxygenase, providing enhanced ovarian cancer immune-chemotherapy</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">14854</span>– <span class="NLM_lpage">14857</span>, <span class="refDoi"> DOI: 10.1021/jacs.5b10182</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.5b10182" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=14854-14857&author=S.+G.+Awuahauthor=Y.+R.+Zhengauthor=P.+M.+Brunoauthor=M.+T.+Hemannauthor=S.+J.+Lippard&title=A+Pt%28IV%29+pro-drug+preferentially+targets+indoleamine-2%2C3-dioxygenase%2C+providing+enhanced+ovarian+cancer+immune-chemotherapy&doi=10.1021%2Fjacs.5b10182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy</span></div><div class="casAuthors">Awuah, Samuel G.; Zheng, Yao-Rong; Bruno, Peter M.; Hemann, Michael T.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">14854-14857</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Expression of indoleamine-2,3-dioxygenase (IDO), an immunosuppressive enzyme in human tumors, leads to immune evasion and tumor tolerance.  IDO is therefore a tumor immunotherapeutic target, and several IDO inhibitors are currently undergoing clin. trials.  IDO inhibitors can enhance the efficacy of common cancer chemotherapeutics.  Here the authors investigate Pt(IV)-(D)-1-methyltryptophan conjugates cis,cis,trans-[Pt(NH3)2Cl2(O2C-D-1-MT)2] (1) and cis,cis,trans-[Pt(NH3)2Cl2(O2CC2H4OCNHC2H4O2C-D-1MT)(O2CNHC16H33)] (2) for combined immunomodulation and DNA crosslink-triggered apoptosis for cancer "immuno-chemotherapy".  Compd. (2) effectively kills hormone-dependent, cisplatin-resistant human ovarian cancer cells, inhibiting IDO by transcriptional deregulation of the autocrine-signaling loop IDO-AHR-IL6, which blocks kynurenine prodn. and promotes T-cell proliferation.  Addnl., (1) and (2) display low toxicity in mice and are stable in blood.  To the authors' knowledge, this construct is the first Pt drug candidate with immune checkpoint blockade properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjz_KgWt-JOLVg90H21EOLACvtfcHk0likw7__FXTmlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVahtrbI&md5=04851d0bb481296b00294bc985190c28</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjacs.5b10182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.5b10182%26sid%3Dliteratum%253Aachs%26aulast%3DAwuah%26aufirst%3DS.%2BG.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DBruno%26aufirst%3DP.%2BM.%26aulast%3DHemann%26aufirst%3DM.%2BT.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DA%2520Pt%2528IV%2529%2520pro-drug%2520preferentially%2520targets%2520indoleamine-2%252C3-dioxygenase%252C%2520providing%2520enhanced%2520ovarian%2520cancer%2520immune-chemotherapy%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D14854%26epage%3D14857%26doi%3D10.1021%2Fjacs.5b10182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">A cisplatin-loaded immuno-chemotherapeutic nanohybrid bearing immune checkpoint inhibitors for enhanced cervical cancer therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3426</span>– <span class="NLM_lpage">3430</span>, <span class="refDoi"> DOI: 10.1002/anie.201800422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1002%2Fanie.201800422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlalsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3426-3430&author=N.+Wangauthor=Z.+Wangauthor=Z.+Xuauthor=X.+Chenauthor=G.+Zhu&title=A+cisplatin-loaded+immuno-chemotherapeutic+nanohybrid+bearing+immune+checkpoint+inhibitors+for+enhanced+cervical+cancer+therapy&doi=10.1002%2Fanie.201800422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">A Cisplatin-Loaded Immunochemotherapeutic Nanohybrid Bearing Immune Checkpoint Inhibitors for Enhanced Cervical Cancer Therapy</span></div><div class="casAuthors">Wang, Na; Wang, Zhigang; Xu, Zoufeng; Chen, Xianfeng; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3426-3430</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The efficacy of conventional chemotherapy is hindered by cancer cell escape from the immune system.  A multifunctional nanohybrid system is reported for effective immunochemotherapy against cervical cancer.  This nanohybrid contains both immune checkpoint inhibitor and cisplatin anticancer prodrug, showing improved cellular accumulation and increased binding of Pt to DNA and resulting in elevated apoptosis than using cisplatin alone when tested in cervical cancer cells.  The immune checkpoint inhibitor enables the inhibition of indoleamine-2,3-dioxygenase and reverses immunosuppressive T cells to recognize cancer cells, leading to T cell proliferation and activation, cancer cell cycle arrest, and ultimately increased cancer cell death.  The nanohybrid is also active in vivo against the growth of human cervical tumors.  Overall, a strategy is provided using a multifunctional nanohybrid system to boost the antitumor activity of cisplatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE2q4eLm-CS7Vg90H21EOLACvtfcHk0liW_UjhOXxKQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlalsbo%253D&md5=05cd2f86034d70a7d4f8a944594e1778</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fanie.201800422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201800422%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DA%2520cisplatin-loaded%2520immuno-chemotherapeutic%2520nanohybrid%2520bearing%2520immune%2520checkpoint%2520inhibitors%2520for%2520enhanced%2520cervical%2520cancer%2520therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D3426%26epage%3D3430%26doi%3D10.1002%2Fanie.201800422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röhrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Challenges in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">9421</span>– <span class="NLM_lpage">9437</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=9421-9437&author=U.+F.+R%C3%B6hrigauthor=S.+R.+Majjigapuauthor=P.+Vogelauthor=V.+Zoeteauthor=O.+Michielin&title=Challenges+in+the+discovery+of+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+inhibitors&doi=10.1021%2Facs.jmedchem.5b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Vogel, Pierre; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9421-9437</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) as an attractive target for anticancer therapy in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies.  Many novel IDO1 inhibitor scaffolds have been described, and a few potent compds. have entered clin. trials.  However, a significant no. of the reported compds. contain problematic functional groups, suggesting that enzyme inhibition could be the result of undesirable side reactions instead of selective binding to IDO1.  Here, we describe issues in the employed exptl. protocols, review and classify reported IDO1 inhibitors, and suggest different approaches for confirming viable inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR3nr-l4vgNLVg90H21EOLACvtfcHk0liW_UjhOXxKQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChsrw%253D&md5=1b44178d33badc00215915c28d027b5d</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00326%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6hrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DChallenges%2520in%2520the%2520discovery%2520of%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D9421%26epage%3D9437%26doi%3D10.1021%2Facs.jmedchem.5b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uyttenhove, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Théta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eynde, B. J. V.</span></span> <span> </span><span class="NLM_article-title">Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1269</span>– <span class="NLM_lpage">1274</span>, <span class="refDoi"> DOI: 10.1038/nm934</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnm934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=14502282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD3sXns1Clu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=1269-1274&author=C.+Uyttenhoveauthor=L.+Pilotteauthor=I.+Th%C3%A9taauthor=V.+Stroobantauthor=D.+Colauauthor=N.+Parmentierauthor=T.+Boonauthor=B.+J.+V.+Eynde&title=Evidence+for+a+tumoral+immune+resistance+mechanism+based+on+tryptophan+degradation+by+indoleamine+2%2C3-dioxygenase&doi=10.1038%2Fnm934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase</span></div><div class="casAuthors">Uyttenhove, Catherine; Pilotte, Luc; Theate, Ivan; Stroobant, Vincent; Colau, Didier; Parmentier, Nicolas; Boon, Thierry; Van den Eynde, Benoit J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1269-1274</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">T lymphocytes undergo proliferation arrest when exposed to tryptophan shortage, which can be provoked by indoleamine 2,3-dioxygenase (IDO), an enzyme that is expressed in placenta and catalyzes tryptophan degrdn.  Here we show that most human tumors constitutively express IDO.  We also obsd. that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice.  This effect is accompanied by a lack of accumulation of specific T cells at the tumor site and can be partly reverted by systemic treatment of mice with an inhibitor of IDO, in the absence of noticeable toxicity.  These results suggest that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2g0Nw1Orz7rVg90H21EOLACvtfcHk0ljOUm-Sps19Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXns1Clu7c%253D&md5=c2be3620862064fb40da547f976ccf95</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnm934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm934%26sid%3Dliteratum%253Aachs%26aulast%3DUyttenhove%26aufirst%3DC.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DTh%25C3%25A9ta%26aufirst%3DI.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DParmentier%26aufirst%3DN.%26aulast%3DBoon%26aufirst%3DT.%26aulast%3DEynde%26aufirst%3DB.%2BJ.%2BV.%26atitle%3DEvidence%2520for%2520a%2520tumoral%2520immune%2520resistance%2520mechanism%2520based%2520on%2520tryptophan%2520degradation%2520by%2520indoleamine%25202%252C3-dioxygenase%26jtitle%3DNat.%2520Med.%26date%3D2003%26volume%3D9%26spage%3D1269%26epage%3D1274%26doi%3D10.1038%2Fnm934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, A. L.</span></span> <span> </span><span class="NLM_article-title">Indolamine 2,3-dioxygenase and tumor-induced tolerance</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">1147</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1172/JCI31178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1172%2FJCI31178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=17476344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Omtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=1147-1154&author=D.+H.+Munnauthor=A.+L.+Mellor&title=Indolamine+2%2C3-dioxygenase+and+tumor-induced+tolerance&doi=10.1172%2FJCI31178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-dioxygenase and tumor-induced tolerance</span></div><div class="casAuthors">Munn, David H.; Mellor, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1147-1154</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Tumors arise from normal cells of the body through genetic mutation.  Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; i.e., it is tolerant of these antigens.  This acquired state of tolerance must be overcome for cancer immunotherapy to succeed.  Indoleamine 2,3-dioxygenase (IDO) is one mol. mechanism that contributes to tumor-induced tolerance.  IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression.  It can also function as an antagonist to other activators of antitumor immunity.  Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGmm42-SIElbVg90H21EOLACvtfcHk0ljOUm-Sps19Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Omtro%253D&md5=b8faf9b3398a23896cca34128636c787</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1172%2FJCI31178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31178%26sid%3Dliteratum%253Aachs%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DMellor%26aufirst%3DA.%2BL.%26atitle%3DIndolamine%25202%252C3-dioxygenase%2520and%2520tumor-induced%2520tolerance%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D1147%26epage%3D1154%26doi%3D10.1172%2FJCI31178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Godin-Ethier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanafi, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccirillo, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapointe, R.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">6985</span>– <span class="NLM_lpage">6991</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1158%2F1078-0432.CCR-11-1331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=22068654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=6985-6991&author=J.+Godin-Ethierauthor=L.+A.+Hanafiauthor=C.+A.+Piccirilloauthor=R.+Lapointe&title=Indoleamine+2%2C3-dioxygenase+expression+in+human+cancers%3A+clinical+and+immunologic+perspectives&doi=10.1158%2F1078-0432.CCR-11-1331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives</span></div><div class="casAuthors">Godin-Ethier, Jessica; Hanafi, Laila-Aicha; Piccirillo, Ciriaco A.; Lapointe, Rejean</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6985-6991</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolizing enzyme with immune-regulating activities in many contexts, such as fetal protection, allograft protection, and cancer progression.  Clin. trials are currently evaluating IDO inhibition with 1-methyltryptophan in cancer immunotherapy.  However, the exact role of tryptophan catabolism by IDO in human cancers remains poorly understood.  Here, we review several studies that correlate IDO expression in human cancer samples and tumor-draining lymph nodes, with relevant clin. or immunol. parameters.  IDO expression in various histol. cancer types seems to decrease tumor infiltration of immune cells and to increase the proportion of regulatory T lymphocytes in the infiltrate.  The impact of IDO on different immune cell infiltration leads to the conclusion that IDO neg. regulates the recruitment of antitumor immune cells.  In addn., increased IDO expression correlates with diverse tumor progression parameters and shorter patient survival.  In summary, in the vast majority of the reported studies, IDO expression is correlated with a less favorable prognosis.  As we may see results from the first clin. trials with 1-methyltryptophan in years to come, this review brings together IDO studies from human studies and aims to help appreciate outcomes from current and future trials.  Consequently, IDO inhibition seems a promising approach for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFcLrhJoibc7Vg90H21EOLACvtfcHk0ljOUm-Sps19Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht7rO&md5=4fe628fdb524657dba690497e7d0f067</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1331%26sid%3Dliteratum%253Aachs%26aulast%3DGodin-Ethier%26aufirst%3DJ.%26aulast%3DHanafi%26aufirst%3DL.%2BA.%26aulast%3DPiccirillo%26aufirst%3DC.%2BA.%26aulast%3DLapointe%26aufirst%3DR.%26atitle%3DIndoleamine%25202%252C3-dioxygenase%2520expression%2520in%2520human%2520cancers%253A%2520clinical%2520and%2520immunologic%2520perspectives%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D6985%26epage%3D6991%26doi%3D10.1158%2F1078-0432.CCR-11-1331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8321</span>– <span class="NLM_lpage">8331</span>, <span class="refDoi"> DOI: 10.1021/jm401195n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401195n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8321-8331&author=S.+Yangauthor=X.+Liauthor=F.+Huauthor=Y.+Liauthor=Y.+Yangauthor=J.+Yanauthor=C.+Kuangauthor=Q.+Yang&title=Discovery+of+tryptanthrin+derivatives+as+potent+inhibitors+of+indoleamine+2%2C3-dioxygenase+with+therapeutic+activity+in+Lewis+lung+cancer+%28LLC%29+tumor-bearing+mice&doi=10.1021%2Fjm401195n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice</span></div><div class="casAuthors">Yang, Shuangshuang; Li, Xishuai; Hu, Fangfang; Li, Yinlong; Yang, Yunyun; Yan, Junkai; Kuang, Chunxiang; Yang, Qing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8321-8331</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO-1) is emerging as an important new therapeutic target for the treatment of cancer, neurol. disorders, and other diseases that are characterized by pathol. tryptophan metab.  However, only a few structural classes are known to be IDO-1 inhibitors.  In this study, a natural compd. tryptanthrin was discovered to be a novel potent IDO-1 inhibitor by screening of indole-based structures.  Three series of 13 tryptanthrin derivs. were synthesized, and the structure-activity anal. was undertaken.  The optimization led to the identification of 5c, which exhibited the inhibitory activity at a nanomolar level.  In vitro 5c dramatically augmented the proliferation of T cells.  When administered to Lewis lung cancer (LLC) tumor-bearing mice, 5c significantly inhibited IDO-1 activity and suppressed tumor growth.  In addn., 5c reduced the nos. of Foxp3+ regulatory T cells (Tregs), which are known to prevent the development of efficient antitumor immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5ioPL3rWy1bVg90H21EOLACvtfcHk0lh_09QwDeV-kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFynsrjL&md5=ac744f81ce97b0435f2bfd240e1393a1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm401195n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401195n%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DKuang%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520tryptanthrin%2520derivatives%2520as%2520potent%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520with%2520therapeutic%2520activity%2520in%2520Lewis%2520lung%2520cancer%2520%2528LLC%2529%2520tumor-bearing%2520mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8321%26epage%3D8331%26doi%3D10.1021%2Fjm401195n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heikkila, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaara, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Smitten, K. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakkila, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leidenius, M. H. K.</span></span> <span> </span><span class="NLM_article-title">Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1186/1471-2407-9-231</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1186%2F1471-2407-9-231" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=19604349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BD1Mrktl2qsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=231-241&author=A.+S.+Mansfieldauthor=P.+S.+Heikkilaauthor=A.+T.+Vaaraauthor=K.+A.+J.+von+Smittenauthor=J.+M.+Vakkilaauthor=M.+H.+K.+Leidenius&title=Simultaneous+Foxp3+and+IDO+expression+is+associated+with+sentinel+lymph+node+metastases+in+breast+cancer&doi=10.1186%2F1471-2407-9-231"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer</span></div><div class="casAuthors">Mansfield Aaron S; Heikkila Paivi S; Vaara Ari T; von Smitten Karl A J; Vakkila Jukka M; Leidenius Marjut H K</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There is evidence that the immune systems of patients with breast cancer are dysfunctional.  Regulatory T cells (Tregs), and IDO, an immunosuppressive enzyme, are associated with more advanced disease in some cancers and may promote immunologic tolerance to tumors.  Our aim was to assess whether expression of Foxp3, a marker of Tregs, and IDO were linked with nodal metastasis in breast cancer patients.  Inhibitors of IDO are available and could potentially demonstrate utility in breast cancer if IDO drives progression of disease.  METHODS:  Sentinel lymph nodes (SLN) of 47 breast cancer patients with varying degrees of nodal disease and 10 controls were evaluated for expression of Foxp3 and IDO using immunohistochemistry.  Positively stained cells were quantified and their distribution within the SLN noted.  RESULTS:  The proportion of Foxp3+ cells was higher in SLN of cancer patients than controls (19% v. 10%, p < 0.001).  Specifically, there were more Foxp3+ cells in SLN with metastasis than tumor-free SLN (20% v. 14%, p = 0.02).  The proportion IDO+ cell in SLN of cancer patients was not statistically different than controls (4.0% v. 1.6%, p = 0.08).  In order to demonstrate the combined immunosuppressive effect of Foxp3 and IDO, we categorized each SLN as positive or negative for Foxp3 and IDO.  The Foxp3+/IDO+ group almost exclusively consisted of cancer patients with node positive disease.  CONCLUSION:  In conclusion, our study shows that Foxp3+ cells are associated with more advanced disease in breast cancer, a finding that is proving to be true in many other cancers.  As IDO has been found to promote differentiation of Tregs, IDO may become a suitable target to abrogate the development of T-cell tolerance and to promote an effective immune response to breast cancer.  Our results about the combined expression of IDO and Foxp3 in metastastic SLN support this assumption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQiWWVmEk4LDwpJitSxOdIlfW6udTcc2eZ1wOVRi6GU3bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mrktl2qsQ%253D%253D&md5=a9993b26a4dd34154b5272c37a05dac6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-9-231&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-9-231%26sid%3Dliteratum%253Aachs%26aulast%3DMansfield%26aufirst%3DA.%2BS.%26aulast%3DHeikkila%26aufirst%3DP.%2BS.%26aulast%3DVaara%26aufirst%3DA.%2BT.%26aulast%3Dvon%2BSmitten%26aufirst%3DK.%2BA.%2BJ.%26aulast%3DVakkila%26aufirst%3DJ.%2BM.%26aulast%3DLeidenius%26aufirst%3DM.%2BH.%2BK.%26atitle%3DSimultaneous%2520Foxp3%2520and%2520IDO%2520expression%2520is%2520associated%2520with%2520sentinel%2520lymph%2520node%2520metastases%2520in%2520breast%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D231%26epage%3D241%26doi%3D10.1186%2F1471-2407-9-231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1845</span>– <span class="NLM_lpage">1853</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1158%2F0008-5472.CAN-09-3613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20160032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFWju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1845-1853&author=A.+J.+Mullerauthor=J.+B.+DuHadawayauthor=D.+Jallerauthor=P.+Curtisauthor=R.+Metzauthor=G.+C.+Prendergast&title=Immunotherapeutic+suppression+of+indoleamine+2%2C3-dioxygenase+and+tumor+growth+with+ethyl+pyruvate&doi=10.1158%2F0008-5472.CAN-09-3613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate</span></div><div class="casAuthors">Muller, Alexander J.; DuHadaway, James B.; Jaller, Daniel; Curtis, Peter; Metz, Richard; Prendergast, George C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1845-1853</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Efforts to improve cancer care in the developing world will benefit from the identification of simple, inexpensive, and broadly applicable medical modalities based on emergent innovations in treatment, such as targeting mechanisms of tumoral immune tolerance.  In this report, we offer preclin. evidence that the low-cost, anti-inflammatory agent Et pyruvate elicits a potent immune-based antitumor response through inhibition of indoleamine 2,3-dioxygenase (IDO), a key tolerogenic enzyme for many human tumors.  Consistent with its reported ability to interfere with NF-κB function, Et pyruvate blocks IDO induction both in vitro and in vivo.  Antitumor activity was achieved in mice with a noncytotoxic dosing regimen of Et pyruvate shown previously to protect against lethality from sepsis.  Similar outcomes were obtained with the functional Et pyruvate analog 2-acetamidoacrylate.  Et pyruvate was ineffective at suppressing tumor outgrowth in both athymic and Ido1-deficient mice, providing in vivo corroboration of the importance of T-cell-dependent immunity and IDO targeting for Et pyruvate to achieve antitumor efficacy.  Although Et pyruvate has undergone early-phase clin. testing, this was done without consideration of its possible applicability to cancer.  Our findings that IDO is effectively blocked by Et pyruvate treatment deepen emerging links between IDO and inflammatory processes.  Further, these findings rationalize oncol. applications for this agent by providing a compelling basis to reposition Et pyruvate as a low-cost immunochemotherapy for clin. evaluation in cancer patients.  Cancer Res; 70(5); 1845-53.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkSC_ZW9ndLVg90H21EOLACvtfcHk0ljjjhhir-ACOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFWju78%253D&md5=3d6e683754a5f97ef5215319ad454e2c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3613%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DJaller%26aufirst%3DD.%26aulast%3DCurtis%26aufirst%3DP.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DImmunotherapeutic%2520suppression%2520of%2520indoleamine%25202%252C3-dioxygenase%2520and%2520tumor%2520growth%2520with%2520ethyl%2520pyruvate%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1845%26epage%3D1853%26doi%3D10.1158%2F0008-5472.CAN-09-3613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donover, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutanto-Ward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1038/nm1196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnm1196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=15711557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BD2M7hs1Wiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=312-319&author=A.+J.+Mullerauthor=J.+B.+DuHadawayauthor=P.+S.+Donoverauthor=E.+Sutanto-Wardauthor=G.+C.+Prendergast&title=Inhibition+of+indoleamine+2%2C3-dioxygenase%2C+an+immunoregulatory+target+of+the+cancer+suppression+gene+Bin1%2C+potentiates+cancer+chemotherapy&doi=10.1038%2Fnm1196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy</span></div><div class="casAuthors">Muller Alexander J; DuHadaway James B; Donover P Scott; Sutanto-Ward Erika; Prendergast George C</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">312-9</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Immune escape is a crucial feature of cancer progression about which little is known.  Elevation of the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) in tumor cells can facilitate immune escape.  Not known is how IDO becomes elevated or whether IDO inhibitors will be useful for cancer treatment.  Here we show that IDO is under genetic control of Bin1, which is attenuated in many human malignancies.  Mouse knockout studies indicate that Bin1 loss elevates the STAT1- and NF-kappaB-dependent expression of IDO, driving escape of oncogenically transformed cells from T cell-dependent antitumor immunity.  In MMTV-Neu mice, an established breast cancer model, we show that small-molecule inhibitors of IDO cooperate with cytotoxic agents to elicit regression of established tumors refractory to single-agent therapy.  Our findings suggest that Bin1 loss promotes immune escape in cancer by deregulating IDO and that IDO inhibitors may improve responses to cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmoMRy8m8ZDAyMywPm6HgQfW6udTcc2eZ5ICIbwO04zLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M7hs1Wiuw%253D%253D&md5=2871eb26a11432381462091144b227f1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnm1196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1196%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DDonover%26aufirst%3DP.%2BS.%26aulast%3DSutanto-Ward%26aufirst%3DE.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26atitle%3DInhibition%2520of%2520indoleamine%25202%252C3-dioxygenase%252C%2520an%2520immunoregulatory%2520target%2520of%2520the%2520cancer%2520suppression%2520gene%2520Bin1%252C%2520potentiates%2520cancer%2520chemotherapy%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D312%26epage%3D319%26doi%3D10.1038%2Fnm1196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7364</span>– <span class="NLM_lpage">7367</span>, <span class="refDoi"> DOI: 10.1021/jm900518f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900518f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7364-7367&author=E.+W.+Yueauthor=B.+Doutyauthor=B.+Waylandauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=C.+Liuauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=B.+Metcalfauthor=P.+A.+Scherleauthor=A.+P.+Combs&title=Discovery+of+potent+competitive+inhibitors+of+indoleamine+2%2C3-dioxygenase+with+in+vivo+pharmacodynamic+activity+and+efficacy+in+a+mouse+melanoma+model&doi=10.1021%2Fjm900518f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model</span></div><div class="casAuthors">Yue, Eddy W.; Douty, Brent; Wayland, Brian; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Liu, Changnian; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Metcalf, Brian; Scherle, Peggy A.; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7364-7367</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO).  Optimization led to the identification of (I), which is a potent (HeLa IC50 = 19 nM) competitive inhibitor of IDO.  Testing of I in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZsq88hx0J77Vg90H21EOLACvtfcHk0lgmDitu1m5ing"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVSksb8%253D&md5=328d92bffb88a86da030c31eff707dc6</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm900518f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900518f%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DDiscovery%2520of%2520potent%2520competitive%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%2520with%2520in%2520vivo%2520pharmacodynamic%2520activity%2520and%2520efficacy%2520in%2520a%2520mouse%2520melanoma%2520model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7364%26epage%3D7367%26doi%3D10.1021%2Fjm900518f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coluccia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passacantilli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famiglini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patsilinakos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzoccoli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sisinni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takikawa, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvestri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regina, G. L.</span></span> <span> </span><span class="NLM_article-title">New inhibitors of indoleamine 2,3-dioxygenase 1: molecular modeling studies, synthesis, and biological evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9760</span>– <span class="NLM_lpage">9773</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9760-9773&author=A.+Colucciaauthor=S.+Passacantilliauthor=V.+Famigliniauthor=M.+Sabatinoauthor=A.+Patsilinakosauthor=R.+Ragnoauthor=C.+Mazzoccoliauthor=L.+Sisinniauthor=A.+Okunoauthor=O.+Takikawaauthor=R.+Silvestriauthor=G.+L.+Regina&title=New+inhibitors+of+indoleamine+2%2C3-dioxygenase+1%3A+molecular+modeling+studies%2C+synthesis%2C+and+biological+evaluation&doi=10.1021%2Facs.jmedchem.6b00718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation</span></div><div class="casAuthors">Coluccia, Antonio; Passacantilli, Sara; Famiglini, Valeria; Sabatino, Manuela; Patsilinakos, Alexandros; Ragno, Rino; Mazzoccoli, Carmela; Sisinni, Lorenza; Okuno, Alato; Takikawa, Osamu; Silvestri, Romano; La Regina, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9760-9773</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an attractive target for anticancer therapy.  Herein, we report a virtual screening study which led to the identification of compd. I as a new IDO1 inhibitor.  In order to improve the biol. activity of the identified hit, arylthioindoles were synthesized and tested.  Among these, deriv. II exhibited an IC50 value of 7 μM, being the most active compd. of the series.  Furthermore, compds. I and II induced a dose-dependent growth inhibition in IDO1 expressing cancer cell lines HTC116 and HT29.  3-D QSAR studies were carried out in order to rationalize obtained results and suggest new chem. modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxfHwAbMNZXrVg90H21EOLACvtfcHk0lgmDitu1m5ing"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SmtL7I&md5=9a1267db6fdeadfbbb693464ba4dddd6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00718%26sid%3Dliteratum%253Aachs%26aulast%3DColuccia%26aufirst%3DA.%26aulast%3DPassacantilli%26aufirst%3DS.%26aulast%3DFamiglini%26aufirst%3DV.%26aulast%3DSabatino%26aufirst%3DM.%26aulast%3DPatsilinakos%26aufirst%3DA.%26aulast%3DRagno%26aufirst%3DR.%26aulast%3DMazzoccoli%26aufirst%3DC.%26aulast%3DSisinni%26aufirst%3DL.%26aulast%3DOkuno%26aufirst%3DA.%26aulast%3DTakikawa%26aufirst%3DO.%26aulast%3DSilvestri%26aufirst%3DR.%26aulast%3DRegina%26aufirst%3DG.%2BL.%26atitle%3DNew%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase%25201%253A%2520molecular%2520modeling%2520studies%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9760%26epage%3D9773%26doi%3D10.1021%2Facs.jmedchem.6b00718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Phenyl benzenesulfonylhydrazides exhibit selective indoleamine 2,3-dioxygenase inhibition with potent in vivo pharmacodynamic activity and antitumor efficacy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ltLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=419-430&author=S.+Y.+Linauthor=T.+K.+Yehauthor=C.+C.+Kuoauthor=J.+S.+Songauthor=M.+F.+Chengauthor=F.+Y.+Liaoauthor=M.+W.+Chaoauthor=H.+L.+Huangauthor=Y.+L.+Chenauthor=C.+Y.+Yangauthor=M.+H.+Wuauthor=C.+L.+Hsiehauthor=W.+Hsiaoauthor=Y.+H.+Pengauthor=J.+S.+Wuauthor=L.+M.+Linauthor=M.+Sunauthor=Y.+S.+Chaoauthor=C.+Shihauthor=S.+Y.+Wuauthor=S.+L.+Panauthor=M.+S.+Hungauthor=S.+H.+Ueng&title=Phenyl+benzenesulfonylhydrazides+exhibit+selective+indoleamine+2%2C3-dioxygenase+inhibition+with+potent+in+vivo+pharmacodynamic+activity+and+antitumor+efficacy&doi=10.1021%2Facs.jmedchem.5b01640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy</span></div><div class="casAuthors">Lin, Shu-Yu; Yeh, Teng-Kuang; Kuo, Ching-Chuan; Song, Jen-Shin; Cheng, Ming-Fu; Liao, Fang-Yu; Chao, Min-Wu; Huang, Han-Li; Chen, Yi-Lin; Yang, Chun-Yu; Wu, Mine-Hsine; Hsieh, Chia-Ling; Hsiao, Wenchi; Peng, Yi-Hui; Wu, Jian-Sung; Lin, Li-Mei; Sun, Manwu; Chao, Yu-Sheng; Shih, Chuan; Wu, Su-Ying; Pan, Shiow-Lin; Hung, Ming-Shiu; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">419-430</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tryptophan metab. has been recognized as an important mechanism in immune tolerance.  Indoleamine 2,3-dioxygenase plays a key role in local tryptophan metab. via the kynurenine pathway and has emerged as a therapeutic target for cancer immunotherapy.  The prior study identified Ph benzenesulfonyl hydrazide as a potent in vitro (though not in vivo) inhibitor of indoleamine 2,3-dioxygenase.  Further lead optimization to improve in vitro potencies and pharmacokinetic profiles resulted in N'-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl hydrazide (I), which demonstrated 59% oral bioavailability and 73% of tumor growth delay without apparent body wt. loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg.  Accordingly, I is proposed as a potential drug lead worthy of advanced preclin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOxVvjSCi13LVg90H21EOLACvtfcHk0liWx3ieN4uEkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ltLjE&md5=63287615c2b038f657cab148d4747e03</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01640%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DKuo%26aufirst%3DC.%2BC.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DHsiao%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DL.%2BM.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DPhenyl%2520benzenesulfonylhydrazides%2520exhibit%2520selective%2520indoleamine%25202%252C3-dioxygenase%2520inhibition%2520with%2520potent%2520in%2520vivo%2520pharmacodynamic%2520activity%2520and%2520antitumor%2520efficacy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D419%26epage%3D430%26doi%3D10.1021%2Facs.jmedchem.5b01640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crosignani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bingham, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottemanne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cannellè, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cauwenberghs, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordonnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroose, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrerié, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maegley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torti, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eynde, B. V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wythes, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel and selective indoleamine 2,3-dioxygenase (IDO-1) inhibitor 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and its characterization as a potential clinical candidate</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9617</span>– <span class="NLM_lpage">9629</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00974</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00974" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9617-9629&author=S.+Crosignaniauthor=P.+Binghamauthor=P.+Bottemanneauthor=H.+Cannell%C3%A8author=S.+Cauwenberghsauthor=M.+Cordonnierauthor=D.+Dalvieauthor=F.+Derooseauthor=J.+L.+Fengauthor=B.+Gomesauthor=S.+Greasleyauthor=S.+E.+Kaiserauthor=M.+Krausauthor=M.+Negreri%C3%A9author=K.+Maegleyauthor=N.+Millerauthor=B.+W.+Murrayauthor=M.+Schneiderauthor=J.+Soloweijauthor=A.+E.+Stewartauthor=J.+Tumangauthor=V.+R.+Tortiauthor=B.+V.+D.+Eyndeauthor=M.+Wythes&title=Discovery+of+a+novel+and+selective+indoleamine+2%2C3-dioxygenase+%28IDO-1%29+inhibitor+3-%285-fluoro-1H-indol-3-yl%29pyrrolidine-2%2C5-dione+%28EOS200271%2FPF-06840003%29+and+its+characterization+as+a+potential+clinical+candidate&doi=10.1021%2Facs.jmedchem.7b00974"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate</span></div><div class="casAuthors">Crosignani, Stefano; Bingham, Patrick; Bottemanne, Pauline; Cannelle, Helene; Cauwenberghs, Sandra; Cordonnier, Marie; Dalvie, Deepak; Deroose, Frederik; Feng, Jun Li; Gomes, Bruno; Greasley, Samantha; Kaiser, Stephen E.; Kraus, Manfred; Negrerie, Michel; Maegley, Karen; Miller, Nichol; Murray, Brion W.; Schneider, Manfred; Soloweij, James; Stewart, Albert E.; Tumang, Joseph; Torti, Vince R.; Van Den Eynde, Benoit; Wythes, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9617-9629</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment.  IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function.  As such, IDO-1 is a nexus for the induction of a key immunosuppressive mechanism and represents an important immunotherapeutic target in oncol.  Starting from HTS hit I, IDO-1 inhibitor II has been developed.  The structure-activity relationship around II is described and rationalized using the x-ray crystal structure of II bound to human IDO-1, which shows that II, differently from most of the IDO-1 inhibitors described so far, does not bind to the heme iron atom and has a novel binding mode.  Clin. candidate II shows good potency in an IDO-1 human whole blood assay and also shows a very favorable ADME profile leading to favorable predicted human pharmacokinetic properties, including a predicted half-life of 16-19 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogfHmZRAC-dLVg90H21EOLACvtfcHk0lgvCagk-CJ8oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslOns7%252FK&md5=dc2e45c243aa22c100ccc39db9b5918a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00974%26sid%3Dliteratum%253Aachs%26aulast%3DCrosignani%26aufirst%3DS.%26aulast%3DBingham%26aufirst%3DP.%26aulast%3DBottemanne%26aufirst%3DP.%26aulast%3DCannell%25C3%25A8%26aufirst%3DH.%26aulast%3DCauwenberghs%26aufirst%3DS.%26aulast%3DCordonnier%26aufirst%3DM.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDeroose%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DGomes%26aufirst%3DB.%26aulast%3DGreasley%26aufirst%3DS.%26aulast%3DKaiser%26aufirst%3DS.%2BE.%26aulast%3DKraus%26aufirst%3DM.%26aulast%3DNegreri%25C3%25A9%26aufirst%3DM.%26aulast%3DMaegley%26aufirst%3DK.%26aulast%3DMiller%26aufirst%3DN.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSoloweij%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DA.%2BE.%26aulast%3DTumang%26aufirst%3DJ.%26aulast%3DTorti%26aufirst%3DV.%2BR.%26aulast%3DEynde%26aufirst%3DB.%2BV.%2BD.%26aulast%3DWythes%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520and%2520selective%2520indoleamine%25202%252C3-dioxygenase%2520%2528IDO-1%2529%2520inhibitor%25203-%25285-fluoro-1H-indol-3-yl%2529pyrrolidine-2%252C5-dione%2520%2528EOS200271%252FPF-06840003%2529%2520and%2520its%2520characterization%2520as%2520a%2520potential%2520clinical%2520candidate%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9617%26epage%3D9629%26doi%3D10.1021%2Facs.jmedchem.7b00974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shia, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Important hydrogen bond networks in indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor design revealed by crystal structures of imidazoleisoindole derivatives with IDO1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01390</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01390" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKjtLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=282-293&author=Y.+H.+Pengauthor=S.+H.+Uengauthor=C.+T.+Tsengauthor=M.+S.+Hungauthor=J.+S.+Songauthor=J.+S.+Wuauthor=F.+Y.+Liaoauthor=Y.+S.+Fanauthor=M.+H.+Wuauthor=W.+C.+Hsiaoauthor=C.+C.+Hsuehauthor=S.+Y.+Linauthor=C.+Y.+Chengauthor=C.+H.+Tuauthor=L.+C.+Leeauthor=M.+F.+Chengauthor=K.+S.+Shiaauthor=C.+Shihauthor=S.+Y.+Wu&title=Important+hydrogen+bond+networks+in+indoleamine+2%2C3-dioxygenase+1+%28IDO1%29+inhibitor+design+revealed+by+crystal+structures+of+imidazoleisoindole+derivatives+with+IDO1&doi=10.1021%2Facs.jmedchem.5b01390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1</span></div><div class="casAuthors">Peng, Yi-Hui; Ueng, Shau-Hua; Tseng, Chen-Tso; Hung, Ming-Shiu; Song, Jen-Shin; Wu, Jian-Sung; Liao, Fang-Yu; Fan, Yu-Shiou; Wu, Mine-Hsine; Hsiao, Wen-Chi; Hsueh, Ching-Cheng; Lin, Shu-Yu; Cheng, Chia-Yi; Tu, Chih-Hsiang; Lee, Lung-Chun; Cheng, Ming-Fu; Shia, Kak-Shan; Shih, Chuan; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1), promoting immune escape of tumors, is a therapeutic target for the cancer immunotherapy.  A no. of IDO1 inhibitors have been identified, but only limited structural biol. studies of IDO1 inhibitors are available to provide insights on the binding mechanism of IDO1.  In this study, we present the structure of IDO1 in complex with 24, a NLG919 analog with potent activity.  The complex structure revealed the imidazole nitrogen atom of 24 to coordinate with the heme iron, and the imidazoleisoindole core situated in pocket A with the 1-cyclohexylethanol moiety extended to pocket B to interact with the surrounding residues.  Most interestingly, 24 formed an extensive hydrogen bond network with IDO1, which is a distinct feature of IDO1/24 complex structure and is not obsd. in the other IDO1 complex structures.  Further structure-activity relationship, UV spectra, and structural biol. studies of several analogs of 24 demonstrated that extensive hydrophobic interactions and the unique hydrogen bonding network contribute to the great potency of imidazoleisoindole derivs.  These results are expected to facilitate the structure-based drug design of new IDO inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodJqtuECqcsrVg90H21EOLACvtfcHk0lgvCagk-CJ8oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKjtLnJ&md5=2258be36595a3fa8e6c9064b2f15e1de</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01390%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26aulast%3DTseng%26aufirst%3DC.%2BT.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DFan%26aufirst%3DY.%2BS.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsiao%26aufirst%3DW.%2BC.%26aulast%3DHsueh%26aufirst%3DC.%2BC.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DCheng%26aufirst%3DC.%2BY.%26aulast%3DTu%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DShia%26aufirst%3DK.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26atitle%3DImportant%2520hydrogen%2520bond%2520networks%2520in%2520indoleamine%25202%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitor%2520design%2520revealed%2520by%2520crystal%2520structures%2520of%2520imidazoleisoindole%2520derivatives%2520with%2520IDO1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D282%26epage%3D293%26doi%3D10.1021%2Facs.jmedchem.5b01390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhavoronkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozerov, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makarev, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artemov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysocki, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimmagadda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidransky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borrello, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedi, A.</span></span> <span> </span><span class="NLM_article-title">Bifunctional immune checkpoint-targeted antibodyligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy</span>. <i>Nat. commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">741</span> <span class="refDoi"> DOI: 10.1038/s41467-017-02696-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fs41467-017-02696-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=29467463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BC1MrktVWnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=R.+Raviauthor=K.+A.+Noonanauthor=V.+Phamauthor=R.+Bediauthor=A.+Zhavoronkovauthor=I.+V.+Ozerovauthor=E.+Makarevauthor=A.+V.+Artemovauthor=P.+T.+Wysockiauthor=R.+Mehraauthor=S.+Nimmagaddaauthor=L.+Marchionniauthor=D.+Sidranskyauthor=I.+M.+Borrelloauthor=E.+Izumchenkoauthor=A.+Bedi&title=Bifunctional+immune+checkpoint-targeted+antibodyligand+traps+that+simultaneously+disable+TGF%CE%B2+enhance+the+efficacy+of+cancer+immunotherapy&doi=10.1038%2Fs41467-017-02696-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy</span></div><div class="casAuthors">Ravi Rajani; Pham Vui; Wysocki Piotr T; Sidransky David; Izumchenko Evgeny; Bedi Atul; Noonan Kimberly A; Borrello Ivan M; Bedi Rishi; Zhavoronkov Alex; Ozerov Ivan V; Makarev Eugene; V Artemov Artem; Mehra Ranee; Nimmagadda Sridhar; Marchionni Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">741</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A majority of cancers fail to respond to immunotherapy with antibodies targeting immune checkpoints, such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1)/PD-1 ligand (PD-L1).  Cancers frequently express transforming growth factor-β (TGFβ), which drives immune dysfunction in the tumor microenvironment by inducing regulatory T cells (Tregs) and inhibiting CD8(+) and TH1 cells.  To address this therapeutic challenge, we invent bifunctional antibody-ligand traps (Y-traps) comprising an antibody targeting CTLA-4 or PD-L1 fused to a TGFβ receptor II ectodomain sequence that simultaneously disables autocrine/paracrine TGFβ in the target cell microenvironment (a-CTLA4-TGFβRIIecd and a-PDL1-TGFβRIIecd). a-CTLA4-TGFβRIIecd is more effective in reducing tumor-infiltrating Tregs and inhibiting tumor progression compared with CTLA-4 antibody (Ipilimumab).  Likewise, a-PDL1-TGFβRIIecd exhibits superior antitumor efficacy compared with PD-L1 antibodies (Atezolizumab or Avelumab).  Our data demonstrate that Y-traps counteract TGFβ-mediated differentiation of Tregs and immune tolerance, thereby providing a potentially more effective immunotherapeutic strategy against cancers that are resistant to current immune checkpoint inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRLqYwFBe0wFSCEBeYuoi7AfW6udTcc2eYVgW4s4uvkGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrktVWnsw%253D%253D&md5=df34e44475f80baee5692fb615fa09a2</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41467-017-02696-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-017-02696-6%26sid%3Dliteratum%253Aachs%26aulast%3DRavi%26aufirst%3DR.%26aulast%3DNoonan%26aufirst%3DK.%2BA.%26aulast%3DPham%26aufirst%3DV.%26aulast%3DBedi%26aufirst%3DR.%26aulast%3DZhavoronkov%26aufirst%3DA.%26aulast%3DOzerov%26aufirst%3DI.%2BV.%26aulast%3DMakarev%26aufirst%3DE.%26aulast%3DArtemov%26aufirst%3DA.%2BV.%26aulast%3DWysocki%26aufirst%3DP.%2BT.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DNimmagadda%26aufirst%3DS.%26aulast%3DMarchionni%26aufirst%3DL.%26aulast%3DSidransky%26aufirst%3DD.%26aulast%3DBorrello%26aufirst%3DI.%2BM.%26aulast%3DIzumchenko%26aufirst%3DE.%26aulast%3DBedi%26aufirst%3DA.%26atitle%3DBifunctional%2520immune%2520checkpoint-targeted%2520antibodyligand%2520traps%2520that%2520simultaneously%2520disable%2520TGF%25CE%25B2%2520enhance%2520the%2520efficacy%2520of%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520commun.%26date%3D2018%26volume%3D9%26doi%3D10.1038%2Fs41467-017-02696-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span> <span> </span><span class="NLM_article-title">Immunosuppressive networks in the tumour environment and their therapeutic relevance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">274</span>, <span class="refDoi"> DOI: 10.1038/nrc1586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc1586" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=15776005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=263-274&author=W.+Zou&title=Immunosuppressive+networks+in+the+tumour+environment+and+their+therapeutic+relevance&doi=10.1038%2Fnrc1586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Immunosuppressive networks in the tumor environment and their therapeutic relevance</span></div><div class="casAuthors">Zou, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-274</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  It is well known that many tumors are potentially immunogenic, as corroborated by the presence of tumor-specific immune responses in vivo.  Nonetheless, spontaneous clearance of established tumors by endogenous immune mechanisms is rare.  Therefore, the focus of most cancer immunotherapies is to supplement essential immunogenic elements to boost tumor-specific immunity.  Why then has tumor immunotherapy resulted in a generally poor clin. efficiency.  The reason might lie in the increasingly documented fact that tumors develop diverse strategies that escape tumor-specific immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYn6QskoTkQrVg90H21EOLACvtfcHk0lhZR2PMpCTb2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7g%253D&md5=46d0056c242606494cfb09740ffa3fc2</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc1586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1586%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DW.%26atitle%3DImmunosuppressive%2520networks%2520in%2520the%2520tumour%2520environment%2520and%2520their%2520therapeutic%2520relevance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D263%26epage%3D274%26doi%3D10.1038%2Fnrc1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span> <span> </span><span class="NLM_article-title">Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1038/nri1995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnri1995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=17186030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCht7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=41-51&author=H.+Yuauthor=M.+Kortylewskiauthor=D.+Pardoll&title=Crosstalk+between+cancer+and+immune+cells%3A+role+of+STAT3+in+the+tumour+microenvironment&doi=10.1038%2Fnri1995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment</span></div><div class="casAuthors">Yu, Hua; Kortylewski, Marcin; Pardoll, Drew</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-51</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Immune cells in the tumor microenvironment not only fail to mount an effective anti-tumor immune response, but also interact intimately with the transformed cells to promote oncogenesis actively.  Signal transducer and activator of transcription 3 (STAT3), which is a point of convergence for numerous oncogenic signaling pathways, is constitutively activated both in tumor cells and in immune cells in the tumor microenvironment.  Constitutively activated STAT3 inhibits the expression of mediators necessary for immune activation against tumor cells.  Furthermore, STAT3 activity promotes the prodn. of immunosuppressive factors that activate STAT3 in diverse immune-cell subsets, altering gene expression programs and, thereby, restraining anti-tumor immune responses.  As such, STAT3 propagates several levels of crosstalk between tumor cells and their immunol. microenvironment, leading to tumor-induced immunosuppression.  Consequently, STAT3 has emerged as a promising target for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYT6B6OheWubVg90H21EOLACvtfcHk0lhZR2PMpCTb2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCht7fE&md5=1b6bd983fb7a7baba5d3a4087cbd65ce</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnri1995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1995%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DKortylewski%26aufirst%3DM.%26aulast%3DPardoll%26aufirst%3DD.%26atitle%3DCrosstalk%2520between%2520cancer%2520and%2520immune%2520cells%253A%2520role%2520of%2520STAT3%2520in%2520the%2520tumour%2520microenvironment%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2007%26volume%3D7%26spage%3D41%26epage%3D51%26doi%3D10.1038%2Fnri1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buettner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">736</span>– <span class="NLM_lpage">746</span>, <span class="refDoi"> DOI: 10.1038/nrc3818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc3818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=25342631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=736-746&author=H.+Yuauthor=H.+Leeauthor=A.+Herrmannauthor=R.+Buettnerauthor=R.+Jove&title=Revisiting+STAT3+signalling+in+cancer%3A+new+and+unexpected+biological+functions&doi=10.1038%2Fnrc3818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting STAT3 signalling in cancer: new and unexpected biological functions</span></div><div class="casAuthors">Yu, Hua; Lee, Heehyoung; Herrmann, Andreas; Buettner, Ralf; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">736-746</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins, particularly STAT3, are among the most promising new targets for cancer therapy.  In addn. to interleukin-6 (IL-6) and its family members, multiple pathways, including G-protein-coupled receptors (GPCRs), Toll-like receptors (TLRs) and microRNAs were recently identified to regulate JAK-STAT signalling in cancer.  Well known for its role in tumor cell proliferation, survival, invasion and immunosuppression, JAK-STAT3 signalling also promotes cancer through inflammation, obesity, stem cells and the pre-metastatic niche.  In addn. to its established role as a transcription factor in cancer, STAT3 regulates mitochondrion functions, as well as gene expression through epigenetic mechanisms.  Newly identified regulators and functions of JAK-STAT3 in tumors are important targets for potential therapeutic strategies in the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3PGL62I5KvrVg90H21EOLACvtfcHk0ljylK_uaxTa2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSmtLnF&md5=355a07303813d7ecadb4b085c33c5e0a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrc3818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3818%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHerrmann%26aufirst%3DA.%26aulast%3DBuettner%26aufirst%3DR.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DRevisiting%2520STAT3%2520signalling%2520in%2520cancer%253A%2520new%2520and%2520unexpected%2520biological%2520functions%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D736%26epage%3D746%26doi%3D10.1038%2Fnrc3818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Debnath, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neamati, N.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6645</span>– <span class="NLM_lpage">6668</span>, <span class="refDoi"> DOI: 10.1021/jm300207s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300207s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6645-6668&author=B.+Debnathauthor=S.+Xuauthor=N.+Neamati&title=Small+molecule+inhibitors+of+signal+transducer+and+activator+of+transcription+3+%28Stat3%29+protein&doi=10.1021%2Fjm300207s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (Stat3) Protein</span></div><div class="casAuthors">Debnath, Bikash; Xu, Shili; Neamati, Nouri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6645-6668</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Signal transducer and activator of transcription 3 (Stat3) is a transcription factor belonging to the STAT protein family, members of which regulate a wide variety of biol. processes, including cell growth, proliferation, survival, differentiation, development, movement and inflammation in response to extracellular signaling mols. such as cytokines and growth factors.  Receptor assocd. tyrosine kinases phosphorylate Stat3 protein at Tyr705 and enable it to dimerize and subsequently enter the nucleus where it activates the transcription of its target genes.  Accumulating evidence has established Stat3's role in oncogenesis, cardiovascular diseases, rheumatoid arthritis, fibrotic, and Alzheimer's diseases.  Thus, Stat3 inhibition is a promising therapeutic approach not only for cancer, but also for other diseases.  Although Stat3 has been considered as an important therapeutic target, progress in discovery and development of effective and specific Stat3 inhibitors remains slow.  In this article we summarize Stat3 inhibitors published between 2006 and 2011.  New strategies along with novel technologies are required to achieve breakthrough in the development of Stat3 inhibitors that can be translated into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWWQl9gV1-ZLVg90H21EOLACvtfcHk0ljylK_uaxTa2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnsl2msrc%253D&md5=f5f3ac9f8fc2326c75edd2a9c136275b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300207s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300207s%26sid%3Dliteratum%253Aachs%26aulast%3DDebnath%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DNeamati%26aufirst%3DN.%26atitle%3DSmall%2520molecule%2520inhibitors%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520%2528Stat3%2529%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6645%26epage%3D6668%26doi%3D10.1021%2Fjm300207s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibi, M.</span></span> <span> </span><span class="NLM_article-title">Roles of STAT3 in mediating the cell growth, dierentiation and survival signals relayed through the IL-6 family of cytokine receptors</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2548</span>– <span class="NLM_lpage">2556</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fsj.onc.1203551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10851053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVGhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=2548-2556&author=T.+Hiranoauthor=K.+Ishiharaauthor=M.+Hibi&title=Roles+of+STAT3+in+mediating+the+cell+growth%2C+dierentiation+and+survival+signals+relayed+through+the+IL-6+family+of+cytokine+receptors&doi=10.1038%2Fsj.onc.1203551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors</span></div><div class="casAuthors">Hirano, Toshio; Ishihara, Katsuhiko; Hibi, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2548-2556</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 161 refs.  Members of the IL-6 cytokine family are involved in a variety of biol. responses, including the immune response, inflammation, hematopoiesis, and oncogenesis by regulating cell growth, survival, and differentiation.  These cytokines use gp130 as a common receptor subunit.  The binding of ligand to gp130 activates the JAK/STAT signal transduction pathway, where STAT3 plays a central role in transmitting the signals from the membrane to the nucleus.  STAT3 is essential for gp130-mediated cell survival and G1 to S cell-cycle-transition signals.  Both c-myc and pim have been identified as target genes of STAT3 and together can compensate for STAT3 in cell survival and cell-cycle transition.  STAT3 is also required for gp130-mediated maintenance of the pluripotential state of proliferating embryonic stem cells and for the gp130-induced macrophage differentiation of M1 cells.  Furthermore, STAT3 regulates cell movement, such as leukocyte, epidermal cell, and keratinocyte migration.  STAT3 also appears to regulate B cell differentiation into antibody-forming plasma cells.  Since the IL-6/gp130/STAT3 signaling pathway is involved in both B cell growth and differentiation into plasma cells it is likely to play a central role in the generation of plasma cell neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK3d_L_4rbebVg90H21EOLACvtfcHk0ljylK_uaxTa2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVGhsbY%253D&md5=01613b7de53ff21fe213230ff9528809</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203551%26sid%3Dliteratum%253Aachs%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DIshihara%26aufirst%3DK.%26aulast%3DHibi%26aufirst%3DM.%26atitle%3DRoles%2520of%2520STAT3%2520in%2520mediating%2520the%2520cell%2520growth%252C%2520dierentiation%2520and%2520survival%2520signals%2520relayed%2520through%2520the%2520IL-6%2520family%2520of%2520cytokine%2520receptors%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D2548%26epage%3D2556%26doi%3D10.1038%2Fsj.onc.1203551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span> <span> </span><span class="NLM_article-title">Antagonizing STAT3 dimerization with a rhodium(III) complex</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">9178</span>– <span class="NLM_lpage">9182</span>, <span class="refDoi"> DOI: 10.1002/anie.201404686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1002%2Fanie.201404686" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVKlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=9178-9182&author=D.+L.+Maauthor=L.+J.+Liuauthor=K.+H.+Leungauthor=Y.+T.+Chenauthor=H.+J.+Zhongauthor=D.+S.+H.+Chanauthor=H.+M.+D.+Wangauthor=C.+H.+Leung&title=Antagonizing+STAT3+dimerization+with+a+rhodium%28III%29+complex&doi=10.1002%2Fanie.201404686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonizing STAT3 Dimerization with a Rhodium(III) Complex</span></div><div class="casAuthors">Ma, Dik-Lung; Liu, Li-Juan; Leung, Ka-Ho; Chen, Yen-Ting; Zhong, Hai-Jing; Chan, Daniel Shiu-Hin; Wang, Hui-Min David; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">9178-9182</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Kinetically inert metal complexes have arisen as promising alternatives to existing platinum and ruthenium chemotherapeutics.  Reported herein, to the knowledge, is the first example of a substitutionally inert, Group 9 organometallic compd. as a direct inhibitor of signal transducer and activator of transcription 3 (STAT3) dimerization.  From a series of cyclometalated rhodium(III) and iridium(III) complexes, a rhodium(III) complex emerged as a potent inhibitor of STAT3 that targeted the SH2 domain and inhibited STAT3 phosphorylation and dimerization.  Significantly, the complex exhibited potent antitumor activities in an in vivo mouse xenograft model of melanoma.  This study demonstrates that rhodium complexes may be developed as effective STAT3 inhibitors with potent antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomCWV-3XvfFbVg90H21EOLACvtfcHk0lirLmksnx9PDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVKlurs%253D&md5=6972af909d01a82ae3acabb013601bd9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fanie.201404686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201404686%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DD.%2BL.%26aulast%3DLiu%26aufirst%3DL.%2BJ.%26aulast%3DLeung%26aufirst%3DK.%2BH.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DZhong%26aufirst%3DH.%2BJ.%26aulast%3DChan%26aufirst%3DD.%2BS.%2BH.%26aulast%3DWang%26aufirst%3DH.%2BM.%2BD.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26atitle%3DAntagonizing%2520STAT3%2520dimerization%2520with%2520a%2520rhodium%2528III%2529%2520complex%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D9178%26epage%3D9182%26doi%3D10.1002%2Fanie.201404686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kujawski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilon-Thomas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulé, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerr, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Inhibiting stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1314</span>– <span class="NLM_lpage">1321</span>, <span class="refDoi"> DOI: 10.1038/nm1325</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnm1325" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=16288283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yisr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=1314-1321&author=M.+Kortylewskiauthor=M.+Kujawskiauthor=T.+Wangauthor=S.+Weiauthor=S.+Zhangauthor=S.+Pilon-Thomasauthor=G.+Niuauthor=H.+Kayauthor=J.+Mul%C3%A9author=W.+G.+Kerrauthor=R.+Joveauthor=D.+Pardollauthor=H.+Yu&title=Inhibiting+stat3+signaling+in+the+hematopoietic+system+elicits+multicomponent+antitumor+immunity&doi=10.1038%2Fnm1325"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity</span></div><div class="casAuthors">Kortylewski, Marcin; Kujawski, Maciej; Wang, Tianhong; Wei, Sheng; Zhang, Shumin; Pilon-Thomas, Shari; Niu, Guilian; Kay, Heidi; Mule, James; Kerr, William G.; Jove, Richard; Pardoll, Drew; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1314-1321</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The immune system can act as an extrinsic suppressor of tumors.  Thus, tumor progression depends in part on mechanisms that down-modulate intrinsic immune surveillance.  Identifying these inhibitory pathways may provide promising targets to enhance antitumor immunity.  Here, the authors show that Stat3 is constitutively activated in diverse tumor-infiltrating immune cells, and ablating Stat3 in hematopoietic cells triggers an intrinsic immune-surveillance system that inhibits tumor growth and metastasis.  The authors obsd. a markedly enhanced function of dendritic cells, T cells, natural killer (NK) cells, and neutrophils in tumor-bearing mice with Stat3-/- hematopoietic cells, and showed that tumor regression requires immune cells.  Targeting Stat3 with a small-mol. drug induces T cell- and NK cell-dependent growth inhibition of established tumors otherwise resistant to direct killing by the inhibitor.  Thus, Stat3 signaling restrains natural tumor immune surveillance and inhibiting hematopoietic Stat3 in tumor-bearing hosts elicits multicomponent therapeutic antitumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolny_AzPS9lLVg90H21EOLACvtfcHk0lirLmksnx9PDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yisr3I&md5=69d67d733f183d81742dde37f367053d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnm1325&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1325%26sid%3Dliteratum%253Aachs%26aulast%3DKortylewski%26aufirst%3DM.%26aulast%3DKujawski%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DPilon-Thomas%26aufirst%3DS.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DKay%26aufirst%3DH.%26aulast%3DMul%25C3%25A9%26aufirst%3DJ.%26aulast%3DKerr%26aufirst%3DW.%2BG.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DInhibiting%2520stat3%2520signaling%2520in%2520the%2520hematopoietic%2520system%2520elicits%2520multicomponent%2520antitumor%2520immunity%26jtitle%3DNat.%2520Med.%26date%3D2005%26volume%3D11%26spage%3D1314%26epage%3D1321%26doi%3D10.1038%2Fnm1325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Litzenburger, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Opitz, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauschenbach, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höfer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deimling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wick, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platten, M.</span></span> <span> </span><span class="NLM_article-title">Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.1637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.18632%2Foncotarget.1637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24657910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BC2crmtlelug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1038-1051&author=U.+M.+Litzenburgerauthor=C.+A.+Opitzauthor=F.+Sahmauthor=K.+J.+Rauschenbachauthor=S.+Trumpauthor=M.+Winterauthor=M.+Ottauthor=K.+Ochsauthor=C.+Lutzauthor=X.+Liuauthor=N.+Anastasovauthor=I.+Lehmannauthor=T.+H%C3%B6ferauthor=A.+Deimlingauthor=W.+Wickauthor=M.+Platten&title=Constitutive+IDO+expression+in+human+cancer+is+sustained+by+an+autocrine+signaling+loop+involving+IL-6%2C+STAT3+and+the+AHR&doi=10.18632%2Foncotarget.1637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR</span></div><div class="casAuthors">Litzenburger Ulrike M; Opitz Christiane A; Sahm Felix; Rauschenbach Katharina J; Trump Saskia; Winter Marcus; Ott Martina; Ochs Katharina; Lutz Christian; Liu Xiangdong; Anastasov Natasa; Lehmann Irina; Hofer Thomas; von Deimling Andreas; Wick Wolfgang; Platten Michael</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1038-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Indoleamine-2,3-dioxygenase (IDO) inhibitors have entered clinical trials based on their ability to restore anti-tumor immunity in preclinical studies.  However, the mechanisms leading to constitutive expression of IDO in human tumors are largely unknown.  Here we analyzed the pathways mediating constitutive IDO expression in human cancer.  IDO-positive tumor cells and tissues showed basal phosphorylation and acetylation of STAT3 as evidenced by western blotting and immunoprecipitation.  Inhibition of IL-6 or STAT3 using siRNA and/or pharmacological inhibitors reduced IDO mRNA and protein expression as well as kynurenine formation.  In turn, IDO enzymatic activity activated the AHR as shown by the induction of AHR target genes.  IDO-mediated AHR activation induced IL-6 expression, while inhibition or knockdown of the AHR reduced IL-6 expression.  IDO activity thus sustains its own expression via an autocrine AHR-IL-6-STAT3 signaling loop.  Inhibition of the AHR-IL-6-STAT3 signaling loop restored T-cell proliferation in mixed leukocyte reactions performed in the presence of IDO-expressing human cancer cells.  Identification of the IDO-AHR-IL-6-STAT3 signaling loop maintaining IDO expression in human cancers reveals novel therapeutic targets for the inhibition of this core pathway promoting immunosuppression of human cancers.  The relevance of the IDO-AHR-IL-6-STAT3 transcriptional circuit is underscored by the finding that high expression of its members IDO, STAT3 and the AHR target gene CYP1B1 is associated with reduced relapse-free survival in lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQ4F7N8tAxhwqdek-gHSrIfW6udTcc2eZr8t6TYF_5iLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crmtlelug%253D%253D&md5=fe0bcfa48ed6b492ff6dff5dff5c869c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1637%26sid%3Dliteratum%253Aachs%26aulast%3DLitzenburger%26aufirst%3DU.%2BM.%26aulast%3DOpitz%26aufirst%3DC.%2BA.%26aulast%3DSahm%26aufirst%3DF.%26aulast%3DRauschenbach%26aufirst%3DK.%2BJ.%26aulast%3DTrump%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DOchs%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DAnastasov%26aufirst%3DN.%26aulast%3DLehmann%26aufirst%3DI.%26aulast%3DH%25C3%25B6fer%26aufirst%3DT.%26aulast%3DDeimling%26aufirst%3DA.%26aulast%3DWick%26aufirst%3DW.%26aulast%3DPlatten%26aufirst%3DM.%26atitle%3DConstitutive%2520IDO%2520expression%2520in%2520human%2520cancer%2520is%2520sustained%2520by%2520an%2520autocrine%2520signaling%2520loop%2520involving%2520IL-6%252C%2520STAT3%2520and%2520the%2520AHR%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D1038%26epage%3D1051%26doi%3D10.18632%2Foncotarget.1637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fujita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagishita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeshita, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nokihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ochiya, T.</span></span> <span> </span><span class="NLM_article-title">The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-smallcell lung cancer</span>. <i>Mol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">717</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1038/mt.2015.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fmt.2015.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=25597412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=717-727&author=Y.+Fujitaauthor=S.+Yagishitaauthor=K.+Hagiwaraauthor=Y.+Yoshiokaauthor=N.+Kosakaauthor=F.+Takeshitaauthor=T.+Fujiwaraauthor=K.+Tsutaauthor=H.+Nokiharaauthor=T.+Tamuraauthor=H.+Asamuraauthor=M.+Kawaishiauthor=K.+Kuwanoauthor=T.+Ochiya&title=The+clinical+relevance+of+the+miR-197%2FCKS1B%2FSTAT3-mediated+PD-L1+network+in+chemoresistant+non-smallcell+lung+cancer&doi=10.1038%2Fmt.2015.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer</span></div><div class="casAuthors">Fujita, Yu; Yagishita, Shigehiro; Hagiwara, Keitaro; Yoshioka, Yusuke; Kosaka, Nobuyoshi; Takeshita, Fumitaka; Fujiwara, Tomohiro; Tsuta, Koji; Nokihara, Hiroshi; Tamura, Tomohide; Asamura, Hisao; Kawaishi, Makoto; Kuwano, Kazuyoshi; Ochiya, Takahiro</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">717-727</span>CODEN:
                <span class="NLM_cas:coden">MTOHCK</span>;
        ISSN:<span class="NLM_cas:issn">1525-0016</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Programmed cell death ligand-1 (PD-L1) has recently gained considerable attention for its role in tumor immune escape.  Here, we identify a miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer (NSCLC), independent of immunoinhibitory signals.  MiR-197 is downregulated in platinum-resistant NSCLC specimens, resulting in the promotion of chemoresistance, tumorigenicity, and pulmonary metastasis in vitro and in vivo.  Mechanistic investigations reveal that a miR-197-mediated CKS1B/STAT3 axis exerts tumor progression regulated by various oncogenic genes (Bcl-2, c-Myc, and cyclin D1), and PD-L1 is a putative biomarker of this axis.  Furthermore, we demonstrate that a miR-197 mimic sensitizes PD-L1high drug-resistant cells to chemotherapy.  These results indicate that the biol. interaction between PD-L1 and chemoresistance occurs through the microRNA regulatory cascade.  More importantly, expression levels of miR-197 are inversely correlated with PD-L1 expression (n = 177; P = 0.026) and are assocd. with worse overall survival (P = 0.015).  Our discoveries suggest that the miR-197/CKS1B/STAT3-mediated network can drive tumor PD-L1 expression as a biomarker of this cascade, and miR-197 replacement therapy may be a potential treatment strategy for chemoresistant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3_HY07pVy6LVg90H21EOLACvtfcHk0lghONq0hKd7pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOqs7o%253D&md5=0f14ec8da56cb12e0361771d8ff50203</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fmt.2015.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmt.2015.10%26sid%3Dliteratum%253Aachs%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DYagishita%26aufirst%3DS.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DYoshioka%26aufirst%3DY.%26aulast%3DKosaka%26aufirst%3DN.%26aulast%3DTakeshita%26aufirst%3DF.%26aulast%3DFujiwara%26aufirst%3DT.%26aulast%3DTsuta%26aufirst%3DK.%26aulast%3DNokihara%26aufirst%3DH.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DAsamura%26aufirst%3DH.%26aulast%3DKawaishi%26aufirst%3DM.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DOchiya%26aufirst%3DT.%26atitle%3DThe%2520clinical%2520relevance%2520of%2520the%2520miR-197%252FCKS1B%252FSTAT3-mediated%2520PD-L1%2520network%2520in%2520chemoresistant%2520non-smallcell%2520lung%2520cancer%26jtitle%3DMol.%2520Ther.%26date%3D2015%26volume%3D23%26spage%3D717%26epage%3D727%26doi%3D10.1038%2Fmt.2015.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergamini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">2-phenoxy-1,4-naphthoquinones: from a multitarget antitrypanosomal to a potential antitumor profile</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6422</span>– <span class="NLM_lpage">6434</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00748</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00748" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6422-6434&author=F.+Pratiauthor=C.+Bergaminiauthor=M.+T.+Molinaauthor=F.+Falchiauthor=A.+Cavalliauthor=M.+Kaiserauthor=R.+Brunauthor=R.+Fatoauthor=M.+L.+Bolognesi&title=2-phenoxy-1%2C4-naphthoquinones%3A+from+a+multitarget+antitrypanosomal+to+a+potential+antitumor+profile&doi=10.1021%2Facs.jmedchem.5b00748"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile</span></div><div class="casAuthors">Prati, Federica; Bergamini, Christian; Molina, Maria Teresa; Falchi, Federico; Cavalli, Andrea; Kaiser, Marcel; Brun, Reto; Fato, Romana; Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6422-6434</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivs. was initially developed to optimize the antitrypanosomatid profile of the multitarget hit compd. B6 (1).  The whole series was evaluated against the three most important human trypanosomatid pathogens (Trypanosoma brucei rhodesiense, Trypanosoma cruzi, and Leishmania donovani), and two compds. (14 and 21) showed good activity, despite a concomitant mammalian cytotoxicity.  Furthermore, a subset also inhibited the glycolytic TbGAPDH enzyme in vitro.  In light of these results and aware of the antitumor properties of quinones, the anticancer potential of some selected derivs. was investigated.  Intriguingly, the tested compds. displayed antitumor activity, while being less toxic against noncancerous cells.  The obsd. cytotoxic potency was ascribed to a multitarget mechanism of action accounting for hGAPDH inhibition and mitochondrial toxicity.  Overall, the development of further derivs., able to finely modulate multiple pathways of cancer or parasite cell metab., might lead to more effective treatments against these devastating diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt4mNbBYvHMLVg90H21EOLACvtfcHk0lgE082CLZm93Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs7jP&md5=cc969a5d9e4ad7d18e3b7ebd7340e863</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00748%26sid%3Dliteratum%253Aachs%26aulast%3DPrati%26aufirst%3DF.%26aulast%3DBergamini%26aufirst%3DC.%26aulast%3DMolina%26aufirst%3DM.%2BT.%26aulast%3DFalchi%26aufirst%3DF.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DKaiser%26aufirst%3DM.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DFato%26aufirst%3DR.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3D2-phenoxy-1%252C4-naphthoquinones%253A%2520from%2520a%2520multitarget%2520antitrypanosomal%2520to%2520a%2520potential%2520antitumor%2520profile%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6422%26epage%3D6434%26doi%3D10.1021%2Facs.jmedchem.5b00748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiménez-Alonso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orellana, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estévez-Braun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravelo, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Sacau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machín, F.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">6761</span>– <span class="NLM_lpage">6772</span>, <span class="refDoi"> DOI: 10.1021/jm800499x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800499x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKlurjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6761-6772&author=S.+Jim%C3%A9nez-Alonsoauthor=H.+C.+Orellanaauthor=A.+Est%C3%A9vez-Braunauthor=A.+G.+Raveloauthor=E.+P%C3%A9rez-Sacauauthor=F.+Mach%C3%ADn&title=Design+and+synthesis+of+a+novel+series+of+pyranonaphthoquinones+as+topoisomerase+II+catalytic+inhibitors&doi=10.1021%2Fjm800499x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of a Novel Series of Pyranonaphthoquinones as Topoisomerase II Catalytic Inhibitors</span></div><div class="casAuthors">Jimenez-Alonso, Sandra; Chavez Orellana, Haydee; Estevez-Braun, Ana; Ravelo, Angel G.; Perez-Sacau, Elisa; Machin, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6761-6772</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of previous pharmacophore modeling studies of naphthoquinones derivs., a new set of pyranonaphthoquinones, e. g. I, was designed and prepd.  These compds. were obtained through a direct and highly efficient approach based on an intramol. domino Knoevenagel hetero Diels-Alder reaction from lawsone (2-hydroxynaphthoquinone) and a variety of aldehydes contg. an alkene.  The synthesized pyranonaphthoquinones were evaluated against the α isoform of human topoisomerase II (hTopoIIα).  Among the 11 derivs. studied, we found that six of them act as catalytic inhibitors of the enzyme in vitro.  These six derivs. strongly preclude the enzyme from decatenating or relaxing suitable substrates.  Finally, we correlate their active/inactive status with docking studies of these novel compds. into the ATPase domain of hTopoIIα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSqywp9jc7gbVg90H21EOLACvtfcHk0lgE082CLZm93Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKlurjK&md5=1fdb6ddd077087415b8ba3c8f8cc605f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm800499x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800499x%26sid%3Dliteratum%253Aachs%26aulast%3DJim%25C3%25A9nez-Alonso%26aufirst%3DS.%26aulast%3DOrellana%26aufirst%3DH.%2BC.%26aulast%3DEst%25C3%25A9vez-Braun%26aufirst%3DA.%26aulast%3DRavelo%26aufirst%3DA.%2BG.%26aulast%3DP%25C3%25A9rez-Sacau%26aufirst%3DE.%26aulast%3DMach%25C3%25ADn%26aufirst%3DF.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520a%2520novel%2520series%2520of%2520pyranonaphthoquinones%2520as%2520topoisomerase%2520II%2520catalytic%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6761%26epage%3D6772%26doi%3D10.1021%2Fjm800499x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WGuida, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebti, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1978</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.1021/jm201118h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201118h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVGlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1978-1998&author=Y.+Geauthor=A.+Kaziauthor=F.+Marsilioauthor=Y.+Luoauthor=S.+Jainauthor=W.+Brooksauthor=K.+G.+Danielauthor=C.+WGuidaauthor=S.+M.+Sebtiauthor=H.+R.+Lawrence&title=Discovery+and+synthesis+of+hydronaphthoquinones+as+novel+proteasome+inhibitors&doi=10.1021%2Fjm201118h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Synthesis of Hydronaphthoquinones as Novel Proteasome Inhibitors</span></div><div class="casAuthors">Ge, Yiyu; Kazi, Aslamuzzaman; Marsilio, Frank; Luo, Yunting; Jain, Sanjula; Brooks, Wesley; Daniel, Kenyon G.; Guida, Wayne C.; Sebti, Said M.; Lawrence, Harshani R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1978-1998</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Screening efforts led to the identification of PI-8182 (I, 2-[[1-hydroxy-4-[(2-thienylsulfonyl)amino]-2-naphthalenyl]thio]acetic acid), an inhibitor of the chymotrypsin-like (CT-L) activity of the proteasome.  Compd. I contains a hydronaphthoquinone pharmacophore with a thioglycolic acid side chain at position 2 and thiophene sulfonamide at position 4.  An efficient synthetic route to the hydronaphthoquinone sulfonamide scaffold was developed, and compd. I was synthesized inhouse to confirm the structure and activity (IC50 = 3.0 ± 1.6 μM [n = 25]).  Novel hydronaphthoquinone derivs. of I were designed, synthesized, and evaluated as proteasome inhibitors.  The structure-activity relationship (SAR) guided synthesis of more than 170 derivs. revealed that the thioglycolic acid side chain is required and the carboxylic acid group of this side chain is crit. to the CT-L inhibitory activity of compd. I.  Furthermore, replacement of the carboxylic acid with carboxylic acid isosteres such as tetrazole or triazole greatly improves potency.  Compds. with a thio-tetrazole or thio-triazole side chain in position 2, where the thiophene was replaced by hydrophobic aryl moieties, were the most active compds. with up to 20-fold greater CT-L inhibition (IC50 = 150 nM) than compd. I.  The synthetic iterations described here not only led to improving potency in vitro but also resulted in the identification of compds. that are more active such as N-[4-hydroxy-3-(1H-tetrazol-5-ylthio)-1-naphthalenyl]-4'-(trifluoromethyl)biphenyl-4-sulfonamide (IC50 = 0.44 to 1.01 μM) than I (IC50 = 3.54 to 7.22 μM) at inhibiting the proteasome CT-L activity in intact breast cancer cells.  Treatment with this more active compd. also resulted in the accumulation of ubiquitinated cellular proteins and inhibition of tumor cell proliferation of breast cancer cells.  The hit I and its analog inhibited proteasome CT-L activity irreversibly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofTgJ17P5sRrVg90H21EOLACvtfcHk0li9NC1-b2Qj6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVGlsA%253D%253D&md5=d663a8a5444fba3c6a005666dbbab280</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm201118h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201118h%26sid%3Dliteratum%253Aachs%26aulast%3DGe%26aufirst%3DY.%26aulast%3DKazi%26aufirst%3DA.%26aulast%3DMarsilio%26aufirst%3DF.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DBrooks%26aufirst%3DW.%26aulast%3DDaniel%26aufirst%3DK.%2BG.%26aulast%3DWGuida%26aufirst%3DC.%26aulast%3DSebti%26aufirst%3DS.%2BM.%26aulast%3DLawrence%26aufirst%3DH.%2BR.%26atitle%3DDiscovery%2520and%2520synthesis%2520of%2520hydronaphthoquinones%2520as%2520novel%2520proteasome%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1978%26epage%3D1998%26doi%3D10.1021%2Fjm201118h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuHadaway, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaLonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prendergast, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1021/jm7014155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7014155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1cXislKqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1706-1718&author=S.+Kumarauthor=W.+P.+Malachowskiauthor=J.+B.+DuHadawayauthor=J.+M.+LaLondeauthor=P.+J.+Carrollauthor=D.+Jallerauthor=R.+Metzauthor=G.+C.+Prendergastauthor=A.+J.+Muller&title=Indoleamine+2%2C3-dioxygenase+is+the+anticancer+target+for+a+novel+series+of+potent+naphthoquinone-based+inhibitors&doi=10.1021%2Fjm7014155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Indoleamine 2,3-Dioxygenase Is the Anticancer Target for a Novel Series of Potent Naphthoquinone-Based Inhibitors</span></div><div class="casAuthors">Kumar, Sanjeev; Malachowski, William P.; DuHadaway, James B.; LaLonde, Judith M.; Carroll, Patrick J.; Jaller, Daniel; Metz, Richard; Prendergast, George C.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1706-1718</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathol. immune suppression.  While small mol. inhibitors of IDO exist, there remains a dearth of high-potency compds. offering in vivo efficacy and clin. translational potential.  In this study, the authors address this gap by defining a new class of naphthoquinone-based IDO inhibitors exemplified by the natural product menadione, which is shown in mouse tumor models to have similar antitumor activity to previously characterized IDO inhibitors.  Genetic validation that IDO is the crit. in vivo target is demonstrated using IDO-null mice.  Elaboration of menadione to a pyranonaphthoquinone has yielded low nanomolar potency inhibitors, including new compds. which are the most potent reported to date (Ki = 61-70 nM).  Synthetic accessibility of this class will facilitate preclin. chem.-genetic studies as well as further optimization of pharmacol. parameters for clin. translation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1ZM1JKuRtPbVg90H21EOLACvtfcHk0li9NC1-b2Qj6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXislKqtL4%253D&md5=9d3c1bc16796927ab88fc5d6b6ef065a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm7014155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7014155%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DDuHadaway%26aufirst%3DJ.%2BB.%26aulast%3DLaLonde%26aufirst%3DJ.%2BM.%26aulast%3DCarroll%26aufirst%3DP.%2BJ.%26aulast%3DJaller%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DR.%26aulast%3DPrendergast%26aufirst%3DG.%2BC.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DIndoleamine%25202%252C3-dioxygenase%2520is%2520the%2520anticancer%2520target%2520for%2520a%2520novel%2520series%2520of%2520potent%2520naphthoquinone-based%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1706%26epage%3D1718%26doi%3D10.1021%2Fjm7014155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span> <span> </span><span class="NLM_article-title">Identification of substituted naphthotriazolediones as novel tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7807</span>– <span class="NLM_lpage">7819</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7807-7819&author=J.+S.+Wuauthor=S.+Y.+Linauthor=F.+Y.+Liaoauthor=W.+C.+Hsiaoauthor=L.+C.+Leeauthor=Y.+H.+Pengauthor=C.+L.+Hsiehauthor=M.+H.+Wuauthor=J.+S.+Songauthor=A.+Yuehauthor=C.+H.+Chenauthor=S.+H.+Yehauthor=C.+Y.+Liuauthor=S.+Y.+Linauthor=T.+K.+Yehauthor=J.+T.+A.+Hsuauthor=C.+Shihauthor=S.+H.+Uengauthor=M.+S.+Hungauthor=S.+Y.+Wu&title=Identification+of+substituted+naphthotriazolediones+as+novel+tryptophan+2%2C3-dioxygenase+%28TDO%29+inhibitors+through+structure-based+virtual+screening&doi=10.1021%2Facs.jmedchem.5b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening</span></div><div class="casAuthors">Wu, Jian-Sung; Lin, Shu-Yu; Liao, Fang-Yu; Hsiao, Wen-Chi; Lee, Lung-Chun; Peng, Yi-Hui; Hsieh, Chia-Ling; Wu, Mine-Hsine; Song, Jen-Shin; Yueh, Andrew; Chen, Chun-Hwa; Yeh, Shiu-Hwa; Liu, Chia-Yeh; Lin, Shu-Yi; Yeh, Teng-Kuang; Hsu, John T.-A.; Shih, Chuan; Ueng, Shau-Hua; Hung, Ming-Shiu; Wu, Su-Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7807-7819</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based virtual screening strategy, comprising homol. modeling, ligand-support binding site optimization, virtual screening, and structure clustering anal., was developed and used to identify novel tryptophan 2,3-dioxygenase (TDO) inhibitors.  Compd. 1 (IC50 = 711 nM), selected by virtual screening, showed inhibitory activity toward TDO and was subjected to structural modifications and mol. docking studies.  This resulted in the identification of a potent TDO selective inhibitor (11e, IC50 = 30 nM), making it a potential compd. for further investigation as a cancer therapeutic and other TDO-related targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_08WPyOJIMbVg90H21EOLACvtfcHk0liuJ2PiRHQ7_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKit7vI&md5=3aea83affb3164c94f8cbfead21dbcce</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00921%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DHsiao%26aufirst%3DW.%2BC.%26aulast%3DLee%26aufirst%3DL.%2BC.%26aulast%3DPeng%26aufirst%3DY.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DYueh%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DYeh%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DC.%2BY.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DYeh%26aufirst%3DT.%2BK.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%2BA.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DWu%26aufirst%3DS.%2BY.%26atitle%3DIdentification%2520of%2520substituted%2520naphthotriazolediones%2520as%2520novel%2520tryptophan%25202%252C3-dioxygenase%2520%2528TDO%2529%2520inhibitors%2520through%2520structure-based%2520virtual%2520screening%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7807%26epage%3D7819%26doi%3D10.1021%2Facs.jmedchem.5b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2718</span>– <span class="NLM_lpage">2731</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01489</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01489" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2718-2731&author=W.+Yuauthor=C.+Liauthor=W.+Zhangauthor=Y.+Xiaauthor=S.+Liauthor=J.+Linauthor=K.+Yuauthor=M.+Liuauthor=L.+Yangauthor=J.+Luoauthor=Y.+Chenauthor=H.+Sunauthor=L.+Kong&title=Discovery+of+an+orally+selective+inhibitor+of+signal+transducer+and+activator+of+transcription+3+using+advanced+multiple+ligand+simultaneous+docking&doi=10.1021%2Facs.jmedchem.6b01489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking</span></div><div class="casAuthors">Yu, Wenying; Li, Chenglong; Zhang, Wenda; Xia, Yuanzheng; Li, Shanshan; Lin, Jia-yuh; Yu, Keqin; Liu, Mu; Yang, Lei; Luo, Jianguang; Chen, Yijun; Sun, Hongbin; Kong, Lingyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2718-2731</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting signal transducer and activator of transcription 3 (STAT3) is a potential anticancer strategy.  However, STAT3 inhibitors with good selectivity and bioavailability are rare.  The aim of this study was to discover selective direct STAT3 inhibitors with good drug-likeness.  By advanced multiple ligand simultaneous docking (AMLSD) method, compd. 9 (5,8-dioxo-6-((2-(piperazin-1-yl)phenyl)amino)-5,8-dihydronaphthalene-1-sulfonamide) was designed as an orally-bioavailable STAT3 inhibitor, which presented superior druggability and selectivity to other representative STAT3 inhibitors.  Compd. 9 directly and selectively inhibited the pY705 site of STAT3 with an affinity (Ki) of 440nM.  The IC50 of 9 for breast cancer cell MDA-MB-231 was 184-fold lower than its IC50 for normal breast epithelial cell MCF-10A.  Compd. 9 in vivo induced significant antitumor responses better than Gefitinib and its therapeutic index should be over 100, indicating good safety of 9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiT8F_tCrky7Vg90H21EOLACvtfcHk0lgU4JA2JnEckw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFalurw%253D&md5=d9554e49fd17a559e8c7171f36c53607</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01489%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DKong%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520selective%2520inhibitor%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520using%2520advanced%2520multiple%2520ligand%2520simultaneous%2520docking%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2718%26epage%3D2731%26doi%3D10.1021%2Facs.jmedchem.6b01489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandur, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, B. B.</span></span> <span> </span><span class="NLM_article-title">5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-09-0257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1158%2F1541-7786.MCR-09-0257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20068065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntVChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=107-118&author=S.+K.+Sandurauthor=M.+K.+Pandeyauthor=B.+Sungauthor=B.+B.+Aggarwal&title=5-hydroxy-2-methyl-1%2C4-naphthoquinone%2C+a+vitamin+K3+analogue%2C+suppresses+STAT3+activation+pathway+through+induction+of+protein+tyrosine+phosphatase%2C+SHP-1%3A+potential+role+in+chemosensitization&doi=10.1158%2F1541-7786.MCR-09-0257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">5-Hydroxy-2-Methyl-1,4-Naphthoquinone, a Vitamin K3 Analogue, Suppresses STAT3 Activation Pathway through Induction of Protein Tyrosine Phosphatase, SHP-1: Potential Role in Chemosensitization</span></div><div class="casAuthors">Sandur, Santosh K.; Pandey, Manoj K.; Sung, Bokyung; Aggarwal, Bharat B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">107-118</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The activation of signal transducers and activators of transcription 3 (STAT3) has been linked with carcinogenesis through survival, proliferation, and angiogenesis of tumor cells.  Agents that can suppress STAT3 activation have potential not only for prevention but also for treatment of cancer.  In the present report, we investigated whether 5-hydroxy-2-methyl-1,4-naphthoquinone (plumbagin), an analog of vitamin K, and isolated from chitrak (Plumbago zeylanica), an Ayurvedic medicinal plant, can modulate the STAT3 pathway.  We found that plumbagin inhibited both constitutive and interleukin 6-inducible STAT3 phosphorylation in multiple myeloma (MM) cells and this correlated with the inhibition of c-Src, Janus-activated kinase (JAK)1, and JAK2 activation.  Vanadate, however, reversed the plumbagin-induced downregulation of STAT3 activation, suggesting the involvement of a protein tyrosine phosphatase.  Indeed, we found that plumbagin induced the expression of the protein tyrosine phosphatase, SHP-1, and silencing of the SHP-1 abolished the effect of plumbagin.  This agent also downregulated the expression of STAT3-regulated cyclin D1, Bcl-xL, and vascular endothelial growth factor; activated caspase-3; induced poly (ADP ribose) polymerase cleavage; and increased the sub-G1 population of MM cells.  Consistent with these results, overexpression of constitutive active STAT3 significantly reduced the plumbagin-induced apoptosis.  When compared with AG490, a rationally designed STAT3/JAK2 inhibitor, plumbagin was found more potent in suppressing the proliferation of cells.  Plumbagin also significantly potentiated the apoptotic effects of thalidomide and bortezomib in MM cells.  Overall, these results suggest that the plumbagin inhibits STAT3 activation pathway through the induction of SHP-1 and this may mediate the sensitization of STAT3 overexpressing cancers to chemotherapeutic agents.Mol Cancer Res; 8(1); 107-118.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEfWjYszUxp7Vg90H21EOLACvtfcHk0lgU4JA2JnEckw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntVChtQ%253D%253D&md5=70d7ff84abe86dceee49dd6e75dcabf0</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-09-0257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-09-0257%26sid%3Dliteratum%253Aachs%26aulast%3DSandur%26aufirst%3DS.%2BK.%26aulast%3DPandey%26aufirst%3DM.%2BK.%26aulast%3DSung%26aufirst%3DB.%26aulast%3DAggarwal%26aufirst%3DB.%2BB.%26atitle%3D5-hydroxy-2-methyl-1%252C4-naphthoquinone%252C%2520a%2520vitamin%2520K3%2520analogue%252C%2520suppresses%2520STAT3%2520activation%2520pathway%2520through%2520induction%2520of%2520protein%2520tyrosine%2520phosphatase%252C%2520SHP-1%253A%2520potential%2520role%2520in%2520chemosensitization%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2010%26volume%3D8%26spage%3D107%26epage%3D118%26doi%3D10.1158%2F1541-7786.MCR-09-0257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tojo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamioka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ota, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isobe, Y.</span></span> <span> </span><span class="NLM_article-title">Crystal structures and structure–activity relationships of imidazothiazole derivatives as IDO1 inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1123</span>, <span class="refDoi"> DOI: 10.1021/ml500247w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500247w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1119-1123&author=S.+Tojoauthor=T.+Kohnoauthor=T.+Tanakaauthor=S.+Kamiokaauthor=Y.+Otaauthor=T.+Ishiiauthor=K.+Kamimotoauthor=S.+Asanoauthor=Y.+Isobe&title=Crystal+structures+and+structure%E2%80%93activity+relationships+of+imidazothiazole+derivatives+as+IDO1+inhibitors&doi=10.1021%2Fml500247w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors</span></div><div class="casAuthors">Tojo, Shingo; Kohno, Tetsuya; Tanaka, Tomoyuki; Kamioka, Seiji; Ota, Yosuke; Ishii, Takayuki; Kamimoto, Keiko; Asano, Shigehiro; Isobe, Yoshiaki</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1119-1123</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is considered as a promising target for the treatment of several diseases, including neurol. disorders and cancer.  We report here the crystal structures of two IDO1/IDO1 inhibitor complexes, one of which shows that Amg-1 is directly bound to the heme iron of IDO1 with a clear induced fit.  We also describe the identification and preliminary optimization of imidazothiazole derivs. as novel IDO1 inhibitors.  Using our crystal structure information and structure-activity relationships (SAR) at the pocket-B of IDO1, we found a series of urea derivs. as potent IDO1 inhibitors and revealed that generation of an induced fit and the resulting interaction with Phe226 and Arg231 are essential for potent IDO1 inhibitory activity.  The results of this study are very valuable for understanding the mechanism of IDO1 activation, which is very important for structure-based drug design (SBDD) to discover potent IDO1 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO6dAvsq0nObVg90H21EOLACvtfcHk0lhuVELLvGNhSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSnsLnI&md5=7eaf3faae0c29a60de5f23a48a079af7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fml500247w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500247w%26sid%3Dliteratum%253Aachs%26aulast%3DTojo%26aufirst%3DS.%26aulast%3DKohno%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKamioka%26aufirst%3DS.%26aulast%3DOta%26aufirst%3DY.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DKamimoto%26aufirst%3DK.%26aulast%3DAsano%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DY.%26atitle%3DCrystal%2520structures%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520imidazothiazole%2520derivatives%2520as%2520IDO1%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D5%26spage%3D1119%26epage%3D1123%26doi%3D10.1021%2Fml500247w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hazimi, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Faham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghazzali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Farhan, K.</span></span> <span> </span><span class="NLM_article-title">Microwave irradiation: a facile, scalable and convenient method for synthesis of N-phthaloylamino acids</span>. <i>Arab. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1016/j.arabjc.2010.06.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.arabjc.2010.06.020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2012&pages=285-289&author=H.+M.+Al-Hazimiauthor=A.+El-Fahamauthor=M.+Ghazzaliauthor=K.+Al-Farhan&title=Microwave+irradiation%3A+a+facile%2C+scalable+and+convenient+method+for+synthesis+of+N-phthaloylamino+acids&doi=10.1016%2Fj.arabjc.2010.06.020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.arabjc.2010.06.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.arabjc.2010.06.020%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Hazimi%26aufirst%3DH.%2BM.%26aulast%3DEl-Faham%26aufirst%3DA.%26aulast%3DGhazzali%26aufirst%3DM.%26aulast%3DAl-Farhan%26aufirst%3DK.%26atitle%3DMicrowave%2520irradiation%253A%2520a%2520facile%252C%2520scalable%2520and%2520convenient%2520method%2520for%2520synthesis%2520of%2520N-phthaloylamino%2520acids%26jtitle%3DArab.%2520J.%2520Chem.%26date%3D2012%26volume%3D5%26spage%3D285%26epage%3D289%26doi%3D10.1016%2Fj.arabjc.2010.06.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueng, S. H.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3403</span>– <span class="NLM_lpage">3406</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.05.084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.bmcl.2014.05.084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24939758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=3403-3406&author=M.+F.+Chengauthor=M.+S.+Hungauthor=J.+S.+Songauthor=S.+Y.+Linauthor=F.+Y.+Liaoauthor=M.+H.+Wuauthor=W.+Hsiaoauthor=C.+L.+Hsiehauthor=J.+S.+Wuauthor=Y.+S.+Chaoauthor=C.+Shihauthor=S.+Y.+Wuauthor=S.+H.+Ueng&title=Discovery+and+structure-activity+relationships+of+phenyl+benzenesulfonylhydrazides+as+novel+indoleamine+2%2C3-dioxygenase+inhibitors&doi=10.1016%2Fj.bmcl.2014.05.084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors</span></div><div class="casAuthors">Cheng, Ming-Fu; Hung, Ming-Shiu; Song, Jen-Shin; Lin, Shu-Yu; Liao, Fang-Yu; Wu, Mine-Hsine; Hsiao, Wenchi; Hsieh, Chia-Ling; Wu, Jian-Sung; Chao, Yu-Sheng; Shih, Chuan; Wu, Su-Ying; Ueng, Shau-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3403-3406</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of Ph benzenesulfonylhydrazides has been identified as potent inhibitors of indoleamine 2,3-dioxygenase (IDO), and their structure-activity relationship was explored.  Coupling reactions between various benzenesulfonyl chlorides and phenylhydrazides were utilized to synthesize the sulfonylhydrazides bearing various substituents.  Compd. 3i exhibited 61 nM of IC50 in enzymic assay and 172 nM of EC50 in the HeLa cell.  The computational study of 3i suggested that the major interactions between 3i and IDO protein are the coordination of sulfone and heme iron, the hydrogen bonding and hydrophobic interactions between 3i and IDO.  This novel class of IDO inhibitor provides a new direction to discover effective anti-cancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCMHnPLf2u5LVg90H21EOLACvtfcHk0lhuVELLvGNhSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVWhtbrM&md5=560f7daccbb56934079c186991fd1b52</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.05.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.05.084%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BF.%26aulast%3DHung%26aufirst%3DM.%2BS.%26aulast%3DSong%26aufirst%3DJ.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BY.%26aulast%3DLiao%26aufirst%3DF.%2BY.%26aulast%3DWu%26aufirst%3DM.%2BH.%26aulast%3DHsiao%26aufirst%3DW.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DWu%26aufirst%3DJ.%2BS.%26aulast%3DChao%26aufirst%3DY.%2BS.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DUeng%26aufirst%3DS.%2BH.%26atitle%3DDiscovery%2520and%2520structure-activity%2520relationships%2520of%2520phenyl%2520benzenesulfonylhydrazides%2520as%2520novel%2520indoleamine%25202%252C3-dioxygenase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D3403%26epage%3D3406%26doi%3D10.1016%2Fj.bmcl.2014.05.084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, W.</span></span> <span> </span><span class="NLM_article-title">Why is the oxidation state of iron crucial for the activity of heme dependent aldoxime dehydratase? A QM/MM study</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">9396</span>– <span class="NLM_lpage">9408</span>, <span class="refDoi"> DOI: 10.1021/jp305510c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp305510c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCmtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2012&pages=9396-9408&author=R.+Z.+Liaoauthor=W.+Thiel&title=Why+is+the+oxidation+state+of+iron+crucial+for+the+activity+of+heme+dependent+aldoxime+dehydratase%3F+A+QM%2FMM+study&doi=10.1021%2Fjp305510c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Why Is the Oxidation State of Iron Crucial for the Activity of Heme-Dependent Aldoxime Dehydratase? A QM/MM Study</span></div><div class="casAuthors">Liao, Rong-Zhen; Thiel, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">9396-9408</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-5207</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aldoxime dehydratase is a heme-contg. enzyme that utilizes the ferrous rather than the ferric ion to catalyze the synthesis of nitriles by dehydration of the substrate.  We report a theor. study of this enzyme aimed at elucidating its catalytic mechanism and understanding this oxidn. state preference (Fe2+ vs. Fe3+).  The uncatalyzed dehydration reaction was modeled by including three and four water mols. to assist in the proton transfer, but the computed barriers were very high at both the DFT (B3LYP) and coupled cluster CCSD(T) levels.  The enzymic dehydration of Z-acetaldoxime was explored through QM/MM calcn. using two different QM regions and covering all three possible spin states.  The reaction starts by substrate coordination to Fe2+ via its nitrogen atom to form a six-coordinated singlet reactant complex.  The ferrous heme catalyzes the N-O bond cleavage by transferring one electron to the antibond in the singlet state, while His320 functions as a general acid to deliver a proton to the leaving hydroxide, thus facilitating its departure.  The key intermediate is identified as an FeIII(CH3CH=N·) species (triplet or open-shell singlet), with the closed-shell singlet FeII(CH3CH=N+) being about 6 kcal/mol higher.  Subsequently, the same His320 residue abstrs. the α-proton, coupled with electron transfer back to the iron center.  Both steps are calcd. to have feasible barriers (14-15 kcal/mol), in agreement with exptl. kinetic studies.  For the same mode of substrate coordination, the ferric heme does not catalyze the N-O bond cleavage, because the reaction is endothermic by about 40 kcal/mol, mainly due to the energetic penalty for oxidizing the ferric heme.  The alternative binding option, in which the anionic aldoxime coordinates to the ferric ion via its oxyanion, also results in a high barrier (around 30 kcal/mol), mainly because of the large endothermicity assocd. with the generation of a suitable base (neutral His320) for proton abstraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnw_Dxn1xpvbVg90H21EOLACvtfcHk0lgupXAw0hpJfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCmtrzK&md5=e9157236a8fedbd4ab62ab94a51ee8ee</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjp305510c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp305510c%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DR.%2BZ.%26aulast%3DThiel%26aufirst%3DW.%26atitle%3DWhy%2520is%2520the%2520oxidation%2520state%2520of%2520iron%2520crucial%2520for%2520the%2520activity%2520of%2520heme%2520dependent%2520aldoxime%2520dehydratase%253F%2520A%2520QM%252FMM%2520study%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2012%26volume%3D116%26spage%3D9396%26epage%3D9408%26doi%3D10.1021%2Fjp305510c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wayland, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takvorian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bower, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbury, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Combs, A. P.</span></span> <span> </span><span class="NLM_article-title">INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immunooncology</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">486</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00391</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00391" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=486-491&author=E.+W.+Yueauthor=R.+Sparksauthor=P.+Polamauthor=D.+Modiauthor=B.+Doutyauthor=B.+Waylandauthor=B.+Glassauthor=A.+Takvorianauthor=J.+Glennauthor=W.+Zhuauthor=M.+Bowerauthor=X.+Liuauthor=L.+Leffetauthor=Q.+Wangauthor=K.+J.+Bowmanauthor=M.+J.+Hansburyauthor=M.+Weiauthor=Y.+Liauthor=R.+Wynnauthor=T.+C.+Burnauthor=H.+K.+Koblishauthor=J.+S.+Fridmanauthor=T.+Emmauthor=P.+A.+Scherleauthor=B.+Metcalfauthor=A.+P.+Combs&title=INCB24360+%28Epacadostat%29%2C+a+highly+potent+and+selective+indoleamine-2%2C3-dioxygenase+1+%28IDO1%29+inhibitor+for+immunooncology&doi=10.1021%2Facsmedchemlett.6b00391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology</span></div><div class="casAuthors">Yue, Eddy W.; Sparks, Richard; Polam, Padmaja; Modi, Dilip; Douty, Brent; Wayland, Brian; Glass, Brian; Takvorian, Amy; Glenn, Joseph; Zhu, Wenyu; Bower, Michael; Liu, Xiangdong; Leffet, Lynn; Wang, Qian; Bowman, Kevin J.; Hansbury, Michael J.; Wei, Min; Li, Yanlong; Wynn, Richard; Burn, Timothy C.; Koblish, Holly K.; Fridman, Jordan S.; Emm, Tom; Scherle, Peggy A.; Metcalf, Brian; Combs, Andrew P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">486-491</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A data-centric medicinal chem. approach led to the invention of a potent and selective IDO1 inhibitor 4f, INCB24360 (epacadostat).  The mol. structure of INCB24360 contains several previously unknown or underutilized functional groups in drug substances, including a hydroxyamidine, furazan, bromide and sulfamide.  These moieties taken together in a single structure afford a compd. which falls outside of "drug-like" space.  Nevertheless, the in vitro ADME data is consistent with the good cell permeability and oral bioavailability obsd. in all species (rat, dog, monkey) tested.  The extensive intramol. hydrogen bonding obsd. in the small mol. crystal structure of 4f is believed to significantly contribute to the obsd. permeability and PK.  Epacadostat in combination with anti-PD1 mAb pembrolizumab is currently being studied in a phase 3 clin. trial in patients with unresectable or metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpm79ArpY1yLVg90H21EOLACvtfcHk0lgupXAw0hpJfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Gqsb0%253D&md5=92bebde519334e9e2a776250bb0258ac</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00391%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DE.%2BW.%26aulast%3DSparks%26aufirst%3DR.%26aulast%3DPolam%26aufirst%3DP.%26aulast%3DModi%26aufirst%3DD.%26aulast%3DDouty%26aufirst%3DB.%26aulast%3DWayland%26aufirst%3DB.%26aulast%3DGlass%26aufirst%3DB.%26aulast%3DTakvorian%26aufirst%3DA.%26aulast%3DGlenn%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DBower%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLeffet%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DBowman%26aufirst%3DK.%2BJ.%26aulast%3DHansbury%26aufirst%3DM.%2BJ.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DKoblish%26aufirst%3DH.%2BK.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DEmm%26aufirst%3DT.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DCombs%26aufirst%3DA.%2BP.%26atitle%3DINCB24360%2520%2528Epacadostat%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520indoleamine-2%252C3-dioxygenase%25201%2520%2528IDO1%2529%2520inhibitor%2520for%2520immunooncology%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D486%26epage%3D491%26doi%3D10.1021%2Facsmedchemlett.6b00391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Röhrig, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majjigapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosdidier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroobant, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilotte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den
Eynde, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoete, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michielin, O.</span></span> <span> </span><span class="NLM_article-title">Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5270</span>– <span class="NLM_lpage">5290</span>, <span class="refDoi"> DOI: 10.1021/jm300260v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300260v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1yiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5270-5290&author=U.+F.+R%C3%B6hrigauthor=S.+R.+Majjigapuauthor=A.+Grosdidierauthor=S.+Bronauthor=V.+Stroobantauthor=L.+Pilotteauthor=D.+Colauauthor=P.+Vogelauthor=B.+J.+Van+den%0AEyndeauthor=V.+Zoeteauthor=O.+Michielin&title=Rational+design+of+4-aryl-1%2C2%2C3-triazoles+for+indoleamine+2%2C3-dioxygenase+1+inhibition&doi=10.1021%2Fjm300260v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of 4-Aryl-1,2,3-Triazoles for Indoleamine 2,3-Dioxygenase 1 Inhibition</span></div><div class="casAuthors">Rohrig, Ute F.; Majjigapu, Somi Reddy; Grosdidier, Aurelien; Bron, Sylvian; Stroobant, Vincent; Pilotte, Luc; Colau, Didier; Vogel, Pierre; Van den Eynde, Benoit J.; Zoete, Vincent; Michielin, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5270-5290</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Indoleamine 2,3-dioxygenase 1 (IDO1) is an important therapeutic target for the treatment of diseases such as cancer that involve pathol. immune escape.  Starting from the scaffold of our previously discovered IDO1 inhibitor 4-phenyl-1,2,3-triazole, we used computational structure-based methods to design more potent ligands.  This approach yielded highly efficient low mol. wt. inhibitors, the most active being of nanomolar potency both in an enzymic and in a cellular assay, while showing no cellular toxicity and a high selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO).  A quant. structure-activity relationship based on the electrostatic ligand-protein interactions in the docked binding modes and on the quantum chem. derived charges of the triazole ring demonstrated a good explanatory power for the obsd. activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CFYZnWiLSLVg90H21EOLACvtfcHk0liudGHRjPwQmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1yiu7c%253D&md5=6ba6c0b628165673cd49c7a950ed885e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm300260v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300260v%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25B6hrig%26aufirst%3DU.%2BF.%26aulast%3DMajjigapu%26aufirst%3DS.%2BR.%26aulast%3DGrosdidier%26aufirst%3DA.%26aulast%3DBron%26aufirst%3DS.%26aulast%3DStroobant%26aufirst%3DV.%26aulast%3DPilotte%26aufirst%3DL.%26aulast%3DColau%26aufirst%3DD.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DVan%2Bden%2BEynde%26aufirst%3DB.%2BJ.%26aulast%3DZoete%26aufirst%3DV.%26aulast%3DMichielin%26aufirst%3DO.%26atitle%3DRational%2520design%2520of%25204-aryl-1%252C2%252C3-triazoles%2520for%2520indoleamine%25202%252C3-dioxygenase%25201%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5270%26epage%3D5290%26doi%3D10.1021%2Fjm300260v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schenkman, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sligar, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinti, D. L.</span></span> <span> </span><span class="NLM_article-title">Substrate interaction with cytochrome P-450</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">71</span>, <span class="refDoi"> DOI: 10.1016/0163-7258(81)90075-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2F0163-7258%2881%2990075-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=7019934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADyaL3MXhtFKjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1981&pages=43-71&author=J.+B.+Schenkmanauthor=S.+G.+Sligarauthor=D.+L.+Cinti&title=Substrate+interaction+with+cytochrome+P-450&doi=10.1016%2F0163-7258%2881%2990075-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate interaction with cytochrome P-450</span></div><div class="casAuthors">Schenkman, John B.; Sligar, Stephen G.; Cinti, Dominick L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-71</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    </div><div class="casAbstract">A review with 127 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMfbDvPjv3o7Vg90H21EOLACvtfcHk0liudGHRjPwQmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXhtFKjtLk%253D&md5=b9d1f290388d5a8754c16ece14cdc049</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0163-7258%2881%2990075-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0163-7258%252881%252990075-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchenkman%26aufirst%3DJ.%2BB.%26aulast%3DSligar%26aufirst%3DS.%2BG.%26aulast%3DCinti%26aufirst%3DD.%2BL.%26atitle%3DSubstrate%2520interaction%2520with%2520cytochrome%2520P-450%26jtitle%3DPharmacol.%2520Ther.%26date%3D1981%26volume%3D12%26spage%3D43%26epage%3D71%26doi%3D10.1016%2F0163-7258%2881%2990075-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Powell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steadman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soudy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyauchi, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crosby, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reisinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winfield, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finniear, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leary, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotinou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djordjevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsirka, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zachary, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selwood, D. L.</span></span> <span> </span><span class="NLM_article-title">Small molecule neuropilin-1 antagonists combine antiangiogenic and antitumor activity with immune modulation through reduction of transforming trowth factor beta (TGFβ) production in regulatory T-cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4135</span>– <span class="NLM_lpage">4154</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00210</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00210" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnsFSgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4135-4154&author=J.+Powellauthor=F.+Motaauthor=D.+Steadmanauthor=C.+Soudyauthor=J.+T.+Miyauchiauthor=S.+Crosbyauthor=A.+Jarvisauthor=T.+Reisingerauthor=N.+Winfieldauthor=G.+Evansauthor=A.+Finniearauthor=T.+Yellandauthor=Y.+T.+Chouauthor=A.+W.+E.+Chanauthor=A.+O.+Learyauthor=L.+Chengauthor=D.+Liuauthor=C.+Fotinouauthor=C.+Milagreauthor=J.+F.+Martinauthor=H.+Jiaauthor=P.+Frankelauthor=S.+Djordjevicauthor=S.+E.+Tsirkaauthor=I.+C.+Zacharyauthor=D.+L.+Selwood&title=Small+molecule+neuropilin-1+antagonists+combine+antiangiogenic+and+antitumor+activity+with+immune+modulation+through+reduction+of+transforming+trowth+factor+beta+%28TGF%CE%B2%29+production+in+regulatory+T-cells&doi=10.1021%2Facs.jmedchem.8b00210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells</span></div><div class="casAuthors">Powell, Jonathan; Mota, Filipa; Steadman, David; Soudy, Christelle; Miyauchi, Jeremy T.; Crosby, Stuart; Jarvis, Ashley; Reisinger, Tifelle; Winfield, Natalie; Evans, Graham; Finniear, Aled; Yelland, Tamas; Chou, Yi-Tai; Chan, A. W. Edith; O'Leary, Andrew; Cheng, Lili; Liu, Dan; Fotinou, Constantina; Milagre, Carla; Martin, John F.; Jia, Haiyan; Frankel, Paul; Djordjevic, Snezana; Tsirka, Stella E.; Zachary, Ian C.; Selwood, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4135-4154</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the design, synthesis and comprehensive biol. evaluation of a range of some potent small-mol. neuropilin-1 (NRP1) antagonists.  NRP1 is implicated in the immune response to tumors, particularly in Treg cell fragility, required for PD1 checkpoint blockade.  The design of these compds. was based on a previously identified compd. EG00229 which was used a starting point for optimization.  Through targeting of specific amino-acid residues addnl. H-bonding interactions were introduced, which led to increases in binding affinity and potency.  The design of these mols. was informed and supported by X-ray crystal structures.  Pharmacokinetic data was obtained for some of the most potent compds., and compd. 1 (EG01377) was identified as having properties suitable for further investigation.  Compd. 1 was then tested in several in vitro assays, and was shown to have anti-angiogenic, anti-migratory and anti-tumor effects.  Remarkably, 1 was shown to be selective for NRP1 over the closely related protein NRP2.  In purified Nrp1+, FoxP3+, CD25+ populations of Tregs from mice 1 was able to block a glioma conditioned medium induced increase in TGFβ prodn.  This study therefore represents a comprehensive characterization of a small-mol. NRP1 antagonist, and provides the basis for future in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNGxPChEZvNbVg90H21EOLACvtfcHk0lifj6WJ-36idg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnsFSgu7c%253D&md5=3917a78cce28364a8db538e6fae98582</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00210%26sid%3Dliteratum%253Aachs%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DMota%26aufirst%3DF.%26aulast%3DSteadman%26aufirst%3DD.%26aulast%3DSoudy%26aufirst%3DC.%26aulast%3DMiyauchi%26aufirst%3DJ.%2BT.%26aulast%3DCrosby%26aufirst%3DS.%26aulast%3DJarvis%26aufirst%3DA.%26aulast%3DReisinger%26aufirst%3DT.%26aulast%3DWinfield%26aufirst%3DN.%26aulast%3DEvans%26aufirst%3DG.%26aulast%3DFinniear%26aufirst%3DA.%26aulast%3DYelland%26aufirst%3DT.%26aulast%3DChou%26aufirst%3DY.%2BT.%26aulast%3DChan%26aufirst%3DA.%2BW.%2BE.%26aulast%3DLeary%26aufirst%3DA.%2BO.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DFotinou%26aufirst%3DC.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DJ.%2BF.%26aulast%3DJia%26aufirst%3DH.%26aulast%3DFrankel%26aufirst%3DP.%26aulast%3DDjordjevic%26aufirst%3DS.%26aulast%3DTsirka%26aufirst%3DS.%2BE.%26aulast%3DZachary%26aufirst%3DI.%2BC.%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26atitle%3DSmall%2520molecule%2520neuropilin-1%2520antagonists%2520combine%2520antiangiogenic%2520and%2520antitumor%2520activity%2520with%2520immune%2520modulation%2520through%2520reduction%2520of%2520transforming%2520trowth%2520factor%2520beta%2520%2528TGF%25CE%25B2%2529%2520production%2520in%2520regulatory%2520T-cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4135%26epage%3D4154%26doi%3D10.1021%2Facs.jmedchem.8b00210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munn, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Expression of indoleamine 2,3- dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1172/JCI21583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1172%2FJCI21583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=15254595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlvFWmsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2004&pages=280-290&author=D.+H.+Munnauthor=M.+D.+Sharmaauthor=D.+Hou&title=Expression+of+indoleamine+2%2C3-+dioxygenase+by+plasmacytoid+dendritic+cells+in+tumor-draining+lymph+nodes&doi=10.1172%2FJCI21583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes</span></div><div class="casAuthors">Munn, David H.; Sharma, Madhav D.; Hou, Deyan; Baban, Babak; Lee, Jeffrey R.; Antonia, Scott J.; Messina, Jane L.; Chandler, Phillip; Koni, Pandelakis A.; Mellor, Andrew L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-290</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">One mechanism contributing to immunol. unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs.  We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO).  Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs.  Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs.  Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice.  Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19.  We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGNDuxa-Ss3bVg90H21EOLACvtfcHk0lifj6WJ-36idg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlvFWmsbg%253D&md5=da173363d15fb2bda14b1be20d2e41cd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1172%2FJCI21583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI21583%26sid%3Dliteratum%253Aachs%26aulast%3DMunn%26aufirst%3DD.%2BH.%26aulast%3DSharma%26aufirst%3DM.%2BD.%26aulast%3DHou%26aufirst%3DD.%26atitle%3DExpression%2520of%2520indoleamine%25202%252C3-%2520dioxygenase%2520by%2520plasmacytoid%2520dendritic%2520cells%2520in%2520tumor-draining%2520lymph%2520nodes%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2004%26volume%3D114%26spage%3D280%26epage%3D290%26doi%3D10.1172%2FJCI21583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza, S. M.</span></span> <span> </span><span class="NLM_article-title">The anticancer effects of vitamin K</span>. <i>Altern. Med. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">303</span>– <span class="NLM_lpage">318</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=12946240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A280%3ADC%252BD3svgslGgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2003&pages=303-318&author=D.+W.+Lamsonauthor=S.+M.+Plaza&title=The+anticancer+effects+of+vitamin+K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The anticancer effects of vitamin K</span></div><div class="casAuthors">Lamson Davis W; Plaza Steven M</div><div class="citationInfo"><span class="NLM_cas:title">Alternative medicine review : a journal of clinical therapeutic</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">303-18</span>
        ISSN:<span class="NLM_cas:issn">1089-5159</span>.
    </div><div class="casAbstract">Vitamin K, an essential nutrient often associated with the clotting cascade, has been the focus of considerable research demonstrating an anticancer potential.  Much of this research has focused on vitamin K3, although vitamins K2 and K1 have also been shown to have anticancer effects.  Early studies of vitamin K3 employed an oxidative model to explain the anticancer effects seen in both in vitro and in vivo studies; however, this model does not adequately address the action of vitamins K1 and K2.  Recent research has demonstrated the anticancer action of vitamin K may act at the level of tyrosine kinases and phosphatases, modulating various transcription factors such as Myc and Fos.  Tyrosine kinases associated with cyclins have also been shown to be affected by vitamin K, which can lead to cell cycle arrest and cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnvsAxza7Swkg6wdEZmT2rfW6udTcc2eYwkN-WU2CqHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgslGgtA%253D%253D&md5=7211b5edc1c7eaf4ecf2112517ad7827</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLamson%26aufirst%3DD.%2BW.%26aulast%3DPlaza%26aufirst%3DS.%2BM.%26atitle%3DThe%2520anticancer%2520effects%2520of%2520vitamin%2520K%26jtitle%3DAltern.%2520Med.%2520Rev.%26date%3D2003%26volume%3D8%26spage%3D303%26epage%3D318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senovilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitvogel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span> <span> </span><span class="NLM_article-title">The secret ally: immunostimulation by anticancer drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nrd3626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrd3626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=22301798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=215-233&author=L.+Galluzziauthor=L.+Senovillaauthor=L.+Zitvogelauthor=G.+Kroemer&title=The+secret+ally%3A+immunostimulation+by+anticancer+drugs&doi=10.1038%2Fnrd3626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The secret ally: immunostimulation by anticancer drugs</span></div><div class="casAuthors">Galluzzi, Lorenzo; Senovilla, Laura; Zitvogel, Laurence; Kroemer, Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-233</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  It has recently become clear that the tumor microenvironment, and in particular the immune system, has a crucial role in modulating tumor progression and response to therapy.  Indicators of an ongoing immune response, such as the compn. of the intratumoral immune infiltrate, as well as polymorphisms in genes encoding immune modulators, have been correlated with therapeutic outcome.  Moreover, several anticancer agents - including classical chemotherapeutics and targeted compds. - stimulate tumor-specific immune responses either by inducing the immunogenic death of tumor cells or by engaging immune effector mechanisms.  Here, we discuss the mol. and cellular circuitries whereby cytotoxic agents can activate the immune system against cancer, and their therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouW7RYumw6QrVg90H21EOLACvtfcHk0lgXJzscQmR38g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gitb4%253D&md5=abed8d097aa5bb5588e6d553eead9a16</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fnrd3626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3626%26sid%3Dliteratum%253Aachs%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DSenovilla%26aufirst%3DL.%26aulast%3DZitvogel%26aufirst%3DL.%26aulast%3DKroemer%26aufirst%3DG.%26atitle%3DThe%2520secret%2520ally%253A%2520immunostimulation%2520by%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D215%26epage%3D233%26doi%3D10.1038%2Fnrd3626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bracci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiavoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sistigu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belardelli, F.</span></span> <span> </span><span class="NLM_article-title">Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1038/cdd.2013.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fcdd.2013.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=23787994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFCqtbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=15-25&author=L.+Bracciauthor=G.+Schiavoniauthor=A.+Sistiguauthor=F.+Belardelli&title=Immune-based+mechanisms+of+cytotoxic+chemotherapy%3A+implications+for+the+design+of+novel+and+rationale-based+combined+treatments+against+cancer&doi=10.1038%2Fcdd.2013.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer</span></div><div class="casAuthors">Bracci, L.; Schiavoni, G.; Sistigu, A.; Belardelli, F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-25</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Conventional anticancer chemotherapy has been historically thought to act through direct killing of tumor cells.  This concept stems from the fact that cytotoxic drugs interfere with DNA synthesis and replication.  Accumulating evidence, however, indicates that the antitumor activities of chemotherapy also rely on several off-target effects, esp. directed to the host immune system, that cooperate for successful tumor eradication.  Chemotherapeutic agents stimulate both the innate and adaptive arms of the immune system through several modalities: (i) by promoting specific rearrangements on dying tumor cells, which render them visible to the immune system; (ii) by influencing the homeostasis of the hematopoietic compartment through transient lymphodepletion followed by rebound replenishment of immune cell pools; (iii) by subverting tumor-induced immunosuppressive mechanisms and (iv) by exerting direct or indirect stimulatory effects on immune effectors.  Among the indirect ways of immune cell stimulation, some cytotoxic drugs have been shown to induce an immunogenic type of cell death in tumor cells, resulting in the emission of specific signals that trigger phagocytosis of cell debris and promote the maturation of dendritic cells, ultimately resulting in the induction of potent antitumor responses.  Here, we provide an extensive overview of the multiple immune-based mechanisms exploited by the most commonly employed cytotoxic drugs, with the final aim of identifying prerequisites for optimal combination with immunotherapy strategies for the development of more effective treatments against cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB7GLQr9KSpbVg90H21EOLACvtfcHk0lgXJzscQmR38g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFCqtbnE&md5=93bba735c9d507198e7892d830805f8d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2013.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2013.67%26sid%3Dliteratum%253Aachs%26aulast%3DBracci%26aufirst%3DL.%26aulast%3DSchiavoni%26aufirst%3DG.%26aulast%3DSistigu%26aufirst%3DA.%26aulast%3DBelardelli%26aufirst%3DF.%26atitle%3DImmune-based%2520mechanisms%2520of%2520cytotoxic%2520chemotherapy%253A%2520implications%2520for%2520the%2520design%2520of%2520novel%2520and%2520rationale-based%2520combined%2520treatments%2520against%2520cancer%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2014%26volume%3D21%26spage%3D15%26epage%3D25%26doi%3D10.1038%2Fcdd.2013.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flick, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaLonde, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malachowski, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. J.</span></span> <span> </span><span class="NLM_article-title">The tumor-selective cytotoxic agent β-lapachone is a potent inhibitor of IDO1</span>. <i>Int. J. Tryptophan Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.4137/IJTR.S12094</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.4137%2FIJTR.S12094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24023520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2gs73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=35-45&author=H.+E.+Flickauthor=J.+M.+LaLondeauthor=W.+P.+Malachowskiauthor=A.+J.+Muller&title=The+tumor-selective+cytotoxic+agent+%CE%B2-lapachone+is+a+potent+inhibitor+of+IDO1&doi=10.4137%2FIJTR.S12094"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The tumor-selective cytotoxic agent β-lapachone is a potent inhibitor of IDO1</span></div><div class="casAuthors">Flick, Hollie E.; LaLonde, Judith M.; Malachowski, William P.; Muller, Alexander J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Tryptophan Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-45</span>CODEN:
                <span class="NLM_cas:coden">IJTRBS</span>;
        ISSN:<span class="NLM_cas:issn">1178-6469</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">β-Lapachone is a naturally occurring 1,2-naphthoquinone-based compd. that has been advanced into clin. trials based on its tumor-selective cytotoxic properties.  Previously, we focused on the related 1,4-naphthoquinone pharmacophore as a basic core structure for developing a series of potent indoleamine 2,3-dioxygenase 1 (IDO1) enzyme inhibitors.  In this study, we identified IDO1 inhibitory activity as a previously unrecognized attribute of the clin. candidate β-lapachone.  Enzyme kinetics-based anal. of β-lapachone indicated an uncompetitive mode of inhibition, while computational modeling predicted binding within the IDO1 active site consistent with other naphthoquinone derivs.  Inhibition of IDO1 has previously been shown to breach the pathogenic tolerization that constrains the immune system from being able to mount an effective anti-tumor response.  Thus, the finding that β-lapachone has IDO1 inhibitory activity adds a new dimension to its potential utility as an anti-cancer agent distinct from its cytotoxic properties, and suggests that a synergistic benefit can be achieved from its combined cytotoxic and immunol. effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVmjPfcd508LVg90H21EOLACvtfcHk0ljgC15UYTAuuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2gs73M&md5=d432e109c20ca5a92c26d6dda24ef4b7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.4137%2FIJTR.S12094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FIJTR.S12094%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DH.%2BE.%26aulast%3DLaLonde%26aufirst%3DJ.%2BM.%26aulast%3DMalachowski%26aufirst%3DW.%2BP.%26aulast%3DMuller%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520tumor-selective%2520cytotoxic%2520agent%2520%25CE%25B2-lapachone%2520is%2520a%2520potent%2520inhibitor%2520of%2520IDO1%26jtitle%3DInt.%2520J.%2520Tryptophan%2520Res.%26date%3D2013%26volume%3D6%26spage%3D35%26epage%3D45%26doi%3D10.4137%2FIJTR.S12094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridewell, D. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosim-Satyaputra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ching, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamie, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span> <span> </span><span class="NLM_article-title">Natural product-inspired pyranonaphthoquinone inhibitors of indoleamine 2,3-dioxygenase-1 (IDO-1)</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1071/CH12393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1071%2FCH12393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2013&pages=40-49&author=D.+J.+A.+Bridewellauthor=J.+Sperryauthor=J.+R.+Smithauthor=P.+Kosim-Satyaputraauthor=L.+M.+Chingauthor=J.+F.+Jamieauthor=M.+A.+Brimble&title=Natural+product-inspired+pyranonaphthoquinone+inhibitors+of+indoleamine+2%2C3-dioxygenase-1+%28IDO-1%29&doi=10.1071%2FCH12393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Natural Product-Inspired Pyranonaphthoquinone Inhibitors of Indoleamine 2,3-Dioxygenase-1 (IDO-1)*</span></div><div class="casAuthors">Bridewell, David J. A.; Sperry, Jonathan; Smith, Jason R.; Kosim-Satyaputra, Priambudi; Ching, Lai-Ming; Jamie, Joanne F.; Brimble, Margaret A.</div><div class="citationInfo"><span class="NLM_cas:title">Australian Journal of Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">40-49</span>CODEN:
                <span class="NLM_cas:coden">AJCHAS</span>;
        ISSN:<span class="NLM_cas:issn">0004-9425</span>.
    
            (<span class="NLM_cas:orgname">CSIRO Publishing</span>)
        </div><div class="casAbstract">A series of pyranonaphthoquinone derivs. possessing structural features present in both natural products annulin B and exiguamine A have been shown to exhibit low micromolar inhibition of indoleamine 2,3-dioxygenase-1 (IDO-1).  These inhibitors retain activity against the enzyme in a cellular context with an approx. one-log loss of dose potency against IDO-1 in cells.  One particular analog, triazole 8 shows good inhibition of IDO-1 along with little loss of cell viability at low drug concns.  These results have extended the naphthoquinone series of novel IDO-1 inhibitors based on lead compds. from nature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG_O1UCqyQf7Vg90H21EOLACvtfcHk0ljgC15UYTAuuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVylsLY%253D&md5=236dfa68088e25fdabca5e2ab6e1f288</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1071%2FCH12393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1071%252FCH12393%26sid%3Dliteratum%253Aachs%26aulast%3DBridewell%26aufirst%3DD.%2BJ.%2BA.%26aulast%3DSperry%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DJ.%2BR.%26aulast%3DKosim-Satyaputra%26aufirst%3DP.%26aulast%3DChing%26aufirst%3DL.%2BM.%26aulast%3DJamie%26aufirst%3DJ.%2BF.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26atitle%3DNatural%2520product-inspired%2520pyranonaphthoquinone%2520inhibitors%2520of%2520indoleamine%25202%252C3-dioxygenase-1%2520%2528IDO-1%2529%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2013%26volume%3D66%26spage%3D40%26epage%3D49%26doi%3D10.1071%2FCH12393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzo-Castrillejo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimble, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machínb, F.</span></span> <span> </span><span class="NLM_article-title">Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">7131</span>– <span class="NLM_lpage">7137</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.08.064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.bmc.2009.08.064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=19783445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ais7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=7131-7137&author=J.+Sperryauthor=I.+Lorenzo-Castrillejoauthor=M.+A.+Brimbleauthor=F.+Mach%C3%ADnb&title=Pyranonaphthoquinone+derivatives+of+eleutherin%2C+ventiloquinone+L%2C+thysanone+and+nanaomycin+A+possessing+a+diverse+topoisomerase+II+inhibition+and+cytotoxicity+spectrum&doi=10.1016%2Fj.bmc.2009.08.064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum</span></div><div class="casAuthors">Sperry, Jonathan; Lorenzo-Castrillejo, Isabel; Brimble, Margaret A.; Machin, Felix</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7131-7137</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of pyranonaphthoquinone derivs. related to the known topoisomerase II inhibitor eleutherin have been shown to act as specific topoisomerase II catalytic inhibitors, with several analogs displaying greater potency than the natural product itself.  Amongst the compds. tested were the natural products ventiloquinone L and thysanone with a diverse range of topoisomerase II inhibition properties being obsd.  Interestingly, the natural products are generally weaker inhibitors than their synthetic counterparts, emphasizing that subtle changes in the basic mol. structure of a natural product led to significant changes in the inhibition profile.  It has also been demonstrated for the first time that analogs related to nanaomycin A and cardinalin-type dimeric pyranonaphthoquinones exhibit potent topoisomerase II inhibitory properties.  With respect to structural features, it appears that the nature of the substituents at C1 on the pyran ring and oxygenated substituents on the aryl ring are crit. for anti-topoII activity.  Importantly, the topoisomerase II inhibition strength does not correlate well with the measured cytotoxicity against yeast, indicating that other mol. features in the pyranonaphthoquinone family must be considered for the design and use of this structural class as highly specific topoisomerase II inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbSbL4p1TXtLVg90H21EOLACvtfcHk0lijlhzVeHd5hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ais7vL&md5=a72aa9abe49e8716eac942ca1e8a0f63</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.08.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.08.064%26sid%3Dliteratum%253Aachs%26aulast%3DSperry%26aufirst%3DJ.%26aulast%3DLorenzo-Castrillejo%26aufirst%3DI.%26aulast%3DBrimble%26aufirst%3DM.%2BA.%26aulast%3DMach%25C3%25ADnb%26aufirst%3DF.%26atitle%3DPyranonaphthoquinone%2520derivatives%2520of%2520eleutherin%252C%2520ventiloquinone%2520L%252C%2520thysanone%2520and%2520nanaomycin%2520A%2520possessing%2520a%2520diverse%2520topoisomerase%2520II%2520inhibition%2520and%2520cytotoxicity%2520spectrum%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D7131%26epage%3D7137%26doi%3D10.1016%2Fj.bmc.2009.08.064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel STAT3 small molecule inhibitors via in silico site directed fragment-based drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4402</span>– <span class="NLM_lpage">4412</span>, <span class="refDoi"> DOI: 10.1021/jm400080c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400080c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVOktbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4402-4412&author=W.+Yuauthor=H.+Xiaoauthor=J.+Linauthor=C.+Li&title=Discovery+of+novel+STAT3+small+molecule+inhibitors+via+in+silico+site+directed+fragment-based+drug+design&doi=10.1021%2Fjm400080c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel STAT3 Small Molecule Inhibitors via in Silico Site-Directed Fragment-Based Drug Design</span></div><div class="casAuthors">Yu, Wenying; Xiao, Hui; Lin, Jiayuh; Li, Chenglong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4402-4412</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Constitutive activation of signal transducer and activator of transcription 3 (STAT3) has been validated as an attractive therapeutic target for cancer therapy.  To stop both STAT3 activation and dimerization, a viable strategy is to design inhibitors blocking its SH2 domain phosphotyrosine binding site that is responsible for both actions.  A new fragment-based drug design (FBDD) strategy, in silico site-directed FBDD, was applied in this study.  A designed novel compd., 5,8-dioxo-6-(pyridin-3-ylamino)-5,8-dihydronaphthalene-1-sulfonamide (LY5), was confirmed to bind to STAT3 SH2 by fluorescence polarization assay.  In addn., four out of the five chosen compds. have IC50 values lower than 5 μM for the U2OS cancer cells. 8 (LY5) has an IC50 range in 0.5-1.4 μM in various cancer cell lines. 8 also suppresses tumor growth in an in vivo mouse model.  This study has demonstrated the utility of this approach and could be used to other drug targets in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq76v3IMxJHwLVg90H21EOLACvtfcHk0lijlhzVeHd5hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVOktbk%253D&md5=7231b2e9682f9e9046debcaa461a1d59</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm400080c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400080c%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520novel%2520STAT3%2520small%2520molecule%2520inhibitors%2520via%2520in%2520silico%2520site%2520directed%2520fragment-based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4402%26epage%3D4412%26doi%3D10.1021%2Fjm400080c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STATs in cancer inflammation and immunity: a leading role for STAT3</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">798</span>– <span class="NLM_lpage">809</span>, <span class="refDoi"> DOI: 10.1038/nrc2734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1038%2Fnrc2734" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=19851315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=798-809&author=H.+Yuauthor=D.+Pardollauthor=R.+Jove&title=STATs+in+cancer+inflammation+and+immunity%3A+a+leading+role+for+STAT3&doi=10.1038%2Fnrc2734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">STATs in cancer inflammation and immunity: a leading role for STAT3</span></div><div class="casAuthors">Yu, Hua; Pardoll, Drew; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">798-809</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Commensurate with their roles in regulating cytokine-dependent inflammation and immunity, signal transducer and activator of transcription (STAT) proteins are central in detg. whether immune responses in the tumor microenvironment promote or inhibit cancer.  Persistently activated STAT3 and, to some extent, STAT5 increase tumor cell proliferation, survival and invasion while suppressing anti-tumor immunity.  The persistent activation of STAT3 also mediates tumor-promoting inflammation.  STAT3 has this dual role in tumor inflammation and immunity by promoting pro-oncogenic inflammatory pathways, including nuclear factor-κB (NF-κB) and interleukin-6 (IL-6)-GP130-Janus kinase (JAK) pathways, and by opposing STAT1- and NF-κB-mediated T helper 1 anti-tumor immune responses.  Consequently, STAT3 is a promising target to redirect inflammation for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYvEMN5YrxbbVg90H21EOLACvtfcHk0lgZA0WNGaKxhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjur%252FP&md5=e431d0bd9eabd8f1ef703211be3d5cc9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnrc2734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2734%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTATs%2520in%2520cancer%2520inflammation%2520and%2520immunity%253A%2520a%2520leading%2520role%2520for%2520STAT3%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D798%26epage%3D809%26doi%3D10.1038%2Fnrc2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hossain, D. M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swiderski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span> <span> </span><span class="NLM_article-title">Leukemia cell–targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1182/blood-2013-07-517987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1182%2Fblood-2013-07-517987" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=24169824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2014&pages=15-25&author=D.+M.+S.+Hossainauthor=C.+D.+Santosauthor=Q.+Zhangauthor=A.+Kozlowskaauthor=H.+Liuauthor=C.+Gaoauthor=D.+Moreiraauthor=P.+Swiderskiauthor=A.+Jozwiakauthor=J.+Klineauthor=S.+Formanauthor=R.+Bhatiaauthor=Y.+H.+Kuoauthor=M.+Kortylewski&title=Leukemia+cell%E2%80%93targeted+STAT3+silencing+and+TLR9+triggering+generate+systemic+antitumor+immunity&doi=10.1182%2Fblood-2013-07-517987"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity</span></div><div class="casAuthors">Hossain, Dewan Md. Sakib; Dos Santos, Cedric; Zhang, Qifang; Kozlowska, Anna; Liu, Hongjun; Gao, Chan; Moreira, Dayson; Swiderski, Piotr; Jozwiak, Agnieszka; Kline, Justin; Forman, Stephen; Bhatia, Ravi; Kuo, Ya-Huei; Kortylewski, Marcin</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-25</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Signal transducer and activator of transcription 3 (STAT3) is an oncogene and immune checkpoint commonly activated in cancer cells and in tumor-assocd. immune cells.  We previously developed an immunostimulatory strategy based on targeted Stat3 silencing in Toll-like receptor 9 (TLR9)-pos. hematopoietic cells using CpG-small interfering RNA (siRNA) conjugates.  Here, we assessed the therapeutic effect of systemic STAT3 blocking/TLR9 triggering in disseminated acute myeloid leukemia (AML).  We used mouse Cbfb-MYH11/Mpl-induced leukemia model, which mimics human inv(16) AML.  Our results demonstrate that i.v. delivered CpG-Stat3 siRNA, but not control oligonucleotides, can eradicate established AML and impair leukemia-initiating potential.  These antitumor effects require host's effector T cells but not TLR9-pos. antigen-presenting cells.  Instead, CpG-Stat3 siRNA has direct immunogenic effect on AML cells in vivo upregulating major histocompatibility complex class-II, costimulatory and proinflammatory mediators, such as interleukin-12, while downregulating coinhibitory PD-L1 mol.  Systemic injections of CpG-Stat3 siRNA generate potent tumor antigen-specific immune responses, increase the ratio of tumor-infiltrating CD8+ T cells to regulatory T cells in various organs, and result in CD8+ T-cell-dependent regression of leukemia.  Our findings underscore the potential of using targeted STAT3 inhibition/TLR9 triggering to break tumor tolerance and induce immunity against AML and potentially other TLR9-pos. blood cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoa3zReNBlrLVg90H21EOLACvtfcHk0lgZA0WNGaKxhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVClsQ%253D%253D&md5=15bd14a956844af565dd4b3c72bd7da8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-07-517987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-07-517987%26sid%3Dliteratum%253Aachs%26aulast%3DHossain%26aufirst%3DD.%2BM.%2BS.%26aulast%3DSantos%26aufirst%3DC.%2BD.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DKozlowska%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DMoreira%26aufirst%3DD.%26aulast%3DSwiderski%26aufirst%3DP.%26aulast%3DJozwiak%26aufirst%3DA.%26aulast%3DKline%26aufirst%3DJ.%26aulast%3DForman%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DR.%26aulast%3DKuo%26aufirst%3DY.%2BH.%26aulast%3DKortylewski%26aufirst%3DM.%26atitle%3DLeukemia%2520cell%25E2%2580%2593targeted%2520STAT3%2520silencing%2520and%2520TLR9%2520triggering%2520generate%2520systemic%2520antitumor%2520immunity%26jtitle%3DBlood%26date%3D2014%26volume%3D123%26spage%3D15%26epage%3D25%26doi%3D10.1182%2Fblood-2013-07-517987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nair, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toor, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkord, E.</span></span> <span> </span><span class="NLM_article-title">Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1080/14728222.2018.1471137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1080%2F14728222.2018.1471137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=29702007" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2018&pages=547-557&author=V.+S.+Nairauthor=S.+M.+Toorauthor=B.+R.+Aliauthor=E.+Elkord&title=Dual+inhibition+of+STAT1+and+STAT3+activation+downregulates+expression+of+PD-L1+in+human+breast+cancer+cells&doi=10.1080%2F14728222.2018.1471137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1080%2F14728222.2018.1471137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14728222.2018.1471137%26sid%3Dliteratum%253Aachs%26aulast%3DNair%26aufirst%3DV.%2BS.%26aulast%3DToor%26aufirst%3DS.%2BM.%26aulast%3DAli%26aufirst%3DB.%2BR.%26aulast%3DElkord%26aufirst%3DE.%26atitle%3DDual%2520inhibition%2520of%2520STAT1%2520and%2520STAT3%2520activation%2520downregulates%2520expression%2520of%2520PD-L1%2520in%2520human%2520breast%2520cancer%2520cells%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2018%26volume%3D22%26spage%3D547%26epage%3D557%26doi%3D10.1080%2F14728222.2018.1471137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temkin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuntzen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieghart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck-Radosavljevic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leffert, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">286</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2009.12.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.ccr.2009.12.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20227042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsVWqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=286-297&author=G.+Heauthor=G.+Y.+Yuauthor=V.+Temkinauthor=H.+Ogataauthor=C.+Kuntzenauthor=T.+Sakuraiauthor=W.+Sieghartauthor=M.+Peck-Radosavljevicauthor=H.+L.+Leffertauthor=M.+Karin&title=Hepatocyte+IKK%CE%B2%2FNF-%CE%BAB+inhibits+tumor+promotion+and+progression+by+preventing+oxidative+stress-driven+STAT3+activation&doi=10.1016%2Fj.ccr.2009.12.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation</span></div><div class="casAuthors">He, Guobin; Yu, Guann-Yi; Temkin, Vladislav; Ogata, Hisanobu; Kuntzen, Christian; Sakurai, Toshiharu; Sieghart, Wolfgang; Peck-Radosavljevic, Markus; Leffert, Hyam L.; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">286-297</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The NF-κB activating kinase IKKβ suppresses early chem. induced liver tumorigenesis by inhibiting hepatocyte death and compensatory proliferation.  To study IKKβ's role in late tumor promotion and progression, we developed a transplant system that allows initiated mouse hepatocytes to form hepatocellular carcinomas (HCC) in host liver after a long latency.  Deletion of IKKβ long after initiation accelerated HCC development and enhanced proliferation of tumor initiating cells.  These effects of IKKβ/NF-κB were cell autonomous and correlated with increased accumulation of reactive oxygen species that led to JNK and STAT3 activation.  Hepatocyte-specific STAT3 ablation prevented HCC development.  The neg. crosstalk between NF-κB and STAT3, which is also evident in human HCC, is a crit. regulator of liver cancer development and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVvGfhbfqwL7Vg90H21EOLACvtfcHk0ljoAq67-zY-fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsVWqtb8%253D&md5=fd21b8a893dd147e8eada63aebccb810</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2009.12.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2009.12.048%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DG.%26aulast%3DYu%26aufirst%3DG.%2BY.%26aulast%3DTemkin%26aufirst%3DV.%26aulast%3DOgata%26aufirst%3DH.%26aulast%3DKuntzen%26aufirst%3DC.%26aulast%3DSakurai%26aufirst%3DT.%26aulast%3DSieghart%26aufirst%3DW.%26aulast%3DPeck-Radosavljevic%26aufirst%3DM.%26aulast%3DLeffert%26aufirst%3DH.%2BL.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DHepatocyte%2520IKK%25CE%25B2%252FNF-%25CE%25BAB%2520inhibits%2520tumor%2520promotion%2520and%2520progression%2520by%2520preventing%2520oxidative%2520stress-driven%2520STAT3%2520activation%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D17%26spage%3D286%26epage%3D297%26doi%3D10.1016%2Fj.ccr.2009.12.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">STAT3 is necessary for proliferation and survival in colon cancer–initiating cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">7226</span>– <span class="NLM_lpage">7237</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-4660</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1158%2F0008-5472.CAN-10-4660" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=21900397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCmsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=7226-7237&author=L.+Linauthor=A.+Liuauthor=Z.+Pengauthor=H.-J.+Linauthor=P.-K.+Liauthor=C.+Liauthor=J.+Lin&title=STAT3+is+necessary+for+proliferation+and+survival+in+colon+cancer%E2%80%93initiating+cells&doi=10.1158%2F0008-5472.CAN-10-4660"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">STAT3 Is Necessary for Proliferation and Survival in Colon Cancer-Initiating Cells</span></div><div class="casAuthors">Lin, Li; Liu, Aiguo; Peng, Zhengang; Lin, Huey-Jen; Li, Pui-Kai; Li, Chenglong; Lin, Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7226-7237</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">STAT3 is constitutively activated in colon cancer but its contributions in cancer-initiating cells have not been explored.  In this study, we characterized STAT3 in aldehyde dehydrogenase (ALDH)-pos. (ALDH+) and CD133-pos. (CD133+) subpopulations of human colon tumor cells that exhibited more potent tumor-initiating ability than ALDH-/CD133- cells in tumor xenograft assays in mice.  We found that ALDH+/CD133+ cells expressed higher levels of the active phosphorylated form of STAT3 than either ALDH-/CD133- or unfractionated colon cancer cells.  STAT3 inhibition by RNA interference-mediated knockdown or small-mol. inhibitors LLL12 or Stattic blocked downstream target gene expression, cell viability, and tumorsphere-forming capacity in cancer-initiating cells.  Similarly, treatment of mouse tumor xenografts with STAT3 short hairpin RNA (shRNA), interleukin 6 shRNA, or LLL12 inhibited tumor growth.  Our results establish that STAT3 is constitutively activated in colon cancer-initiating cells and that these cells are sensitive to STAT3 inhibition.  These findings establish a powerful rationale to develop STAT3 inhibitory strategies for treating advanced colorectal cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRqdoOohnuUrVg90H21EOLACvtfcHk0ljoAq67-zY-fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCmsb%252FE&md5=3819d2dbe037ec37fd5426cc333d212e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-4660&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-4660%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DPeng%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DH.-J.%26aulast%3DLi%26aufirst%3DP.-K.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DSTAT3%2520is%2520necessary%2520for%2520proliferation%2520and%2520survival%2520in%2520colon%2520cancer%25E2%2580%2593initiating%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D7226%26epage%3D7237%26doi%3D10.1158%2F0008-5472.CAN-10-4660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercado-Uribe, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bast, R. C.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">2730</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1002/cncr.22293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1002%2Fcncr.22293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=17063503" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCmu7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=2730-2740&author=D.+G.+Rosenauthor=I.+Mercado-Uribeauthor=G.+Yangauthor=R.+C.+Bastauthor=H.+M.+Aminauthor=R.+Laiauthor=J.+Liu&title=The+role+of+constitutively+active+signal+transducer+and+activator+of+transcription+3+in+ovarian+tumorigenesis+and+prognosis&doi=10.1002%2Fcncr.22293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The role of constitutively active signal tranducer and activator of transcription 3 in ovarian tumorigenesis and prognosis</span></div><div class="casAuthors">Rosen, Daniel G.; Mercado-Uribe, Imelda; Yang, Gong; Bast, Robert C., Jr.; Amin, Hesham M.; Lai, Raymond; Liu, Jinsong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2730-2740</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND. Signal transducer and activator of transcription 3 (Stat3), which is a latent transcription factor that participates in the transcriptional activation of apoptosis and cell cycle progression, has been implicated as an oncogene in several neoplastic diseases.  However, the specific role of Stat3 in ovarian carcinogenesis remains poorly understood.  The objectives of the current study were to examine the effect of Stat3 activation on the phenotypic transformation of an immortalized, non-tumorigenic ovarian epithelial cell line and to evaluate the expression of tyrosine-activated Stat3 (pStat3) in tissue microarrays from 303 ovarian carcinomas to det. its prognostic relevance and to correlate its expression with several upstream oncogenes of Stat3 and with the oncogenes involved in apoptosis and proliferation.  METHODS. Overexpression of pStat3 was weakly tumorigenic and produced measurable tumors in mice in 1 of 3 clones.  Using tissue microarrays from a large group of patients with primary ovarian carcinoma, the expression of pStat3 was correlated with the expression of growth factor receptors (HER-2/neu and epidermal growth factor receptor [EGFR]), interleukin 6, and the proliferation and apoptosis markers Ki-67, Bcl-2, and Bcl-xL and with clinicopathol. variables and patient survival.  RESULTS. High pStat3 expression in the tumor tissue microarray was assocd. with high levels of HER-2/neu, EGFR, and Ki-67.  No correlation was obsd. between overall pStat3 levels and any other clinicopathol. variables tested.  High nuclear expression of pStat3 (>10% of pos.-stained cells) was linked with poor overall survival.  CONCLUSIONS. The activation and translocation of pStat3 to the nucleus are frequent events in ovarian carcinoma that are assocd. with a poor prognosis.  Further studies are needed to elucidate the mechanism of activation of Stat3, its effects on downstream targets, and its role in the neoplastic transformation of epithelial ovarian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXSLNY-ed0jrVg90H21EOLACvtfcHk0ljoAq67-zY-fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCmu7bM&md5=c67244c62ab24f7829ba687ef9d39839</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fcncr.22293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.22293%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DD.%2BG.%26aulast%3DMercado-Uribe%26aufirst%3DI.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DBast%26aufirst%3DR.%2BC.%26aulast%3DAmin%26aufirst%3DH.%2BM.%26aulast%3DLai%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DThe%2520role%2520of%2520constitutively%2520active%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520in%2520ovarian%2520tumorigenesis%2520and%2520prognosis%26jtitle%3DCancer%26date%3D2006%26volume%3D107%26spage%3D2730%26epage%3D2740%26doi%3D10.1002%2Fcncr.22293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunning, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">A novel small-molecule disrupts stat3 SH2 domain–phosphotyrosine interactions and stat3-dependent tumor processes</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1398</span>– <span class="NLM_lpage">1409</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2010.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1016%2Fj.bcp.2010.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20067773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVCnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2010&pages=1398-1409&author=X.+Zhangauthor=P.+Yueauthor=S.+Fletcherauthor=W.+Zhaoauthor=P.+T.+Gunningauthor=J.+Turkson&title=A+novel+small-molecule+disrupts+stat3+SH2+domain%E2%80%93phosphotyrosine+interactions+and+stat3-dependent+tumor+processes&doi=10.1016%2Fj.bcp.2010.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes</span></div><div class="casAuthors">Zhang, Xiaolei; Yue, Peibin; Fletcher, Steven; Zhao, Wei; Gunning, Patrick T.; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1398-1409</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mol. modeling of the phosphotyrosine (pTyr)-SH2 domain interaction in the Stat3:Stat3 dimerization, combined with in silico structural anal. of the Stat3 dimerization disruptor, S3I-201, has furnished a diverse set of analogs.  We present evidence from in vitro biochem. and biophys. studies that the structural analog, S3I-201.1066 (I) directly interacts with Stat3 or the SH2 domain, with an affinity (KD) of 2.74 μM, and disrupts the binding of Stat3 to the cognate pTyr-peptide, GpYLPQTV-NH2, with an IC50 of 23 μM.  Moreover, I selectively blocks the assocn. of Stat3 with the epidermal growth factor receptor (EGFR), and inhibits Stat3 tyrosine phosphorylation and nuclear translocation in EGF-stimulated mouse fibroblasts.  In cancer cells that harbor aberrant Stat3 activity, I inhibits constitutive Stat3 DNA-binding and transcriptional activities.  By contrast, I has no effect on Src activation or the EGFR-mediated activation of the Erk1/2MAPK pathway.  I selectively suppresses the viability, survival, and malignant transformation of the human breast and pancreatic cancer lines and the v-Src-transformed mouse fibroblasts harboring persistently active Stat3.  Treatment with I of malignant cells harboring aberrantly active Stat3 down-regulated the expression of c-Myc, Bcl-xL, Survivin, the matrix metalloproteinase 9, and VEGF.  The in vivo administration of I-induced significant antitumor response in mouse models of human breast cancer, which correlates with the inhibition of constitutively active Stat3 and the suppression of known Stat3-regulated genes.  Our studies identify a novel small-mol. that binds with a high affinity to Stat3, blocks Stat3 activation and function, and thereby induces antitumor response in human breast tumor xenografts harboring persistently active Stat3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxJzIoqCaQHbVg90H21EOLACvtfcHk0lj4gn83ZVWO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVCnsL8%253D&md5=4a196103d1d0f6d057715ff4cd2d7498</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DGunning%26aufirst%3DP.%2BT.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DA%2520novel%2520small-molecule%2520disrupts%2520stat3%2520SH2%2520domain%25E2%2580%2593phosphotyrosine%2520interactions%2520and%2520stat3-dependent%2520tumor%2520processes%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D79%26spage%3D1398%26epage%3D1409%26doi%3D10.1016%2Fj.bcp.2010.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaganathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span> <span> </span><span class="NLM_article-title">A cell-permeable STAT3 SH2 domain mimetic inhibits STAT3 activation and induces antitumor cell effects in vitro</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">35855</span>– <span class="NLM_lpage">35865</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.154088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=10.1074%2Fjbc.M110.154088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=20807764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlyntLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=35855-35865&author=W.+Zhaoauthor=S.+Jaganathanauthor=J.+Turkson&title=A+cell-permeable+STAT3+SH2+domain+mimetic+inhibits+STAT3+activation+and+induces+antitumor+cell+effects+in+vitro&doi=10.1074%2Fjbc.M110.154088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A Cell-permeable Stat3 SH2 Domain Mimetic Inhibits Stat3 Activation and Induces Antitumor Cell Effects in Vitro</span></div><div class="casAuthors">Zhao, Wei; Jaganathan, Soumya; Turkson, James</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">35855-35865</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Given the role of constitutively active Signal Transducer and Activator of Transcription (Stat) 3 in human tumors, Stat3 inhibitors would be useful as novel therapeutics and as tools for probing Stat3-mediated tumor processes.  We herein report that a 28-mer peptide, SPI, derived from the Stat3 SH2 domain, replicates Stat3 biochem. properties.  Studies show SPI and Stat3 (or Stat3 SH2 domain) bind with similar affinities to known Stat3-binding phosphotyrosine (pY) peptide motifs, including those of the epidermal growth factor receptor (EGFR) and the high-affinity, IL-6R/gp130-derived pY-peptide, GpYLPQTV-NH2.  Consequently, SPI functions as a potent and selective inhibitor of Stat3 SH2 domain:pTyr interactions and disrupts the binding of Stat3 to the IL-6R/gp130 peptide, GpYLPQTV-NH2.  Fluorescence imaging and immunofluorescence staining/laser-scanning confocal microscopy show SPI is cell membrane-permeable, assocs. with the cytoplasmic tail of EGFR in NIH3T3/hEGFR, and is present in the cytoplasm, but strongly localized at the plasma membrane and in the nucleus in malignant cells harboring persistently active Stat3.  Moreover, SPI specifically blocks constitutive Stat3 phosphorylation, DNA binding activity, and transcriptional function in malignant cells, with little or no effect on the induction of Stat1, Stat5, and Erk1/2MAPK pathways, or on general pTyr profile at the concns. that inhibit Stat3 activity.  Significantly, treatment with SPI of human breast, pancreatic, prostate, and non-small cell lung cancer cells harboring constitutively active Stat3 induced extensive morphol. changes, assocd. with viability loss and apoptosis.  Our study identifies SPI as a novel mol. probe for interrogating Stat3 signaling and that functions as a selective inhibitor of Stat3 activation with antitumor cell effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5xNMqd5Ho5rVg90H21EOLACvtfcHk0lj4gn83ZVWO2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlyntLfL&md5=a1ac33150ab27d501fdb519800a3b406</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.154088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.154088%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DJaganathan%26aufirst%3DS.%26aulast%3DTurkson%26aufirst%3DJ.%26atitle%3DA%2520cell-permeable%2520STAT3%2520SH2%2520domain%2520mimetic%2520inhibits%2520STAT3%2520activation%2520and%2520induces%2520antitumor%2520cell%2520effects%2520in%2520vitro%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D35855%26epage%3D35865%26doi%3D10.1074%2Fjbc.M110.154088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5','PDB','4PK5'); return false;">PDB: 4PK5</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i87"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01386">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_07273"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01386?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01386</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Binding modes of <b>8u</b> in complex with IDO1 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PK5">4PK5</a>); UV spectra of ferric IDO1 without and with compound <b>8u</b>; effects of the indicated treatments of <b>8u</b> on B16-F10 melanoma tumor xenografts in C57BL/6 mice; inhibition of tumor growth for compound <b>8u</b> and doxorubicin (DOX) in nude mice bearing HepG2 xenograft model; inhibitory effects of <b>8u</b> on STATs; table of docking scores (kcal/mol) for all studied compounds; table of STAT3 binding affinities of selected 2-amino-1,4-naphthoquinone derivatives; and <sup>1</sup>H NMR, <sup>13</sup>C NMR, HR-MS, and HPLC of target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_001.pdf">jm9b01386_si_001.pdf (8.18 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01386/suppl_file/jm9b01386_si_002.csv">jm9b01386_si_002.csv (6.33 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01386&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01386%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-4%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01386" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0ada2b8f6d96e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
